U.S. patent application number 14/972482 was filed with the patent office on 2017-12-07 for substituted indoles.
This patent application is currently assigned to AbbVie Inc.. The applicant listed for this patent is AbbVie Inc.. Invention is credited to Yujia Dai, Justin Dietrich, William McClellan, Mike Michaelides, Ramzi Sweis, Noel Wilson.
Application Number | 20170349589 14/972482 |
Document ID | / |
Family ID | 59065851 |
Filed Date | 2017-12-07 |
United States Patent
Application |
20170349589 |
Kind Code |
A9 |
Dai; Yujia ; et al. |
December 7, 2017 |
Substituted Indoles
Abstract
The invention provides for compounds of formula (I) ##STR00001##
wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6
have any of the values defined in the specification, and
pharmaceutically acceptable salts thereof, that are useful as
agents in the treatment of diseases and conditions mediated and
modulated by SUV420H1. Also provided are pharmaceutical
compositions comprised of one or more compounds of formula (I).
Inventors: |
Dai; Yujia; (Gurnee, IL)
; McClellan; William; (Waukegan, IL) ;
Michaelides; Mike; (Libertyville, IL) ; Sweis;
Ramzi; (Lake Bluff, IL) ; Wilson; Noel;
(Kenosha, WI) ; Dietrich; Justin; (Lindenhurst,
IL) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
AbbVie Inc. |
North Chicago |
IL |
US |
|
|
Assignee: |
AbbVie Inc.
North Chicago
IL
|
Prior
Publication: |
|
Document Identifier |
Publication Date |
|
US 20170174688 A1 |
June 22, 2017 |
|
|
Family ID: |
59065851 |
Appl. No.: |
14/972482 |
Filed: |
December 17, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
62093523 |
Dec 18, 2014 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
G01N 2333/91017
20130101; C07D 519/00 20130101; G01N 2500/04 20130101; C12Q 1/48
20130101; C07D 473/34 20130101 |
International
Class: |
C07D 473/34 20060101
C07D473/34; C07D 519/00 20060101 C07D519/00; C12Q 1/48 20060101
C12Q001/48 |
Claims
1. A compound having formula (I) or a pharmaceutically acceptable
salt thereof ##STR00010## wherein R.sup.1 is hydrogen,
--C(O)(C.sub.1-C.sub.6 alkyl), --(C.sub.1-C.sub.6 alkylenyl)-OH,
--C(H)(benzyl)-NH.sub.2, --C(H)(phenyl)-NH.sub.2,
--(C.sub.1-C.sub.6 alkylenyl)-NR.sup.1AR.sup.1B, or
--(C.sub.1-C.sub.6 alkylenyl)-N(R.sup.j)C(O)R.sup.1C; R.sup.1A and
R.sup.1B are each independently hydrogen, C.sub.1-C.sub.6
haloalkyl, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.4 alkenyl,
--(CH.sub.2).sub.m-G.sup.1A, --(C.sub.1-C.sub.6
alkylenyl)-L.sup.1A-X, or --(CH.sub.2).sub.n-G.sup.1A-L.sup.1B-G;
or R.sup.1A and R.sup.1B together with the nitrogen atom to which
they are attached, form a C.sub.5-C.sub.6 heterocycloalkyl which is
optionally substituted with 1, 2, or 3 substituents independently
selected from the group consisting of C.sub.1-C.sub.6 haloalkyl,
C.sub.1-C.sub.6 alkyl, and oxo; R.sup.1C is C.sub.1-C.sub.6
haloalkyl, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.4 alkenyl,
--(CH.sub.2).sub.m-G.sup.1A, --(C.sub.1-C.sub.6
alkylenyl)-L.sup.1A-X, or --(CH.sub.2).sub.n-G.sup.1A-L.sup.1B-G;
G.sup.1A and G, at each occurrence, are each independently phenyl,
cycloalkyl, cycloalkenyl, heteroaryl, or heterocycle; wherein each
G.sup.1A and G are optionally substituted with 1, 2, or 3
independently selected R.sup.u; L.sup.1A, at each occurrence, is
independently O, N(H), or C(O)O; X, at each occurrence, is
independently H, C.sub.1-C.sub.6 alkyl, or C.sub.1-C.sub.6
haloalkyl; L.sup.1B, at each occurrence, is independently a bond,
--C.sub.1-C.sub.3 alkylenyl, 0, --O--C.sub.1-C.sub.3 alkylenyl-,
C(O), or --N(H)C(O)--; m is 0, 1, or 2; n is 0, 1, or 2; R.sup.2 is
hydrogen, halogen, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.4 alkenyl,
or G.sup.2A; wherein G.sup.2A is C.sub.3-C.sub.6 cycloalkyl,
C.sub.5-C.sub.6 cycloalkenyl, phenyl, or C.sub.5-C.sub.6
heteroaryl; and each G.sup.2A is optionally substituted with 1, 2,
or 3 independently selected R.sup.u groups; R.sup.3 is hydrogen,
halogen, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.4 alkenyl, G.sup.3A,
-G.sup.3A-G.sup.A, or -G.sup.3A-L.sup.3-Y; G.sup.3A, at each
occurrence, is independently C.sub.5-C.sub.6 cycloalkenyl,
C.sub.3-C.sub.6 cycloalkyl, phenyl, C.sub.5-C.sub.6 heteroaryl,
heterocycle; wherein each G.sup.3A is optionally substituted with
1, 2, or 3 independently selected R.sup.u groups; G.sup.A is
C.sub.3-C.sub.6 cycloalkyl or C.sub.5-C.sub.6 heterocycloalkyl;
each of which is optionally substituted with 1, 2, or 3
independently selected R.sup.u groups; L.sup.3 is C.sub.1-C.sub.3
alkylenyl, C(O), or --C(O)N(H)--; Y is --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.j).sub.2, C.sub.3-C.sub.6 cycloalkyl, or
C.sub.5-C.sub.6 heterocycloalkyl, wherein the C.sub.3-C.sub.6
cycloalkyl and the C.sub.5-C.sub.6 heterocycloalkyl are each
optionally substituted with 1, 2, or 3 substituents independently
selected from the group consisting of C.sub.1-C.sub.3 alkyl,
halogen, and C.sub.1-C.sub.3 haloalkyl; R.sup.4 is hydrogen,
halogen, or --(C.sub.1-C.sub.6 alkylenyl)-C(O)NR.sup.4AR.sup.4B;
wherein R.sup.4A and R.sup.4B are each independently hydrogen or
C.sub.1-C.sub.6 alkyl; R.sup.5 is hydrogen, halogen,
C.sub.2-C.sub.4 alkenyl, C.sub.1-C.sub.6 alkyl, or phenyl wherein
the phenyl is optionally substituted with 1, 2, or 3 independently
selected R.sup.u groups; R.sup.6 is hydrogen, halogen,
C.sub.1-C.sub.3 alkyl, or cyclopropyl; wherein the cyclopropyl is
optionally substituted with 1, 2, or 3 substituents independently
selected from the group consisting of halogen, C.sub.1-C.sub.3
alkyl, and C.sub.1-C.sub.3 haloalkyl; R.sup.u, at each occurrence,
is independently C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl,
C.sub.2-C.sub.6 alkynyl, halogen, C.sub.1-C.sub.6 haloalkyl, --CN,
oxo, NO.sub.2, --OR.sup.j, --OC(O)R.sup.k, --OC(O)N(R.sup.j).sub.2,
--SR.sup.j, --S(O).sub.2R.sup.j, --S(O).sub.2N(R.sup.j).sub.2,
--C(O)R.sup.j, --C(O)OR.sup.j, --C(O)N(R.sup.j).sub.2,
--N(R.sup.j).sub.2, --N(R.sup.j)C(O)R.sup.k,
--N(R.sup.j)S(O).sub.2R.sup.k, --N(R.sup.j)C(O)O(R.sup.k),
--N(R.sup.j)C(O)N(R.sup.j).sub.2, --(C.sub.1-C.sub.6
alkylenyl)-OR.sup.j, --(C.sub.1-C.sub.6 alkylenyl)-OC(O)R.sup.k,
--(C.sub.1-C.sub.6 alkylenyl)-OC(O)N(W).sub.2, --(C.sub.1-C.sub.6
alkylenyl)-SR.sup.j, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2R.sup.j, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2N(R.sup.j).sub.2, --(C.sub.1-C.sub.6
alkylenyl)-C(O)R.sup.j, --(C.sub.1-C.sub.6 alkylenyl)-C(O)OR.sup.j,
--(C.sub.1-C.sub.6 alkylenyl)-C(O)N(R.sup.j).sub.2,
--(C.sub.1-C.sub.6 alkylenyl)-N(R.sup.j).sub.2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.j)C(O)R.sup.k, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.j)S(O).sub.2R.sup.k, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.j)C(O)O(R.sup.k), --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.j)C(O)N(R.sup.j).sub.2, or --(C.sub.1-C.sub.6
alkylenyl)-CN; R.sup.j, at each occurrence, is independently
hydrogen, C.sub.1-C.sub.6 alkyl, or C.sub.1-C.sub.6 haloalkyl; and
R.sup.k, at each occurrence, is independently C.sub.1-C.sub.6 alkyl
or C.sub.1-C.sub.6 haloalkyl.
2. The compound of claim 1 or a pharmaceutically acceptable salt
thereof, wherein R.sup.1 is hydrogen, --C(H)(benzyl)-NH.sub.2,
--C(H)(phenyl)-NH.sub.2, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.1AR.sup.1B, or --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.j)C(O)R.sup.1C.
3. The compound of claim 1 or a pharmaceutically acceptable salt
thereof, wherein R.sup.1 is --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.1AR.sup.1B or --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.j)C(O)R.sup.1C.
4. The compound of claim 1 or a pharmaceutically acceptable salt
thereof, wherein R.sup.3 is hydrogen, halogen, C.sub.2-C.sub.4
alkenyl, G.sup.3A, -G.sup.3A-G.sup.A, or -G.sup.3A-L.sup.3-Y.
5. The compound of claim 1 or a pharmaceutically acceptable salt
thereof, wherein R.sup.3 is halogen.
6. The compound of claim 1 or a pharmaceutically acceptable salt
thereof, wherein R.sup.3 is halogen; and R.sup.2, R.sup.4, R.sup.5,
and R.sup.6 are hydrogen.
7. The compound of claim 1 or a pharmaceutically acceptable salt
thereof, wherein R.sup.3 is halogen; R.sup.2, R.sup.4, R.sup.5, and
R.sup.6 are hydrogen; and R.sup.1 is --C(O)(C.sub.1-C.sub.6 alkyl),
--(C.sub.1-C.sub.6 alkylenyl)-OH, --C(H)(benzyl)-NH.sub.2,
--C(H)(phenyl)-NH.sub.2, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.1AR.sup.1B, or --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.j)C(O)R.sup.1C.
8. The compound of claim 1 or a pharmaceutically acceptable salt
thereof, wherein R.sup.3 is G.sup.3A.
9. The compound of claim 1 or a pharmaceutically acceptable salt
thereof, wherein R.sup.3 is G.sup.3A; and R.sup.2, R.sup.4,
R.sup.5, and R.sup.6 are hydrogen.
10. The compound of claim 1 or a pharmaceutically acceptable salt
thereof, wherein R.sup.3 is G.sup.3A; R.sup.2, R.sup.4, R.sup.5,
and R.sup.6 are hydrogen; and R.sup.1 is --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.1AR.sup.1B or --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.j)C(O)R.sup.1C.
11. The compound of claim 1 or a pharmaceutically acceptable salt
thereof, wherein R.sup.3 is G.sup.3A; wherein G.sup.3A is
cyclohexenyl optionally substituted with 1, 2, or 3 independently
selected R.sup.u groups; R.sup.2, R.sup.4, R.sup.5, and R.sup.6 are
hydrogen; and R.sup.1 is --(CH.sub.2)--N(R.sup.j)C(O)R.sup.1C
wherein R.sup.1C is --(CH.sub.2).sub.m-G.sup.1A wherein m is 0 or
1.
12. The compound of claim 1 or a pharmaceutically acceptable salt
thereof, wherein R.sup.3 is -G.sup.3A-G.sup.A.
13. The compound of claim 1 or a pharmaceutically acceptable salt
thereof, wherein R.sup.3 is -G.sup.3A-G.sup.A; and R.sup.2,
R.sup.4, R.sup.5, and R.sup.6 are hydrogen.
14. The compound of claim 1 or a pharmaceutically acceptable salt
thereof, wherein R.sup.3 is -G.sup.3A-G.sup.A; R.sup.2, R.sup.4,
R.sup.5, and R.sup.6 are hydrogen; and R.sup.1 is
--(C.sub.1-C.sub.6 alkylenyl)-NR.sup.1AR.sup.1B or
--(C.sub.1-C.sub.6 alkylenyl)-N(R.sup.j)C(O)R.sup.1C.
15. The compound of claim 14 or a pharmaceutically acceptable salt
thereof, wherein G.sup.3A is phenyl optionally substituted with 1,
2, or 3 independently selected R.sup.u groups; and G.sup.A is
C.sub.5-C.sub.6 heterocycloalkyl optionally substituted with 1, 2,
or 3 independently selected R.sup.u groups.
16. The compound of claim 1 or a pharmaceutically acceptable salt
thereof, wherein R.sup.3 is -G.sup.3A-L.sup.3-Y.
17. The compound of claim 1 or a pharmaceutically acceptable salt
thereof, wherein R.sup.3 is -G.sup.3A-L.sup.3-Y; and R.sup.2,
R.sup.4, R.sup.5, and R.sup.6 are hydrogen.
18. The compound of claim 1 or a pharmaceutically acceptable salt
thereof, wherein R.sup.3 is -G.sup.3A-L.sup.3-Y; R.sup.2, R.sup.4,
R.sup.5, and R.sup.6 are hydrogen; and R.sup.1 is
--(C.sub.1-C.sub.6 alkylenyl)-NR.sup.1AR.sup.1B or
--(C.sub.1-C.sub.6 alkylenyl)-N(R.sup.j)C(O)R.sup.1C.
19. The compound of claim 18 or a pharmaceutically acceptable salt
thereof, wherein G.sup.3A is phenyl optionally substituted with 1,
2, or 3 independently selected R.sup.u groups; and L.sup.3 is
--CH.sub.2--, C(O), or --C(O)N(H)--.
20. The compound of claim 1 or a pharmaceutically acceptable salt
thereof, wherein R.sup.2 is hydrogen, halogen, C.sub.1-C.sub.6
alkyl, C.sub.2-C.sub.4 alkenyl, or G.sup.2A; wherein G.sup.2A is
C.sub.5-C.sub.6 cycloalkenyl, phenyl, or C.sub.5-C.sub.6
heteroaryl; and each G.sup.2A is optionally substituted with 1, 2,
or 3 independently selected R.sup.u groups.
21. The compound of claim 1 or a pharmaceutically acceptable salt
thereof, wherein R.sup.2 is hydrogen, halogen, C.sub.1-C.sub.6
alkyl, C.sub.2-C.sub.4 alkenyl, or G.sup.2A; wherein G.sup.2A is
C.sub.5-C.sub.6 cycloalkenyl, phenyl, or C.sub.5-C.sub.6
heteroaryl; and each G.sup.2A is optionally substituted 1, 2, or 3
independently selected R.sup.u groups; and R.sup.3, R.sup.4,
R.sup.5, and R.sup.6 are hydrogen.
22. The compound of claim 1 or a pharmaceutically acceptable salt
thereof, wherein R.sup.3, R.sup.4, R.sup.5, and R.sup.6 are
hydrogen; R.sup.2 is hydrogen, halogen, C.sub.1-C.sub.6 alkyl,
C.sub.2-C.sub.4 alkenyl, or G.sup.2A; wherein G.sup.2A is
C.sub.5-C.sub.6 cycloalkenyl, phenyl, or C.sub.5-C.sub.6
heteroaryl; and each G.sup.2A is optionally substituted 1, 2, or 3
independently selected R.sup.u groups; and R.sup.1 is
--(C.sub.1-C.sub.6 alkylenyl)-NR.sup.1AR.sup.1B or
--(C.sub.1-C.sub.6 alkylenyl)-N(R.sup.j)C(O)R.sup.1C.
23. The compound of claim 1 or a pharmaceutically acceptable salt
thereof, wherein R.sup.2, R.sup.3, R.sup.4, and R.sup.6 are
hydrogen; and R.sup.5 is hydrogen, halogen, C.sub.2-C.sub.4
alkenyl, or phenyl wherein the phenyl is optionally substituted
with 1, 2, or 3 independently selected R.sup.u groups.
24. The compound of claim 1 or a pharmaceutically acceptable salt
thereof, wherein R.sup.2, R.sup.3, R.sup.4, and R.sup.6 are
hydrogen; R.sup.5 is hydrogen, halogen, C.sub.2-C.sub.4 alkenyl, or
phenyl wherein the phenyl is optionally substituted with 1, 2, or 3
independently selected R.sup.u groups; and R.sup.1 is
--(C.sub.1-C.sub.6 alkylenyl)-NR.sup.1AR.sup.1B.
25. The compound of claim 1 or a pharmaceutically acceptable salt
thereof, wherein the compound is selected from the group consisting
of 9-[(3-bromo-1H-indol-7-yl)methyl]-9H-purin-6-amine;
9-(1H-indol-7-ylmethyl)-2-methyl-9H-purin-6-amine;
9-(1H-indol-7-ylmethyl)-9H-purin-6-amine;
2-cyclopropyl-9-(1H-indol-7-ylmethyl)-9H-purin-6-amine;
{7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methanol;
9-{[2-(aminomethyl)-1H-indol-7-yl]methyl}-9H-purin-6-amine;
9-{[2-(aminomethyl)-5-chloro-1H-indol-7-yl]methyl}-9H-purin-6-amine;
9-{[2-(aminomethyl)-5-ethenyl-1H-indol-7-yl]methyl}-9H-purin-6-amine;
9-{[2-(aminomethyl)-5-(cyclopent-1-en-1-yl)-1H-indol-7-yl]methyl}-9H-puri-
n-6-amine;
9-{[2-(aminomethyl)-5-(3,6-dihydro-2H-pyran-4-yl)-1H-indol-7-yl-
]methyl}-9H-purin-6-amine;
9-{[2-(aminomethyl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-7-yl]meth-
yl}-9H-purin-6-amine;
9-{[2-(aminomethyl)-5-(4,4-difluorocyclohex-1-en-1-yl)-1H-indol-7-yl]meth-
yl}-9H-purin-6-amine;
1-[4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}-3,-
6-dihydropyridin-1(2H)-yl]ethanone;
1-[5-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}-3,-
6-dihydropyridin-1(2H)-yl]ethanone;
1-(4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}pip-
eridin-1-yl)ethanone;
9-{[2-(aminomethyl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-indol-7-yl]methyl}-9H-
-purin-6-amine;
9-{[2-(aminomethyl)-5-(pyrimidin-5-yl)-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine;
9-{[2-(aminomethyl)-5-(pyridin-3-yl)-1H-indol-7-yl]methyl}-9H-purin--
6-amine;
9-{[2-(aminomethyl)-5-(pyridin-4-yl)-1H-indol-7-yl]methyl}-9H-pur-
in-6-amine;
9-{[2-(aminomethyl)-5-phenyl-1H-indol-7-yl]methyl}-9H-purin-6-amine;
9-{[2-(aminomethyl)-5-(4-chlorophenyl)-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine;
9-{[2-(aminomethyl)-5-(3-chlorophenyl)-1H-indol-7-yl]methyl}-9H-puri-
n-6-amine;
9-{[2-(aminomethyl)-5-(2-chlorophenyl)-1H-indol-7-yl]methyl}-9H-
-purin-6-amine;
9-{[2-(aminomethyl)-5-(4-fluorophenyl)-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine;
9-{[2-(aminomethyl)-5-(2-fluorophenyl)-1H-indol-7-yl]methyl}-9H-puri-
n-6-amine;
9-{[2-(aminomethyl)-5-(6-methoxypyridin-3-yl)-1H-indol-7-yl]met-
hyl}-9H-purin-6-amine;
4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}benzen-
esulfonamide;
9-{[2-(aminomethyl)-5-(4-methylphenyl)-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine;
9-{[2-(aminomethyl)-5-(3-methylphenyl)-1H-indol-7-yl]methyl}-9H-puri-
n-6-amine;
9-{[2-(aminomethyl)-5-(2-methylphenyl)-1H-indol-7-yl]methyl}-9H-
-purin-6-amine;
(4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}pheny-
l)methanol;
9-{[2-(aminomethyl)-5-(4-methoxyphenyl)-1H-indol-7-yl]methyl}-9H-purin-6--
amine;
9-{[2-(aminomethyl)-5-(3-methoxyphenyl)-1H-indol-7-yl]methyl}-9H-pu-
rin-6-amine;
9-{[2-(aminomethyl)-5-(2-methoxyphenyl)-1H-indol-7-yl]methyl}-9H-purin-6--
amine;
9-({2-(aminomethyl)-5-[4-(methylsulfonyl)phenyl]-1H-indol-7-yl}meth-
yl)-9H-purin-6-amine;
4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}benzon-
itrile;
3-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl-
}benzonitrile;
3-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}benzam-
ide;
N-(4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl-
}phenyl)methanesulfonamide;
N-(3-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}phe-
nyl)methanesulfonamide;
9-{[2-(aminomethyl)-5-(4-ethylphenyl)-1H-indol-7-yl]methyl}-9H-purin-6-am-
ine; methyl
4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}benzoa-
te;
(4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}ph-
enyl)acetonitrile;
3-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}-N-eth-
ylbenzamide;
4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}-N,N-d-
imethylbenzamide;
3-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}-N,N-d-
imethylbenzamide;
4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}-N-[2--
(dimethylamino)ethyl]benzamide;
4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}-N-cyc-
lopropylbenzamide;
3-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}-N-cyc-
lopropylbenzamide;
9-({2-(aminomethyl)-5-[3-(morpholin-4-yl)phenyl]-1H-indol-7-yl}methyl)-9H-
-purin-6-amine;
(3-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}pheny-
l)(morpholin-4-yl)methanone;
9-{[2-(aminomethyl)-5-{4-[(4-methylpiperazin-1-yl)methyl]phenyl}-1H-indol-
-7-yl]methyl}-9H-purin-6-amine;
9-{[2-(aminomethyl)-5-{3-[(4-methylpiperazin-1-yl)methyl]phenyl}-1H-indol-
-7-yl]methyl}-9H-purin-6-amine;
(4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}pheny-
l)(4-methylpiperazin-1-yl)methanone;
9-{[2-(aminomethyl)-5-(2,3-dihydro-1-benzofuran-5-yl)-1H-indol-7-yl]methy-
l}-9H-purin-6-amine;
9-{[2-(aminomethyl)-6-chloro-1H-indol-7-yl]methyl}-9H-purin-6-amine;
9-{[2-(aminomethyl)-6-ethenyl-1H-indol-7-yl]methyl}-9H-purin-6-amine;
9-{[2-(aminomethyl)-6-(prop-1-en-2-yl)-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine;
9-{[2-(aminomethyl)-6-phenyl-1H-indol-7-yl]methyl}-9H-purin-6-amine;
9-{[2-(aminomethyl)-4-chloro-1H-indol-7-yl]methyl}-9H-purin-6-amine;
9-{[2-(aminomethyl)-4-ethenyl-1H-indol-7-yl]methyl}-9H-purin-6-amine;
9-{[2-(aminomethyl)-4-ethyl-1H-indol-7-yl]methyl}-9H-purin-6-amine;
9-{[2-(aminomethyl)-4-(prop-1-en-2-yl)-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine;
9-{[2-(aminomethyl)-4-(propan-2-yl)-1H-indol-7-yl]methyl}-9H-purin-6-
-amine;
9-{[2-(aminomethyl)-4-(cyclopent-1-en-1-yl)-1H-indol-7-yl]methyl}--
9H-purin-6-amine;
9-{[2-(aminomethyl)-4-(1-methyl-1H-pyrazol-4-yl)-1H-indol-7-yl]methyl}-9H-
-purin-6-amine;
9-{[2-(aminomethyl)-4-(pyridin-3-yl)-1H-indol-7-yl]methyl}-9H-purin-6-ami-
ne;
9-{[2-(aminomethyl)-4-phenyl-1H-indol-7-yl]methyl}-9H-purin-6-amine;
9-{[2-(aminomethyl)-4-(3-chlorophenyl)-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine;
9-{[2-(aminomethyl)-4-(2-chlorophenyl)-1H-indol-7-yl]methyl}-9H-puri-
n-6-amine;
9-{[2-(aminomethyl)-4-(4-fluorophenyl)-1H-indol-7-yl]methyl}-9H-
-purin-6-amine;
9-{[2-(aminomethyl)-4-(2-fluorophenyl)-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine;
9-{[2-(aminomethyl)-4-(4-methylphenyl)-1H-indol-7-yl]methyl}-9H-puri-
n-6-amine;
9-{[2-(aminomethyl)-4-(3-methylphenyl)-1H-indol-7-yl]methyl}-9H-
-purin-6-amine;
9-{[2-(aminomethyl)-4-(2-methylphenyl)-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine;
9-{[2-(aminomethyl)-4-(4-methoxyphenyl)-1H-indol-7-yl]methyl}-9H-pur-
in-6-amine;
9-{[2-(aminomethyl)-4-(3-methoxyphenyl)-1H-indol-7-yl]methyl}-9H-purin-6--
amine;
9-{[2-(aminomethyl)-4-(2-methoxyphenyl)-1H-indol-7-yl]methyl}-9H-pu-
rin-6-amine;
9-({2-(aminomethyl)-4-[4-(methylsulfonyl)phenyl]-1H-indol-7-yl}methyl)-9H-
-purin-6-amine;
4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-4-yl}benzon-
itrile;
3-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-4-yl-
}benzonitrile;
3-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-4-yl}benzam-
ide;
N-(4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-4-yl-
}phenyl)methanesulfonamide;
4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-4-yl}-N,N-d-
imethylbenzamide;
1-{7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}ethanone;
9-{[2-(1-aminoethyl)-5-chloro-1H-indol-7-yl]methyl}-9H-purin-6-amine;
9-({5-chloro-2-[(methylamino)methyl]-1H-indol-7-yl}methyl)-9H-purin-6-ami-
ne;
1-{7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}propan-1-o-
ne;
9-{[2-(1-aminopropyl)-5-chloro-1H-indol-7-yl]methyl}-9H-purin-6-amine;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)aceta-
mide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-
prop-2-enamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)propa-
namide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methy-
l)-2-methoxyacetamide;
3-[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)amin-
o]propanoic acid; 9-({5-chloro-2-[(diethyl
amino)methyl]-1H-indol-7-yl}methyl)-9H-purin-6-amine;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)butan-
amide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl-
)-2-methylpropanamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-me-
thoxypropanamide;
2,2'-[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)i-
mino]diacetic acid;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-me-
thylbutanamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-hy-
droxy-3-methylbutanamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3,3--
dimethylbutanamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-me-
thylpentanamide; tert-butyl
[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)amino]-
acetate;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}meth-
yl)cyclopropanecarboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-me-
thylcyclopropanecarboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-me-
thylcyclopropanecarboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-cy-
clopropylacetamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)cyclo-
butanecarboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-hy-
droxycyclobutanecarboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)tetra-
hydrofuran-2-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)tetra-
hydrofuran-3-carboxamide;
(2S)--N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl-
)pyrrolidine-2-carboxamide;
(2R)--N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl-
)pyrrolidine-2-carboxamide;
(2S)--N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl-
)-5-oxopyrrolidine-2-carboxamide;
(2R)--N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl-
)-5-oxopyrrolidine-2-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)cyclo-
pentanecarboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(p-
yrrolidin-1-yl)acetamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-cy-
clopentylacetamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-(p-
yrrolidin-1-yl)propanamide; tert-butyl
(2S)-2-[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl-
)carbamoyl]pyrrolidine-1-carboxylate; tert-butyl
(2R)-2-[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl-
)carbamoyl]pyrrolidine-1-carboxylate;
9-({5-chloro-2-[(1,1-dioxidothiomorpholin-4-yl)methyl]-1H-indol-7-yl}meth-
yl)-9H-purin-6-amine;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)tetra-
hydro-2H-pyran-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(m-
orpholin-4-yl)acetamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)cyclo-
hexanecarboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-me-
thylcyclohexanecarboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-me-
thylcyclohexanecarboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-me-
thylcyclohexanecarboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-me-
thylcyclohexanecarboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-cy-
clohexylacetamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-me-
thoxycyclohexanecarboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-(p-
iperidin-1-yl)propanamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)tricy-
clo[3.3.1.1.sup.3,7]decane-1-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl)methyl]-5-chloro-1H-indol-2-yl}methy-
l)-1,2-thiazole-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,3--
thiazole-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,2--
thiazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,3--
thiazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,2--
oxazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-p-
yrazole-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-p-
yrazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)thiop-
hene-2-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)thiop-
hene-3-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-p-
yrrole-2-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-5-me-
thyl-1,3-thiazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-me-
thyl-1,3-thiazole-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-5-me-
thyl-1,2-oxazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-me-
thyl-1,2-oxazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-me-
thyl-1H-pyrazole-3-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-me-
thyl-1H-pyrazole-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-me-
thyl-1H-imidazole-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-me-
thyl-1H-imidazole-2-carboxamide;
5-amino-N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}meth-
yl)-3-methyl-1,2-oxazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-me-
thylthiophene-3-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-me-
thylthiophene-2-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-me-
thoxythiophene-3-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-me-
thoxythiophene-2-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-me-
thyl-1H-pyrrole-2-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2,4--
dimethyl-1,3-thiazole-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3,5--
dimethyl-1,2-oxazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(1,2,5,6-tetrahydropyridin-3-yl)--
1H-indol-2-yl}methyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-phenyl-1H-indol-2-yl}methyl)-3,5--
dimethyl-1,2-oxazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4-fluorophenyl)-1H-indol-2-yl}me-
thyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4-sulfamoylphenyl)-1H-indol-2-yl-
}methyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4-methylphenyl)-1H-indol-2-yl}me-
thyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4-methoxyphenyl)-1H-indol-2-yl}m-
ethyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(3-methoxyphenyl)-1H-indol-2-yl}m-
ethyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-[4-(methylsulfonyl)phenyl]-1H-ind-
ol-2-yl}methyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4-cyanophenyl)-1H-indol-2-yl}met-
hyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(3-cyanophenyl)-1H-indol-2-yl}met-
hyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(3-carbamoylphenyl)-1H-indol-2-yl-
}methyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide;
N-[(7-[(6-amino-9H-purin-9-yl)methyl]-5-{4-[(methyl
sulfonyl)amino]phenyl}-1H-indol-2-yl)methyl]-3,5-dimethyl-1,2-oxazole-4-c-
arboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-[4-(cyanomethyl)phenyl]-1H-indol--
2-yl}methyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-[4-(dimethylcarbamoyl)phenyl]-1H--
indol-2-yl}methyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-[3-(dimethylcarbamoyl)phenyl]-1H--
indol-2-yl}methyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-[3-(cyclopropylcarbamoyl)phenyl]--
1H-indol-2-yl}methyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-[3-(morpholin-4-yl)phenyl]-1H-ind-
ol-2-yl}methyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-[3-(morpholin-4-ylcarbonyl)phenyl-
]-1H-indol-2-yl}methyl)-3, 5-dimethyl-1,2-oxazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-5-et-
hyl-1,2-oxazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,5--
dimethyl-1H-pyrazole-3-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,3--
dimethyl-1H-pyrazole-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,3--
dimethyl-1H-pyrazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-5-et-
hyl-3-methyl-1,2-oxazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-et-
hyl-5-methyl-1,2-oxazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-5-(p-
ropan-2-yl)-1,2-oxazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-et-
hyl-3,5-dimethyl-1H-pyrazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-5-cy-
clopropyl-1,2-oxazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-5-cy-
clopropyl-3-methyl-1,2-oxazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl)methyl]-5-chloro-1H-indol-2-yl}methy-
l)-1-methyl-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4,5,-
6,7-tetrahydropyrazolo[1,5-a]pyridine-3-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)pyraz-
ine-2-carboxamide;
9-({2-[amino(phenyl)methyl]-5-chloro-1H-indol-7-yl}methyl)-9H-purin-6-ami-
ne;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)py-
ridine-2-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)pyrid-
ine-3-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-6-hy-
droxypyridine-2-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-ox-
o-1,2-dihydropyridine-3-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-me-
thylpyridazine-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(1,2,3,6-tetrahydropyridin-4-yl)--
1H-indol-2-yl}methyl)-3-methylpyridazine-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4,4-difluorocyclohex-1-en-1-yl)--
1H-indol-2-yl}methyl)-3-methylpyridazine-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-[1-(methylsulfonyl)-1,2,3,6-tetra-
hydropyridin-4-yl]-1H-indol-2-yl}methyl)-3-methylpyridazine-4-carboxamide;
N-({5-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-7-[(6-amino-9H-purin-9-yl-
)methyl]-1H-indol-2-yl}methyl)-3-methylpyridazine-4-carboxamide;
tert-butyl
4-{7-[(6-amino-9H-purin-9-yl)methyl]-2-({[(3-methylpyridazin-4-yl)carbony-
l]amino}methyl)-1H-indol-5-yl}-3,6-dihydropyridine-1(2H)-carboxylate;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-5-me-
thylpyrazine-2-carboxamide;
9-{[2-(1-amino-2-phenylethyl)-5-chloro-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine;
9-({2-[(benzylamino)methyl]-5-chloro-1H-indol-7-yl}methyl)-9H-purin--
6-amine;
9-[(2-{[(2-bromobenzyl)amino]methyl}-5-chloro-1H-indol-7-yl)methy-
l]-9H-purin-6-amine;
9-[(5-chloro-2-{[(3-chlorobenzyl)amino]methyl}-1H-indol-7-yl)methyl]-9H-p-
urin-6-amine;
9-[(5-chloro-2-{[(2-chlorobenzyl)amino]methyl}-1H-indol-7-yl)methyl]-9H-p-
urin-6-amine;
9-[(5-chloro-2-{[(2,6-dichlorobenzyl)amino]methyl}-1H-indol-7-yl)methyl]--
9H-purin-6-amine;
9-[(5-chloro-2-{[(3,5-dichlorobenzyl)amino]methyl}-1H-indol-7-yl)methyl]--
9H-purin-6-amine;
9-[(5-chloro-2-{[(3,4-dichlorobenzyl)amino]methyl}-1H-indol-7-yl)methyl]--
9H-purin-6-amine;
9-[(5-chloro-2-{[(2-fluorobenzyl)amino]methyl}-1H-indol-7-yl)methyl]-9H-p-
urin-6-amine;
9-[(5-chloro-2-{[(2-chloro-6-fluorobenzyl)amino]methyl}-1H-indol-7-yl)met-
hyl]-9H-purin-6-amine;
9-[(5-chloro-2-{[(3-chloro-5-fluorobenzyl)amino]methyl}-1H-indol-7-yl)met-
hyl]-9H-purin-6-amine;
9-[(5-chloro-2-{[(2-chloro-5-fluorobenzyl)amino]methyl}-1H-indol-7-yl)met-
hyl]-9H-purin-6-amine;
9-[(5-chloro-2-{[(3-chloro-2-fluorobenzyl)amino]methyl}-1H-indol-7-yl)met-
hyl]-9H-purin-6-amine;
9-[(5-chloro-2-{[(2,6-difluorobenzyl)amino]methyl}-1H-indol-7-yl)methyl]--
9H-purin-6-amine;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)benza-
mide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-
-4-chlorobenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-ch-
lorobenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-fl-
uorobenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-fl-
uorobenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-fl-
uorobenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-br-
omo-6-fluorobenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-ch-
loro-6-fluorobenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2,6--
difluorobenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-fl-
uoro-6-hydroxybenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(p-
yridin-2-yl)acetamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl)methyl]-5-chloro-1H-indol-2-yl}methy-
l)-2-(pyridin-3-yl)acetamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(p-
yridin-4-yl)acetamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-me-
thylpyridine-3-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3,6--
dimethylpyridazine-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(1,2,3,6-tetrahydropyridin-4-yl)--
1H-indol-2-yl}methyl)-3,6-dimethylpyridazine-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4,4-difluorocyclohex-1-en-1-yl)--
1H-indol-2-yl}methyl)-3,6-dimethylpyridazine-4-carboxamide;
N-({5-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-7-[(6-amino-9H-purin-9-yl-
)methyl]-1H-indol-2-yl}methyl)-3,6-dimethylpyridazine-4-carboxamide;
N-({5-(1-acetyl-1,4,5,6-tetrahydropyridin-3-yl)-7-[(6-amino-9H-purin-9-yl-
)methyl]-1H-indol-2-yl}methyl)-3,6-dimethylpyridazine-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-4-chloro-1H-indol-2-yl}methyl)-3,6--
dimethylpyridazine-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-6-cy-
anopyridine-3-carboxamide;
9-[(5-chloro-2-{[(4-methylbenzyl)amino]methyl}-1H-indol-7-yl)methyl]-9H-p-
urin-6-amine;
9-[(5-chloro-2-{[(2-methylbenzyl)amino]methyl}-1H-indol-7-yl)methyl]-9H-p-
urin-6-amine;
9-[(5-chloro-2-{[(2-chloro-6-methylbenzyl)amino]methyl}-1H-indol-7-yl)met-
hyl]-9H-purin-6-amine;
9-[(5-chloro-2-{[(2-fluoro-6-methylbenzyl)amino]methyl}-1H-indol-7-yl)met-
hyl]-9H-purin-6-amine;
9-[(5-chloro-2-{[(2-fluoro-3-methylbenzyl)amino]methyl}-1H-indol-7-yl)met-
hyl]-9H-purin-6-amine;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-me-
thylbenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-me-
thylbenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-me-
thylbenzamide;
9-[(5-chloro-2-{[(3-methoxybenzyl)amino]methyl}-1H-indol-7-yl)methyl]-9H--
purin-6-amine;
9-[(5-chloro-2-{[(2-methoxybenzyl)amino]methyl}-1H-indol-7-yl)methyl]-9H--
purin-6-amine;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(4-
-chlorophenyl)acetamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(3-
-chlorophenyl)acetamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(2-
-chlorophenyl)acetamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(4-
-fluorophenyl)acetamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(3-
-fluorophenyl)acetamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(2-
-fluorophenyl)acetamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(t-
rifluoromethyl)benzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-me-
thoxybenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-me-
thoxybenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-me-
thoxybenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(d-
ifluoromethoxy)benzamide; 9-{[5-chloro-2-({[3-(methyl
sulfonyl)benzyl]amino}methyl)-1H-indol-7-yl]methyl}-9H-purin-6-amine;
9-{[5-chloro-2-({[4-fluoro-3-(methylsulfonyl)benzyl]amino}methyl)-1H-indo-
l-7-yl]methyl}-9H-purin-6-amine;
9-{[5-chloro-2-({[3-fluoro-4-(methylsulfonyl)benzyl]amino}methyl)-1H-indo-
l-7-yl]methyl}-9H-purin-6-amine;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(m-
ethylsulfonyl)benzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-ch-
loro-4-(methyl sulfonyl)benzamide;
4-{[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)ami-
no]methyl}benzonitrile;
3-{[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)ami-
no]methyl}benzonitrile;
2-{[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)ami-
no]methyl}benzonitrile;
3-{[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)ami-
no]methyl}-4-fluorobenzonitrile;
5-amino-N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}meth-
yl)-2-methylbenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-cy-
anobenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-cy-
anobenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-cy-
anobenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(m-
ethylamino)benzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-ch-
loro-4-cyanobenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(1,2,3,6-tetrahydropyridin-4-yl)--
1H-indol-2-yl}methyl)-2-chloro-4-cyanobenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4,4-difluorocyclohex-1-en-1-yl)--
1H-indol-2-yl}methyl)-2-chloro-4-cyanobenzamide;
N-({5-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-7-[(6-amino-9H-purin-9-yl-
)methyl]-1H-indol-2-yl}methyl)-2-chloro-4-cyanobenzamide;
N-({5-(1-acetyl-1,4,5,6-tetrahydropyridin-3-yl)-7-[(6-amino-9H-purin-9-yl-
)methyl]-1H-indol-2-yl}methyl)-2-chloro-4-cyanobenzamide;
N-({5-(1-acetylpiperidin-4-yl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-
-2-yl}methyl)-2-chloro-4-cyanobenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-4-chloro-1H-indol-2-yl}methyl)-2-ch-
loro-4-cyanobenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2,6--
dichloro-4-cyanobenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-cy-
ano-2-fluorobenzamide; N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(3,
6-dihydro-2H-pyran-4-yl)-1H-indol-2-yl}methyl)-4-cyano-2-fluorobenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(1,2,3,6-tetrahydropyridin-4-yl)--
1H-indol-2-yl}methyl)-4-cyano-2-fluorobenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4,4-difluorocyclohex-1-en-1-yl)--
1H-indol-2-yl}methyl)-4-cyano-2-fluorobenzamide;
N-({5-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-7-[(6-amino-9H-purin-9-yl-
)methyl]-1H-indol-2-yl}methyl)-4-cyano-2-fluorobenzamide;
tert-butyl
4-(7-[(6-amino-9H-purin-9-yl)methyl]-2-{[(4-cyano-2-fluorobenzoyl)amino]m-
ethyl}-1H-indol-5-yl)-3,6-dihydropyridine-1(2H)-carboxylate;
9-[(5-chloro-2-{[(2,6-dimethylbenzyl)amino]methyl}-1H-indol-7-yl)methyl]--
9H-purin-6-amine;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-ph-
enylpropanamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(4-
-methylphenyl)acetamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(3-
-methylphenyl)acetamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(2-
-methylphenyl)acetamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2,6--
dimethylbenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-et-
hylbenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(4-
-methoxyphenyl)acetamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(2-
-methoxyphenyl)acetamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-me-
thoxy-6-methylbenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-me-
thoxy-4-methylbenzamide;
4-(aminomethyl)-N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4,4-difluorocycl-
ohexyl)-1H-indol-2-yl}methyl)-2-methylbenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-(d-
imethylamino)benzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-cy-
ano-2-methylbenzamide; N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(3,
6-dihydro-2H-pyran-4-yl)-1H-indol-2-yl}methyl)-4-cyano-2-methylbenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(1,2,3,6-tetrahydropyridin-4-yl)--
1H-indol-2-yl}methyl)-4-cyano-2-methylbenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4,4-difluorocyclohex-1-en-1-yl)--
1H-indol-2-yl}methyl)-4-cyano-2-methylbenzamide;
N-({5-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-7-[(6-amino-9H-purin-9-yl-
)methyl]-1H-indol-2-yl}methyl)-4-cyano-2-methylbenzamide;
tert-butyl
4-(7-[(6-amino-9H-purin-9-yl)methyl]-2-{[(4-cyano-2-methylbenzoyl)amino]m-
ethyl}-1H-indol-5-yl)-3,6-dihydropyridine-1(2H)-carboxylate;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-(d-
imethylamino)benzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(e-
thylamino)benzamide;
4-{[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)ami-
no]methyl}-3-methoxybenzonitrile;
4-(acetylamino)-N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-
-yl}methyl)benzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(p-
ropan-2-yl)benzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-(4-
-methoxyphenyl)propanamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-(3-
-methoxyphenyl)propanamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-[4-
-(dimethylamino)phenyl]acetamide;
4-{[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)ami-
no]methyl}-N,N-dimethylbenzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-(2-
-fluorophenyl)pyrrolidine-1-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(p-
yrrolidin-1-ylcarbonyl)benzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(t-
etrahydro-2H-pyran-4-yloxy)benzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(p-
iperidin-1-yl)benzamide;
9-{[5-chloro-2-({[3-(piperidin-1-ylmethyl)benzyl]amino}methyl)-1H-indol-7-
-yl]methyl}-9H-purin-6-amine;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(p-
iperidin-1-ylcarbonyl)benzamide;
9-({5-chloro-2-[({3-[2-(piperidin-1-yl)ethoxy]benzyl}amino)methyl]-1H-ind-
ol-7-yl}methyl)-9H-purin-6-amine;
N-({7-[(6-amino-9H-purin-9-yl)methyl)methyl]-5-chloro-1H-indol-2-yl}methy-
l)-5-methyl-3-phenyl-1,2-oxazole-4-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(1-
-methyl-1H-imidazol-2-yl)benzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(b-
enzoylamino)benzamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,2,-
3-benzothiadiazole-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3H-i-
midazo[4,5-b]pyridine-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-b-
enzotriazole-6-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-b-
enzotriazole-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3H-i-
midazo[4,5-b]pyridine-6-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-5-fl-
uoro-1H-benzotriazole-6-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,3--
benzothiazole-6-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,3--
benzothiazole-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)thien-
o[3,2-b]pyridine-6-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,3--
benzoxazole-6-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,3--
benzoxazole-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)furo[-
3,2-b]pyridine-6-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-hy-
droxy-1,3-benzothiazole-6-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-i-
ndazole-6-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-p-
yrrolo[3,2-b]pyridine-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-b-
enzimidazole-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-b-
enzimidazole-6-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-i-
ndazole-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-p-
yrrolo[2,3-b]pyridine-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-ch-
loro-1H-pyrrolo[2,3-b]pyridine-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-5-ch-
loro-1H-pyrrolo[2,3-b]pyridine-6-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-fl-
uoro-1H-indazole-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-me-
thyl[1,2]oxazolo[5,4-b]pyridine-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-me-
thyl-1H-benzotriazole-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-me-
thyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-be-
nzothiophene-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-be-
nzofuran-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-i-
ndole-6-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-i-
ndole-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl)methyl]-5-chloro-1H-indol-2-yl}methy-
l)-2-methyl-1,3-benzothiazole-6-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-me-
thyl-1,3-benzoxazole-6-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-me-
thyl-1H-indazole-6-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-me-
thyl-1H-benzimidazole-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-me-
thyl-1H-indazole-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-me-
thyl-1H-benzimidazole-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-me-
thyl-1-benzofuran-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-me-
thyl-1H-indole-6-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-me-
thyl-1H-indole-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,2--
dimethyl-1H-benzimidazole-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-et-
hyl-1H-benzimidazole-6-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-cy-
ano-1H-indole-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-(p-
ropan-2-yl)[1,2]oxazolo[5,4-b]pyridine-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-(p-
ropan-2-yl)-1H-benzotriazole-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-(p-
ropan-2-yl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-me-
thoxy-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2,3--
dimethyl-1H-indole-6-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2,3--
dimethyl-1H-indole-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-(2-
-hydroxyethyl)-2-methyl-1H-benzimidazole-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-6-me-
thyl-1-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,2,-
3-trimethyl-1H-indole-5-carboxamide; and
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-bu-
tyl-1,3-benzoxazole-5-carboxamide.
26. A pharmaceutical composition comprising a therapeutically
effective amount of a compound of formula (I) according to claim 1,
or a pharmaceutically acceptable salt thereof, in combination with
a pharmaceutically acceptable carrier.
27. A kit for use in measuring the activity of SUV420H1 or a
fragment thereof in a biological sample in vitro or in vivo,
comprising (i) a first composition comprising a compound of formula
(I) according to claim 1; and (ii) instructions for: (a) contacting
the composition with the biological sample; and (b) measuring
activity of said SUV420H1 or a fragment thereof.
28. A method for modulating SUV420H1 in a membrane of a cell,
comprising the step of contacting said cell with a compound of
formula (I) according to claim 1 or a pharmaceutically acceptable
salt thereof.
29. A method of treating a condition, disease, or disorder in a
subject implicated by SUV420H1 activity, comprising the step of
administering to said subject a therapeutically effective amount of
a compound of formula (I) according to claim 1 or a
pharmaceutically acceptable salt thereof.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional
Application No. 62/093,523, filed Dec. 18, 2014, which is
incorporated herein by reference for all purposes.
BACKGROUND
[0002] Histone methyltransferases (HMTs), a class of enzymatic
"writers" of epigenetic marks, have recently emerged as targets of
potential therapeutic value. They catalyze the methylation of
histone lysines and arginines utilizing S-adenosyl-methionine (SAM)
as the cofactor/methyl-source. This process can result in either
the activation or repression of transcription. Dysregulation of
methylation at specific histone sites (alterations in the "histone
code") has been implicated in many cancers such as breast cancers,
prostate cancers, renal cell carcinoma, and myeloid and
lymphoblastic leukaemia (Chi P. et al. (2010) Nat. Rev. Cancer 10,
457-469). Hence, targeting HMT activity has been the subject of
much investigation in the field of oncology.
[0003] Suppressor of variegation 4-20 homolog 1 (SUV420H1) is a SET
domain-containing histone methyltransferase that localizes to
heterochromatin (Schotta G. et al. (2004) Genes & development
18: 1251-1262). There are two isoforms of SUV420H1, both of which
contain the conserved SET domain but differ at their C-termini, as
well as a closely related homolog, SUV420H2 (Tsang L. W. et al.
(2010) PloS one 5: e14447). SUV420H1 binds heterochromatin protein
1 (HP1) and this interaction functions to recruit SUV420H1 to
heterochromatin. SUV420H1 catalyzes the di-methylation of histone
H4 at lysine 20 (H4K20), which mediates a number of biological
processes, including DNA replication, DNA damage-induced stress
signaling, and the maintenance of pericentric and telomeric
heterochromatin (Schotta G. et al. (2004) Genes & development
18: 1251-1262; Benetti R. et al. (2007) The Journal of cell biology
178: 925-936; Schotta G. et al. (2008) Genes & development 22:
2048-2061; Beck D. B. et al. (2012) Genes & development 26:
2580-2589; Kuo A. J. et al. (2012) Nature 484: 115-119; Tuzon C. T.
et al. (2014) Cell reports 8: 430-438).
[0004] There is an increasing body of evidence indicating SUV420H1
plays a key role in cell growth and proliferation, and may be
associated with proliferative diseases such as cancers. SUV420H1
knockout animals show embryonic and perinatal lethality (Schotta G.
et al. (2008) Genes & development 22: 2048-2061). Furthermore,
SUV420H1-deficient cells show reduced proliferation rates and
growth arrest/senescence due to defects in DNA replication during S
phase (Schotta G. et al. (2008) Genes & development 22:
2048-2061). Mechanistically, these defects in DNA replication arise
from the lack of SUV420H1-dependent H4K20 dimethylation and
subsequent inhibition of replication origin licensing (Beck D. B.
et al. (2012) Genes & development 26: 2580-2589; Kuo A. J. et
al. (2012) Nature 484: 115-119). Indeed, proteins involved in
replication origin licensing have been pursued as targets for
cancer therapy (Lei M. (2005) Current cancer drug targets 5:
365-380; Zimmerman K. M. et al. (2013) Molecular cancer research:
MCR 11: 370-380). SUV420H1 is also important in regulating
non-homologous end joining processes during the DNA damage response
to double strand breaks (Schotta G. et al. (2008) Genes &
development 22: 2048-2061; Tuzon C. T. et al. (2014) Cell reports
8: 430-438). In particular, inhibition of non-homologous end
joining processes has been shown to sensitize pancreatic, breast,
cervical and colon cancer cells to DNA damaging agents (Zhao Y. et
al. (2006) Cancer research 66: 5354-5362; Chen X. et al. (2008)
Cancer research 68: 3169-3177; Li Y. H. et al. (2012) PloS one 7:
e39588).
[0005] Currently no small molecule inhibitors of SUV420H1 have been
reported. Accordingly, there is a need for novel compounds able to
inhibit SUV420H1.
SUMMARY OF THE INVENTION
[0006] In one aspect the invention provides for compounds of
formula (I)
##STR00002##
or a pharmaceutically acceptable salt thereof, wherein:
[0007] R.sup.1 is hydrogen, --C(O)(C.sub.1-C.sub.6 alkyl),
--(C.sub.1-C.sub.6 alkylenyl)-OH, --C(H)(benzyl)-NH.sub.2,
--C(H)(phenyl)-NH.sub.2, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.1AR.sup.1B, or --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.j)C(O)R.sup.1C;
[0008] R.sup.1A and R.sup.1B are each independently hydrogen,
C.sub.1-C.sub.6 haloalkyl, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.4
alkenyl, --(CH.sub.2).sub.m-G.sup.1A, --(C.sub.1-C.sub.6
alkylenyl)-L.sup.1A-X, or --(CH.sub.2).sub.n-G.sup.1A-L.sup.1B-G;
or
[0009] R.sup.1A and R.sup.1B together with the nitrogen atom to
which they are attached, form a C.sub.5-C.sub.6 heterocycloalkyl
which is optionally substituted with 1, 2, or 3 substituents
independently selected from the group consisting of C.sub.1-C.sub.6
haloalkyl, C.sub.1-C.sub.6 alkyl, and oxo;
[0010] R.sup.1C is C.sub.1-C.sub.6 haloalkyl, C.sub.1-C.sub.6
alkyl, C.sub.2-C.sub.4 alkenyl, --(CH.sub.2).sub.m-G.sup.1A,
--(C.sub.1-C.sub.6 alkylenyl)-L.sup.1A-X, or
--(CH.sub.2).sub.n-G.sup.1A-L.sup.1B-G;
[0011] G.sup.1A and G, at each occurrence, are each independently
phenyl, cycloalkyl, cycloalkenyl, heteroaryl, or heterocycle;
wherein each G.sup.1A and G is optionally substituted with 1, 2, or
3 independently selected R.sup.u;
[0012] L.sup.1A, at each occurrence, is independently O, N(H), or
C(O)O;
[0013] X, at each occurrence, is independently H, C.sub.1-C.sub.6
alkyl, or C.sub.1-C.sub.6 haloalkyl;
[0014] L.sup.1B, at each occurrence, is independently a bond,
--C.sub.1-C.sub.3 alkylenyl, 0, --O--C.sub.1-C.sub.3 alkylenyl-,
C(O), or --N(H)C(O)--;
[0015] m is 0, 1, or 2;
[0016] n is 0, 1, or 2;
[0017] R.sup.2 is hydrogen, halogen, C.sub.1-C.sub.6 alkyl,
C.sub.2-C.sub.4 alkenyl, or G.sup.2A; wherein G.sup.2A is
C.sub.3-C.sub.6 cycloalkyl, C.sub.5-C.sub.6 cycloalkenyl, phenyl,
or C.sub.5-C.sub.6 heteroaryl; and each G.sup.2A is optionally
substituted with 1, 2, or 3 independently selected R.sup.u
groups;
[0018] R.sup.3 is hydrogen, halogen, C.sub.1-C.sub.6 alkyl,
C.sub.2-C.sub.4 alkenyl, G.sup.3A, -G.sup.3A-G.sup.A, or
-G.sup.3A-L.sup.3-Y;
[0019] G.sup.3A, at each occurrence, is independently
C.sub.5-C.sub.6 cycloalkenyl, C.sub.3-C.sub.6 cycloalkyl, phenyl,
C.sub.5-C.sub.6 heteroaryl, heterocycle; wherein each G.sup.3A is
optionally substituted with 1, 2, or 3 independently selected
R.sup.u groups;
[0020] G.sup.A is C.sub.3-C.sub.6 cycloalkyl or C.sub.5-C.sub.6
heterocycloalkyl; each of which is optionally substituted with 1,
2, or 3 independently selected R.sup.u groups;
[0021] L.sup.3 is C.sub.1-C.sub.3 alkylenyl, C(O), or
--C(O)N(H)--;
[0022] Y is --(C.sub.1-C.sub.6 alkylenyl)-N(R.sup.j).sub.2,
C.sub.3-C.sub.6 cycloalkyl, or C.sub.5-C.sub.6 heterocycloalkyl,
wherein the C.sub.3-C.sub.6 cycloalkyl and the C.sub.5-C.sub.6
heterocycloalkyl are each optionally substituted with 1, 2, or 3
substituents independently selected from the group consisting of
C.sub.1-C.sub.3 alkyl, halogen, and C.sub.1-C.sub.3 haloalkyl;
[0023] R.sup.4 is hydrogen, halogen, or --(C.sub.1-C.sub.6
alkylenyl)-C(O)NR.sup.4AR.sup.4B; wherein R.sup.4A and R.sup.4B are
each independently hydrogen or C.sub.1-C.sub.6 alkyl;
[0024] R.sup.5 is hydrogen, halogen, C.sub.2-C.sub.4 alkenyl,
C.sub.1-C.sub.6 alkyl, or phenyl wherein the phenyl is optionally
substituted with 1, 2, or 3 independently selected R.sup.u
groups;
[0025] R.sup.6 is hydrogen, halogen, C.sub.1-C.sub.3 alkyl, or
cyclopropyl; wherein the cyclopropyl is optionally substituted with
1, 2, or 3 substituents independently selected from the group
consisting of halogen, C.sub.1-C.sub.3 alkyl, and C.sub.1-C.sub.3
haloalkyl;
[0026] R.sup.u, at each occurrence, is independently
C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6
alkynyl, halogen, C.sub.1-C.sub.6 haloalkyl, --CN, oxo, NO.sub.2,
--OR.sup.j, --OC(O)R.sup.k, --OC(O)N(R.sup.j).sub.2, --SR.sup.j,
--S(O).sub.2R.sup.j, --S(O).sub.2N(R.sup.j).sub.2, --C(O)R.sup.j,
--C(O)OR.sup.j, --C(O)N(R.sup.j).sub.2, --N(R.sup.j).sub.2,
--N(R.sup.j)C(O)R.sup.k, --N(R.sup.j)S(O).sub.2R.sup.k,
--N(R.sup.j)C(O)O(R.sup.k), --N(R.sup.j)C(O)N(R.sup.j).sub.2,
--(C.sub.1-C.sub.6 alkylenyl)-OR.sup.j, --(C.sub.1-C.sub.6
alkylenyl)-OC(O)R.sup.k, --(C.sub.1-C.sub.6
alkylenyl)-OC(O)N(R.sup.j).sub.2, --(C.sub.1-C.sub.6
alkylenyl)-SR.sup.j, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2R.sup.j, --(C.sub.1-C.sub.6
alkylenyl)-S(O).sub.2N(R.sup.j).sub.2, --(C.sub.1-C.sub.6
alkylenyl)-C(O)R.sup.j, --(C.sub.1-C.sub.6 alkylenyl)-C(O)OR.sup.j,
--(C.sub.1-C.sub.6 alkylenyl)-C(O)N(R.sup.j).sub.2,
--(C.sub.1-C.sub.6 alkylenyl)-N(R.sup.j).sub.2, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.j)C(O)R.sup.k, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.j)S(O).sub.2R.sup.k, --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.j)C(O)O(R.sup.k), --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.j)C(O)N(R.sup.j).sub.2, or --(C.sub.1-C.sub.6
alkylenyl)-CN;
[0027] R.sup.j, at each occurrence, is independently hydrogen,
C.sub.1-C.sub.6 alkyl, or C.sub.1-C.sub.6 haloalkyl; and
[0028] R.sup.k, at each occurrence, is independently
C.sub.1-C.sub.6 alkyl or C.sub.1-C.sub.6 haloalkyl.
[0029] Another aspect of the invention relates to pharmaceutical
compositions comprising compounds of the invention.
[0030] The compounds, compositions comprising the compounds, and
methods for making the compounds are further described herein.
[0031] These and other objects of the invention are described in
the following paragraphs. These objects should not be deemed to
narrow the scope of the invention.
DETAILED DESCRIPTION OF THE INVENTION
[0032] Described herein are compounds of formula (I)
##STR00003##
wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6
are defined above in the Summary of the Invention and below in the
Detailed Description. Further, compositions comprising such
compounds and methods for making such compounds are also
included.
[0033] Compounds included herein may contain one or more
variable(s) that occur more than one time in any substituent or in
the formulae herein. Definition of a variable on each occurrence is
independent of its definition at another occurrence. Further,
combinations of substituents are permissible only if such
combinations result in stable compounds. Stable compounds are
compounds, which may be isolated from a reaction mixture.
DEFINITIONS
[0034] It is noted that, as used in this specification and the
intended claims, the singular form "a," "an," and "the" include
plural referents unless the context clearly dictates otherwise.
Thus, for example, reference to "a compound" includes a single
compound as well as one or more of the same or different compounds,
reference to "optionally a pharmaceutically acceptable carrier"
refers to a single optional pharmaceutically acceptable carrier as
well as one or more pharmaceutically acceptable carriers, and the
like.
[0035] As used in the specification and the appended claims, unless
specified to the contrary, the following terms have the meaning
indicated:
[0036] The term "alkenyl" as used herein, means a straight or
branched hydrocarbon chain containing from 2 to 10 carbons and
containing at least one carbon-carbon double bond. The term
"C.sub.2-C.sub.6 alkenyl" or "C.sub.2-C.sub.4 alkenyl" means an
alkenyl group containing 2-6 carbon atoms or 2-4 carbon atoms
respectively. Non-limiting examples of alkenyl include
buta-1,3-dienyl, ethenyl, 2-propenyl, 2-methyl-2-propenyl,
3-butenyl, 4-pentenyl, and 5-hexenyl.
[0037] The term "alkyl" as used herein, means a saturated, straight
or branched hydrocarbon chain radical. In some instances, the
number of carbon atoms in an alkyl moiety is indicated by the
prefix "C.sub.x-C.sub.y", wherein x is the minimum and y is the
maximum number of carbon atoms in the substituent. Thus, for
example, "C.sub.1-C.sub.6 alkyl" means to an alkyl substituent
containing from 1 to 6 carbon atoms and "C.sub.1-C.sub.3 alkyl"
refers to an alkyl substituent containing from 1 to 3 carbon atoms.
Representative examples of C.sub.1-C.sub.6 alkyl include, but are
not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl,
sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl,
n-hexyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl,
3,3-dimethylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl,
2,2-dimethylpropyl, 1-methylpropyl, 2-methylpropyl, 1-ethylpropyl,
and 1,2,2-trimethylpropyl.
[0038] The term "alkylene" or "alkylenyl" means a divalent radical
derived from a straight or branched, saturated hydrocarbon chain,
for example, of 1 to 10 carbon atoms or of 1 to 6 carbon atoms
(C.sub.1-C.sub.6 alkylenyl) or of 1 to 4 carbon atoms or of 1 to 3
carbon atoms (C.sub.1-C.sub.3 alkylenyl) or of 2 to 6 carbon atoms
(C.sub.2-C.sub.6 alkylenyl). Examples of C.sub.1-C.sub.6 alkylenyl
include, but are not limited to, --CH.sub.2--,
--CH.sub.2CH.sub.2--,
--C((CH.sub.3).sub.2)--CH.sub.2CH.sub.2CH.sub.2--,
--C((CH.sub.3).sub.2)--CH.sub.2CH.sub.2,
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2--, and
--CH.sub.2CH(CH.sub.3)CH.sub.2--.
[0039] The term "C.sub.2-C.sub.6 alkynyl" as used herein, means a
straight or branched chain hydrocarbon radical containing from 2 to
6 carbon atoms and containing at least one carbon-carbon triple
bond. Representative examples of C.sub.2-C.sub.6 alkynyl include,
but are not limited, to acetylenyl, 1-propynyl, 2-propynyl,
3-butynyl, 2-pentynyl, and 1-butynyl.
[0040] The term "cycloalkyl" as used herein, refers to a radical
that is a monocyclic cycloalkyl or a bicyclic cycloalkyl. The
monocyclic cycloalkyl is a carbocyclic ring system containing three
to eight carbon atoms, zero heteroatoms and zero double bonds.
Examples of monocyclic cycloalkyl include cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. The bicyclic
cycloalkyl is a monocyclic cycloalkyl fused to a monocyclic
cycloalkyl ring. The monocyclic and the bicyclic cycloalkyl groups
may further contain one or two alkylene bridges, each consisting of
one, two, three, or four carbon atoms in length, and each bridge
links two non-adjacent carbon atoms of the ring system.
Non-limiting examples of bicyclic ring systems include
bicyclo[3.1.1]heptyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.2]octyl,
bicyclo[1.1.1]pentyl, bicyclo[3.2.2]nonyl, bicyclo[3.3.1]nonyl,
bicyclo[4.2.1]nonyl, tricyclo[3.3.1.0.sup.3,7]nonyl
(octahydro-2,5-methanopentalene or noradamantyl), and
tricyclo[3.3.1.1.sup.3,7]decane (adamantyl). The monocyclic and the
bicyclic cycloalkyls, including exemplary rings, are optionally
substituted. The monocyclic cycloalkyl and the bicyclic cycloalkyl
are attached to the parent molecular moiety through any
substitutable carbon atom contained within the ring systems.
[0041] The term "C.sub.3-C.sub.6 cycloalkyl" as used herein, means
cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl, each of which
is optionally substituted.
[0042] The term "cycloalkenyl" as used herein, refers to a
monocyclic or a bicyclic hydrocarbon ring radical. The monocyclic
cycloalkenyl has four-, five-, six-, seven- or eight carbon atoms
and zero heteroatoms. The four-membered ring systems have one
double bond, the five- or six-membered ring systems have one or two
double bonds, and the seven- or eight-membered ring systems have
one, two, or three double bonds. Representative examples of
monocyclic cycloalkenyl groups include, but are not limited to,
cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, and
cyclooctenyl. The bicyclic cycloalkenyl is a monocyclic
cycloalkenyl fused to a monocyclic cycloalkyl group, or a
monocyclic cycloalkenyl fused to a monocyclic cycloalkenyl group.
The monocyclic and bicyclic cycloalkenyl ring may further contain
one or two alkylene bridges, each consisting of one, two, or three
carbon atoms, and each linking two non-adjacent carbon atoms of the
ring system. Representative examples of the bicyclic cycloalkenyl
groups include, but are not limited to,
4,5,6,7-tetrahydro-3aH-indene, octahydronaphthalenyl, and
1,6-dihydro-pentalene. The monocyclic and the bicyclic
cycloalkenyls, including exemplary rings, are optionally
substituted. The monocyclic cycloalkenyl and bicyclic cycloalkenyl
are attached to the parent molecular moiety through any
substitutable atom contained within the ring systems.
[0043] The term "C.sub.5-C.sub.6 cycloalkenyl" as used herein,
means cyclopentenyl and cyclohexenyl; each of which is optionally
substituted.
[0044] The term "halo" or "halogen" as used herein, means Cl, Br,
I, and F.
[0045] The term "haloalkyl" as used herein, means an alkyl group,
as defined herein, in which one, two, three, four, five or six
hydrogen atoms are replaced by halogen. The term "C.sub.1-C.sub.6
haloalkyl" means a C.sub.1-C.sub.6 alkyl group, as defined herein,
in which one, two, three, four, five, or six hydrogen atoms are
replaced by halogen. The term "C.sub.1-C.sub.3 haloalkyl" means a
C.sub.1-C.sub.3 alkyl group, as defined herein, in which one, two,
three, four, or five hydrogen atoms are replaced by halogen.
Representative examples of C.sub.1-C.sub.6 haloalkyl include, but
are not limited to, chloromethyl, 2-fluoroethyl, 2,2-difluoroethyl,
fluoromethyl, 2,2,2-trifluoroethyl, trifluoromethyl,
difluoromethyl, pentafluoroethyl, 2-chloro-3-fluoropentyl,
trifluorobutyl, and trifluoropropyl.
[0046] The term "heterocycle" or "heterocyclic" as used herein,
means a radical of a monocyclic heterocycle and a bicyclic
heterocycle ring structure that may be saturated (i.e.
heterocycloalkyl) or partially saturated (i.e. heterocycloalkenyl).
A monocyclic heterocycle is a three-, four-, five-, six-, seven-,
or eight-membered carbocyclic ring wherein at least one carbon atom
is replaced by heteroatom independently selected from the group
consisting of O, N, and S. A three- or four-membered ring contains
zero or one double bond, and one heteroatom selected from the group
consisting of O, N, and S. A five-membered ring contains zero or
one double bond and one, two, or three heteroatoms selected from
the group consisting of O, N, and S. Examples of five-membered
heterocyclic rings include those containing in the ring: 1 O; 1 S;
1 N; 2 N; 3 N; 1 S and 1 N; 1 S, and 2 N; 1 O and 1 N; or 1 O and 2
N. Non limiting examples of 5-membered heterocyclic groups include
1,3-dioxolanyl, tetrahydrofuranyl, dihydrofuranyl,
tetrahydrothienyl, dihydrothienyl, imidazolidinyl, oxazolidinyl,
imidazolinyl, isoxazolidinyl, pyrazolidinyl, pyrazolinyl,
pyrrolidinyl, 2-pyrrolinyl, 3-pyrrolinyl, thiazolinyl, and
thiazolidinyl. A six-membered ring contains zero, one, or two
double bonds and one, two, or three heteroatoms selected from the
group consisting of O, N, and S. Examples of six-membered
heterocyclic rings include those containing in the ring: 1 O; 2 O;
1 S; 2 S; 1 N; 2 N; 3 N; 1 S, 1 O, and 1 N; 1 S and 1 N; 1 S and 2
N; 1 Sand 10; 1 S and 2 O; 1 O and 1 N; and 1 O and 2 N. Examples
of 6-membered heterocyclic groups include tetrahydropyranyl,
dioxanyl, 1,4-dithianyl, hexahydropyrimidine, morpholinyl,
piperazinyl, piperidinyl, 1,2,3,4-tetrahydropyridinyl,
1,2,3,6-tetrahydropyridinyl, tetrahydrothiopyranyl,
thiomorpholinyl, thioxanyl, and trithianyl. Seven- and
eight-membered rings contains zero, one, two, or three double bonds
and one, two, or three heteroatoms selected from the group
consisting of O, N, and S. Representative examples of monocyclic
heterocycles include, but are not limited to, azetidinyl, azepanyl,
aziridinyl, diazepanyl, dihydropyranyl, 1,3-dioxanyl,
1,3-dioxolanyl, 1,3-dithiolanyl, 1,3-dithianyl, imidazolinyl,
imidazolidinyl, isothiazolinyl, isothiazolidinyl, isoxazolinyl,
isoxazolidinyl, morpholinyl, oxadiazolinyl, oxadiazolidinyl,
oxazolinyl, oxazolidinyl, oxetanyl, piperazinyl, piperidinyl,
pyranyl, pyrazolinyl, pyrazolidinyl, pyrrolinyl, pyrrolidinyl,
tetrahydrofuranyl, tetrahydropyridinyl, tetrahydropyranyl,
tetrahydrothienyl, thiadiazolinyl, thiadiazolidinyl, thiazolinyl,
thiazolidinyl, thiomorpholinyl, thiopyranyl, and trithianyl. The
bicyclic heterocycle is a monocyclic heterocycle fused to a phenyl
group, or a monocyclic heterocycle fused to a monocyclic
cycloalkyl, or a monocyclic heterocycle fused to a monocyclic
cycloalkenyl, or a monocyclic heterocycle fused to a monocyclic
heterocycle. Representative examples of bicyclic heterocycles
include, but are not limited to, benzopyranyl, benzothiopyranyl,
2,3-dihydrobenzofuranyl, 2,3-dihydrobenzothienyl,
2,3-dihydro-1H-indolyl, 3,4-dihydroisoquinolin-2(1H)-yl,
2,3,4,6-tetrahydro-1H-pyrido[1,2-a]pyrazin-2-yl,
hexahydropyrano[3,4-b][1,4]oxazin-1(5H)-yl. The monocyclic
heterocycle and the bicyclic heterocycle may contain one or two
alkylene bridges, each consisting of no more than four carbon atoms
and each linking two non-adjacent atoms of the ring system.
Examples of such bridged heterocycle include, but are not limited
to, azabicyclo[2.2.1]heptyl (including
2-azabicyclo[2.2.1]hept-2-yl), 8-azabicyclo[3.2.1]oct-8-yl,
octahydro-2,5-epoxypentalene,
hexahydro-2H-2,5-methanocyclopenta[b]furan,
hexahydro-1H-1,4-methanocyclopenta[c]furan, aza-admantane
(1-azatricyclo[3.3.1.1.sup.3,7]decane), and oxa-adamantane
(2-oxatricyclo[3.3.1.1.sup.3,7]decane). The monocyclic and the
bicyclic heterocycles, including exemplary rings, are optionally
substituted. The monocyclic and the bicyclic heterocycles are
connected to the parent molecular moiety through any carbon atom or
any nitrogen atom contained within the ring systems. The nitrogen
and sulfur heteroatoms in the heterocycle rings may optionally be
oxidized (e.g. 1,1-dioxidotetrahydrothienyl,
1,1-dioxido-1,2-thiazolidinyl, 1,1-dioxidothiomorpholinyl)) and the
nitrogen atoms may optionally be quarternized.
[0047] The term "C.sub.4-C.sub.6 heterocycloalkyl" as used herein,
means a 4, 5, or 6 membered monocyclic heterocycloalkyl as defined
herein above. Examples of C.sub.4-C.sub.6 heterocycloalkyl include,
but are not limited to, azetidinyl, pyrrolidinyl,
tetrahydrofuranyl, tetrahydropyranyl, piperazinyl, piperidinyl,
thiomorpholinyl, and morpholinyl. The C.sub.4-C.sub.6
heterocycloalkyl, including exemplary rings, are optionally
substituted.
[0048] The term "C.sub.5-C.sub.6 heterocycloalkyl" as used herein,
means a 5 or 6 membered monocyclic heterocycloalkyl as defined
herein above. Examples of C.sub.5-C.sub.6 heterocycloalkyl include,
but are not limited to, pyrrolidinyl, tetrahydrofuranyl,
tetrahydropyranyl, piperazinyl, piperidinyl, thiomorpholinyl, and
morpholinyl. The C.sub.5-C.sub.6 heterocycloalkyl, including
exemplary rings, are optionally substituted.
[0049] The term "C.sub.5-C.sub.6 heterocycloalkenyl" as used
herein, means a 5 or 6 membered monocyclic heterocycloalkenyl as
defined herein above. Examples of C.sub.5-C.sub.6
heterocycloalkenyl include, but are not limited to, dihydropyranyl,
1,2,3,4-tetrahydropyridinyl, and 1,2,3,6-tetrahydropyridinyl. The
C.sub.5-C.sub.6 heterocycloalkenyl, including exemplary rings, are
optionally substituted.
[0050] The term "heteroaryl" as used herein, means a monocyclic
heteroaryl and a bicyclic heteroaryl. The monocyclic heteroaryl is
a five- or six-membered carbocyclic ring wherein at least one
carbon atom is replaced by heteroatom independently selected from
the group consisting of O, N, and S. The five-membered ring
contains two double bonds. The five-membered ring may contain one
heteroatom selected from O or S; or one, two, three, or four
nitrogen atoms and optionally further contain one oxygen or one
sulfur atom. The six-membered ring contains three double bonds and
one, two, three or four nitrogen atoms. Representative examples of
monocyclic heteroaryl include, but are not limited to, furanyl,
imidazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, 1,3-oxazolyl,
pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl,
pyrrolyl, tetrazolyl, thiadiazolyl, 1,3-thiazolyl, thienyl,
triazolyl, and triazinyl. The bicyclic heteroaryl consists of a
monocyclic heteroaryl fused to a phenyl, or a monocyclic heteroaryl
fused to a monocyclic cycloalkyl, or a monocyclic heteroaryl fused
to a monocyclic cycloalkenyl, or a monocyclic heteroaryl fused to a
monocyclic heteroaryl, or a monocyclic heteroaryl fused to a
monocyclic heterocycle. Representative examples of bicyclic
heteroaryls include, but are not limited to, benzofuranyl,
benzothienyl, benzoxazolyl, benzimidazolyl, benzoxadiazolyl,
benzothiazolyl, 1H-benzo[d][1,2,3]triazolyl, furo[3,2-b]pyridinyl,
phthalazinyl, benzo[d][1,2,3]thiadiazole,
3H-imidazo[4,5-b]pyridinyl, imidazo[1,2-a]pyridinyl,
1H-pyrrolo[3,2-b]pyridinyl, 1H-pyrrolo[2,3-b]pyridinyl,
1H-pyrazolo[3,4-b]pyridinyl, indazolyl, indolyl, isoindolyl,
isoxazolo[5,4-b]pyridinyl, isoquinolinyl, naphthyridinyl,
pyridoimidazolyl, quinolinyl, thieno[3,2-b]pyridinyl,
thiazolo[5,4-b]pyridin-2-yl, and thiazolo[5,4-d]pyrimidin-2-yl. The
monocyclic and bicyclic heteroaryls, including exemplary rings, are
optionally substituted unless otherwise indicated. The monocyclic
and bicyclic heteroaryls are connected to the parent molecular
moiety through any substitutable carbon atom or any substitutable
nitrogen atom contained within the ring systems. The nitrogen atom
in the heteroaryl rings may optionally be oxidized and may
optionally be quarternized.
[0051] The term "C.sub.5-C.sub.6 heteroaryl" as used herein, means
a 5- or 6-membered monocyclic heteroaryl as described above.
Examples of C.sub.5-C.sub.6 heteroaryl include furanyl, thienyl,
pyrazolyl, imidazolyl, 1,2,4-oxadiazolyl, 1,2,4-triazolyl,
1,3-thiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, and pyrazinyl.
The C.sub.5-C.sub.6 heteroaryls, including exemplary rings, are
optionally substituted.
[0052] The term "heteroatom" as used herein, means a nitrogen,
oxygen, and sulfur.
[0053] The term "oxo" as used herein, means a .dbd.O group.
[0054] The term "radiolabel" refers to a compound of the invention
in which at least one of the atoms is a radioactive atom or
radioactive isotope, wherein the radioactive atom or isotope
spontaneously emits gamma rays or energetic particles, for example
alpha particles or beta particles, or positrons. Examples of such
radioactive atoms include, but are not limited to, .sup.3H
(tritium), .sup.14C, .sup.11C, .sup.15O, .sup.18F, .sup.35S,
.sup.123I, and .sup.125I.
[0055] If a moiety is described as "substituted", a non-hydrogen
radical is in the place of hydrogen radical of any substitutable
atom of the moiety. Thus, for example, a substituted heterocycle
moiety is a heterocycle moiety in which at least one non-hydrogen
radical is in the place of a hydrogen radical on the heterocycle.
It should be recognized that if there are more than one
substitution on a moiety, each non-hydrogen radical may be
identical or different (unless otherwise stated).
[0056] If a moiety is described as being "optionally substituted,"
the moiety may be either (1) not substituted or (2) substituted. If
a moiety is described as being optionally substituted with up to a
particular number of non-hydrogen radicals, that moiety may be
either (1) not substituted; or (2) substituted by up to that
particular number of non-hydrogen radicals or by up to the maximum
number of substitutable positions on the moiety, whichever is less.
Thus, for example, if a moiety is described as a heteroaryl
optionally substituted with up to 3 non-hydrogen radicals, then any
heteroaryl with less than 3 substitutable positions would be
optionally substituted by up to only as many non-hydrogen radicals
as the heteroaryl has substitutable positions. To illustrate,
tetrazolyl (which has only one substitutable position) would be
optionally substituted with up to one non-hydrogen radical. To
illustrate further, if an amino nitrogen is described as being
optionally substituted with up to 2 non-hydrogen radicals, then a
primary amino nitrogen will be optionally substituted with up to 2
non-hydrogen radicals, whereas a secondary amino nitrogen will be
optionally substituted with up to only 1 non-hydrogen radical.
[0057] Unless otherwise indicated, the terms C.sub.1-C.sub.6 alkyl,
C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.6 haloalkyl, and
C.sub.1-C.sub.3 haloalkyl are not further substituted.
[0058] The terms "treat", "treating", and "treatment" refer to a
method of alleviating or abrogating a disease and/or its attendant
symptoms.
[0059] The terms "prevent", "preventing", and "prevention" refer to
a method of preventing the onset of a disease and/or its attendant
symptoms or barring a subject from acquiring a disease. As used
herein, "prevent", "preventing" and "prevention" also include
delaying the onset of a disease and/or its attendant symptoms and
reducing a subject's risk of acquiring a disease.
[0060] The phrase "therapeutically effective amount" means an
amount of a compound, or a pharmaceutically acceptable salt
thereof, sufficient to prevent the development of or to alleviate
to some extent one or more of the symptoms of the condition or
disorder being treated when administered alone or in conjunction
with another therapeutic agent or treatment in a particular subject
or subject population. For example in a human or other mammal, a
therapeutically effective amount may be determined experimentally
in a laboratory or clinical setting, or may be the amount required
by the guidelines of the United States Food and Drug
Administration, or equivalent foreign agency, for the particular
disease and subject being treated.
[0061] The term "subject" is defined herein to refer to animals
such as mammals, including, but not limited to, primates (e.g.,
humans), cows, sheep, goats, pigs, horses, dogs, cats, rabbits,
rats, mice and the like. In preferred embodiments, the subject is a
human.
Compounds
[0062] Compounds of the invention have the general formula (I) as
described above.
[0063] Particular values of variable groups are as follows. Such
values may be used where appropriate with any of the other values,
definitions, claims or embodiments defined hereinbefore or
hereinafter.
[0064] In certain embodiments, R.sup.1 is hydrogen,
--C(H)(benzyl)-NH.sub.2, --C(H)(phenyl)-NH.sub.2,
--(C.sub.1-C.sub.6 alkylenyl)-NR.sup.1AR.sup.1B, or
--(C.sub.1-C.sub.6 alkylenyl)-N(R.sup.j)C(O)R.sup.1C.
[0065] In certain embodiments, R.sup.1 is hydrogen.
[0066] In certain embodiments, R.sup.1 is --C(O)(C.sub.1-C.sub.6
alkyl), --(C.sub.1-C.sub.6 alkylenyl)-OH, --C(H)(benzyl)-NH.sub.2,
--C(H)(phenyl)-NH.sub.2, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.1AR.sup.1B, or --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.j)C(O)R.sup.1C.
[0067] In certain embodiments, R.sup.1 is --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.1AR.sup.1B or --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.j)C(O)R.sup.1C.
[0068] In certain embodiments, R.sup.1 is --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.1AR.sup.1B.
[0069] In certain embodiments, R.sup.1 is --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.j)C(O)R.sup.1C.
[0070] In certain embodiments, R.sup.2 is hydrogen.
[0071] In certain embodiments, R.sup.2 is halogen, C.sub.1-C.sub.6
alkyl, C.sub.2-C.sub.4 alkenyl, or G.sup.2A; wherein G.sup.2A is
C.sub.3-C.sub.6 cycloalkyl, C.sub.5-C.sub.6 cycloalkenyl, phenyl,
or C.sub.5-C.sub.6 heteroaryl; and each G.sup.2A is optionally
substituted. In some such embodiments, G.sup.2A is C.sub.5-C.sub.6
cycloalkenyl, phenyl, or C.sub.5-C.sub.6 heteroaryl; and each
G.sup.2A is optionally substituted. In some such embodiments,
G.sup.2A is phenyl, pyridinyl, pyrazolyl, or cyclopentenyl, each of
which is optionally substituted. In some such embodiments, G.sup.2A
is optionally substituted phenyl. In some such embodiments,
G.sup.2A is optionally substituted C.sub.5-C.sub.6 cycloalkenyl. In
some such embodiments, G.sup.2A is optionally substituted
cyclopentenyl. In some such embodiments, G.sup.2A is optionally
substituted C.sub.5-C.sub.6 heteroaryl. In some such embodiments,
G.sup.2A is pyridinyl or pyrazolyl, each of which is optionally
substituted.
[0072] In certain embodiments, R.sup.2 is Cl, CH.sub.3,
CH.sub.2CH.sub.3, ethenyl, prop-1-en-2-yl, or G.sup.2A; wherein
G.sup.2A is phenyl, pyridinyl, pyrazolyl, or cyclopentenyl, wherein
each G.sup.2A is optionally substituted.
[0073] In certain embodiments, R.sup.3 is hydrogen, halogen,
C.sub.2-C.sub.4 alkenyl, G.sup.3A, -G.sup.3A-G.sup.A, or
-G.sup.3A-L.sup.3-Y.
[0074] In certain embodiments, R.sup.3 is hydrogen.
[0075] In certain embodiments, R.sup.3 is halogen, C.sub.1-C.sub.6
alkyl, C.sub.2-C.sub.4 alkenyl, G.sup.3A, -G.sup.3A-G.sup.A, or
-G.sup.3A-L.sup.3-Y.
[0076] In certain embodiments, R.sup.3 is halogen, C.sub.2-C.sub.4
alkenyl, G.sup.3A, -G.sup.3A-G.sup.A, or -G.sup.3A-L.sup.3-Y.
[0077] In certain embodiments, R.sup.3 is halogen. In some such
embodiments, R.sup.3 is Cl.
[0078] In certain embodiments, R.sup.3 is C.sub.2-C.sub.4 alkenyl.
In some such embodiments, R.sup.3 is ethenyl.
[0079] In certain embodiments, R.sup.3 is G.sup.3A.
[0080] In certain embodiments, R.sup.3 is G.sup.3A wherein G.sup.3A
is cyclopentenyl, cyclohexenyl, cyclohexyl, dihydropyranyl,
tetrahydropyridinyl, piperidinyl, dihydrobenzofuranyl, indazolyl,
pyridinyl, pyrimidinyl, or phenyl; each of which is optionally
substituted.
[0081] In certain embodiments, R.sup.3 is G.sup.3A wherein G.sup.3A
is optionally substituted cyclohexenyl. In some such embodiments,
G.sup.3A is cyclohexenyl substituted with 1 or 2 halogen. In some
such embodiments, G.sup.3A is cyclohexenyl substituted with two
halogens wherein the halogens are F.
[0082] In certain embodiments, R.sup.3 is -G.sup.3A-G.sup.A or
-G.sup.3A-L.sup.3-Y.
[0083] In certain embodiments, R.sup.3 is -G.sup.3A-G.sup.A or
-G.sup.3A-L.sup.3-Y; wherein G.sup.3A is optionally substituted
phenyl, and G.sup.A is optionally substituted C.sub.5-C.sub.6
heterocyloalkyl.
[0084] In certain embodiments, R.sup.3 is -G.sup.3A-G.sup.A or
-G.sup.3A-L.sup.3-Y; wherein G.sup.3A is optionally substituted
phenyl, Y is --(C.sub.1-C.sub.6 alkylenyl)-N(R.sup.j).sub.2,
optionally substituted cyclopropyl, optionally substituted
morpholinyl, or optionally substituted piperidinyl, and G.sup.A is
optionally substituted morpholinyl.
[0085] In certain embodiments, R.sup.3 is -G.sup.3A-G.sup.A. In
some such embodiments, G.sup.3A is optionally substituted phenyl
and G.sup.A is optionally substituted C.sub.5-C.sub.6
heterocycloalkyl.
[0086] In certain embodiments, R.sup.3 is -G.sup.3A-L.sup.3-Y. In
some such embodiments, G.sup.3A is optionally substituted phenyl;
and L.sup.3 is --CH.sub.2--, C(O), or --C(O)N(H)--.
[0087] In certain embodiments, R.sup.4 is hydrogen.
[0088] In certain embodiments, R.sup.4 is halogen or
--(C.sub.1-C.sub.6 alkylenyl)-C(O)NR.sup.4AR.sup.4B. In some such
embodiments R.sup.4 is Br or --(C.sub.1-C.sub.2
alkylenyl)-C(O)NR.sup.4AR.sup.4B wherein R.sup.4A and R.sup.4B are
each independently hydrogen or C.sub.1-C.sub.3 alkyl.
[0089] In certain embodiments, R.sup.5 is hydrogen, halogen,
C.sub.2-C.sub.4 alkenyl, or optionally substituted phenyl.
[0090] In certain embodiments, R.sup.5 is hydrogen.
[0091] In certain embodiments, R.sup.5 is halogen, C.sub.2-C.sub.4
alkenyl, or optionally substituted phenyl.
[0092] In some such embodiments, R.sup.5 is Cl, ethenyl,
prop-1-en-2-yl, or optionally substituted phenyl.
[0093] In certain embodiments, R.sup.6 is hydrogen.
[0094] In certain embodiments, R.sup.6 is C.sub.1-C.sub.3 alkyl or
optionally substituted cyclopropyl. In some such embodiments,
R.sup.6 is CH.sub.3 or unsubstituted cyclopropyl.
[0095] Various embodiments of substituents R.sup.1, R.sup.2,
R.sup.3, R.sup.4, R.sup.5, and R.sup.6 have been discussed above.
These substituents embodiments may be combined to form various
embodiments of the invention. All embodiments of present compounds,
formed by combining the substituent embodiments discussed above are
within the scope of Applicant's invention, and some illustrative
embodiments of present compounds are provided below.
[0096] In one embodiment, the invention is directed to compounds of
formula (I) wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5,
and R.sup.6 are hydrogen.
[0097] In one embodiment, the invention is directed to compounds of
formula (I) wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5
are hydrogen, and R.sup.6 is hydrogen, C.sub.1-C.sub.3 alkyl, or
optionally substituted cyclopropyl. In some such embodiments,
R.sup.6 is hydrogen, CH.sub.3, or unsubstituted cyclopropyl.
[0098] In one embodiment, the invention is directed to compounds of
formula (I) wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5
are hydrogen.
[0099] In one embodiment, the invention is directed to compounds of
formula (I) wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5
are hydrogen, and R.sup.6 is C.sub.1-C.sub.3 alkyl or optionally
substituted cyclopropyl. In some such embodiments, R.sup.6 is
CH.sub.3 or unsubstituted cyclopropyl.
[0100] In one embodiment, the invention is directed to compounds of
formula (I) wherein R.sup.4, R.sup.5, and R.sup.6 are hydrogen.
[0101] In one embodiment, the invention is directed to compounds of
formula (I) wherein R.sup.1 is hydrogen, --C(H)(benzyl)-NH.sub.2,
--C(H)(phenyl)-NH.sub.2, --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.1AR.sup.1B, or --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.j)C(O)R.sup.1C.
[0102] In one embodiment, the invention is directed to compounds of
formula (I) wherein R.sup.1 is --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.1AR.sup.1B or --(C.sub.1-C.sub.6
alkylenyl)-N(R.sup.j)C(O)R.sup.1C.
[0103] In one embodiment, the invention is directed to compounds of
formula (I) wherein R.sup.3 is hydrogen, halogen, C.sub.2-C.sub.4
alkenyl, G.sup.3A, -G.sup.3A-G.sup.A, or -G.sup.3A-L.sup.3-Y.
[0104] In one embodiment, the invention is directed to compounds of
formula (I) wherein R.sup.3 is halogen.
[0105] In one embodiment, the invention is directed to compounds of
formula (I) wherein
[0106] R.sup.3 is halogen; and
[0107] R.sup.2, R.sup.4, R.sup.5, and R.sup.6 are hydrogen.
[0108] In one embodiment, the invention is directed to compounds of
formula (I) wherein
[0109] R.sup.3 is halogen;
[0110] R.sup.2, R.sup.4, R.sup.5, and R.sup.6 are hydrogen; and
[0111] R.sup.1 is --C(O)(C.sub.1-C.sub.6 alkyl), --(C.sub.1-C.sub.6
alkylenyl)-OH, --C(H)(benzyl)-NH.sub.2, --C(H)(phenyl)-NH.sub.2,
--(C.sub.1-C.sub.6 alkylenyl)-NR.sup.1AR.sup.1B, or
--(C.sub.1-C.sub.6 alkylenyl)-N(R.sup.j)C(O)R.sup.1C.
[0112] In one embodiment, the invention is directed to compounds of
formula (I) wherein
[0113] R.sup.3 is halogen;
[0114] R.sup.2, R.sup.4, R.sup.5, and R.sup.6 are hydrogen; and
[0115] R.sup.1 is --(C.sub.1-C.sub.6 alkylenyl)-NR.sup.1AR.sup.1B
or --(C.sub.1-C.sub.6 alkylenyl)-N(R.sup.j)C(O)R.sup.1C.
[0116] In one embodiment, the invention is directed to compounds of
formula (I) wherein R.sup.3 is G.sup.3A.
[0117] In one embodiment, the invention is directed to compounds of
formula (I) wherein
[0118] R.sup.3 is G.sup.3A; and
[0119] R.sup.2, R.sup.4, R.sup.5, and R.sup.6 are hydrogen.
[0120] In one embodiment, the invention is directed to compounds of
formula (I) wherein
[0121] R.sup.3 is G.sup.3A;
[0122] R.sup.2, R.sup.4, R.sup.5, and R.sup.6 are hydrogen; and
[0123] R.sup.1 is --(C.sub.1-C.sub.6 alkylenyl)-NR.sup.1AR.sup.1B
or --(C.sub.1-C.sub.6 alkylenyl)-N(R.sup.j)C(O)R.sup.1C.
[0124] In one embodiment, the invention is directed to compounds of
formula (I) wherein
[0125] R.sup.3 is G.sup.3A; wherein G.sup.3A is cyclohexenyl
optionally substituted with 1, 2, or 3 independently selected
R.sup.u;
[0126] R.sup.2, R.sup.4, R.sup.5, and R.sup.6 are hydrogen; and
[0127] R.sup.1 is --(CH.sub.2)--N(R.sup.j)C(O)R.sup.1C wherein
R.sup.1C is --(CH.sub.2).sub.m-G.sup.1A wherein m is 0 or 1.
[0128] In one embodiment, the invention is directed to compounds of
formula (I) wherein R.sup.3 is -G.sup.3A-G.sup.A.
[0129] In one embodiment, the invention is directed to compounds of
formula (I) wherein
[0130] R.sup.3 is -G.sup.3A-G.sup.A; and
[0131] R.sup.2, R.sup.4, R.sup.5, and R.sup.6 are hydrogen.
[0132] In one embodiment, the invention is directed to compounds of
formula (I) wherein
[0133] R.sup.3 is -G.sup.3A-G.sup.A;
[0134] R.sup.2, R.sup.4, R.sup.5, and R.sup.6 are hydrogen; and
[0135] R.sup.1 is --(C.sub.1-C.sub.6 alkylenyl)-NR.sup.1AR.sup.1B
or --(C.sub.1-C.sub.6 alkylenyl)-N(R.sup.j)C(O)R.sup.1C.
[0136] In one embodiment, the invention is directed to compounds of
formula (I) wherein
[0137] R.sup.3 is -G.sup.3A-G.sup.A;
[0138] R.sup.2, R.sup.4, R.sup.5, and R.sup.6 are hydrogen;
[0139] R.sup.1 is --(C.sub.1-C.sub.6 alkylenyl)-NR.sup.1AR.sup.1B
or --(C.sub.1-C.sub.6 alkylenyl)-N(R.sup.j)C(O)R.sup.1C; and
[0140] G.sup.3A is phenyl optionally substituted with 1, 2, or 3
independently selected R.sup.u; and
[0141] G.sup.A is C.sub.5-C.sub.6 heterocycloalkyl optionally
substituted with 1, 2, or 3 independently selected R.sup.u.
[0142] In one embodiment, the invention is directed to compounds of
formula (I) wherein R.sup.3 is -G.sup.3A-L.sup.3-Y.
[0143] In one embodiment, the invention is directed to compounds of
formula (I) wherein
[0144] R.sup.3 is -G.sup.3A-L.sup.3-Y; and
[0145] R.sup.2, R.sup.4, R.sup.5, and R.sup.6 are hydrogen.
[0146] In one embodiment, the invention is directed to compounds of
formula (I) wherein
[0147] R.sup.3 is -G.sup.3A-L.sup.3-Y;
[0148] R.sup.2, R.sup.4, R.sup.5, and R.sup.6 are hydrogen; and
[0149] R.sup.1 is --(C.sub.1-C.sub.6 alkylenyl)-NR.sup.1AR.sup.1B
or --(C.sub.1-C.sub.6 alkylenyl)-N(R.sup.j)C(O)R.sup.1C.
[0150] In one embodiment, the invention is directed to compounds of
formula (I) wherein
[0151] R.sup.3 is -G.sup.3A-L.sup.3-Y;
[0152] R.sup.2, R.sup.4, R.sup.5, and R.sup.6 are hydrogen;
[0153] R.sup.1 is --(C.sub.1-C.sub.6 alkylenyl)-NR.sup.1AR.sup.1B
or --(C.sub.1-C.sub.6 alkylenyl)-N(R.sup.j)C(O)R.sup.1C.
[0154] G.sup.3A is phenyl optionally substituted with 1, 2, or 3
independently selected R.sup.u groups; and
[0155] L.sup.3 is --CH.sub.2--, C(O), or --C(O)N(H)--.
[0156] In one embodiment, the invention is directed to compounds of
formula (I) wherein
[0157] R.sup.2 is hydrogen, halogen, C.sub.1-C.sub.6 alkyl,
C.sub.2-C.sub.4 alkenyl, or G.sup.2A; wherein G.sup.2A is
C.sub.5-C.sub.6 cycloalkenyl, phenyl, or C.sub.5-C.sub.6
heteroaryl; and each G.sup.2A is optionally substituted with 1, 2,
or 3 independently selected R.sup.u groups.
[0158] In one embodiment, the invention is directed to compounds of
formula (I) wherein
[0159] R.sup.2 is hydrogen, halogen, C.sub.1-C.sub.6 alkyl,
C.sub.2-C.sub.4 alkenyl, or G.sup.2A; wherein G.sup.2A is
C.sub.5-C.sub.6 cycloalkenyl, phenyl, or C.sub.5-C.sub.6
heteroaryl; and each G.sup.2A is optionally substituted with 1, 2,
or 3 independently selected R.sup.u groups; and
[0160] R.sup.3, R.sup.4, R.sup.5, and R.sup.6 are hydrogen.
[0161] In one embodiment, the invention is directed to compounds of
formula (I) wherein
[0162] R.sup.3, R.sup.4, R.sup.5, and R.sup.6 are hydrogen;
[0163] R.sup.2 is hydrogen, halogen, C.sub.1-C.sub.6 alkyl,
C.sub.2-C.sub.4 alkenyl, or G.sup.2A; wherein G.sup.2A is
C.sub.5-C.sub.6 cycloalkenyl, phenyl, or C.sub.5-C.sub.6
heteroaryl; and each G.sup.2A is optionally substituted with 1, 2,
or 3 independently selected R.sup.u groups; and
[0164] R.sup.1 is --(C.sub.1-C.sub.6 alkylenyl)-NR.sup.1AR.sup.1B
or --(C.sub.1-C.sub.6 alkylenyl)-N(R.sup.j)C(O)R.sup.1C.
[0165] In one embodiment, the invention is directed to compounds of
formula (I) wherein
[0166] R.sup.2, R.sup.3, R.sup.4, and R.sup.6 are hydrogen; and
[0167] R.sup.5 is hydrogen, halogen, C.sub.2-C.sub.4 alkenyl, or
phenyl wherein the phenyl is optionally substituted with 1, 2, or 3
independently selected R.sup.u groups.
[0168] In one embodiment, the invention is directed to compounds of
formula (I) wherein
[0169] R.sup.2, R.sup.3, R.sup.4, and R.sup.6 are hydrogen;
[0170] R.sup.5 is hydrogen, halogen, C.sub.2-C.sub.4 alkenyl, or
phenyl wherein the phenyl is optionally substituted with 1, 2, or 3
independently selected R.sup.u groups; and
[0171] R.sup.1 is --(C.sub.1-C.sub.6
alkylenyl)-NR.sup.1AR.sup.1B.
[0172] Exemplary compounds of formula (I) include, but are not
limited to: [0173]
9-[(3-bromo-1H-indol-7-yl)methyl]-9H-purin-6-amine; [0174]
9-(1H-indol-7-ylmethyl)-2-methyl-9H-purin-6-amine; [0175]
9-(1H-indol-7-ylmethyl)-9H-purin-6-amine; [0176]
2-cyclopropyl-9-(1H-indol-7-ylmethyl)-9H-purin-6-amine; [0177]
{7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methanol;
[0178] 9-{[2-(aminomethyl)-1H-indol-7-yl]methyl}-9H-purin-6-amine;
[0179]
9-{[2-(aminomethyl)-5-chloro-1H-indol-7-yl]methyl}-9H-purin-6-amine;
[0180]
9-{[2-(aminomethyl)-5-ethenyl-1H-indol-7-yl]methyl}-9H-purin-6-ami-
ne; [0181]
9-{[2-(aminomethyl)-5-(cyclopent-1-en-1-yl)-1H-indol-7-yl]methy-
l}-9H-purin-6-amine; [0182]
9-{[2-(aminomethyl)-5-(3,6-dihydro-2H-pyran-4-yl)-1H-indol-7-yl]methyl}-9-
H-purin-6-amine; [0183]
9-{[2-(aminomethyl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-7-yl]meth-
yl}-9H-purin-6-amine; [0184]
9-{[2-(aminomethyl)-5-(4,4-difluorocyclohex-1-en-1-yl)-1H-indol-7-yl]meth-
yl}-9H-purin-6-amine; [0185]
1-[4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}-3,-
6-dihydropyridin-1(2H)-yl]ethanone; [0186]
1-[5-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}-3,-
6-dihydropyridin-1(2H)-yl]ethanone; [0187]
1-(4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}pip-
eridin-1-yl)ethanone; [0188]
9-{[2-(aminomethyl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-indol-7-yl]methyl}-9H-
-purin-6-amine; [0189]
9-{[2-(aminomethyl)-5-(pyrimidin-5-yl)-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine; [0190]
9-{[2-(aminomethyl)-5-(pyridin-3-yl)-1H-indol-7-yl]methyl}-9H-purin-6-ami-
ne; [0191]
9-{[2-(aminomethyl)-5-(pyridin-4-yl)-1H-indol-7-yl]methyl}-9H-p-
urin-6-amine; [0192]
9-{[2-(aminomethyl)-5-phenyl-1H-indol-7-yl]methyl}-9H-purin-6-amine;
[0193]
9-{[2-(aminomethyl)-5-(4-chlorophenyl)-1H-indol-7-yl]methyl}-9H-pu-
rin-6-amine; [0194]
9-{[2-(aminomethyl)-5-(3-chlorophenyl)-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine; [0195]
9-{[2-(aminomethyl)-5-(2-chlorophenyl)-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine; [0196]
9-{[2-(aminomethyl)-5-(4-fluorophenyl)-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine; [0197]
9-{[2-(aminomethyl)-5-(2-fluorophenyl)-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine; [0198]
9-{[2-(aminomethyl)-5-(6-methoxypyridin-3-yl)-1H-indol-7-yl]methyl}-9H-pu-
rin-6-amine; [0199]
4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}benzen-
esulfonamide; [0200]
9-{[2-(aminomethyl)-5-(4-methylphenyl)-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine; [0201]
9-{[2-(aminomethyl)-5-(3-methylphenyl)-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine; [0202]
9-{[2-(aminomethyl)-5-(2-methylphenyl)-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine; [0203]
(4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}pheny-
l)methanol; [0204]
9-{[2-(aminomethyl)-5-(4-methoxyphenyl)-1H-indol-7-yl]methyl}-9H-purin-6--
amine; [0205]
9-{[2-(aminomethyl)-5-(3-methoxyphenyl)-1H-indol-7-yl]methyl}-9H-purin-6--
amine; [0206]
9-{[2-(aminomethyl)-5-(2-methoxyphenyl)-1H-indol-7-yl]methyl}-9H-purin-6--
amine; [0207]
9-({2-(aminomethyl)-5-[4-(methylsulfonyl)phenyl]-1H-indol-7-yl}methyl)-9H-
-purin-6-amine; [0208]
4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}benzon-
itrile; [0209]
3-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}benzon-
itrile; [0210]
3-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}benzam-
ide; [0211]
N-(4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}phe-
nyl)methanesulfonamide; [0212]
N-(3-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}phe-
nyl)methanesulfonamide; [0213]
9-{[2-(aminomethyl)-5-(4-ethylphenyl)-1H-indol-7-yl]methyl}-9H-purin-6-am-
ine; [0214] methyl
4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}benzoa-
te; [0215]
(4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol--
5-yl}phenyl)acetonitrile; [0216]
3-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}-N-eth-
ylbenzamide; [0217]
4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}-N,N-d-
imethylbenzamide; [0218]
3-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}-N,N-d-
imethylbenzamide; [0219]
4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}-N-[2--
(dimethylamino)ethyl]benzamide; [0220]
4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}-N-cyc-
lopropylbenzamide; [0221]
3-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}-N-cyc-
lopropylbenzamide; [0222]
9-({2-(aminomethyl)-5-[3-(morpholin-4-yl)phenyl]-1H-indol-7-yl}methyl)-9H-
-purin-6-amine; [0223]
(3-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}pheny-
l)(morpholin-4-yl)methanone; [0224]
9-{[2-(aminomethyl)-5-{4-[(4-methylpiperazin-1-yl)methyl]phenyl}-1H-indol-
-7-yl]methyl}-9H-purin-6-amine; [0225]
9-{[2-(aminomethyl)-5-{3-[(4-methylpiperazin-1-yl)methyl]phenyl})-1H-indo-
l-7-yl]methyl}-9H-purin-6-amine; [0226]
(4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}pheny-
l)(4-methylpiperazin-1-yl)methanone; [0227]
9-{[2-(aminomethyl)-5-(2,3-dihydro-1-benzofuran-5-yl)-1H-indol-7-yl]methy-
l}-9H-purin-6-amine; [0228]
9-{[2-(aminomethyl)-6-chloro-1H-indol-7-yl]methyl}-9H-purin-6-amine;
[0229]
9-{[2-(aminomethyl)-6-ethenyl-1H-indol-7-yl]methyl}-9H-purin-6-ami-
ne; [0230]
9-{[2-(aminomethyl)-6-(prop-1-en-2-yl)-1H-indol-7-yl]methyl}-9H-
-purin-6-amine; [0231]
9-{[2-(aminomethyl)-6-phenyl-1H-indol-7-yl]methyl}-9H-purin-6-amine;
[0232]
9-{[2-(aminomethyl)-4-chloro-1H-indol-7-yl]methyl}-9H-purin-6-amin-
e; [0233]
9-{[2-(aminomethyl)-4-ethenyl-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine; [0234]
9-{[2-(aminomethyl)-4-ethyl-1H-indol-7-yl]methyl}-9H-purin-6-amine;
[0235]
9-{[2-(aminomethyl)-4-(prop-1-en-2-yl)-1H-indol-7-yl]methyl}-9H-pu-
rin-6-amine; [0236]
9-{[2-(aminomethyl)-4-(propan-2-yl)-1H-indol-7-yl]methyl}-9H-purin-6-amin-
e; [0237]
9-{[2-(aminomethyl)-4-(cyclopent-1-en-1-yl)-1H-indol-7-yl]methyl-
}-9H-purin-6-amine; [0238]
9-{[2-(aminomethyl)-4-(1-methyl-1H-pyrazol-4-yl)-1H-indol-7-yl]methyl}-9H-
-purin-6-amine; [0239]
9-{[2-(aminomethyl)-4-(pyridin-3-yl)-1H-indol-7-yl]methyl}-9H-purin-6-ami-
ne; [0240]
9-{[2-(aminomethyl)-4-phenyl-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine; [0241]
9-{[2-(aminomethyl)-4-(3-chlorophenyl)-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine; [0242]
9-{[2-(aminomethyl)-4-(2-chlorophenyl)-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine; [0243]
9-{[2-(aminomethyl)-4-(4-fluorophenyl)-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine; [0244]
9-{[2-(aminomethyl)-4-(2-fluorophenyl)-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine; [0245]
9-{[2-(aminomethyl)-4-(4-methylphenyl)-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine; [0246]
9-{[2-(aminomethyl)-4-(3-methylphenyl)-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine; [0247]
9-{[2-(aminomethyl)-4-(2-methylphenyl)-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine; [0248]
9-{[2-(aminomethyl)-4-(4-methoxyphenyl)-1H-indol-7-yl]methyl}-9H-purin-6--
amine; [0249]
9-{[2-(aminomethyl)-4-(3-methoxyphenyl)-1H-indol-7-yl]methyl}-9H-purin-6--
amine; [0250]
9-{[2-(aminomethyl)-4-(2-methoxyphenyl)-1H-indol-7-yl]methyl}-9H-purin-6--
amine; [0251]
9-({2-(aminomethyl)-4-[4-(methylsulfonyl)phenyl]-1H-indol-7-yl}methyl)-9H-
-purin-6-amine; [0252]
4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-4-yl}benzon-
itrile; [0253]
3-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-4-yl}benzon-
itrile; [0254]
3-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-4-yl}benzam-
ide; [0255]
N-(4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-4-yl}phe-
nyl)methanesulfonamide; [0256]
4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-4-yl}-N,N-d-
imethylbenzamide; [0257]
1-{7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}ethanone;
[0258]
9-{[2-(1-aminoethyl)-5-chloro-1H-indol-7-yl]methyl}-9H-purin-6-ami-
ne; [0259]
9-({5-chloro-2-[(methylamino)methyl]-1H-indol-7-yl}methyl)-9H-p-
urin-6-amine; [0260]
1-{7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}propan-1-one;
[0261]
9-{[2-(1-aminopropyl)-5-chloro-1H-indol-7-yl]methyl}-9H-purin-6-am-
ine; [0262]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)aceta-
mide; [0263]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)prop--
2-enamide; [0264]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)propa-
namide; [0265]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-me-
thoxyacetamide; [0266]
3-[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)amin-
o]propanoic acid; [0267] 9-({5-chloro-2-[(diethyl
amino)methyl]-1H-indol-7-yl}methyl)-9H-purin-6-amine; [0268]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)butan-
amide; [0269]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-me-
thylpropanamide; [0270]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-me-
thoxypropanamide; [0271]
2,2'-[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)i-
mino]diacetic acid; [0272]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-me-
thylbutanamide; [0273]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-hy-
droxy-3-methylbutanamide; [0274]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3,3--
dimethylbutanamide; [0275]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-me-
thylpentanamide; [0276] tert-butyl
[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)amino]-
acetate; [0277]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)cyclo-
propanecarboxamide; [0278]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-me-
thylcyclopropanecarboxamide; [0279]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-me-
thylcyclopropanecarboxamide; [0280]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-cy-
clopropylacetamide; [0281]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)cyclo-
butanecarboxamide; [0282]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-hy-
droxycyclobutanecarboxamide; [0283]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)tetra-
hydrofuran-2-carboxamide; [0284]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)tetra-
hydrofuran-3-carboxamide; [0285]
(2S)--N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl-
)pyrrolidine-2-carboxamide; [0286]
(2R)--N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl-
)pyrrolidine-2-carboxamide; [0287] (2
S)--N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)--
5-oxopyrrolidine-2-carboxamide; [0288]
(2R)--N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl-
)-5-oxopyrrolidine-2-carboxamide; [0289]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)cyclo-
pentanecarboxamide; [0290]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(p-
yrrolidin-1-yl)acetamide; [0291]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-cy-
clopentylacetamide; [0292]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-(p-
yrrolidin-1-yl)propanamide; [0293] tert-butyl
(2S)-2-[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl-
)carbamoyl]pyrrolidine-1-carboxylate; [0294] tert-butyl
(2R)-2-[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl-
)carbamoyl]pyrrolidine-1-carboxylate; [0295]
9-({5-chloro-2-[(1,1-dioxidothiomorpholin-4-yl)methyl]-1H-indol-7-yl}meth-
yl)-9H-purin-6-amine; [0296]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)tetra-
hydro-2H-pyran-4-carboxamide; [0297]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(m-
orpholin-4-yl)acetamide; [0298]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)cyclo-
hexanecarboxamide; [0299]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-me-
thylcyclohexanecarboxamide; [0300]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-me-
thylcyclohexanecarboxamide; [0301]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-me-
thylcyclohexanecarboxamide; [0302]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-me-
thylcyclohexanecarboxamide; [0303]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-cy-
clohexylacetamide; [0304]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-me-
thoxycyclohexanecarboxamide; [0305]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-(p-
iperidin-1-yl)propanamide; [0306]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)tricy-
clo[3.3.1.1.sup.3,7]decane-1-carboxamide; [0307]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,2--
thiazole-5-carboxamide; [0308]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,3--
thiazole-5-carboxamide; [0309]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,2--
thiazole-4-carboxamide; [0310]
N-({7-[(6-amino-9H-purin-9-yl)methyl)methyl]-5-chloro-1H-indol-2-yl}methy-
l)-1,3-thiazole-4-carboxamide; [0311]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,2--
oxazole-4-carboxamide; [0312]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-p-
yrazole-5-carboxamide; [0313]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-p-
yrazole-4-carboxamide; [0314]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)thiop-
hene-2-carboxamide; [0315]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)thiop-
hene-3-carboxamide; [0316]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-p-
yrrole-2-carboxamide; [0317]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-5-me-
thyl-1,3-thiazole-4-carboxamide; [0318]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-me-
thyl-1,3-thiazole-5-carboxamide; [0319]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-5-me-
thyl-1,2-oxazole-4-carboxamide; [0320]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-me-
thyl-1,2-oxazole-4-carboxamide; [0321]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-me-
thyl-1H-pyrazole-3-carboxamide; [0322]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-me-
thyl-1H-pyrazole-5-carboxamide; [0323]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-me-
thyl-1H-imidazole-5-carboxamide; [0324]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-me-
thyl-1H-imidazole-2-carboxamide; [0325]
5-amino-N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}meth-
yl)-3-methyl-1,2-oxazole-4-carboxamide; [0326]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-me-
thylthiophene-3-carboxamide; [0327]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-me-
thylthiophene-2-carboxamide; [0328]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-me-
thoxythiophene-3-carboxamide; [0329]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-me-
thoxythiophene-2-carboxamide;
[0330]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methy-
l)-1-methyl-1H-pyrrole-2-carboxamide; [0331]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2,4--
dimethyl-1,3-thiazole-5-carboxamide; [0332]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3,5--
dimethyl-1,2-oxazole-4-carboxamide; [0333]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(1,2,5,6-tetrahydropyridin-3-yl)--
1H-indol-2-yl}methyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide;
[0334]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-phenyl-1H-indol-2-yl}methyl)-3,5--
dimethyl-1,2-oxazole-4-carboxamide; [0335]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4-fluorophenyl)-1H-indol-2-yl}me-
thyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide; [0336]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4-sulfamoylphenyl)-1H-indol-2-yl-
}methyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide; [0337]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4-methylphenyl)-1H-indol-2-yl}me-
thyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide; [0338]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4-methoxyphenyl)-1H-indol-2-yl}m-
ethyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide; [0339]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(3-methoxyphenyl)-1H-indol-2-yl}m-
ethyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide; [0340]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-[4-(methylsulfonyl)phenyl]-1H-ind-
ol-2-yl}methyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide; [0341]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4-cyanophenyl)-1H-indol-2-yl}met-
hyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide; [0342]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(3-cyanophenyl)-1H-indol-2-yl}met-
hyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide; [0343]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(3-carbamoylphenyl)-1H-indol-2-yl-
}methyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide; [0344]
N-[(7-[(6-amino-9H-purin-9-yl)methyl]-5-{4-[(methyl
sulfonyl)amino]phenyl}-1H-indol-2-yl)methyl]-3,5-dimethyl-1,2-oxazole-4-c-
arboxamide; [0345]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-[4-(cyanomethyl)phenyl]-1H-indol--
2-yl}methyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide; [0346]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-[4-(dimethylcarbamoyl)phenyl]-1H--
indol-2-yl}methyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide; [0347]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-[3-(dimethylcarbamoyl)phenyl]-1H--
indol-2-yl}methyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide; [0348]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-[3-(cyclopropylcarbamoyl)phenyl]--
1H-indol-2-yl}methyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide;
[0349]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-[3-(morpholin-4-yl)phenyl]-1H-ind-
ol-2-yl}methyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide; [0350]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-[3-(morpholin-4-ylcarbonyl)phenyl-
]-1H-indol-2-yl}methyl)-3, 5-dimethyl-1,2-oxazole-4-carboxamide;
[0351]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-5-et-
hyl-1,2-oxazole-4-carboxamide; [0352]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,5--
dimethyl-1H-pyrazole-3-carboxamide; [0353]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,3--
dimethyl-1H-pyrazole-5-carboxamide; [0354]
N-({7-[(6-amino-9H-purin-9-yl)methyl)methyl]-5-chloro-1H-indol-2-yl}methy-
l)-1,3-dimethyl-1H-pyrazole-4-carboxamide; [0355]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-5-et-
hyl-3-methyl-1,2-oxazole-4-carboxamide; [0356]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-et-
hyl-5-methyl-1,2-oxazole-4-carboxamide; [0357]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-5-(p-
ropan-2-yl)-1,2-oxazole-4-carboxamide; [0358]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-et-
hyl-3,5-dimethyl-1H-pyrazole-4-carboxamide; [0359]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-5-cy-
clopropyl-1,2-oxazole-4-carboxamide; [0360]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-5-cy-
clopropyl-3-methyl-1,2-oxazole-4-carboxamide; [0361]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-me-
thyl-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carboxamide; [0362]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4,5,-
6,7-tetrahydropyrazolo[1,5-a]pyridine-3-carboxamide; [0363]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)pyraz-
ine-2-carboxamide; [0364]
9-({2-[amino(phenyl)methyl]-5-chloro-1H-indol-7-yl}methyl)-9H-purin-6-ami-
ne; [0365]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}me-
thyl)pyridine-2-carboxamide; [0366]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)pyrid-
ine-3-carboxamide; [0367]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-6-hy-
droxypyridine-2-carboxamide; [0368]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-ox-
o-1,2-dihydropyridine-3-carboxamide; [0369]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-me-
thylpyridazine-4-carboxamide; [0370]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(1,2,3,6-tetrahydropyridin-4-yl)--
1H-indol-2-yl}methyl)-3-methylpyridazine-4-carboxamide; [0371]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4,4-difluorocyclohex-1-en-1-yl)--
1H-indol-2-yl}methyl)-3-methylpyridazine-4-carboxamide; [0372]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-[1-(methylsulfonyl)-1,2,3,6-tetra-
hydropyridin-4-yl]-1H-indol-2-yl}methyl)-3-methylpyridazine-4-carboxamide;
[0373]
N-({5-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-7-[(6-amino-9H-pur-
in-9-yl)methyl]-1H-indol-2-yl}methyl)-3-methylpyridazine-4-carboxamide;
[0374] tert-butyl
4-{7-[(6-amino-9H-purin-9-yl)methyl]-2-({[(3-methylpyridazin-4-yl)carbony-
l]amino}methyl)-1H-indol-5-yl}-3,6-dihydropyridine-1(2H)-carboxylate;
[0375]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methy-
l)-5-methylpyrazine-2-carboxamide; [0376]
9-{[2-(1-amino-2-phenylethyl)-5-chloro-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine; [0377]
9-({2-[(benzylamino)methyl]-5-chloro-1H-indol-7-yl}methyl)-9H-purin-6-ami-
ne; [0378]
9-[(2-{[(2-bromobenzyl)amino]methyl}-5-chloro-1H-indol-7-yl)met-
hyl]-9H-purin-6-amine; [0379]
9-[(5-chloro-2-{[(3-chlorobenzyl)amino]methyl}-1H-indol-7-yl)methyl]-9H-p-
urin-6-amine; [0380]
9-[(5-chloro-2-{[(2-chlorobenzyl)amino]methyl}-1H-indol-7-yl)methyl]-9H-p-
urin-6-amine; [0381]
9-[(5-chloro-2-{[(2,6-dichlorobenzyl)amino]methyl}-1H-indol-7-yl)methyl]--
9H-purin-6-amine; [0382]
9-[(5-chloro-2-{[(3,5-dichlorobenzyl)amino]methyl}-1H-indol-7-yl)methyl]--
9H-purin-6-amine; [0383]
9-[(5-chloro-2-{[(3,4-dichlorobenzyl)amino]methyl}-1H-indol-7-yl)methyl]--
9H-purin-6-amine; [0384]
9-[(5-chloro-2-{[(2-fluorobenzyl)amino]methyl}-1H-indol-7-yl)methyl]-9H-p-
urin-6-amine; [0385]
9-[(5-chloro-2-{[(2-chloro-6-fluorobenzyl)amino]methyl}-1H-indol-7-yl)met-
hyl]-9H-purin-6-amine; [0386]
9-[(5-chloro-2-{[(3-chloro-5-fluorobenzyl)amino]methyl}-1H-indol-7-yl)met-
hyl]-9H-purin-6-amine; [0387]
9-[(5-chloro-2-{[(2-chloro-5-fluorobenzyl)amino]methyl}-1H-indol-7-yl)met-
hyl]-9H-purin-6-amine; [0388]
9-[(5-chloro-2-{[(3-chloro-2-fluorobenzyl)amino]methyl}-1H-indol-7-yl)met-
hyl]-9H-purin-6-amine; [0389]
9-[(5-chloro-2-{[(2,6-difluorobenzyl)amino]methyl}-1H-indol-7-yl)methyl]--
9H-purin-6-amine; [0390]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)benza-
mide; [0391]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-ch-
lorobenzamide; [0392]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-ch-
lorobenzamide; [0393]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-fl-
uorobenzamide; [0394]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-fl-
uorobenzamide; [0395]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-fl-
uorobenzamide; [0396]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-br-
omo-6-fluorobenzamide; [0397]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-ch-
loro-6-fluorobenzamide; [0398]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2,6--
difluorobenzamide; [0399]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-fl-
uoro-6-hydroxybenzamide; [0400]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(p-
yridin-2-yl)acetamide; [0401]
N-({7-[(6-amino-9H-purin-9-yl)methyl)methyl]-5-chloro-1H-indol-2-yl}methy-
l)-2-(pyridin-3-yl)acetamide; [0402]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(p-
yridin-4-yl)acetamide; [0403]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-me-
thylpyridine-3-carboxamide; [0404]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3,6--
dimethylpyridazine-4-carboxamide; [0405]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(1,2,3,6-tetrahydropyridin-4-yl)--
1H-indol-2-yl}methyl)-3,6-dimethylpyridazine-4-carboxamide; [0406]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4,4-difluorocyclohex-1-en-1-yl)--
1H-indol-2-yl}methyl)-3,6-dimethylpyridazine-4-carboxamide; [0407]
N-({5-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-7-[(6-amino-9H-purin-9-yl-
)methyl]-1H-indol-2-yl}methyl)-3,6-dimethylpyridazine-4-carboxamide;
[0408]
N-({5-(1-acetyl-1,4,5,6-tetrahydropyridin-3-yl)-7-[(6-amino-9H-pur-
in-9-yl)methyl]-1H-indol-2-yl}methyl)-3,6-dimethylpyridazine-4-carboxamide-
; [0409]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-4-chloro-1H-indol-2-yl}meth-
yl)-3,6-dimethylpyridazine-4-carboxamide; [0410]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-6-cy-
anopyridine-3-carboxamide; [0411]
9-[(5-chloro-2-{[(4-methylbenzyl)amino]methyl}-1H-indol-7-yl)methyl]-9H-p-
urin-6-amine; [0412]
9-[(5-chloro-2-{[(2-methylbenzyl)amino]methyl})-1H-indol-7-yl)methyl]-9H--
purin-6-amine; [0413]
9-[(5-chloro-2-{[(2-chloro-6-methylbenzyl)amino]methyl}-1H-indol-7-yl)met-
hyl]-9H-purin-6-amine; [0414]
9-[(5-chloro-2-{[(2-fluoro-6-methylbenzyl)amino]methyl}-1H-indol-7-yl)met-
hyl]-9H-purin-6-amine; [0415]
9-[(5-chloro-2-{[(2-fluoro-3-methylbenzyl)amino]methyl}-1H-indol-7-yl)met-
hyl]-9H-purin-6-amine; [0416]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-me-
thylbenzamide; [0417]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-me-
thylbenzamide; [0418]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-me-
thylbenzamide; [0419]
9-[(5-chloro-2-{[(3-methoxybenzyl)amino]methyl})-1H-indol-7-yl)methyl]-9H-
-purin-6-amine; [0420]
9-[(5-chloro-2-{[(2-methoxybenzyl)amino]methyl}-1H-indol-7-yl)methyl]-9H--
purin-6-amine; [0421]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(4-
-chlorophenyl)acetamide; [0422]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(3-
-chlorophenyl)acetamide; [0423]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(2-
-chlorophenyl)acetamide; [0424]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(4-
-fluorophenyl)acetamide; [0425]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(3-
-fluorophenyl)acetamide; [0426]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(2-
-fluorophenyl)acetamide; [0427]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(t-
rifluoromethyl)benzamide; [0428]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-me-
thoxybenzamide; [0429]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-me-
thoxybenzamide; [0430]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-me-
thoxybenzamide; [0431]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(d-
ifluoromethoxy)benzamide; [0432]
9-{[5-chloro-2-({[3-(methylsulfonyl)benzyl]amino}methyl)-1H-indol-7-yl]me-
thyl}-9H-purin-6-amine; [0433]
9-{[5-chloro-2-({[4-fluoro-3-(methylsulfonyl)benzyl]amino}methyl)-1H-indo-
l-7-yl]methyl}-9H-purin-6-amine; [0434]
9-{[5-chloro-2-({[3-fluoro-4-(methylsulfonyl)benzyl]amino}methyl)-1H-indo-
l-7-yl]methyl}-9H-purin-6-amine; [0435]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(m-
ethyl sulfonyl)benzamide; [0436]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-ch-
loro-4-(methyl sulfonyl)benzamide; [0437]
4-{[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)ami-
no]methyl}benzonitrile; [0438]
3-{[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)ami-
no]methyl}benzonitrile; [0439]
2-{[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)ami-
no]methyl}benzonitrile; [0440]
3-{[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)ami-
no]methyl}-4-fluorobenzonitrile; [0441]
5-amino-N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}meth-
yl)-2-methylbenzamide; [0442]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-cy-
anobenzamide; [0443]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-cy-
anobenzamide; [0444]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-cy-
anobenzamide; [0445]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(m-
ethylamino)benzamide; [0446]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-ch-
loro-4-cyanobenzamide; [0447]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(1,2,3,6-tetrahydropyridin-4-yl)--
1H-indol-2-yl}methyl)-2-chloro-4-cyanobenzamide; [0448]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4,4-difluorocyclohex-1-en-1-yl)--
1H-indol-2-yl}methyl)-2-chloro-4-cyanobenzamide; [0449]
N-({5-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-7-[(6-amino-9H-purin-9-yl-
)methyl]-1H-indol-2-yl}methyl)-2-chloro-4-cyanobenzamide; [0450]
N-({5-(1-acetyl-1,4,5,6-tetrahydropyridin-3-yl)-7-[(6-amino-9H-purin-9-yl-
)methyl]-1H-indol-2-yl}methyl)-2-chloro-4-cyanobenzamide; [0451]
N-({5-(1-acetylpiperidin-4-yl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-
-2-yl}methyl)-2-chloro-4-cyanobenzamide; [0452]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-4-chloro-1H-indol-2-yl}methyl)-2-ch-
loro-4-cyanobenzamide; [0453]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2,6--
dichloro-4-cyanobenzamide; [0454]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-cy-
ano-2-fluorobenzamide; [0455]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(3,6-dihydro-2H-pyran-4-yl)-1H-in-
dol-2-yl}methyl)-4-cyano-2-fluorobenzamide; [0456]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(1,2,3,6-tetrahydropyridin-4-yl)--
1H-indol-2-yl}methyl)-4-cyano-2-fluorobenzamide; [0457]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4,4-difluorocyclohex-1-en-1-yl)--
1H-indol-2-yl}methyl)-4-cyano-2-fluorobenzamide; [0458]
N-({5-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-7-[(6-amino-9H-purin-9-yl-
)methyl]-1H-indol-2-yl}methyl)-4-cyano-2-fluorobenzamide; [0459]
tert-butyl
4-(7-[(6-amino-9H-purin-9-yl)methyl]-2-{[(4-cyano-2-fluorobenzoyl)amino]m-
ethyl}-1H-indol-5-yl)-3,6-dihydropyridine-1(2H)-carboxylate; [0460]
9-[(5-chloro-2-{[(2,6-dimethylbenzyl)amino]methyl}-1H-indol-7-yl)methyl]--
9H-purin-6-amine; [0461]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-ph-
enylpropanamide; [0462]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(4-
-methylphenyl)acetamide;
[0463]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methy-
l)-2-(3-methylphenyl)acetamide; [0464]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(2-
-methylphenyl)acetamide; [0465]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2,6--
dimethylbenzamide; [0466]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-et-
hylbenzamide; [0467]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(4-
-methoxyphenyl)acetamide; [0468]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(2-
-methoxyphenyl)acetamide; [0469]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-me-
thoxy-6-methylbenzamide; [0470]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-me-
thoxy-4-methylbenzamide; [0471]
4-(aminomethyl)-N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4,4-difluorocycl-
ohexyl)-1H-indol-2-yl}methyl)-2-methylbenzamide; [0472]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-(d-
imethylamino)benzamide; [0473]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-cy-
ano-2-methylbenzamide; [0474]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(3,
6-dihydro-2H-pyran-4-yl)-1H-indol-2-yl}methyl)-4-cyano-2-methylbenzamide;
[0475]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(1,2,3,6-tetrahydropyridin-
-4-yl)-1H-indol-2-yl}methyl)-4-cyano-2-methylbenzamide; [0476]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4,4-difluorocyclohex-1-en-1-yl)--
1H-indol-2-yl}methyl)-4-cyano-2-methylbenzamide; [0477]
N-({5-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-7-[(6-amino-9H-purin-9-yl-
)methyl]-1H-indol-2-yl}methyl)-4-cyano-2-methylbenzamide; [0478]
tert-butyl
4-(7-[(6-amino-9H-purin-9-yl)methyl]-2-{[(4-cyano-2-methylbenzoyl)amino]m-
ethyl}-1H-indol-5-yl)-3,6-dihydropyridine-1(2H)-carboxylate; [0479]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-(d-
imethylamino)benzamide; [0480]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(e-
thylamino)benzamide; [0481]
4-{[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)ami-
no]methyl}-3-methoxybenzonitrile; [0482]
4-(acetylamino)-N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-
-yl}methyl)benzamide; [0483]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(p-
ropan-2-yl)benzamide; [0484]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-(4-
-methoxyphenyl)propanamide; [0485]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-(3-
-methoxyphenyl)propanamide; [0486]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-[4-
-(dimethylamino)phenyl]acetamide; [0487]
4-{[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)ami-
no]methyl}-N,N-dimethylbenzamide; [0488]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-(2-
-fluorophenyl)pyrrolidine-1-carboxamide; [0489]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(p-
yrrolidin-1-ylcarbonyl)benzamide; [0490]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(t-
etrahydro-2H-pyran-4-yloxy)benzamide; [0491]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(p-
iperidin-1-yl)benzamide; [0492]
9-{[5-chloro-2-({[3-(piperidin-1-ylmethyl)benzyl]amino}methyl)-1H-indol-7-
-yl]methyl}-9H-purin-6-amine; [0493]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(p-
iperidin-1-ylcarbonyl)benzamide; [0494]
9-({5-chloro-2-[({3-[2-(piperidin-1-yl)ethoxy]benzyl}amino)methyl]-1H-ind-
ol-7-yl}methyl)-9H-purin-6-amine; [0495]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-5-me-
thyl-3-phenyl-1,2-oxazole-4-carboxamide; [0496]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(1-
-methyl-1H-imidazol-2-yl)benzamide; [0497]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(b-
enzoylamino)benzamide; [0498]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,2,-
3-benzothiadiazole-5-carboxamide; [0499]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3H-i-
midazo[4,5-b]pyridine-5-carboxamide; [0500]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-b-
enzotriazole-6-carboxamide; [0501]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-b-
enzotriazole-5-carboxamide; [0502]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3H-i-
midazo[4,5-b]pyridine-6-carboxamide; [0503]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-5-fl-
uoro-1H-benzotriazole-6-carboxamide; [0504]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,3--
benzothiazole-6-carboxamide; [0505]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,3--
benzothiazole-5-carboxamide; [0506]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)thien-
o[3,2-b]pyridine-6-carboxamide; [0507]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,3--
benzoxazole-6-carboxamide; [0508]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,3--
benzoxazole-5-carboxamide; [0509]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)furo[-
3,2-b]pyridine-6-carboxamide; [0510]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-hy-
droxy-1,3-benzothiazole-6-carboxamide; [0511]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-i-
ndazole-6-carboxamide; [0512]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-p-
yrrolo[3,2-b]pyridine-5-carboxamide; [0513]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-b-
enzimidazole-5-carboxamide; [0514]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-b-
enzimidazole-6-carboxamide; [0515]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-i-
ndazole-5-carboxamide; [0516]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-p-
yrrolo[2,3-b]pyridine-5-carboxamide; [0517]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-ch-
loro-1H-pyrrolo[2,3-b]pyridine-5-carboxamide; [0518]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-5-ch-
loro-1H-pyrrolo[2,3-b]pyridine-6-carboxamide; [0519]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-fl-
uoro-1H-indazole-5-carboxamide; [0520]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-me-
thyl[1,2]oxazolo[5,4-b]pyridine-5-carboxamide; [0521]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-me-
thyl-1H-benzotriazole-5-carboxamide; [0522]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-me-
thyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide; [0523]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-be-
nzothiophene-5-carboxamide; [0524]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-be-
nzofuran-5-carboxamide; [0525]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-i-
ndole-6-carboxamide; [0526]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-i-
ndole-5-carboxamide; [0527]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-me-
thyl-1,3-benzothiazole-6-carboxamide; [0528]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-me-
thyl-1,3-benzoxazole-6-carboxamide; [0529]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-me-
thyl-1H-indazole-6-carboxamide; [0530]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-me-
thyl-1H-benzimidazole-5-carboxamide; [0531]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-me-
thyl-1H-indazole-5-carboxamide; [0532]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-me-
thyl-1H-benzimidazole-5-carboxamide; [0533]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-me-
thyl-1-benzofuran-5-carboxamide; [0534]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-me-
thyl-1H-indole-6-carboxamide; [0535]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-me-
thyl-1H-indole-5-carboxamide; [0536]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,2--
dimethyl-1H-benzimidazole-5-carboxamide; [0537]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-et-
hyl-1H-benzimidazole-6-carboxamide; [0538]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-cy-
ano-1H-indole-5-carboxamide; [0539]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-(p-
ropan-2-yl)[1,2]oxazolo[5,4-b]pyridine-5-carboxamide; [0540]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-(p-
ropan-2-yl)-1H-benzotriazole-5-carboxamide; [0541]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-(p-
ropan-2-yl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide; [0542]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-me-
thoxy-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide; [0543]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2,3--
dimethyl-1H-indole-6-carboxamide; [0544]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2,3--
dimethyl-1H-indole-5-carboxamide; [0545]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-(2-
-hydroxyethyl)-2-methyl-1H-benzimidazole-5-carboxamide; [0546]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-6-me-
thyl-1-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide;
[0547]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,2,-
3-trimethyl-1H-indole-5-carboxamide; and [0548]
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-bu-
tyl-1,3-benzoxazole-5-carboxamide.
[0549] Compound names are assigned by using Name 2012 naming
algorithm by Advanced Chemical Development or Struct=Name naming
algorithm as part of CHEMDRAW.RTM. ULTRA v. 12.0.2.1076.
[0550] Compounds of the invention may exist as stereoisomers
wherein asymmetric or chiral centers are present. These
stereoisomers are "R" or "S" depending on the configuration of
substituents around the chiral carbon atom. The terms "R" and "S"
used herein are configurations as defined in IUPAC 1974
Recommendations for Section E, Fundamental Stereochemistry, in Pure
Appl. Chem., 1976, 45: 13-30. The invention contemplates various
stereoisomers and mixtures thereof and these are specifically
included within the scope of this invention. Stereoisomers include
enantiomers and diastereomers, and mixtures of enantiomers or
diastereomers. Individual stereoisomers of compounds of the
invention may be prepared synthetically from commercially available
starting materials which contain asymmetric or chiral centers or by
preparation of racemic mixtures followed by methods of resolution
well-known to those of ordinary skill in the art. These methods of
resolution are exemplified by (1) attachment of a mixture of
enantiomers to a chiral auxiliary, separation of the resulting
mixture of diastereomers by recrystallization or chromatography and
optional liberation of the optically pure product from the
auxiliary as described in Furniss, Hannaford, Smith, and Tatchell,
"Vogel's Textbook of Practical Organic Chemistry", 5th edition
(1989), Longman Scientific & Technical, Essex CM20 2JE,
England, or (2) direct separation of the mixture of optical
enantiomers on chiral chromatographic columns or (3) fractional
recrystallization methods.
[0551] Compounds of the invention may exist as cis or trans
isomers, wherein substituents on a ring may attached in such a
manner that they are on the same side of the ring (cis) relative to
each other, or on opposite sides of the ring relative to each other
(trans). For example, cyclobutane may be present in the cis or
trans configuration, and may be present as a single isomer or a
mixture of the cis and trans isomers. Individual cis or trans
isomers of compounds of the invention may be prepared synthetically
from commercially available starting materials using selective
organic transformations, or prepared in single isomeric form by
purification of mixtures of the cis and trans isomers. Such methods
are well-known to those of ordinary skill in the art, and may
include separation of isomers by recrystallization or
chromatography.
[0552] It should be understood that the compounds of the invention
may possess tautomeric forms, as well as geometric isomers, and
that these also constitute an aspect of the invention.
[0553] The present disclosure includes all pharmaceutically
acceptable isotopically-labelled compounds of formula (I) wherein
one or more atoms are replaced by atoms having the same atomic
number, but an atomic mass or mass number different from the atomic
mass or mass number which predominates in nature. Examples of
isotopes suitable for inclusion in the compounds of the disclosure
include isotopes of hydrogen, such as .sup.2H and .sup.3H, carbon,
such as .sup.11C, .sup.13C and .sup.14C, chlorine, such as
.sup.36Cl, fluorine, such as .sup.18F, iodine, such as .sup.123I
and .sup.125I, nitrogen, such as .sup.13N and .sup.15N, oxygen,
such as .sup.15O, .sup.17O and .sup.18O, phosphorus, such as
.sup.32P, and sulphur, such as .sup.35S. Certain
isotopically-labelled compounds of formula (I), for example, those
incorporating a radioactive isotope, are useful in drug and/or
substrate tissue distribution studies. The radioactive isotopes
tritium, i.e. .sup.3H, and carbon-14, i.e. .sup.14C, are
particularly useful for this purpose in view of their ease of
incorporation and ready means of detection. Substitution with
heavier isotopes such as deuterium, i.e. .sup.2H, may afford
certain therapeutic advantages resulting from greater metabolic
stability, for example, increased in vivo half-life or reduced
dosage requirements, and hence may be preferred in some
circumstances. Substitution with positron emitting isotopes, such
as .sup.11C, .sup.18F, .sup.15O and .sup.13N, can be useful in
Positron Emission Topography (PET) studies for examining substrate
receptor occupancy. Isotopically-labeled compounds of formula (I)
can generally be prepared by conventional techniques known to those
skilled in the art or by processes analogous to those described in
the accompanying Examples using an appropriate isotopically-labeled
reagents in place of the non-labeled reagent previously
employed.
[0554] Thus, the formula drawings within this specification can
represent only one of the possible tautomeric, geometric, or
stereoisomeric forms. It is to be understood that the invention
encompasses any tautomeric, geometric, or stereoisomeric form, and
mixtures thereof, and is not to be limited merely to any one
tautomeric, geometric, or stereoisomeric form utilized within the
formula drawings.
[0555] Compounds of formula (I) may be used in the form of
pharmaceutically acceptable salts. The phrase "pharmaceutically
acceptable salt" means those salts which are, within the scope of
sound medical judgement, suitable for use in contact with the
tissues of humans and lower animals without undue toxicity,
irritation, allergic response and the like and are commensurate
with a reasonable benefit/risk ratio.
[0556] Pharmaceutically acceptable salts have been described in S.
M. Berge et al. J. Pharmaceutical Sciences, 1977, 66: 1-19.
[0557] Compounds of formula (I) may contain either a basic or an
acidic functionality, or both, and may be converted to a
pharmaceutically acceptable salt, when desired, by using a suitable
acid or base. The salts may be prepared in situ during the final
isolation and purification of the compounds of the invention.
[0558] Examples of acid addition salts include, but are not limited
to acetate, adipate, alginate, citrate, aspartate, benzoate,
benzenesulfonate, bisulfate, butyrate, camphorate,
camphorsulfonate, digluconate, glycerophosphate, hemisulfate,
heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide,
hydroiodide, 2-hydroxyethansulfonate (isothionate), lactate,
malate, maleate, methanesulfonate, nicotinate,
2-naphthalenesulfonate, oxalate, palmitoate, pectinate, persulfate,
3-phenylpropionate, picrate, pivalate, propionate, succinate,
tartrate, thiocyanate, phosphate, glutamate, bicarbonate,
p-toluenesulfonate and undecanoate. Also, the basic
nitrogen-containing groups may be quaternized with such agents as
lower alkyl halides such as, but not limited to, methyl, ethyl,
propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates
like dimethyl, diethyl, dibutyl and diamyl sulfates; long chain
halides such as, but not limited to, decyl, lauryl, myristyl and
stearyl chlorides, bromides and iodides; arylalkyl halides like
benzyl and phenethyl bromides and others. Water or oil-soluble or
dispersible products are thereby obtained. Examples of acids which
may be employed to form pharmaceutically acceptable acid addition
salts include such inorganic acids as hydrochloric acid,
hydrobromic acid, sulfuric acid, and phosphoric acid and such
organic acids as acetic acid, fumaric acid, maleic acid,
4-methylbenzenesulfonic acid, succinic acid and citric acid.
[0559] Basic addition salts may be prepared in situ during the
final isolation and purification of compounds of this invention by
reacting a carboxylic acid-containing moiety with a suitable base
such as, but not limited to, the hydroxide, carbonate or
bicarbonate of a pharmaceutically acceptable metal cation or with
ammonia or an organic primary, secondary or tertiary amine.
Pharmaceutically acceptable salts include, but are not limited to,
cations based on alkali metals or alkaline earth metals such as,
but not limited to, lithium, sodium, potassium, calcium, magnesium
and aluminum salts and the like and nontoxic quaternary ammonia and
amine cations including ammonium, tetramethylammonium,
tetraethylammonium, methylamine, dimethylamine, trimethylamine,
triethylamine, diethylamine, ethylamine and the like. Other
examples of organic amines useful for the formation of base
addition salts include ethylenediamine, ethanolamine,
diethanolamine, piperidine, piperazine and the like.
[0560] The term "pharmaceutically acceptable prodrug" or "prodrug"
as used herein, represents those prodrugs of the compounds of the
invention which are, within the scope of sound medical judgement,
suitable for use in contact with the tissues of humans and lower
animals without undue toxicity, irritation, allergic response, and
the like, commensurate with a reasonable benefit/risk ratio, and
effective for their intended use.
[0561] The invention contemplates compounds of formula (I) formed
by synthetic means or formed by in vivo biotransformation of a
prodrug.
[0562] Compounds described herein may exist in unsolvated as well
as solvated forms, including hydrated forms, such as hemi-hydrates.
In general, the solvated forms, with pharmaceutically acceptable
solvents such as water and ethanol among others are equivalent to
the unsolvated forms for the purposes of the invention.
General Synthesis
[0563] The compounds described herein in various embodiments,
including compounds of general formula (I) and specific examples
may be prepared by methodologies known in the art, for example,
through the reaction schemes depicted in schemes 1-5. The variables
R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.1A, R.sup.1B,
R.sup.1C, R.sup.4A, R.sup.4B, G.sup.A, G.sup.2A, G.sup.3A, L.sup.3,
and Y, used in the following schemes have the meanings as set forth
in the summary and detailed description sections, unless otherwise
noted.
[0564] Abbreviations used in the descriptions of the schemes and
the specific examples have the following meanings: DBU for
1,8-diazabicyclo[5.4.0]undec-7-ene, DMF for N,N-dimethylformamide,
DMSO for dimethyl sulfoxide, HATU for
O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate, HOBT for 1-hydroxybenzotriazole hydrate, HPLC
for High Performance Liquid chromatography, LC/MS for liquid
chromatography/mass spectrometry, Prep HPLC for Preparative High
Performance Liquid chromatography, MeOH for methanol, NMR for
nuclear magnetic resonance, SFC for Supercritical Fluid
Chromatography, TFA for trifluoroacetic acid, and THF for
tetrahydrofuran.
##STR00004##
[0565] Compounds of general formula (I) may be prepared utilizing
general procedure as described in Scheme 1.
[0566] Treatment of substituted indoles of general formula (1)
wherein R.sup.2, R.sup.3, and R.sup.4 are hydrogen, or one of
R.sup.2, R.sup.3, and R.sup.4 is halogen, and the others are
hydrogen, and R.sup.100 is hydrogen or --C(O)OC.sub.2H.sub.5, with
di-tert-butyl dicarbonate in the presence of
N,N-dimethylpyridin-4-amine and a base such as, but not limited to,
triethylamine, affords compounds of formula (2). The reaction may
generally be conducted in a solvent such as, but not limited to,
dichloromethane, and at ambient temperature. Conversion of (2) to
(3) may be achieved by treatment with N-bromosuccinimide.
Displacement of the bromine atom in compounds (3) with
purine-6-amine of formula (4a) in the presence of a base such as,
but not limited to, cesium carbonate, and in a solvent such as, but
not limited to, N,N-dimethylformamide, provides compounds of
formula (4). Removal of the tert-butoxycarbonyl protecting group
may be achieved by treatment with an acid such as, but not limited
to, trifluoroacetic acid.
##STR00005##
[0567] Compounds of formula (1a) wherein R.sup.2, R.sup.3, and
R.sup.4 are hydrogen, or one of R.sup.2, R.sup.3, and R.sup.4 is
halogen, and the others are hydrogen may be prepared using general
procedure as depicted in Scheme 2. Anilines of formula (6) may be
treated with an acid such as concentrated hydrochloric acid, and
sodium nitrite, followed by treatment with ethyl
2-methyl-3-oxo-butanoate or ethyl pyruvate, to provide
intermediates of formula (7). Heating of (7) in the presence of
Amberlyst-15 in a solvent such as, but not limited to, toluene, and
at a temperature of about 100.degree. C. to about 130.degree. C.,
provides indoles of formula (1a).
##STR00006## ##STR00007##
[0568] Compounds of general formula (I) wherein R.sup.102 is
hydrogen or halogen, and R.sup.4 is halogen (for example, Br or Cl)
or --CH.sub.2CH.sub.2C(O)NR.sup.4AR.sup.4B may be prepared as shown
in Scheme 3.
[0569] Bromination of compounds (8) with N-bromosuccinimide or
N-chloro succinimide, followed by protection of the indole NH,
using reaction conditions as described in Scheme 1, generates
compounds of formula (10) wherein R.sup.103 is Br or Cl. Treatment
of (10) with ethyl acrylate in the presence of a base (for example,
triethylamine), triphenylphospine, and palladium (I) acetate
provides intermediates of formula (11). Reduction of (11) with
hydrogen in the presence of a catalyst such as, but not limited to,
Pd/C, and in a solvent such as, but not limited to, methanol, at
about 60.degree. C., provides compounds of formula (12). Hydrolysis
of the ester with a base such as, but not limited to lithium
hydroxide, provides the corresponding acids (13). Coupling of the
acids (13) with amines of general formula NHR.sup.4AR.sup.4B, using
methodologies known to one skilled in the art, provides amides of
formula (14). For example, the coupling reaction may be conducted
in the presence of a coupling reagent such as, but not limited to,
HATU, and a base such as, but not limited to, diisopropylethyl
amine, in a solvent such as, but not limited to, DMF, and at
ambient temperature.
##STR00008##
[0570] Compounds of general formula (I) wherein R.sup.1 is
--CH.sub.2NR.sup.1AR.sup.1B or --CH.sub.2N(R.sup.j)C(O)R.sup.1C;
and R.sup.102 is halogen, alkenyl, phenyl, G.sup.2A, G.sup.3A,
-G.sup.3A-G.sup.A, or -G.sup.3A-L.sup.3-Y may be synthesize using
general synthetic scheme as shown in Scheme 4.
[0571] Reduction of the esters of formula (15) by treatment of a
reducing agent such as, but not limited to, lithium aluminum
hydride in a solvent such as, but not limited to, tetrahydrofuran,
provides alcohols of formula (16). Treatment of the alcohols (16)
with diphenyl phosphorazidate in DBU provides azides (17). Upon
treatment with triphenylphosphine, the azides may be converted to
primary amines of formula (18). Coupling of the amines with acids
of formula R.sup.1CC(O)OH using reaction conditions as described in
Scheme (3) provides amides of formula (21). Alternatively, amides
(21) may be obtained from the reaction of (18) with acid chlorides
of formula R.sup.1CC(O)Cl (generated in situ from the corresponding
acid) in the presence of a base such as, but not limited, to
diisopropylethyl amine.
[0572] Treatment of the alcohols with 2-iodoxybenzoic acid and
trifluoroacetic acid provides aldehydes of formula (19). Reductive
amination of (19) with amines of formula NHR.sup.1AR.sup.1B affords
amines of formula (20).
##STR00009##
[0573] Hydrolysis of ester of formula (15) with lithium hydroxide
provides acids of formula (22). Treatment of acids (22) with
N,O-dimethylhydroxylamine in the presence of HATU and a base such
as, but not limited to, triethylamine provides intermediates of
formula (23). Reaction of (23) with an alkyl magnesium bromide such
as, but not limited to, methyl magnesium bromide or ethyl magnesium
bromide, in tetrahydrofuran provides ketones of formula (24).
[0574] Compounds of general formula (20), (21), and (24) wherein
R.sup.102 is Cl may be converted to (20), (21), and (24) wherein
R.sup.102 is alkenyl, phenyl, G.sup.2A, G.sup.3A,
-G.sup.3A-G.sup.A, or -G.sup.3A-L.sup.3-Y respectively using
methodologies known to one skilled in the art. For example, the
chlorides may be treated with an appropriate boronic acids or
derivatives thereof (e.g. boronic esters), in the presence of a
palladium catalyst and a base, and optionally in the presence of a
ligand, and in a suitable solvent at elevated temperature (for
example, at a temperature ranging from about 80.degree. C. to about
150.degree. C.). The reaction may be facilitated by microwave
irradiation. Examples of the palladium catalyst include, but are
not limited to, tetrakis(triphenylphosphine)palladium(0),
tris(dibenzylideneacetone)dipalladium(0), and palladium(II)acetate.
Examples of suitable bases that may be employed include, but are
not limited to, carbonates or phosphates of sodium, potassium, and
cesium; and cesium fluoride. Examples of suitable ligands include,
but are not limited to, tricyclohexylphosphine,
1,3,5,7-tetramethyl-6-phenyl-2,4,8-trioxa-6-phosphaadamantane,
2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (X-phos), and
1,1'-bis(diphenylphosphanyl) ferrocene. Non-limiting examples of
suitable solvent include methanol, n-butanol, dimethoxyethane,
N,N-dimethylformamide, dimethylsulfoxide, dioxane, tetrahydrofuran,
and water, or a mixture thereof.
[0575] Optimal reaction conditions and reaction times for each
individual step may vary depending on the particular reactants
employed and substituents present in the reactants used. Unless
otherwise specified, solvents, temperatures and other reaction
conditions may be readily selected by one of ordinary skill in the
art. Specific procedures are provided in the Synthetic Examples
section. Reactions may be further processed in the conventional
manner, e.g. by eliminating the solvent from the residue and
further purified according to methodologies generally known in the
art such as, but not limited to, crystallization, distillation,
extraction, trituration and chromatography. Unless otherwise
described, the starting materials and reagents are either
commercially available or may be prepared by one skilled in the art
from commercially available materials using methods described in
the chemical literature.
[0576] Routine experimentations, including appropriate manipulation
of the reaction conditions, reagents and sequence of the synthetic
route, protection of any chemical functionality that are not
compatible with the reaction conditions, and deprotection at a
suitable point in the reaction sequence of the method are included
in the scope of the invention. Suitable protecting groups and the
methods for protecting and deprotecting different substituents
using such suitable protecting groups are well known to those
skilled in the art; examples of which can be found in T. Greene and
P. Wuts, Protecting Groups in Organic Synthesis (3.sup.rd ed.),
John Wiley & Sons, NY (1999), which is incorporated herein by
reference in its entirety. Synthesis of the compounds of the
invention may be accomplished by methods analogous to those
described in the synthetic schemes described hereinabove and in
specific examples.
[0577] Starting materials, if not commercially available, may be
prepared by procedures selected from standard organic chemical
techniques, techniques that are analogous to the synthesis of
known, structurally similar compounds, or techniques that are
analogous to the above described schemes or the procedures
described in the synthetic examples section.
[0578] When an optically active form of a compound is required, it
may be obtained by carrying out one of the procedures described
herein using an optically active starting material (prepared, for
example, by asymmetric induction of a suitable reaction step), or
by resolution of a mixture of the stereoisomers of the compound or
intermediates using a standard procedure (such as chromatographic
separation, recrystallization or enzymatic resolution).
[0579] Similarly, when a pure geometric isomer of a compound is
required, it may be prepared by carrying out one of the above
procedures using a pure geometric isomer as a starting material, or
by resolution of a mixture of the geometric isomers of the compound
or intermediates using a standard procedure such as chromatographic
separation.
Pharmaceutical Compositions
[0580] This invention also provides for pharmaceutical compositions
comprising a therapeutically effective amount of a compound of
formula (I), or a pharmaceutically acceptable salt thereof together
with a pharmaceutically acceptable carrier, diluent, or excipient
thereof. The phrase "pharmaceutical composition" refers to a
composition suitable for administration in medical or veterinary
use.
[0581] The pharmaceutical compositions that comprise a compound of
formula (I), alone or in combination with a second therapeutic
agent, may be administered to the subjects orally, rectally,
parenterally, intracisternally, intravaginally, intraperitoneally,
topically (as by powders, ointments or drops), bucally or as an
oral or nasal spray. The term "parenterally" as used herein, refers
to modes of administration which include intravenous,
intramuscular, intraperitoneal, intrasternal, subcutaneous and
intraarticular injection and infusion.
[0582] The term "pharmaceutically acceptable carrier" as used
herein, means a non-toxic, inert solid, semi-solid or liquid
filler, diluent, encapsulating material or formulation auxiliary of
any type. Some examples of materials which may serve as
pharmaceutically acceptable carriers are sugars such as, but not
limited to, lactose, glucose, and sucrose; starches such as, but
not limited to, corn starch and potato starch; cellulose and its
derivatives such as, but not limited to, sodium carboxymethyl
cellulose, ethyl cellulose and cellulose acetate; powdered
tragacanth; malt; gelatin; talc; excipients such as, but not
limited to, cocoa butter and suppository waxes; oils such as, but
not limited to, peanut oil, cottonseed oil, safflower oil, sesame
oil, olive oil, corn oil and soybean oil; glycols; such a propylene
glycol; esters such as, but not limited to, ethyl oleate and ethyl
laurate; agar; buffering agents such as, but not limited to,
magnesium hydroxide and aluminum hydroxide; alginic acid;
pyrogen-free water; isotonic saline; Ringer's solution; ethyl
alcohol, and phosphate buffer solutions, as well as other non-toxic
compatible lubricants such as, but not limited to, sodium lauryl
sulfate and magnesium stearate, as well as coloring agents,
releasing agents, coating agents, sweetening, flavoring and
perfuming agents, preservatives and antioxidants may also be
present in the composition, according to the judgment of the
formulator.
[0583] Pharmaceutical compositions for parenteral injection
comprise pharmaceutically acceptable sterile aqueous or nonaqueous
solutions, dispersions, suspensions, or emulsions as well as
sterile powders for reconstitution into sterile injectable
solutions or dispersions just prior to use. Examples of suitable
aqueous and nonaqueous carriers, diluents, solvents or vehicles
include water, ethanol, polyols (such as glycerol, propylene
glycol, polyethylene glycol and the like), vegetable oils (such as
olive oil), injectable organic esters (such as ethyl oleate), and
suitable mixtures thereof. Proper fluidity may be maintained, for
example, by the use of coating materials such as lecithin, by the
maintenance of the required particle size in the case of
dispersions and by the use of surfactants.
[0584] These compositions may also contain adjuvants such as
preservatives, wetting agents, emulsifying agents and dispersing
agents. Prevention of the action of microorganisms may be ensured
by the inclusion of various antibacterial and antifungal agents,
for example, paraben, chlorobutanol, phenol sorbic acid, and the
like. It may also be desirable to include isotonic agents such as
sugars, sodium chloride, and the like. Prolonged absorption of the
injectable pharmaceutical form may be brought about by the
inclusion of agents which delay absorption, such as aluminum
monostearate and gelatin.
[0585] In some cases, in order to prolong the effect of the drug,
it is desirable to slow the absorption of the drug from
subcutaneous or intramuscular injection. This may be accomplished
by the use of a liquid suspension of crystalline or amorphous
material with poor water solubility. The rate of absorption of the
drug then depends upon its rate of dissolution which, in turn, may
depend upon crystal size and crystalline form. Alternatively,
delayed absorption of a parenterally-administered drug form may be
accomplished by dissolving or suspending the drug in an oil
vehicle.
[0586] Injectable depot forms are made by forming microencapsule
matrices of the drug in biodegradable polymers such as
polylactide-polyglycolide. Depending upon the ratio of drug to
polymer and the nature of the particular polymer employed, the rate
of drug release may be controlled. Examples of other biodegradable
polymers include poly(orthoesters) and poly(anhydrides). Depot
injectable formulations are also prepared by entrapping the drug in
liposomes or microemulsions which are compatible with body
tissues.
[0587] The injectable formulations may be sterilized, for example,
by filtration through a bacterial-retaining filter or by
incorporating sterilizing agents in the form of sterile solid
compositions which may be dissolved or dispersed in sterile water
or other sterile injectable medium just prior to use.
[0588] Solid dosage forms for oral administration include capsules,
tablets, pills, powders and granules. In certain embodiments, solid
dosage forms may contain from 1% to 95% (w/w) of a compound of
formula (I). In certain embodiments, the compound of formula (I)
may be present in the solid dosage form in a range of from 5% to
70% (w/w). In such solid dosage forms, the active compound may be
mixed with at least one inert, pharmaceutically acceptable
excipient or carrier, such as sodium citrate or dicalcium phosphate
and/or a) fillers or extenders such as starches, lactose, sucrose,
glucose, mannitol and silicic acid; b) binders such as
carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone,
sucrose and acacia; c) humectants such as glycerol; d)
disintegrating agents such as agar-agar, calcium carbonate, potato
or tapioca starch, alginic acid, certain silicates and sodium
carbonate; e) solution retarding agents such as paraffin; f)
absorption accelerators such as quaternary ammonium compounds; g)
wetting agents such as cetyl alcohol and glycerol monostearate; h)
absorbents such as kaolin and bentonite clay and i) lubricants such
as talc, calcium stearate, magnesium stearate, solid polyethylene
glycols, sodium lauryl sulfate and mixtures thereof. In the case of
capsules, tablets and pills, the dosage form may also comprise
buffering agents.
[0589] The pharmaceutical composition may be a unit dosage form. In
such form the preparation is subdivided into unit doses containing
appropriate quantities of the active component. The unit dosage
form may be a packaged preparation, the package containing discrete
quantities of preparation, such as packeted tablets, capsules, and
powders in vials or ampules. Also, the unit dosage form may be a
capsule, tablet, cachet, or lozenge itself, or it may be the
appropriate number of any of these in packaged form. The quantity
of active component in a unit dose preparation may be varied or
adjusted from 0.1 mg to 1000 mg, from 1 mg to 100 mg, or from 1% to
95% (w/w) of a unit dose, according to the particular application
and the potency of the active component. The composition may, if
desired, also contain other compatible therapeutic agents.
[0590] The dose to be administered to a subject may be determined
by the efficacy of the particular compound employed and the
condition of the subject, as well as the body weight or surface
area of the subject to be treated. The size of the dose also will
be determined by the existence, nature, and extent of any adverse
side-effects that accompany the administration of a particular
compound in a particular subject. In determining the effective
amount of the compound to be administered in the treatment or
prophylaxis of the disorder being treated, the physician may
evaluate factors such as the circulating plasma levels of the
compound, compound toxicities, and/or the progression of the
disease, etc.
[0591] For administration, compounds may be administered at a rate
determined by factors that may include, but are not limited to, the
LD.sub.50 of the compound, the pharmacokinetic profile of the
compound, contraindicated drugs, and the side-effects of the
compound at various concentrations, as applied to the mass and
overall health of the subject. Administration may be accomplished
via single or divided doses.
[0592] The compounds utilized in the pharmaceutical method of the
invention may be administered at the initial dosage of about 0.001
mg/kg to about 100 mg/kg daily. In certain embodiments, the daily
dose range is from about 0.1 mg/kg to about 10 mg/kg. The dosages,
however, may be varied depending upon the requirements of the
subject, the severity of the condition being treated, and the
compound being employed. Determination of the proper dosage for a
particular situation is within the skill of the practitioner.
Treatment may be initiated with smaller dosages, which are less
than the optimum dose of the compound. Thereafter, the dosage is
increased by small increments until the optimum effect under
circumstances is reached. For convenience, the total daily dosage
may be divided and administered in portions during the day, if
desired.
[0593] Solid compositions of a similar type may also be employed as
fillers in soft and hard-filled gelatin capsules using such
carriers as lactose or milk sugar as well as high molecular weight
polyethylene glycols and the like.
[0594] The solid dosage forms of tablets, dragees, capsules, pills
and granules may be prepared with coatings and shells such as
enteric coatings and other coatings well-known in the
pharmaceutical formulating art. They may optionally contain
opacifying agents and may also be of a composition such that they
release the active ingredient(s) only, or preferentially, in a
certain part of the intestinal tract, optionally, in a delayed
manner. Examples of embedding compositions which may be used
include polymeric substances and waxes.
[0595] The active compounds may also be in micro-encapsulated form,
if appropriate, with one or more of the above-mentioned
carriers.
[0596] Liquid dosage forms for oral administration include
pharmaceutically acceptable emulsions, solutions, suspensions,
syrups and elixirs. In addition to the active compounds, the liquid
dosage forms may contain inert diluents commonly used in the art
such as, for example, water or other solvents, solubilizing agents
and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl
carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate,
propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in
particular, cottonseed, groundnut, corn, germ, olive, castor and
sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene
glycols, and fatty acid esters of sorbitan and mixtures
thereof.
[0597] Besides inert diluents, the oral compositions may also
include adjuvants such as wetting agents, emulsifying and
suspending agents, sweetening, flavoring and perfuming agents.
[0598] Suspensions, in addition to the active compounds, may
contain suspending agents as, for example, ethoxylated isostearyl
alcohols, polyoxyethylene sorbitol and sorbitan esters,
microcrystalline cellulose, aluminum metahydroxide, bentonite,
agar-agar, tragacanth and mixtures thereof.
[0599] Compositions for rectal or vaginal administration are
preferably suppositories which may be prepared by mixing the
compounds with suitable non-irritating carriers or carriers such as
cocoa butter, polyethylene glycol, or a suppository wax which are
solid at room temperature but liquid at body temperature and
therefore melt in the rectum or vaginal cavity and release the
active compound.
[0600] Compounds may also be administered in the form of liposomes.
Liposomes generally may be derived from phospholipids or other
lipid substances. Liposomes are formed by mono- or multi-lamellar
hydrated liquid crystals which are dispersed in an aqueous medium.
Any non-toxic, physiologically acceptable and metabolizable lipid
capable of forming liposomes may be used. The present compositions
in liposome form may contain, in addition to a compound of the
invention, stabilizers, preservatives, excipients, and the like.
Examples of lipids include, but are not limited to, natural and
synthetic phospholipids, and phosphatidyl cholines (lecithins),
used separately or together.
[0601] Methods to form liposomes have been described, see example,
Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press,
New York, N.Y. (1976), p. 33 et seq.
[0602] Dosage forms for topical administration of a compound
described herein include powders, sprays, ointments, and inhalants.
The active compound may be mixed under sterile conditions with a
pharmaceutically acceptable carrier and any needed preservatives,
buffers or propellants which may be required. Opthalmic
formulations, eye ointments, powders and solutions are also
contemplated as being within the scope of this invention.
Methods of Use
[0603] The compounds and compositions using any amount and any
route of administration may be administered to a subject for the
treatment of treating a condition, disease, or disorder implicated
by SUV420H1 activity. In certain embodiments, the invention
provides a method of treating a condition, disease, or disorder
implicated by SUV420H1 activity, the method comprising
administering a therapeutically acceptable amount of a compound of
formula (I) or a pharmaceutically acceptable salt thereof to a
subject in need thereof. In certain embodiments, said subject is a
human. In certain embodiments, the compound or salt thereof is
administered with a pharmaceutically acceptable carrier.
[0604] The term "administering" refers to the method of contacting
a compound with a subject. Thus, the compounds may be administered
by injection, that is, intravenously, intramuscularly,
intracutaneously, subcutaneously, intraduodenally, parentally, or
intraperitoneally. Also, the compounds described herein may be
administered by inhalation, for example, intranasally.
Additionally, the compounds may be administered transdermally,
topically, via implantation, transdermally, topically, and via
implantation. In certain embodiments, the compounds and
compositions thereof may be delivered orally. The compounds may
also be delivered rectally, bucally, intravaginally, ocularly, or
by insufflation. SUV420H1-modulated disorders and conditions may be
treated prophylactically, acutely, and chronically using compounds
and compositions thereof, depending on the nature of the disorder
or condition. Typically, the host or subject in each of these
methods is human, although other mammals may also benefit from the
administration of compounds and compositions thereof as set forth
hereinabove.
[0605] Compounds of the invention are useful as modulators of
SUV420H1. Thus, the compounds and compositions are particularly
useful for treating or lessening the severity, or progression of a
disease, disorder, or a condition where hyperactivity or inactivity
of SUV420H1 is involved. Accordingly, the invention provides a
method for modulating SUV420H1 in a membrane of a cell, comprising
the step of contacting said cell with a compound of formula (I) or
a preferred embodiment thereof as set forth above. One embodiment
is directed to a method of treating a condition, disease, or
disorder in a subject implicated by SUV420H1 activity, comprising
the step of administering to said subject a therapeutically
effective amount of a compound of formula (I) or a preferred
embodiment thereof as set forth above, or a pharmaceutically
acceptable salt thereof. In certain embodiments, the subject is a
mammal. In certain embodiments, the subject is a human.
[0606] One embodiment is directed to a compound according to
formula (I) or a pharmaceutically acceptable salt thereof for use
in medicine.
[0607] One embodiment is directed to a compound according to
formula (I) or a pharmaceutically acceptable salt thereof for use
in the treatment of condition, disease, or disorder in a subject
implicated by SUV420H1 activity.
[0608] One embodiment is directed to the use of a compound
according to formula (I) or a pharmaceutically acceptable salt
thereof in the preparation of a medicament.
[0609] One embodiment is directed to the use of a compound
according to formula (I) in the preparation of a medicament for use
in the treatment of condition, disease, or disorder in a subject
implicated by SUV420H1 activity.
[0610] The present compounds may be co-administered to a subject.
The term "co-administered" means the administration of two or more
different therapeutic agents that are administered to a subject by
combination in the same pharmaceutical composition or separate
pharmaceutical compositions. Thus co-administration involves
administration at the same time of a single pharmaceutical
composition comprising two or more therapeutic agents or
administration of two or more different compositions to the same
subject at the same or different times.
[0611] The compounds of the invention may be co-administered with a
therapeutically effective amount of one or more agents to treat
condition, disease, or disorder in a subject implicated by SUV420H1
activity.
[0612] This invention also is directed to methods of use of the
compounds, salts, compositions, and/or kits of the invention to,
for example, modulate SUV420H1 or fragment thereof, and treat a
disease treatable by modulating SUV420H1 or a fragment thereof.
[0613] This invention also is directed to a use of one or more
compounds and/or salts of the invention in the preparation of a
medicament. The medicament optionally can comprise one or more
additional therapeutic agents. In some embodiments, the medicament
is useful for treating a disease, condition, or disorder implicated
by SUV420H1 activity.
[0614] This invention also is directed to a use of one or more
compounds and/or salts of the invention in the manufacture of a
medicament for the treatment of a disease, condition, or disorder
implicated by SUV420H1 activity. The medicament optionally can
comprise one or more additional therapeutic agents.
[0615] Another aspect of the invention relates to modulating
SUV420H1 activity in a biological sample or a patient (e.g., in
vitro or in vivo), which method comprises administering to the
patient, or contacting said biological sample with a compound of
formula (I) or a composition comprising said compound. The term
"biological sample", as use herein, includes, without limitation,
cell cultures or extracts thereof, biopsied material obtained from
a mammal or extracts thereof, and blood, saliva, urine, feces,
semen, tears, or other body fluids of extracts thereof.
[0616] Modulation of SUV420H1 activity in a biological sample is
useful for a variety of purposes that are known to one of skill in
the art. Examples of such purposes include, but are not limited to,
the study of SUV420H1 activity in biological and pathological
phenomena; and the comparative evaluation of new modulators of
SUV420H1.
[0617] Further benefits of Applicants' invention will be apparent
to one skilled in the art from reading this patent application.
[0618] The following Examples may be used for illustrative purposes
and should not be deemed to narrow the scope of the invention.
EXAMPLES
Example 1
9-[(3-bromo-1H-indol-7-yl)methyl]-9H-purin-6-amine
[0619] Example 5c (100 mg, 0.378 mmol) was dissolved in
N,N-dimethylformamide (2.0 mL), stirred, and cooled to about
0.degree. C. for about 10 minutes. N-bromosuccinimide (74.1 mg,
0.416 mmol) was added. The mixture was stirred at room temperature
overnight. The reaction mixture was diluted with water. The
precipitate was filtered and washed with water, dried in vacuum to
give a red solid, which was purified by reverse phase HPLC (C18,
35-70% acetonitrile/water, 0.05% ammonium hydroxide) to afford the
title compound (55 mg, 0.160 mmol, 42.4% yield). MS (ESI+): m/z 345
(M+H).sup.+, .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 11.82 (s,
1H), 8.25 (s, 1H), 8.16 (s, 1H), 7.69 (s, 1H), 7.36 (d, J=8.0 Hz,
1H), 7.26 (s, 2H), 7.06 (t, J=7.6 Hz, 1H), 6.90 (d, J=6.8 Hz, 1H),
5.64 (s, 2H).
Example 2
3-{7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-3-yl}-N-methylpropanamide
Example 2a
tert-butyl
7-((6-amino-9H-purin-9-yl)methyl)-3-bromo-1H-indole-1-carboxyla-
te
[0620] A mixture of Example 1 (2.0 g, 5.83 mmol) and di-tert-butyl
dicarbonate (2.84 mL, 12.24 mmol) in THF (20 mL) was stirred at
about 25.degree. C. for about 10 minutes in a round-bottomed flask
to give a red suspension. 4-dimethylpyridine (0.142 g, 1.166 mmol)
was added and the reaction mixture was stirred at ambient
temperature overnight. The reaction mixture was diluted with
saturated sodium bicarbonate solution and dichloromethane. The
organic layer was washed with brine, dried over sodium sulfate,
filtered, concentrated under reduced pressure, and purified by
column chromatography on silica gel (a gradient of 1-4% methanol in
dichloromethane:ethyl acetate (1:1)) to give the title compound
(2.0 g, 4.51 mmol, 77% yield) as a pale red solid. MS (ESI+): m/z
445 (M+H)+
Example 2b
(E)-ethyl
3-(7-((6-amino-9H-purin-9-yl)methyl)-1H-indol-3-yl)acrylate
[0621] To a mixture of Example 2a (100 mg, 0.226 mmol), ethyl
acrylate (27.1 mg, 0.271 mmol) and triethylamine (0.063 mL, 0.451
mmol) in N,N-dimethylformamide (2.0 mL) were added
triphenylphosphine (11.83 mg, 0.045 mmol) and palladium(II) acetate
(5.06 mg, 0.023 mmol). The mixture was degassed with argon gas and
heated at 90.degree. C. for 16 hours. The mixture was concentrated
and the residue was purified by reverse phase HPLC (C18, 35-70%
acetonitrile/water, 0.05% ammonium hydroxide) to afford the title
compound (26 mg, 0.072 mmol, 31.8% yield). MS (ESI+): m/z 363
(M+H).sup.+.
Example 2c
ethyl
3-(7-((6-amino-9H-purin-9-yl)methyl)-1H-indol-3-yl)propanoate
[0622] A mixture of Example 2b (50 mg, 0.138 mmol) and Pd/C (14.68
mg, 0.138 mmol) in methanol (5.0 mL) was stirred at ambient
temperature for 12 hours under hydrogen gas atmosphere. The mixture
was diluted with methanol (20 mL), stirred at 60.degree. C. for 10
minutes, and filtered through a pad of celite. The filtrate was
concentrated and purified by reverse phase HPLC (C18, 35-70%
acetonitrile/water, 0.05% ammonium hydroxide) to afford the title
compound (20 mg, 0.055 mmol, 39.8% yield). MS (ESI+): m/z 365
(M+H).sup.+.
Example 2d
3-(7-((6-amino-9H-purin-9-yl)methyl)-1H-indol-3-yl)propanoic
acid
[0623] A mixture of Example 2c (55 mg, 0.151 mmol) and lithium
hydroxide monohydrate (19.00 mg, 0.453 mmol) in a mixture of water
(1.0 mL) and methanol (1.0 mL) was stirred at ambient temperature
for 3 hours. Methanol was removed under reduce pressure. The
residue was acidified with 1M aqueous HCl solution to about pH 5
and purified by reverse phase HPLC (C18, 35-70% acetonitrile/water,
0.05% ammonium hydroxide) to afford the title compound (14 mg,
0.042 mmol, 27.6% yield) as a white solid. MS (ESI+): m/z 337
(M+H).sup.+.
Example 2e
3-{7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-3-yl}-N-methylpropanamide
[0624] To a mixture of Example 2d (40 mg, 0.119 mmol), diethyl
isopropylamine (0.083 mL, 0.476 mmol), HATU (90 mg, 0.238 mmol) in
N,N-dimethylformamide (1.0 mL), methanamine (0.089 mL, 0.178 mmol;
2.0M THF solution) were added. The reaction mixture was stirred at
ambient temperature for 2 hours. The mixture was purified by
reverse phase HPLC (C18, 35-70% acetonitrile/water, 0.05% ammonium
hydroxide) to afford the title compound (23 mg, 0.065 mmol, 54.2%
yield) as a white solid. MS (ESI+): m/z 350 (M+H).sup.+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. 11.09 (s, 1H), 8.24 (s, 1H),
8.17 (s, 1H), 7.76 (d, J=4.8 Hz, 1H), 7.47 (d, J=7.6 Hz, 1H), 7.26
(s, 2H); 7.20 (s, 1H), 6.92 (t, J=7.6 Hz, 1H), 6.83 (d, J=7.2 Hz,
1H), 5.59 (s, 2H), 2.91 (t, J=7.4 Hz, 2H), 2.55 (d, J=4.8 Hz, 3H),
2.40 (t, J=7.8 Hz, 2H).
Example 3
3-{7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-3-yl}-N,N-dimethylpropanamid-
e
[0625] Example 3 was prepared according to the procedure used for
the preparation of Example 2e, substituting dimethylamine for
methylamine. MS (ESI+): m/z 364 (M+H).sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 11.09 (s, 1H), 8.23 (s, 1H), 8.18 (s, 1H),
7.47 (d, J=7.6 Hz, 1H), 7.26 (s, 3H), 6.93 (t, J=7.2 Hz, 1H), 6.85
(d, J=6.8 Hz, 1H), 5.59 (s, 2H), 2.92-2.88 (m, 5H), 2.81 (s, 3H),
2.63 (t, J=7.2 Hz, 2H).
Example 4
9-(1H-indol-7-ylmethyl)-2-methyl-9H-purin-6-amine
Example 4a
tert-butyl 7-methyl-1H-indole-1-carboxylate
[0626] Di-tert-butyl dicarbonate (3.9 g, 17.87 mmol) was added to a
solution of 7-methyl-1H-indole (Aldrich, 2.0 g, 15.25 mmol),
triethylamine (2.5 mL, 17.94 mmol), N,N-dimethylpyridin-4-amine
(0.187 g, 1.531 mmol) and dichloromethane (25 mL). The reaction
mixture was stirred at room temperature for 2 hours. The reaction
mixture was diluted with dichloromethane and was washed with water,
brine, dried (magnesium sulfate), filtered and concentrated. The
crude product was flash chromatographed (Biotage 100 g HP Snap
Cartridge, eluting with heptanes containing a gradient with ethyl
acetate, 0% to 6%) to provide the title compound. MS DCI 249.1
(M+NH.sub.4).sup.+.
Example 4b
tert-butyl 7-(bromomethyl)-1H-indole-1-carboxylate
[0627] A solution of Example 4a (2.57 g, 11.11 mmol),
1-bromopyrrolidine-2,5-dione (1.98 g, 11.12 mmol), benzoic
peroxyanhydride (0.269 g, 1.111 mmol) and carbon tetrachloride (37
mL) was stirred at 85.degree. C. for 5 hours. The reaction mixture
was cooled to room temperature, diluted with dichloromethane and
was washed with saturated aqueous sodium bicarbonate solution,
water, saturated aqueous sodium chloride solution, dried (magnesium
sulfate), filtered and concentrated. The crude product was flash
chromatographed (Biotage 340 g KP Snap Cartridge, eluting with
heptanes containing a gradient with dichloromethane, 0% to 12%) to
afford the title compound. MS DCI 328.9 (M+NH4).sup.+.
Example 4c
tert-butyl
7-((6-amino-2-chloro-9H-purin-9-yl)methyl)-1H-indole-1-carboxyl-
ate
[0628] 2-Chloro-9H-purin-6-amine (Aldrich, 0.481 g, 2.84 mmol) was
added portion wise to a 0.degree. C. suspension of cesium carbonate
(1.09 g, 3.35 mmol) and N,N-dimethylformamide (20 mL). After 10
minutes at 0.degree. C. a solution Example 4b (0.88 g, 2.84 mmol)
and N,N-dimethylformamide (10 mL) was added slowly and the reaction
mixture was stirred at 0.degree. C. for 3 hours. Water was added
and the suspension was stirred at 0.degree. C. for 30 minutes. The
solid was filtered, rinsed with water and was dried (in-vacuo) to
provide the title compound. MS ESI.sup.+ 399.0 (M+H).sup.+.
Example 4d
9-((1H-indol-7-yl)methyl)-2-methyl-9H-purin-6-amine
[0629] In a microwave vial, a solution of Example 4c (30 mg, 0.075
mmol), methylboronic acid (14 mg, 0.234 mmol), potassium phosphate
(47 mg, 0.221 mmol),
{1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene}chloro{3-phenyla-
llyl}palladium(II) (15 mg, 0.023 mmol), dioxane (2.5 mL) and water
(0.8 mL) was degassed with nitrogen. The reaction mixture was
sealed and was heated in a microwave reactor at 150.degree. C. for
1 hour. Another 8 mg of
{1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene}chloro{3-phenylallyl-
}palladium(II) was added, the solution was degassed again with
nitrogen and was heated in the microwave at 150.degree. C. for
another 1 hour. Water and ethyl acetate were added and the layers
were separated. The aqueous layer was extracted two more times with
ethyl acetate. The combined organic extracts were washed with
brine, dried (magnesium sulfate), filtered and concentrated. The
crude product was purified by preparative HPLC on *2-coupled C8 5
um 100 .ANG. columns (30 mm.times.75 mm each) with a gradient of
acetonitrile (A) and 0.1% trifluoroacetic acid in water (B) was
used, at a flow rate of 50 mL/min (0-0.5 min 5% A, 0.5-8.5 min
linear gradient 5-100% A, 8.7-10.7 min 100% A, 10.7-11 min linear
gradient 100-5% A) to provide the title compound. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 11.39 (s, 1H), 8.43 (s, 1H), 8.34 (s,
2H), 7.52 (dd, J=7.9, 4.7 Hz, 1H), 7.47 (dt, J=5.0, 2.7 Hz, 1H),
6.94 (dd, J=8.7, 6.5 Hz, 1H), 6.75 (d, J=7.2 Hz, 1H), 6.52 (q,
J=3.8, 3.1 Hz, 1H), 5.69 (d, J=2.5 Hz, 2H), 2.55 (d, J=5.0 Hz, 3H).
MS ESI+279.1 (M+H).sup.+.
Example 5
9-(1H-indol-7-ylmethyl)-9H-purin-6-amine
Example 5a
tert-butyl 7-(bromomethyl)-1H-indole-1-carboxylate
[0630] A mixture of Example 4a (21 g, 91 mmol), benzoic
peroxyanhydride (1.100 g, 4.54 mmol) and N-bromosuccinimide (17.13
g, 96 mmol) in carbon tetrachloride (200 mL) was heated to about
80.degree. C. for about 2 hours in a 500 mL round-bottomed flask.
The floated succinimide was filtered off and washed with carbon
tetrachloride (10 mL). The solvent was removed in vacuum to afford
the title compound (25 g, 81 mmol, 89% yield) as orange oil.
.sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 7.58-7.53 (m, 2H), 7.26
(d, J=2.4 Hz, 1H); 7.19 (d, J=3.6 Hz, 1H), 6.58 (d, J=3.6 Hz, 1H),
5.24 (s, 2H), 1.68 (s, 9H).
Example 5b
tert-butyl
7-((6-amino-9H-purin-9-yl)methyl)-1H-indole-1-carboxylate
[0631] A mixture of Example 5a (10 g, 32.2 mmol), 9H-purin-6-amine
(4.36 g, 32.2 mmol) and cesium carbonate (12.60 g, 38.7 mmol) in
N,N-dimethylformamide (60 mL) was heated to about 50.degree. C. for
about 2 hours. The reaction solution was cooled to room temperature
and poured into water. The precipitate was filtered and washed with
water, dried in vacuum, and purified by column chromatography on
silica gel (25-75% ethyl acetate in petroleum ether) to afford the
title compound (4.5 g, 12.35 mmol, 38.3% yield). MS (ESI+): m/z 365
(M+H)+.
Example 5c
9-(1H-indol-7-ylmethyl)-9H-purin-6-amine
[0632] A mixture of Example 5b (4.0 g, 10.98 mmol) and
trimethylsilyl chloride (14.03 mL, 110 mmol) in methanol (40 mL)
was stirred at about 60.degree. C. for 16 hours. The solvent was
removed under reduced pressure. Methanol (2.0 mL) was added. The pH
was adjusted to 8-10 with saturated aqueous sodium bicarbonate
solution. The precipitate was stirred for about 10 minutes and
collected by filtration, washed with water and then ether, dried in
vacuum to give a red solid, which was purified by silica gel column
chromatography (dichloromethane:ethyl acetate:methanol=25:25:1) to
afford the title compound (1.16 g, 4.39 mmol, 40.0% yield) as a
white solid. MS (ESI+): m/z 265 (M+H).sup.+; .sup.1H NMR (400 MHz,
DMSO-d.sub.6): .delta. 11.44 (s, 1H), 8.27 (s, 1H), 8.19 (s, 1H),
7.46-7.51 (m, 2H), 7.28 (s, 2H), 6.93 (t, J=7.2 Hz, 1H), 6.83 (d,
J=6.8 Hz, 1H), 6.50 (s, 1H), 5.64 (s, 2H).
Example 6
2-cyclopropyl-9-(1H-indol-7-ylmethyl)-9H-purin-6-amine
[0633] Using the procedure described for Example 4d and
substituting cyclopropylboronic acid for methylboronic acid
provided the title compound. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 11.36 (s, 1H), 8.27 (s, 1H), 7.50 (d, J=7.7 Hz, 1H), 7.44
(t, J=2.7 Hz, 1H), 6.93 (t, J=7.5 Hz, 1H), 6.87 (d, J=7.1 Hz, 1H),
6.52-6.47 (m, 1H), 5.58 (s, 2H), 2.07 (s, 1H), 1.00 (t, J=6.0 Hz,
4H). MS ESI.sup.+ 305.1 (M+H).sup.+.
Example 7
{7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methanol
Example 7a
(E)-ethyl 2-(2-(4-chloro-2-methylphenyl)hydrazono)propanoate
[0634] A 500 mL round-bottomed flask were charged with
4-chloro-2-methylaniline (15.0 g, 106 mmol) and HCl (37%
concentration, 64.4 mL, 773 mmol) and water (100 mL) to give an
off-white suspension. The suspension was cooled to about 0.degree.
C. in an ice bath and a solution of sodium nitrite (7.31 g, 106
mmol) in water (100 mL) was added slowly under stirring, After the
addition, the mixture was stirred for 1 hour. The resulting
solution was then added to a mixture of sodium acetate (87 g, 1059
mmol) and ethyl 2-methyl-3-oxo-butanoate (15.27 g, 106 mmol) in
ethanol (300 mL) and water (1000 mL) at 0.degree. C. The resulting
mixture was stirred at about 0.degree. C. for about 2 hours and
then at ambient temperature overnight. The mixture was extracted
with ethyl acetate (3.times.400 mL), washed sequentially with
water, saturated sodium bicarbonate solution, and brine. The
organic layer was dried with anhydrous sodium sulfate, filtered and
concentrated. The residue was triturated in petroleum ether to give
the title compound (5.6 g, 21.99 mmol, 20.75% yield) as a yellow
solid. MS (ESI+): m/z 255 (M+H).sup.+.
Example 7b
ethyl 5-chloro-7-methyl-1H-indole-2-carboxylate
[0635] A suspension of Example 7a (3.0 g, 11.78 mmol) and amberlyst
15 (10.0 g, 11.78 mmol) in toluene (50 mL) in a sealed tube was
stirred at 120.degree. C. overnight. The reaction mixture was
filtered and the filtrate was concentrated. The residue was
purified by flash column chromatography on silica gel (ethyl
acetate: petroleum ether=1:20) to give the title compound (1.4 g,
5.89 mmol, 50.0% yield) as an off-white solid. MS (ESI+): m/z 238
(M+H).sup.+.
Example 7c
ethyl 5-chloro-7-methyl-1H-indole-2-carboxylate
[0636] To a solution of Example 7b (9.0 g, 37.9 mmol),
triethylamine (6.33 mL, 45.4 mmol), and N,N-dimethylpyridin-4-amine
(0.463 g, 3.79 mmol) in dichloromethane (150 mL) was added
di-tert-butyl dicarbonate (10.55 mL, 45.4 mmol). The reaction
mixture was stirred overnight and then diluted with
dichloromethane. The organic layer was washed sequentially with 0.1
M aqueous HCl solution and brine, dried with anhydrous sodium
sulfate, filtered and concentrated to give the title compound (12.0
g, 35.5 mmol, 94% yield) as a yellow oil. MS (ESI+): m/z 338
(M+H).sup.+.
Example 7d
tert-butyl 2-ethyl
7-(bromomethyl)-5-chloro-1H-indole-1,2-dicarboxylate
[0637] A mixture of Example 7c (6.0 g, 17.76 mmol), benzoic
peroxyanhydride (0.430 g, 1.776 mmol), and N-bromosuccinimide (3.48
g, 19.54 mmol) in carbon tetrachloride (100 mL) was stirred at
80.degree. C. overnight. The mixture was concentrated. The residue
was diluted with ethyl acetate, washed sequentially with water and
brine, dried with anhydrous sodium sulfate, filtered and
concentrated. The residue was purified by flash column
chromatography on silica gel (eluent: 1:60 ethyl acetate/petroleum
ether) to give the title compound (4.2 g, 10.08 mmol, 56.7%
yield).
Example 7e
1-tert-butyl 2-ethyl
7-((6-amino-9H-purin-9-yl)methyl)-5-chloro-1H-indole-1,2-dicarboxylate
[0638] To a solution of Example 7d (50 g, 120 mmol) and
9H-purin-6-amine (14.59 g, 108 mmol) in N,N-dimethylformamide (500
mL) was added Cs.sub.2CO.sub.3 (43.0 g, 132 mmol). The resulting
suspension was stirred at ambient temperature overnight. The
reaction mixture was diluted with water (1500 mL), extracted with
dichloromethane (3.times.300 mL). The combined organic layers were
washed with water (3.times.500 mL), dried with sodium sulfate,
concentrated to about 300 mL volume. The mixture was stirred
overnight. The solid formed was collected by filtration and washed
with dichloromethane (2.times.30 mL) to give the first crops of
des-BOC product Example 7f (3.0 g, 8.0 mmol, 6.7% yield). The
filtrate above was taken into ethyl acetate (300 mL) and washed
with water (3.times.300 mL) to remove residual
N,N-dimethylformamide. The organic layer was dried over sodium
sulfate, filtered and concentrated. The resulting residue was
purified by column chromatography on silica gel (5% methanol in
dichloromethane) to give the Example 7e (18 g, 38.2 mmol, 32%
yield) (MS (ESI+): m/z 471 (M+H).sup.+) and the second crops of
Example 7f (3.5 g, 9.29 mmol, 7.7% yield).
Example 7f
ethyl
7-((6-amino-9H-purin-9-yl)methyl)-5-chloro-1H-indole-2-carboxylate
[0639] Example 7e (15 g, 31.9 mmol) in dichloromethane (200 mL) was
treated with trifluoroacetic acid (44.2 mL, 573 mmol) at 0.degree.
C. under an atmosphere of nitrogen. The resulting mixture was
stirred at ambient temperature overnight. The solvent was removed
under reduced pressure. To the dark oil residue was added water
(100 mL) under stirring. The pH of the solution was adjusted to
about 9 using saturated aqueous sodium carbonate solution. After
stirring for 2 hours, the solid was filtered, washed with water
(3.times.30 mL), and lyophilized to provide title compound (12 g,
27.5 mmol, 86% yield). MS (ESI+): m/z 371 (M+H).sup.+.
Example 7g
(7-((6-amino-9H-purin-9-yl)methyl)-5-chloro-1H-indol-2-yl)methanol
[0640] To a solution of Example 7f (8 g, 21.58 mmol) in anhydrous
THF (200 mL) was added lithium aluminum hydride (43.2 mL, 43.2
mmol, 1 M solution in THF) at 0.degree. C. under an atmosphere of
nitrogen. The resulting mixture was stirred at ambient temperature
overnight. The mixture was quenched with water (4 mL). Magnesium
sulfate (20 g) was added to the mixture. The mixture was stirred
overnight. The suspension was filtered and the filtering cake was
washed with THF (50 mL.times.3). The filter cake was then stirred
in THF (100 mL) for about 1 hour. The suspension was filtered and
the filter cake was washed with THF (50 mL.times.3). All the
organic liquid was combined, dried over anhydrous sodium sulfate,
filtered, and concentrated to give the title compound (5.3 g, 13.7
mmol, 63.5% yield) a yellow solid. MS (ESI+): m/z 329 (M+H)+.
.sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 11.63 (s, 1H), 8.29
(s, 1H), 8.19 (s, 1H), 7.47 (d, J=2.0 Hz, 1H), 7.33 (s, 2H), 6.83
(d, J=2.0 Hz, 1H), 6.34 (d, J=2.0 Hz, 1H), 5.61 (s, 2H), 4.65 (s,
2H).
Example 8
9-{[2-(aminomethyl)-1H-indol-7-yl]methyl}-9H-purin-6-amine
[0641] A microwave tube was charged with Example 9b (0.05 g, 0.153
mmol), 2-cyclopropyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (0.038
g, 0.229 mmol), cesium carbonate (0.149 g, 0.458 mmol) in
1,2-dimethoxyethane (1 mL). The mixture was degassed,
tris(dibenzylideneacetone)dipalladium(0) (0.014 g, 0.015 mmol) and
2-(dicyclohexylphosphino)-2',4',6'-triisopropylbiphenyl (7 mg,
0.015 mmol) were added, the vessel sealed, purged with nitrogen for
5 minutes and heated under microwave irradiation at about
140.degree. C. for about 45 minutes. Water and ethyl acetate were
added and the solid was filtered. The filtrate was partitioned. The
organic layer was washed with brine, dried over magnesium sulfate
and filtered. The filtrate was concentrated and purified by
preparative HPLC (Waters Sunfire C8, 0-95% methanol/water; 1% TFA)
to provide the title compound. .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.37 (s, 1H), 8.21 (s, 1H), 7.63-7.51 (m, 1H), 7.12-6.99
(m, 2H), 6.66 (s, 1H), 5.71 (s, 2H), 4.34 (s, 2H); MS m/z: 277
[M-NH.sub.2].sup.+.
Example 9
9-{[2-(aminomethyl)-5-chloro-1H-indol-7-yl]methyl}-9H-purin-6-amine
Example 9a
9-((2-(azidomethyl)-5-chloro-1H-indol-7-yl)methyl)-9H-purin-6-amine
[0642] To a solution of Example 7g (8 g, 24.33 mmol) in anhydrous
dichloromethane (80 mL) and anhydrous toluene (80 mL) was added
diphenyl phosphorazidate (26.8 g, 97 mmol) and DBU (14.67 mL, 97
mmol) dropwise at ambient temperature under an atmosphere of
nitrogen gas. The resulting mixture was stirred at ambient
temperature overnight. The reaction solution was washed with water
(3.times.75 mL). The organic layer was dried over anhydrous sodium
sulfate, filtered and concentrated. The resulting residue was
purified by column chromatography on silica gel (5% methanol in
dichloromethane) to afford the title compound (4.1 g, 11.59 mmol,
47.6% yield) as a white solid. MS (ESI+): m/z 354 (M+H).sup.+.
Example 9b
9-{[2-(aminomethyl)-5-chloro-1H-indol-7-yl]methyl}-9H-purin-6-amine
[0643] To a solution of Example 9a (25 g, 70.7 mmol) in mixture of
THF (300 mL) and water (150 mL) were added triphenylphosphine (37.1
g, 141 mmol). The resulting mixture was stirred at ambient
temperature overnight. The mixture was concentrated to dryness. The
white residue was washed with ethyl acetate/petroleum ether (2:5)
three times, and then recrystallized in petroleum ether to give the
title compound (20 g, 61.0 mmol, 86% yield). MS (ESI+): m/z 311
(M-NH.sub.2).sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
11.50 (brs, 1H), 8.30 (s, 1H), 8.21 (s, 1H), 7.44 (d, J=2.0 Hz,
1H), 7.34 (s, 2H), 6.77 (s, 1H), 6.31 (s, 1H), 5.60 (s, 2H), 3.90
(s, 2H), 1.95 (brs, 1H).
Example 10
9-{[2-(aminomethyl)-5-ethenyl-1H-indol-7-yl]methyl}-9H-purin-6-amine
[0644] In a microwave tube was charged Example 9b (0.08 g, 0.244
mmol), 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (0.062 mL,
0.366 mmol), potassium phosphate tribasic (0.104 g, 0.488 mmol) in
1,4-dioxane (2 mL) and water (0.11 mL). To the reaction mixture was
added Tris(dibenzylideneacetone)dipalladium(0) (0.022 g, 0.024
mmol) and tricyclohexylphosphine (0.014 g, 0.049 mmol) and the
vessel was sealed and heated in a microwave (Biotage, Initiator) at
about 140.degree. C. for about 45 minutes. The cooled mixture was
filtered through Celite.RTM., and concentrated. The residue was
purified by preparative HPLC (Waters Sunfire C8, 20-50%
acetonitrile/water; 1% TFA) to provide the title compound (0.030 g,
19%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.41 (s, 1H), 8.28
(s, 1H), 7.60 (d, J=1.5 Hz, 1H), 7.29 (d, J=1.5 Hz, 1H), 6.76 (dd,
J=17.6, 10.9 Hz, 1H), 6.65 (s, 1H), 5.73 (s, 2H), 5.65 (dd, J=17.5,
1.0 Hz, 1H), 5.15-5.07 (m, 1H), 4.34 (s, 2H); MS m/z: 303
[M-NH.sub.2].sup.+.
Example 11
9-{[2-(aminomethyl)-5-(cyclopent-1-en-1-yl)-1H-indol-7-yl]methyl}-9H-purin-
-6-amine
[0645] Example 11 was prepared according to the procedure used for
the preparation of Example 10, substituting
2-(cyclopent-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane for
4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 11.54 (s, 1H), 8.39-8.09 (m, 6H), 7.54
(s, 1H), 7.20 (s, 1H), 6.59 (s, 1H), 6.02 (s, 1H), 5.64 (s, 2H),
4.25 (q, J=5.7 Hz, 2H), 2.74-2.56 (m, 2H), 2.48-2.37 (m, 2H), 1.93
(p, J=7.5 Hz, 2H); MS m/z: 343 [M-NH.sub.2].sup.+.
Example 12
9-{[2-(aminomethyl)-5-(3,6-dihydro-2H-pyran-4-yl)-1H-indol-7-yl]methyl}-9H-
-purin-6-amine
[0646] Example 12 was prepared according to the procedure used for
the preparation of Example 10, substituting
2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
for 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane. 1H NMR (400
MHz, CD.sub.3OD) .delta. 8.42 (s, 1H), 8.29 (s, 1H), 7.62 (d, J=1.5
Hz, 1H), 7.29 (d, J=1.6 Hz, 1H), 6.66 (s, 1H), 6.06 (s, 1H), 5.74
(s, 2H), 4.34 (s, 2H), 4.27 (q, J=2.8 Hz, 2H), 3.91 (t, J=5.5 Hz,
2H), 2.52 (s, 2H); MS m/z: 376 [M+H].sup.+.
Example 13
9-{[2-(aminomethyl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indol-7-yl]methy-
l}-9H-purin-6-amine
[0647] In a microwave tube was added Example 9b (0.100 g, 0.305
mmol), tert-butyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-
-carboxylate (0.142 g, 0.458 mmol, Frontier), potassium phosphate
tribasic (0.130 g, 0.610 mmol) and n-butanol (1 mL).
Tris(dibenzylideneacetone)dipalladium(0) (0.028 g, 0.031 mmol) and
tricyclohexylphosphine (0.017 g, 0.061 mmol) were added, the vessel
was sealed, and heated in a microwave (Biotage, Initiator) at about
120.degree. C. for about 30 minutes. The cooled solution was
filtered through Celite.RTM., using 1,4-dioxane then methanol as
eluent. The filtrate was concentrated under reduced pressure. The
crude material was purified using preparative HPLC (Waters Sunfire
C8, 30-80% methanol/water; 0.1 M ammonium acetate) to provide crude
tert-butyl
4-{7-[(6-amino-9H-purin-9-yl)methyl]-2-(aminomethyl)-1H-indol-5-yl}-5,6-d-
ihydropyridine-1(2H)-carboxylate (0.0526 g). The crude material was
treated with 1 mL of 4M HCl in 1,4-dioxane overnight at ambient
temperature with stirring. The material was concentrated to dryness
and the solid was suspended in ether, filtered, washed with ether,
30% methanol/dichloromethane, and dried under vacuum to provide the
title compound (0.019 g, 13%). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.46 (s, 1H), 8.43 (s, 1H), 7.69 (d, J=1.6 Hz, 1H), 7.35
(d, J=1.6 Hz, 1H), 6.70 (s, 1H), 6.11-6.01 (m, 1H), 5.79 (s, 2H),
4.37 (s, 2H), 3.83 (q, J=2.7 Hz, 2H), 3.46 (t, J=6.1 Hz, 2H), 2.84
(dt, J=8.0, 3.9 Hz, 2H); MS m/z: 375 [M+H].sup.+.
Example 14
9-{[2-(aminomethyl)-5-(4,4-difluorocyclohex-1-en-1-yl)-1H-indol-7-yl]methy-
l}-9H-purin-6-amine
[0648] Example 14 was prepared according to the procedure used for
the preparation of Example 10, substituting
2-(4,4-difluorocyclohex-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
e [Frontier] for 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane.
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.38 (s, 1H), 8.23 (s,
1H), 7.60 (d, J=1.6 Hz, 1H), 7.24 (d, J=1.6 Hz, 1H), 6.65 (s, 1H),
5.85 (s, 1H), 5.70 (s, 2H), 4.33 (s, 2H), 2.75-2.59 (m, 4H), 2.15
(dq, J=13.7, 7.0 Hz, 2H); MS m/z: 410 [M+H].sup.+.
Example 15
1-[4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}-3,6-
-dihydropyridin-1(2H)-yl]ethanone
Example 15a
1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridin-1(2H-
)-yl)ethanone
[0649] To a vial was added
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridin-
e, hydrochloric acid (0.25 g, 1.018 mmol), dichloromethane (5 mL)
and diisopropylethylamine (0.88 mL, 5.09 mmol) followed by acetyl
chloride (0.109 mL, 1.527 mmol). The mixture was stirred at room
temperature for about 2 hours, diluted with water, and partitioned.
The organic phase was washed sequentially with sodium bicarbonate,
brine, filtered and concentrated under reduced pressure. The
residue was purified using a silica gel column (ethyl
acetate/heptanes 0-100%) to give the title compound (0.17 g, 67%).
.sup.1H NMR (400 MHz, dimethylsulfoxide-d6) .delta. 6.39 (dt,
J=8.7, 2.6 Hz, 1H), 4.01 (q, J=2.8 Hz, 1H), 3.95 (q, J=2.9 Hz, 1H),
3.44 (dd, J=12.1, 5.8 Hz, 2H), 2.16 (dt, J=5.9, 3.0 Hz, 1H), 2.05
(td, J=5.6, 2.6 Hz, 1H), 1.99 (d, J=10.6 Hz, 3H), 1.20 (s, 12H); MS
m/z: 293 [M+acetonitrile].sup.+.
Example 15b
1-[4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}-3,6-
-dihydropyridin-1(2H)-yl]ethanone
[0650] Example 15b was prepared according to the procedure used for
the preparation of Example 10, substituting Example 15a for
4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane. .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.40 (s, 1H), 8.28 (s, 1H), 7.62 (t, J=2.1
Hz, 1H), 7.26 (s, 1H), 6.66 (s, 1H), 6.01 (s, 1H), 5.73 (s, 2H),
4.34 (s, 2H), 4.17 (dd, J=8.4, 3.0 Hz, 2H), 3.79-3.70 (m, 2H),
2.68-2.51 (m, 2H), 2.15 (d, J=15.6 Hz, 3H); MS m/z: 417
[M+H].sup.+.
Example 16
1-[5-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}-3,6-
-dihydropyridin-1(2H)-yl]ethanone
Example 16a
Mixture of
1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydrop-
yridin-1 (2H)-yl)ethanone and
1-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydropyridin-1(2-
H)-yl)ethanone (1:1)
[0651] Example 16a was prepared according to the procedure used for
the preparation of Example 15a, substituting
5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridin-
e, hydrochloric acid [Frontier] for
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,6-tetrahydropyridin-
e, hydrochloric acid. MS m/z: 252 [M+H].sup.+.
Example 16b
1-[5-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}-3,6-
-dihydropyridin-1(2H)-yl]ethanone
[0652] Example 16b was prepared according to the procedure used for
the preparation of Example 10, substituting Example 16a for
4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane. .sup.1H NMR (500
MHz, CD.sub.3OD) .delta. 8.50-8.39 (m, 1H), 8.39-8.30 (m, 1H),
7.62-7.58 (m, 1H), 7.29 (d, J=1.6 Hz, 1H), 6.70-6.65 (m, 1H),
6.27-6.07 (m, 1H), 5.79-5.71 (m, 2H), 4.42-4.37 (m, 2H), 3.72-3.61
(m, 2H), 2.42-2.34 (m, 1H), 2.31-2.24 (m, 1H), 2.17 (s, 3H); MS
m/z: 417 [M+H].sup.+.
Example 17
1-(4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}pipe-
ridin-1-yl)ethanone
[0653] Example 15b (0.32 g, 0.768 mmol) and 2,2,2-trifluoroethanol
(20 mL) were added to 20% Pd(OH).sub.2/C, wet (0.1 g, 0.073 mmol)
in a 50 mL pressure bottle and stirred or shaken for 16 hours at
50.degree. C. under hydrogen gas (30 psi pressure) and 16 hours at
room temperature. The solvent was removed in vacuo. The residue was
dissolved in 1:1 methanol/dichloromethane and concentrated onto
silica. The crude product was added to a silica gel column and was
eluted with 0.5 M ammonia in methanol/dichloromethane (0-20%).
Collected fractions containing the product were combined and
concentrated to give the crude product which was further purified
using normal phase SFC (ChiralCel IB, 5-50% methanol/CO.sub.2, 0.1%
diethyl amine) to give the title compound (0.052 g, 16%). .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. 8.30 (s, 1H), 8.05 (s, 1H), 7.34
(d, J=1.5 Hz, 1H), 6.39 (s, 1H), 5.59 (s, 2H), 4.64-4.53 (m, 1H),
4.02 (s, 2H), 3.99-3.91 (m, 1H), 3.16 (td, J=13.2, 2.7 Hz, 1H),
2.77 (tt, J=12.2, 3.7 Hz, 1H), 2.64 (td, J=13.0, 2.8 Hz, 1H), 2.11
(s, 3H), 1.90-1.74 (m, 2H), 1.59 (dqd, J=35.3, 12.7, 4.3 Hz, 2H);
MS m/z: 419 [M+H].sup.+.
Example 18
9-{[2-(aminomethyl)-5-(1-methyl-1H-pyrazol-4-yl)-1H-indol-7-yl]methyl}-9H--
purin-6-amine
[0654] Example 18 was prepared according to the procedure used for
the preparation of Example 55, substituting
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperaz-
ine. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.44 (s, 1H), 8.39
(s, 1H), 7.95 (s, 1H), 7.73 (d, J=0.8 Hz, 1H), 7.72 (d, J=1.6 Hz,
1H), 7.22 (d, J=1.6 Hz, 1H), 6.61 (s, 1H), 5.67 (s, 2H), 4.25 (s,
2H), 3.84 (s, 3H). MS (APCI) m/z: 357 (M+H-NH.sub.3).sup.+.
Example 19
9-{[2-(aminomethyl)-5-(pyrimidin-5-yl)-1H-indol-7-yl]methyl}-9H-purin-6-am-
ine
[0655] Example 19 was prepared according to the procedure used for
the preparation of Example 55, substituting pyrimidin-5-ylboronic
acid for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperaz-
ine. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.35 (s, 1H), 8.31
(s, 1H), 8.26 (s, 1H), 7.76 (s, 1H), 7.24 (s, 2H), 7.15 (s, 1H),
5.71 (s, 2H), 4.40 (q, J=6.9 Hz, 2H). MS (APCI) m/z 372
(M+H).sup.+.
Example 20
9-{[2-(aminomethyl)-5-(pyridin-3-yl)-1H-indol-7-yl]methyl}-9H-purin-6-amin-
e
[0656] Example 20 was prepared according to the procedure used for
the preparation of Example 55, substituting pyridin-3-ylboronic
acid for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperaz-
ine. .sup.1H NMR (DMSO-d.sub.6) .delta. 4.30 (s, 2H), 5.76 (s, 2H),
6.76 (s, 1H), 7.44 (d, J=1.7 Hz, 1H), 7.77-7.89 (m, 1H), 8.02 (d,
J=1.6 Hz, 1H), 8.39 (s, 1H), 8.45-8.48 (m, 1H), 8.49 (s, 1H), 8.66
(d, J=5.1, 1.5 Hz, 1H), 8.98 (d, J=2.2 Hz, 1H). MS (APCI) m/z 354
(M+H-NH.sub.3).sup.+.
Example 21
9-{[2-(aminomethyl)-5-(pyridin-4-yl)-1H-indol-7-yl]methyl}-9H-purin-6-amin-
e
[0657] Example 21 was prepared according to the procedure used for
the preparation of Example 55, substituting pyridin-4-ylboronic
acid for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperaz-
ine. .sup.1H NMR (DMSO-d.sub.6) .delta. 4.31 (s, 2H), 5.76 (s, 2H),
6.82 (s, 1H), 7.66 (d, J=1.7 Hz, 1H), 8.21 (d, 2H), 8.30 (d, J=1.7
Hz, 1H), 8.35 (s, 1H), 8.45 (s, 1H), 8.77 (d, 2H). MS (APCI) m/z
371 (M+H).sup.+.
Example 22
9-{[2-(aminomethyl)-5-phenyl-1H-indol-7-yl]methyl}-9H-purin-6-amine
[0658] Example 9b (0.05 g, 0.153 mmol), phenylboronic acid (0.028
g, 0.229 mmol), cesium carbonate (0.149 g, 0.458 mmol) in
1,2-dimethoxyethane (1 mL) were added to a microwave tube. The
reaction was degassed, tris(dibenzylideneacetone)dipalladium(0)
(0.014 g, 0.015 mmol) and
2-(dicyclohexylphosphino)-2',4',6'-triisopropylbiphenyl (0.007 g,
0.015 mmol) were added, the vessel was sealed, purged with nitrogen
for 5 minutes and heated in a microwave (Biotage, Initiator) at
about 140.degree. C. for about 45 minutes. Water and ethyl acetate
were added and the solid was filtered. The filtrate was partitioned
and the organic layer was washed with brine, dried over magnesium
sulfate and filtered. The filtrate was concentrated and purified by
preparative HPLC (Waters Sunfire C8, 0-80% methanol/water; 1% TFA)
followed by trituration 2.times. with ethyl acetate to give the
title compound (0.01 g, 14%). .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.41 (s, 1H), 8.32 (s, 1H), 7.81 (d, J=1.6 Hz, 1H), 7.56
(dd, J=7.5, 1.6 Hz, 2H), 7.46-7.33 (m, 3H), 7.28 (t, J=7.4 Hz, 1H),
6.72 (s, 1H), 5.79 (s, 2H), 4.36 (s, 2H); MS m/z: 353
[M-NH2].sup.+.
Example 23
9-{[2-(aminomethyl)-5-(4-chlorophenyl)-1H-indol-7-yl]methyl}-9H-purin-6-am-
ine
[0659] Example 23 was prepared according to the procedure used for
the preparation of Example 55, substituting (4-chlorophenyl)boronic
acid for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperaz-
ine. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.34 (s, 1H), 8.23
(s, 1H), 8.01 (d, J=8.1 Hz, 2H), 7.87 (d, J=8.8 Hz, 3H), 7.84 (s,
1H), 7.48 (s, 1H), 7.12 (s, 1H), 5.71 (s, 2H), 4.28 (s, 2H). MS
(APCI) m/z: 404 (M+H).sup.+.
Example 24
9-{[2-(aminomethyl)-5-(3-chlorophenyl)-1H-indol-7-yl]methyl}-9H-purin-6-am-
ine
[0660] Example 24 was prepared according to the procedure used for
the preparation of Example 55, substituting (3-chlorophenyl)boronic
acid for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperaz-
ine. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.57 (s, 1H), 8.46
(s, 1H), 8.10 (t, J=1.8 Hz, 1H), 7.92 (d, J=1.5 Hz, 1H), 7.80 (dt,
J=7.6, 1.3 Hz, 1H), 7.75 (dt, J=8.1, 1.3 Hz, 1H), 7.53 (t, J=7.8
Hz, 1H), 7.40 (d, J=1.7 Hz, 1H), 6.73 (s, 1H), 5.78 (s, 2H), 4.29
(s, 2H). MS (APCI) m/z 387 (M+H-NH.sub.3).sup.+.
Example 25
9-{[2-(aminomethyl)-5-(2-chlorophenyl)-1H-indol-7-yl]methyl}-9H-purin-6-am-
ine
[0661] Example 25 was prepared according to the procedure used for
the preparation of Example 55, substituting (2-chlorophenyl)boronic
acid for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperaz-
ine. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.35 (s, 1H), 8.25
(s, 1H), 7.58 (d, J=1.7 Hz, 1H), 7.50 (d, J=7.6 Hz, 1H), 7.28-7.40
(m, 3H), 7.37 (d, J=1.6 hz, 1H), 6.69 (s, 1H), 5.69 (s, 2H), 4.28
(s, 2H). MS (APCI) m/z: 387 (M+H-NH.sub.3).sup.+.
Example 26
9-{[2-(aminomethyl)-5-(4-fluorophenyl)-1H-indol-7-yl]methyl}-9H-purin-6-am-
ine
[0662] Example 26 was prepared according to the procedure used for
the preparation of Example 55, substituting (4-fluorophenyl)boronic
acid for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperaz-
ine. .sup.1H NMR (DMSO-d.sub.6) .delta. 4.28 (s, 2H), 5.74 (s, 2H),
6.70 (s, 1H), 7.22-7.31 (m, 3H), 7.57-7.63 (m, 2H), 7.81 (d, J=1.6
Hz, 1H), 8.40 (s, 1H), 8.51 (s, 1H). MS (APCI) m/z 371
(M+H-NH.sub.3).sup.+.
Example 27
9-{[2-(aminomethyl)-5-(2-fluorophenyl)-1H-indol-7-yl]methyl}-9H-purin-6-am-
ine
[0663] Example 27 was prepared according to the procedure used for
the preparation of Example 55, substituting (2-fluorophenyl)boronic
acid for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperaz-
ine. .sup.1H NMR (DMSO-d.sub.6) .delta. 4.29 (s, 2H), 5.75 (s, 2H),
6.71 (s, 1H), 7.07-7.15 (m, 1H), 7.21-7.31 (m, 2H), 7.33-7.41 (m,
1H), 7.46 (td, J=8.1, 2.0 Hz, 1H), 7.69-7.77 (m, 1H), 8.40 (s, 1H),
8.53 (s, 1H). MS (APCI) m/z: 371 (M+H--NH.sub.3).sup.+.
Example 28
9-{[2-(aminomethyl)-5-(6-methoxypyridin-3-yl)-1H-indol-7-yl]methyl}-9H-pur-
in-6-amine
[0664] Example 28 was prepared according to the procedure used for
the preparation of Example 55, substituting
(6-methoxypyridin-3-yl)boronic acid for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzy-
l)piperazine. .sup.1H NMR (DMSO-d.sub.6) .delta. 3.88 (s, 3H), 4.28
(s, 2H), 5.76 (s, 2H), 6.70 (s, 1H), 6.90 (d, J=8.6 Hz, 1H), 7.25
(d, J=1.7 Hz, 1H), 7.82 (d, J=1.6 Hz, 1H), 7.94 (dd, J=8.6, 2.6 Hz,
1H), 8.36 (d, J=2.5 Hz, 1H), 8.45 (s, 1H), 8.57 (s, 1H). MS (APCI)
m/z 384 (M+H--NH.sub.3).sup.+.
Example 29
4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}benzene-
sulfonamide
[0665] Example 29 was prepared according to the procedure used for
the preparation of Example 55, substituting
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide
for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperaz-
ine. .sup.1H NMR (DMSO-d.sub.6) .delta. 1.08 (s, 3H), 4.29 (s, 2H),
5.75 (s, 2H), 6.74 (s, 1H), 7.39 (d, J=1.7 Hz, 1H), 7.77-7.80 (m,
2H), 7.84-7.89 (m, 2H), 7.94 (d, J=1.7 Hz, 1H), 8.40 (s, 1H), 8.51
(s, 1H). MS (APCI) m/z 432 (M+H--NH.sub.3).sup.+.
Example 30
9-{[2-(aminomethyl)-5-(4-methylphenyl)-1H-indol-7-yl]methyl}-9H-purin-6-am-
ine
[0666] Example 30 was prepared according to the procedure used for
the preparation of Example 55, substituting p-tolylboronic acid for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperaz-
ine. .sup.1H NMR (DMSO-d.sub.6) .delta. 2.32 (s, 3H), 4.27 (s, 2H),
5.73 (s, 2H), 6.69 (s, 1H), 7.23 (s, 1H), 7.24-7.29 (m, 2H),
7.44-7.49 (m, 2H), 7.79 (d, J=1.6 Hz, 1H), 8.39 (s, 1H), 8.51 (s,
1H). MS (APCI) m/z 367 (M+H--NH.sub.3).sup.+.
Example 31
9-{[2-(aminomethyl)-5-(3-methylphenyl)-1H-indol-7-yl]methyl}-9H-purin-6-am-
ine
[0667] Example 31 was prepared according to the procedure used for
the preparation of Example 55, substituting m-tolylboronic acid for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperaz-
ine. .sup.1H NMR (DMSO-d.sub.6) .delta. 2.36 (s, 3H), 4.28 (s, 2H),
5.74 (s, 2H), 6.70 (s, 1H), 7.13 (d, J=7.1 Hz, 1H), 7.28-7.37 (m,
3H), 7.38-7.44 (m, 1H), 7.82 (d, J=1.6 Hz, 1H), 8.41 (s, 1H), 8.53
(s, 1H). MS (APCI) m/z 367 (M+H--NH.sub.3).sup.+.
Example 32
9-{[2-(aminomethyl)-5-(2-methylphenyl)-1H-indol-7-yl]methyl}-9H-purin-6-am-
ine
[0668] Example 32 was prepared according to the procedure used for
the preparation of Example 55, substituting o-tolylboronic acid for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperaz-
ine. .sup.1H NMR (DMSO-d.sub.6) .delta. 2.09 (s, 3H), 4.29 (s, 2H),
5.73 (s, 2H), 6.67 (s, 1H), 6.83 (d, J=1.5 Hz, 1H), 7.09-7.27 (m,
4H), 7.48 (d, J=1.5 Hz, 1H), 8.37 (s, 1H), 8.51 (s, 1H). MS (APCI)
m/z 367 (M+H-NH.sub.3).sup.+.
Example 33
(4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}phenyl-
)methanol
[0669] Example 33 was prepared according to the procedure used for
the preparation of Example 55, substituting
(4-(hydroxymethyl)phenyl)boronic acid for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzy-
l)piperazine. .sup.1H NMR (DMSO-d.sub.6) .delta. 4.28 (s, 2H), 4.52
(s, 2H), 5.74 (s, 2H), 6.70 (s, 1H), 7.29 (d, J=1.7 Hz, 1H), 7.37
(d, 2H), 7.54 (d, 2H), 7.82 (d, J=1.6 Hz, 1H), 8.39 (s, 1H), 8.52
(s, 1H). MS (APCI) m/z 383 (M+H-NH.sub.3).sup.+.
Example 34
9-{[2-(aminomethyl)-5-(4-methoxyphenyl)-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine
[0670] Example 34 was prepared according to the procedure used for
the preparation of Example 55, substituting
(4-methoxyphenyl)boronic acid for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperaz-
ine. .sup.1H NMR (DMSO-d.sub.6) .delta. 3.78 (s, 3H), 4.27 (s, 2H),
5.73 (s, 2H), 6.68 (s, 1H), 6.96-7.01 (m, 2H), 7.23 (d, J=1.7 Hz,
1H), 7.47-7.53 (m, 2H), 7.76 (d, J=1.6 Hz, 1H), 8.40 (s, 1H), 8.52
(s, 1H). MS (APCI) m/z: 383 (M+H--NH.sub.3).sup.+.
Example 35
9-{[2-(aminomethyl)-5-(3-methoxyphenyl)-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine
[0671] Example 35 was prepared according to the procedure used for
the preparation of Example 10, substituting
(3-methoxyphenyl)boronic acid for
4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane. .sup.1H NMR (400
MHz, CD.sub.3OD) .delta. 8.41 (s, 1H), 8.33 (s, 1H), 7.81 (d, J=1.6
Hz, 1H), 7.41 (d, J=1.6 Hz, 1H), 7.31 (t, J=7.9 Hz, 1H), 7.19-7.00
(m, 2H), 6.86 (dd, J=8.2, 2.5 Hz, 1H), 6.72 (s, 1H), 5.79 (s, 2H),
4.36 (s, 2H), 3.83 (s, 3H); MS m/z: 266 [M-adenine].sup.+.
Example 36
9-{[2-(aminomethyl)-5-(2-methoxyphenyl)-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine
[0672] Example 36 was prepared according to the procedure used for
the preparation of Example 55, substituting
(2-methoxyphenyl)boronic acid for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperaz-
ine. .sup.1H NMR (DMSO-d.sub.6) .delta. 3.63 (s, 3H), 4.28 (s, 2H),
5.72 (s, 2H), 6.66 (s, 1H), 6.97-7.03 (m, 2H), 7.05 (d, J=8.2, 1.1
Hz, 1H), 7.23 (dd, J=7.5, 1.7 Hz, 1H), 7.27-7.35 (m, 1H), 7.61 (d,
J=1.5 Hz, 1H), 8.39 (s, 1H), 8.51 (s, 1H). MS (APCI) m/z: 383
(M+H--NH.sub.3).sup.+.
Example 37
9-({2-(aminomethyl)-5-[4-(methylsulfonyl)phenyl]-1H-indol-7-yl}methyl)-9H--
purin-6-amine
[0673] Example 37 was prepared according to the procedure used for
the preparation of Example 55, substituting
(4-(methylsulfonyl)phenyl)boronic acid for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzy-
l)piperazine. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.52 (s,
1H), 8.40 (s, 1H), 8.01 (d, J=8.1 Hz, 2H), 7.98 (d, J=1.9 Hz, 1H),
7.87 (d, J=8.8 Hz, 3H), 7.40 (d, J=1.6 Hz, 1H), 6.75 (s, 1H), 5.76
(s, 2H), 3.22 (s, 3H). MS (APCI) m/z: 448 (M+H).sup.+.
Example 38
4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}benzoni-
trile
[0674] Example 38 was prepared according to the procedure used for
the preparation of Example 55, substituting (4-cyanophenyl)boronic
acid for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperaz-
ine. .sup.1H NMR (DMSO-d.sub.6) .delta. 4.29 (s, 2H), 5.75 (s, 2H),
6.74 (s, 1H), 7.40 (d, J=1.7 Hz, 1H), 7.77-7.85 (m, 2H), 7.84-7.92
(m, 2H), 7.97 (d, J=1.6 Hz, 1H), 8.40 (s, 1H), 8.52 (s, 1H). MS
(APCI) m/z: 378 (M+H--NH.sub.3).sup.+.
Example 39
3-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}benzoni-
trile
[0675] Example 39 was prepared according to the procedure used for
the preparation of Example 55, substituting (3-cyanophenyl)boronic
acid for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperaz-
ine. .sup.1H NMR (DMSO-d.sub.6) .delta. 4.29 (s, 2H), 5.75 (s, 2H),
6.73 (s, 1H), 7.42 (d, J=1.7 Hz, 1H), 7.65 (t, J=7.8 Hz, 1H), 7.76
(dt, J=7.8, 1.3 Hz, 1H), 7.93-7.97 (m, 2H), 8.06 (t, J=1.7 Hz, 1H),
8.41 (s, 1H), 8.52 (s, 1H). MS (APCI) m/z: 378
(M+H--NH.sub.3).sup.+.
Example 40
3-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}benzami-
de
[0676] Example 40 was prepared according to the procedure used for
the preparation of Example 55, substituting
(3-carbamoylphenyl)boronic acid for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)pip-
erazine. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.57 (s, 1H),
8.46 (s, 1H), 8.10 (t, J=1.8 Hz, 1H), 7.92 (d, J=1.5 Hz, 1H), 7.80
(dt, J=7.6, 1.3 Hz, 1H), 7.75 (dt, J=8.1, 1.3 Hz, 1H), 7.53 (t,
J=7.8 Hz, 1H), 7.40 (d, J=1.7 Hz, 1H), 6.73 (s, 1H), 5.78 (s, 2H),
4.29 (s, 2H). MS (APCI) m/z: 413 (M+H).sup.+.
Example 41
N-(4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}phen-
yl)methanesulfonamide
[0677] Example 41 was prepared according to the procedure used for
the preparation of Example 55, substituting
N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanesulfonami-
de for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)p-
iperazine. .sup.1H NMR (DMSO-d.sub.6) .delta. 3.00 (s, 3H), 4.28
(s, 2H), 5.75 (s, 2H), 6.70 (s, 1H), 7.24-7.31 (m, 3H), 7.57 (d,
2H), 7.81 (d, J=1.6 Hz, 1H), 8.43 (s, 1H), 8.54 (s, 1H). MS (APCI)
m/z: 446 (M+H-NH.sub.3).sup.+.
Example 42
N-(3-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}phen-
yl)methanesulfonamide
[0678] Example 42 was prepared according to the procedure used for
the preparation of Example 55, substituting
N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanesulfonami-
de for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)p-
iperazine. .sup.1H NMR (DMSO-d.sub.6) .delta. 3.00 (s, 3H), 4.29
(s, 2H), 5.76 (s, 2H), 6.72 (s, 1H), 7.11-7.16 (m, 1H), 7.20 (d,
J=1.7 Hz, 1H), 7.24-7.36 (m, 2H), 7.36-7.43 (m, 2H), 7.52-7.61 (m,
1H), 7.79 (d, J=1.6 Hz, 1H), 8.40 (s, 1H), 8.53 (s, 1H). MS (APCI)
m/z: 463 (M+H).sup.+.
Example 43
9-{[2-(aminomethyl)-5-(4-ethylphenyl)-1H-indol-7-yl]methyl}-9H-purin-6-ami-
ne
[0679] Example 43 was prepared according to the procedure used for
the preparation of Example 55, substituting (4-ethylphenyl)boronic
acid for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperaz-
ine. .sup.1H NMR (DMSO-d.sub.6) .delta. 1.19 (t, J=7.6 Hz, 3H),
2.62 (q, J=7.6 Hz, 2H), 4.27 (s, 2H), 5.68 (s, 2H), 6.68 (s, 1H),
7.21-7.32 (m, 3H), 7.48 (d, J=8.0 Hz, 2H), 7.78 (d, J=1.6 Hz, 1H),
8.27 (s, 1H), 8.37 (s, 1H). MS (APCI) m/z 381
(M+H-NH.sub.3).sup.+.
Example 44
methyl
4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}-
benzoate
[0680] Example 44 was prepared according to the procedure used for
the preparation of Example 55, substituting
(4-(methoxycarbonyl)phenyl)boronic acid for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperaz-
ine. .sup.1H NMR (DMSO-d.sub.6) .delta. 3.87 (s, 3H), 4.29 (s, 2H),
5.75 (s, 2H), 6.74 (s, 1H), 7.43 (d, J=1.7 Hz, 1H), 7.77 (d, 2H),
7.96 (d, J=1.7 Hz, 1H), 7.98-8.08 (m, 2H), 8.39 (s, 1H), 8.50 (s,
1H); MS (APCI) m/z: 411 (M+H--NH.sub.3).sup.+.
Example 45
(4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}phenyl-
)acetonitrile
[0681] Example 45 was prepared according to the procedure used for
the preparation of Example 55, substituting
(4-(cyanomethyl)phenyl)boronic acid for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzy-
l)piperazine. .sup.1H NMR (DMSO-d.sub.6) .delta. 4.02 (s, 2H), 4.28
(s, 2H), 5.74 (s, 2H), 6.71 (s, 1H), 7.31 (d, J=1.7 Hz, 1H), 7.42
(d, 2H), 7.61 (d, 2H), 7.85 (d, J=1.6 Hz, 1H), 8.39 (s, 1H), 8.50
(s, 1H). MS (APCI) m/z: 409 (M+H).sup.+.
Example 46
3-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}-N-ethy-
lbenzamide
[0682] Example 46 was prepared according to the procedure used for
the preparation of Example 55, substituting
(3-(ethylcarbamoyl)phenyl)boronic acid for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzy-
l)piperazine. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.53 (s,
1H), 8.42 (s, 1H), 8.04 (t, J=1.8 Hz, 1H), 7.91 (d, J=1.7 Hz, 1H),
7.74 (ddt, J=8.1, 6.6, 1.3 Hz, 2H), 6.73 (s, 1H), 5.76 (s, 2H),
4.29 (s, 2H), 3.32 (q, J=7.2 Hz, 2H), 1.15 (t, J=7.5 Hz, 3H). MS
(APCI) m/z: 441 (M+H).sup.+.
Example 47
4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}-N,N-di-
methylbenzamide
[0683] Example 47 was prepared according to the procedure used for
the preparation of Example 55, substituting
(4-(dimethylcarbamoyl)phenyl)boronic acid for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperaz-
ine. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.60 (s, 1H), 8.47
(s, 1H), 7.90 (d, J=1.6 Hz, 1H), 7.83 (d, J=7.9 Hz, 2H), 7.36 (d,
J=7.8 Hz, 2H), 7.34 (d, J=1.7 Hz, 1H), 6.73 (s, 1H), 5.78 (s, 2H),
4.30, (s, 2H), 3.00 (s, 6H). MS (APCI) m/z: 441 (M+H).sup.+.
Example 48
3-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}-N,N-di-
methylbenzamide
[0684] A microwave vial was charged with
tris(dibenzylideneacetone)dipalladium(0) (25 mg, 0.027 mmol), of
potassium phosphate (70 mg, 0.33 mmol) and tricyclohexylphosphine
(20 mg, 0.071 mmol), followed by addition of a solution of Example
9b (25 mg, 0.08 mmol) in dioxane (1.0 mL) and
N,N-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide
(0.15 mmol) in dioxane (0.5 mL) and water (200 .mu.L). The
resulting mixture was heated in the microwave oven (Biotage
Initiator, Power range 0-400 W from magnetron at 2.45 GHz) for 20
minutes at 140.degree. C. The reaction mixture was filtered, and
purified by reverse phase preparative HPLC on a Phenomenex Luna C8
(2) 5 um 100 .ANG. AXIA column (30 mm.times.150 mm). A gradient of
acetonitrile (A) and 0.1% trifluoroacetic acid in water (B) was
used, at a flow rate of 50 mL/min (0-0.5 minutes 10% A, 0.5-6.0
minutes linear gradient 10-100% A, 6.0-7.0 minutes 100% A, 7.0-8.0
minutes linear gradient 100-10% A). An Agilent 1100 Series
Purification system was used, consisting of the following modules:
Agilent 1100 Series LC/MSD SL mass spectrometer with
API-electrospray source; two Agilent 1100 Series preparative pumps;
Agilent 1100 Series isocratic pump; Agilent 1100 Series diode array
detector with preparative (0.3 mm) flow cell; Agilent
active-splitter, IFC-PAL fraction collector/autosampler. The
make-up pump for the mass spectrometer used 3:1 methanol:water with
0.1% formic acid at a flow rate of 1 mL/min. Fraction collection
was automatically triggered when the extracted ion chromatogram
(EIC) for the target mass exceeded the threshold specified in the
method. The system was controlled using Agilent Chemstation (Rev
B.10.03), Agilent A2Prep, and Leap FractPal software, with custom
Chemstation macros for data export. .sup.1H NMR (DMSO-d.sub.6)
.delta. 2.98 (s, 6H), 3.93 (s, 2H), 5.67 (s, 2H), 6.40 (s, 1H),
7.22-7.33 (m, 2H), 7.40-7.58 (m, 2H), 7.58-7.66 (m, 1H), 7.66-7.76
(m, 1H), 8.25 (d, J=9.3 Hz, 2H); (ESI) m/z 441 (M+H).sup.+.
Example 49
4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}-N-[2-(-
dimethylamino)ethyl]benzamide
[0685] Example 49 was prepared according to the procedure used for
the preparation of Example 55, substituting
N-(2-(dimethylamino)ethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl-
)benzamide for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperaz-
ine. .sup.1H NMR (DMSO-d.sub.6) .delta. 2.87 (s, 6H), 3.26-3.30 (m,
2H), 3.61-3.65 (m, 2H), 4.29 (s, 2H), 5.75 (s, 2H), 6.72 (s, 1H),
7.36 (d, J=1.6 Hz, 1H), 7.69-7.75 (m, 2H), 7.88-7.95 (m, 3H), 8.38
(s, 1H), 8.49 (s, 1H). MS (APCI) m/z 484 (M+H).sup.+.
Example 50
4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}-N-cycl-
opropylbenzamide
[0686] Example 50 was prepared according to the procedure used for
the preparation of Example 55, substituting
N-cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide
for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)pip-
erazine. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.51 (s, 1H),
8.39 (s, 1H), 7.91 (d, J=1.6 Hz, 1H), 7.89-7.85 (m, 2H), 7.70-7.63
(m, 2H), 7.36 (d, J=1.7 Hz, 1H), 6.72 (s, 1H), 5.75 (s, 2H), 4.28
(s, 2H), 2.85 (tt, J=7.3, 3.9 Hz, 1H), 0.83-0.49 (m, 6H). MS (APCI)
m/z: 453 (M+H).sup.+.
Example 51
3-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}-N-cycl-
opropylbenzamide
[0687] Example 51 was prepared according to the procedure used for
the preparation of Example 48, substituting
N,N-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide
for (3-(cyclopropylcarbamoyl)phenyl) boronic acid. .sup.1H NMR
(DMSO-d.sub.6) .delta. 0.55-0.67 (m, 2H), 0.67-0.79 (m, 2H),
2.80-2.95 (m, 1H), 3.94 (s, 2H), 5.67 (s, 2H), 6.41 (s, 1H),
7.30-7.39 (m, 1H), 7.46 (t, J=7.7 Hz, 1H), 7.66-7.70 (m, 2H),
7.72-7.79 (m, 1H), 7.94-8.03 (m, 1H), 8.24 (d, J=17.9 Hz, 2H);
(ESI) m/z 453 (M+H).sup.+ and 436 (M-16).
Example 52
9-({2-(aminomethyl)-5-[3-(morpholin-4-yl)phenyl]-1H-indol-7-yl}methyl)-9H--
purin-6-amine
[0688] Example 52 was prepared according to the procedure used for
the preparation of Example 48, substituting
(3-morpholinophenyl)boronic acid hydrochloride for
N,N-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide.
.sup.1H NMR (DMSO-d.sub.6) .delta. 3.12-3.15 (m, 4H), 3.74-3.80 (m,
4H), 3.94 (s, 2H), 5.66 (s, 2H), 6.39 (s, 1H), 6.95-7.05 (m, 2H),
7.16-7.21 (m, 1H), 7.21-7.31 (m, 1H), 7.61-7.70 (m, 1H), 8.18-8.29
(m, 2H); (ESI) m/z 455 (M+H).sup.+ and 438 (M-16).
Example 53
(3-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}phenyl-
)(morpholin-4-yl)methanone
[0689] Example 53 was prepared according to the procedure used for
the preparation of Example 48, substituting
(3-(morpholine-4-carbonyl)phenyl)boronic acid for
N,N-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide.
.sup.1H NMR (DMSO-d.sub.6) .delta. 3.47-3.56 (m, 4H), 3.56-3.67 (m,
4H), 3.94 (s, 2H), 5.67 (s, 2H), 6.41 (s, 1H), 7.23-7.34 (m, 2H),
7.48 (t, J=7.7 Hz, 1H), 7.52-7.56 (m, 1H), 7.61-7.67 (m, 1H),
7.70-7.76 (m, 1H), 8.19-8.30 (m, 2H); (ESI) m/z 483
(M+H).sup.+.
Example 54
9-{[2-(aminomethyl)-5-{4-[(4-methylpiperazin-1-yl)methyl]phenyl}-1H-indol--
7-yl]methyl}-9H-purin-6-amine
[0690] Example 54 was prepared according to the procedure used for
the preparation of Example 55, substituting
1-methyl-4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperaz-
ine for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)-
piperazine. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.51 (s,
1H), 8.38 (s, 1H), 7.85 (d, J=1.6 Hz, 1H), 7.62 (d, J=8.2 Hz, 2H),
7.46 (d, J=8.2 Hz, 2H), 7.25 (d, J=1.7 Hz, 1H), 6.71 (s, 1H), 5.75
(s, 2H), 4.28 (s, 2H), 3.98 (s, 2H), 2.80-3.63 (br m, 8H), 2.81 (d,
3H). MS (APCI) m/z: 482 (M+H).sup.+.
Example 55
9-{[2-(aminomethyl)-5-{3-[(4-methylpiperazin-1-yl)methyl]phenyl}-1H-indol--
7-yl]methyl}-9H-purin-6-amine
[0691] In a microwave vial was added Example 9b (25 mg, 0.076
mmol),
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperaz-
ine (48 mg, 0.15 mmol), potassium phosphate tribasic (32 mg, 0.15
mmol), tris(dibenzylideneacetone)dipalladium (0) (14 mg, 0.014
mmol) and tricyclohexylphosphine (9 mg, 0.032 mmol), followed by
the addition of dry, degassed dioxane (2 mL) and water (0.111 mL).
The vessel was sealed and heated under microwave irradiation using
a Biotage Initiator 60 at 140.degree. C. for 15 minutes. The cooled
solution was then filtered through Celite.RTM., concentrated, and
purified by reverse phase preparative HPLC to provide the title
compound. Preparative HPLC condition: Sample was purified by
preparative HPLC on a Phenomenex Luna C8 (2) 5 .mu.m 100 .ANG. AXIA
column (30 mm.times.150 mm). A gradient of acetonitrile (A) and
0.1% trifluoroacetic acid in water (B) was used, at a flow rate of
50 mL/min (0-0.5 minutes 10% A, 0.5-6.0 minutes linear gradient
10-100% A, 6.0-7.0 minutes 100% A, 7.0-8.0 minutes linear gradient
100-10% A). An Agilent 1100 Series Purification system was used,
consisting of the following modules: Agilent 1100 Series LC/MSD SL
mass spectrometer with API-electrospray source; two Agilent 1100
Series preparative pumps; Agilent 1100 Series isocratic pump;
Agilent 1100 Series diode array detector with preparative (0.3 mm)
flow cell; Agilent active-splitter, IFC-PAL fraction
collector/autosampler. The make-up pump for the mass spectrometer
used 3:1 methanol:water with 0.1% formic acid at a flow rate of 1
mL/min. Fraction collection was automatically triggered when the
extracted ion chromatogram (EIC) for the target mass exceeded the
threshold specified in the method. The system was controlled using
Agilent Chemstation (Rev B.10.03), Agilent A2Prep, and Leap
FractPal software, with custom Chemstation macros for data export.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.46 (s, 1H), 8.36 (s,
1H), 7.84 (d, J=1.6 Hz, 1H), 7.71-7.64 (m, 1H), 7.64-7.38 (m, 4H),
7.32 (d, J=7.4 Hz, 1H), 7.29 (d, J=1.6 Hz, 1H), 6.70 (s, 1H), 5.73
(s, 2H), 4.28 (s, 2H), 3.92 (s, 2H), 2.80 (d, J=1.7 Hz, 3H),
2.7-3.6 (br m, 8H). MS (APCI) m/z: 482 (M+H).sup.+.
Example 56
(4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-5-yl}phenyl-
)(4-methylpiperazin-1-yl)methanone
[0692] Example 56 was prepared according to the procedure used for
the preparation of Example 55, substituting
(4-methylpiperazin-1-yl)(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)p-
henyl)methanone for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperaz-
ine. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.53 (s, 1H), 8.40
(s, 1H), 7.90 (d, J=1.6 Hz, 1H), 7.73-7.65 (m, 2H), 7.56-7.49 (m,
2H), 7.32 (d, J=1.6 Hz, 1H), 6.72 (s, 1H), 5.76 (s, 2H), 4.29 (s,
2H), 3.0-3.6 (br m, 8H), 2.85 (s, 3H). MS (APCI) m/z: 496
(M+H).sup.+.
Example 57
9-{[2-(aminomethyl)-5-(2,3-dihydro-1-benzofuran-5-yl)-1H-indol-7-yl]methyl-
}-9H-purin-6-amine
[0693] Example 57 was prepared according to the procedure used for
the preparation of Example 55, substituting
(2,3-dihydrobenzofuran-5-yl)boronic acid for
1-methyl-4-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperaz-
ine. .sup.1H NMR (DMSO-d.sub.6) .delta. 3.22 (t, J=8.6 Hz, 2H),
4.27 (s, 2H), 4.55 (t, J=8.7 Hz, 2H), 5.72 (s, 2H), 6.66 (s, 1H),
6.81 (d, J=8.3 Hz, 1H), 7.23 (d, J=1.7 Hz, 1H), 7.28 (dd, J=8.3,
2.0 Hz, 1H), 7.44 (d, J=1.9 Hz, 1H), 7.73 (d, J=1.6 Hz, 1H), 8.39
(s, 1H), 8.50 (s, 1H). MS (APCI) m/z: 395
(M+H--NH.sub.3).sup.+.
Example 58
9-{[2-(aminomethyl)-6-chloro-1H-indol-7-yl]methyl}-9H-purin-6-amine
Example 58a
(3-chloro-2-methylphenyl)hydrazine
[0694] 3-chloro-2-methylaniline (30 g, 212 mmol) was treated with
trifluoroacetic acid (65 mL) and concentrated hydrochloric acid
(300 mL, 9874 mmol) in a 250 mL round-bottomed flask and then
stirred at ambient temperature for 10 minutes. The suspension was
cooled to about 0.degree. C. in an ice bath. A solution of sodium
nitrite (17.98 g, 261 mmol) in water (150 mL) was added dropwise
via syringe. After the completion of addition, the mixture was
stirred at 0.degree. C. for 1 hour. A cold solution of tin(II)
chloride (88 g, 466 mmol) in water (50 mL) and concentrated
hydrochloric acid (100 mL, 3291 mmol) were added drop wise via
dropping funnel to the reaction mixture. The mixture was stirred at
ambient temperature, filtered through Buchner funnel to afford the
title compound (40 g, 207 mmol, 98% yield). MS (ESI+): m/z 157
(M+H).sup.+.
Example 58b
(E)-ethyl 2-(2-(3-chloro-2-methylphenyl)hydrazono)propanoate
[0695] Example 58a (39 g, 202 mmol) was dissolved in acetic acid
(20 mL) in a 100 mL round-bottomed flask. Ethyl pyruvate (22.55 mL,
202 mmol) was added slowly. The resulting suspension was stirred at
35.degree. C. for 2 hours, filtered through Buchner funnel to
afford the title compound (40 g, 176 mmol, 87% yield). MS (ESI+):
m/z 255 (M+H).sup.+.
Example 58c
ethyl 6-chloro-7-methyl-1H-indole-2-carboxylate
[0696] To a solution of Example 58b (20 g, 79 mmol) in toluene (300
mL) was added 30 g of Amberlyst-15. The resulting suspension was
stirred at 120.degree. C. for 16 hours. The reaction mixture was
filtered to remove solid material and the filtrate was concentrated
under reduced pressure to afford the title compound (16 g, 67.3
mmol, 86% yield) as a brown solid. MS (ESI+): m/z 238
(M+H).sup.+.
Example 58d
1-tert-butyl 2-ethyl
6-chloro-7-methyl-1H-indole-1,2-dicarboxylate
[0697] To a solution of Example 58c (41 g, 172 mmol) in
dichloromethane (150 mL) was added N,N-dimethylpyridin-4-amine
(2.107 g, 17.25 mmol), triethylamine (28.9 mL, 207 mmol) and
di-tert-butyl dicarbonate (48.1 mL, 207 mmol) at 0.degree. C. The
resulting solution was stirred at 25.degree. C. for 16 hours and
then washed sequentially with water, saturated sodium bicarbonate
solution, and brine. The organic layer was dried with sodium
sulfate, filtered and concentrated under reduced pressure. The
residue was purified by column chromatography using petroleum
ether/ethyl acetate with a gradient from 15/1 to 5/1 to afford the
title compound (49.8 g, 147 mmol, 85% yield). MS (ESI+): m/z 338
(M+H).sup.+.
Example 58e
1-tert-butyl 2-ethyl
7-(bromomethyl)-6-chloro-1H-indole-1,2-dicarboxylate
[0698] To a solution of Example 58d (10 g, 29.6 mmol) in carbon
tetrachloride (50 mL) was added benzoic peroxyanhydride (0.717 g,
2.96 mmol) and N-bromosuccinimide (5.27 g, 29.6 mmol). After
stirring at 85.degree. C. for 16 hours, the mixture was cooled to
0.degree. C. and filtered to remove solid material. The filtrate
was concentrated under reduced pressure. The residue was taken into
ethyl acetate (200 mL), and washed sequentially with water and
brine. The organic layer was dried with anhydrous sodium sulfate,
filtered, and concentrated under reduced pressure to afford the
title compound (12 g, 25.9 mmol, 88% yield). MS (ESI+): m/z 418
(M+H).sup.+.
Example 58f
ethyl
7-((6-amino-9H-purin-9-yl)methyl)-6-chloro-1H-indole-2-carboxylate
[0699] In a 250 mL round-bottomed flask, a mixture of Example 58e
(12 g, 25.9 mmol), 9H-purin-6-amine (3.50 g, 25.9 mmol) and cesium
carbonate (12.67 g, 38.9 mmol) in N,N-dimethylformamide (100 mL)
was stirred at ambient temperature for 16 hours. The reaction
mixture was then diluted with ethyl acetate (300 mL) and washed
sequentially with water (50 mL.times.3), and brine. The organic
layer was dried with sodium sulfate, filtered, and concentrated
under reduced pressure. The residue was re-dissolved in ethyl
acetate (20 mL). Petroleum ether (20 mL) was added. The solid
formed was collected to give a mixture of the tile compound and its
BOC-protected analog. The solid material above was suspended in
dichloromethane (5 mL) and treated with trifluoroacetic acid (5
mL). The mixture was stirred at room temperature for 2 hours and
then concentrated under reduced pressure. The residue was treated
with saturated sodium bicarbonate solution. The solid was collected
by filtration, washed with water, and dried to afford the title
compound (5.5 g, 12.90 mmol, 101% yield) as white solid. MS (ESI+):
m/z 371 (M+H).sup.+.
Example 58g
(7-((6-amino-9H-purin-9-yl)methyl)-6-chloro-1H-indol-2-yl)methanol
[0700] To a suspension of Example 58f (6 g, 14.08 mmol) in THF (100
mL) was added lithium aluminum hydride (56.3 mL, 56.3 mmol, 1.0 M
THF solution) at 0.degree. C. drop wise. The mixture was stirred at
ambient temperature for 5 hours. The reaction mixture was quenched
with water (150 mL) carefully, followed by the addition of ethyl
acetate (400 mL). The mixture was filtered to remove solid
material. The filtrate was extracted with ethyl acetate (2.times.).
The combined organic phases were washed with brine, dried over
anhydrous sodium sulfate, filtered and concentrated under reduce
pressure. The residue was triturated in petroleum ether/ethyl
acetate (10/1, 30 mL) to give the title compound (3.0 g, 64%
yield). MS (ESI+): m/z 329 (M+H).sup.+.
Example 58h
9-((2-(azidomethyl)-6-chloro-1H-indol-7-yl)methyl)-9H-purin-6-amine
[0701] To a suspension of Example 58g (3.6 g, 10.40 mmol) in
dichloromethane (30 mL) and toluene (30 mL) was added diphenyl
phosphorazidate (11.45 g, 41.6 mmol) drop wise and DBU (6.27 mL,
41.6 mmol) at ambient temperature under nitrogen atmosphere. The
resulting mixture was stirred at ambient temperature overnight. The
mixture was poured into ice-water (40 mL) and extracted with
dichloromethane (60 mL.times.2). The combined organic phases were
washed with brine, dried over anhydrous magnesium sulfate,
filtered, and concentrated under reduced pressure. The residue was
purified by column chromatography on silica gel with a gradient of
1-2% methanol in dichloromethane to yield the title compound (1.5
g, 4.24 mmol, 40.8% yield). MS (ESI+): m/z 354 (M+H).sup.+.
Example 58i
9-((2-(aminomethyl)-6-chloro-1H-indol-7-yl)methyl)-9H-purin-6-amine
[0702] To a solution of Example 58h (1.4 g, 3.96 mmol) in THF (10
mL) and water (5 mL) was added triphenylphosphine (2.076 g, 7.91
mmol). The resulting mixture was stirred at ambient temperature
overnight and then concentrated under reduced pressure. The residue
was triturated in petroleum ether/ethyl acetate (5/1, 20 mL) and
then recrystallized in ethyl acetate to give the title compound
(400 mg, 1.159 mmol, 29.3% yield). MS (ESI+): m/z 328 (M+H).sup.+;
.sup.1H NMR: (400 MHz, DMSO-d.sub.6): .delta. 8.24 (s, 1H), 7.80
(s, 1H), 7.38 (d, J=8.4 Hz, 1H), 7.00 (d, J=8.4 Hz, 1H), 6.31 (s,
1H), 5.64 (s, 2H), 3.88 (s, 2H).
Example 59
9-{[2-(aminomethyl)-6-ethenyl-1H-indol-7-yl]methyl}-9H-purin-6-amine
[0703] A nitrogen degassed suspension Example 58i (50 mg, 0.153
mmol), 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (0.039 mL,
0.230 mmol), potassium phosphate (65 mg, 0.306 mmol),
tricyclohexylphosphine (8.3 mg, 0.030 mmol),
tris(dibenzylideneacetone)dipalladium(0) (14 mg, 0.015 mmol),
dioxane (1.0 mL) and water (0.05 mL) was heated in the microwave
(Biotage, Initiator, 200 W) at 140.degree. C. for 1 hour. Water and
ethyl acetate were added and the layers were separated. The aqueous
layer was extracted 2 more times with ethyl acetate and the
combined extracts were washed sequentially with water and brine,
dried (magnesium sulfate), filtered, and concentrated. The crude
product was absorbed onto silica gel and was flash chromatographed
(Biotage 10 g HP Snap Cartridge, eluting with dichloromethane
containing a gradient (2% to 15%) with methanol which contained 1%
NH.sub.4OH) to provide the title compound. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 11.43 (s, 1H), 8.27 (s, 1H), 7.68 (s, 1H),
7.48 (d, J=8.2 Hz, 1H), 7.36-7.23 (m, 4H), 6.37 (s, 1H), 5.79-5.58
(m, 3H), 5.29-5.08 (m, 1H), 3.95 (s, 2H). MS ESI.sup.+ 320.1
(M+H).sup.+.
Example 60
9-{[2-(aminomethyl)-6-(prop-1-en-2-yl)-1H-indol-7-yl]methyl}-9H-purin-6-am-
ine
[0704] Using the procedure described for Example 59 and
substituting
4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane for
4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane provided the title
compound. .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 11.27 (s,
1H), 8.24 (s, 1H), 7.46 (d, J=8.1 Hz, 1H), 7.44 (s, 1H), 7.25 (s,
2H), 6.87 (d, J=8.0 Hz, 1H), 6.31 (s, 1H), 5.53 (s, 2H), 5.16 (t,
J=1.9 Hz, 1H), 4.68-4.47 (m, 1H), 3.86 (s, 2H), 1.94 (s, 3H). MS
ESI.sup.+ 334.1 (M+H).sup.+.
Example 61
9-{[2-(aminomethyl)-6-phenyl-1H-indol-7-yl]methyl}-9H-purin-6-amine
[0705] Using the procedure described for Example 59 and
substituting phenylboronic acid for
4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane provided the title
compound. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.28 (s,
1H), 8.14 (s, 1H), 7.55 (d, J=8.0 Hz, 1H), 7.43-7.26 (m, 3H), 7.20
(d, J=6.3 Hz, 4H), 7.11 (s, 1H), 6.93 (d, J=7.9 Hz, 1H), 6.38 (s,
1H), 5.44 (s, 2H), 3.89 (s, 2H). MS ESI.sup.+ 370.1
(M+H).sup.+.
Example 62
9-{[2-(aminomethyl)-4-chloro-1H-indol-7-yl]methyl}-9H-purin-6-amine
Example 62a
(E)-ethyl
2-((5-chloro-2-methylphenyl)diazenyl)-2-methyl-3-oxobutanoate
[0706] A solution of NaNO.sub.2 (43.9 g, 636 mmol) in H.sub.2O (60
mL) was dropped on to an ice-cooled mixture of
5-chloro-2-methylaniline (90 g, 636 mmol) in concentrated
hydrochloric acid (160 mL) and water (160 mL). After stirring for
20 minutes, a solution of sodium acetate (71.4 g, 871 mmol) in
water (160 mL) was added drop wise via dropping funnel at 0.degree.
C. After stirring for additional 30 minutes, the mixture was added
to an ice-cooled and well-stirred mixture of ethyl
2-methyl-3-oxobutanoate (93 g, 642 mmol) and potassium carbonate
(125 g, 1271 mmol) in methanol (500 mL). The mixture was stirred at
0.degree. C. for 3 hours and then at ambient temperature for 16
hours. Water (700 mL) was added. The aqueous layer was extracted
with ethyl acetate (2.times.500 mL). The combined organic phases
were dried over sodium sulfate, filtered, and concentrated under
reduced pressure to give the title compound (120 g, 404 mmol, 63.6%
yield).
Example 62b
(E)-ethyl 2-(2-(5-chloro-2-methylphenyl)hydrazono)propanoate
[0707] A mixture of Example 62a (60 g, 202 mmol) and concentrated
hydrochloric acid (20 mL) in ethanol (200 mL) was stirred at
100.degree. C. for 1 hour. The solid was collected via filtration
through Buchner funnel and washed with ethanol (30 mL.times.2) to
give the title compound (35 g, 137 mmol, 68% yield). MS (ESI+): m/z
255 (M+H).sup.+.
Example 62c
ethyl 4-chloro-7-methyl-1H-indole-2-carboxylate
[0708] Example 62c was prepared according to the procedure used for
the preparation of Example 58c, substituting Example 62b for
Example 58b. MS (ESI+): m/z 238 (M+H).sup.+.
Example 62d
1-tert-butyl 2-ethyl
4-chloro-7-methyl-1H-indole-1,2-dicarboxylate
[0709] Example 62d was prepared according to the procedure used for
the preparation of Example 58d, substituting Example 62c for
Example 58c. MS (ESI+): m/z 360 (M+Na).sup.+.
Example 62e
1-tert-butyl 2-ethyl
7-(bromomethyl)-4-chloro-1H-indole-1,2-dicarboxylate
[0710] Example 62e was prepared according to the procedure used for
the preparation of Example 58e, substituting Example 62d for
Example 58d. MS (ESI+): m/z 440 (M+Na).sup.+.
Example 62f
1-tert-butyl 2-ethyl
7-((6-amino-9H-purin-9-yl)methyl)-4-chloro-1H-indole-1,2-dicarboxylate
[0711] A mixture of Example 62e (35 g, 84 mmol), 9H-purin-6-amine
(10.21 g, 76 mmol) and cesium carbonate (32.8 g, 101 mmol) in
N,N-dimethylformamide (200 mL) was stirred at room temperature for
16 hours. The reaction mixture was diluted with water and ethyl
acetate. The aqueous layer was extracted with ethyl acetate
(3.times.150 mL). The combined organic phases were washed with
brine, dried with anhydrous sodium sulfate, filtered, and
concentrated. The residue was purified by column chromatography on
silica gel (3% methanol in dichloromethane) to afford the title
compound (16 g, 40.5 mmol, 40.5% yield). MS (ESI+): m/z 471
(M+H).sup.+.
Example 62g
ethyl
7-((6-amino-9H-purin-9-yl)methyl)-4-chloro-1H-indole-2-carboxylate
[0712] Trifluoroacetic acid (45.6 mL, 592 mmol) was added slowly to
a mixture of Example 62f (15.5 g, 32.9 mmol) in dichloromethane
(200 mL) at 0.degree. C. under nitrogen atmosphere. The resulting
mixture was stirred at ambient temperature overnight. After the
removal of solvent under reduced pressure, the residue was treated
with saturated sodium carbonate solution to adjust pH to about 8.
The mixture was stirred at ambient temperature for 2 hours and the
solid material was collected via filtration to afford the title
compound (10.8 g, 28.5 mmol, 87% yield). MS (ESI+): m/z 371
(M+H).sup.+.
Example 62h
(7-((6-amino-9H-purin-9-yl)methyl)-4-chloro-1H-indol-2-yl)methanol
[0713] Example 62h was prepared according to the procedure used for
the preparation of Example 58g, substituting Example 62g for
Example 58f. MS (ESI+): m/z 329 (M+H).sup.+.
Example 62i
9-((2-(azidomethyl)-4-chloro-1H-indol-7-yl)methyl)-9H-purin-6-amine
[0714] Example 62i was prepared according to the procedure used for
the preparation of Example 58h, substituting Example 62h for
Example 58g. MS (ESI+): m/z 354 (M+H).sup.+.
Example 62j
9-((2-(aminomethyl)-4-chloro-1H-indol-7-yl)methyl)-9H-purin-6-amine
[0715] Example 62j was prepared according to the procedure used for
the preparation of Example 58i, substituting Example 62i for
Example 58h. MS (ESI+): m/z 311 (M-NH.sub.2).sup.+; .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 11.68 (brs, 1H), 8.26 (s, 1H),
8.20 (s, 1H), 7.30 (s, 2H), 6.97 (d, J=7.6 Hz, 1H), 6.80 (d, J=7.6
Hz, 1H), 6.39 (s, 1H), 5.61 (s, 2H), 3.94 (s, 2H), 2.30 (brs,
2H).
Example 63
9-{[2-(aminomethyl)-4-ethenyl-1H-indol-7-yl]methyl}-9H-purin-6-amine
[0716] Example 63 was prepared according to the procedure used for
the preparation of Example 10, substituting Example 62j for Example
9b. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.40 (s, 1H), 8.26
(s, 1H), 7.21 (d, J=7.6 Hz, 1H), 7.14-7.01 (m, 2H), 6.90 (s, 1H),
5.89 (dd, J=17.7, 1.3 Hz, 1H), 5.73 (s, 2H), 5.37 (dd, J=11.0, 1.3
Hz, 1H), 4.37 (s, 2H); MS m/z: 303 [M-NH.sub.2].sup.+.
Example 64
9-{[2-(aminomethyl)-4-ethyl-1H-indol-7-yl]methyl}-9H-purin-6-amine
[0717] Example 63 (0.039 g, 0.071 mmol) and tetrahydrofuran (20 mL)
were added to 5% Pd/C (0.008 g, 0.033 mmol) in a 50 mL pressure
bottle and stirred or shaken for 8 hours under hydrogen gas (30 psi
pressure) at room temperature. The solvent was removed in vacuo and
the residue was purified by preparative HPLC (Waters Sunfire C8,
5-100% methanol/water; 1% TFA) to give the title compound (0.012 g,
31%). .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.40 (s, 1H), 8.21
(s, 1H), 7.04 (d, J=7.4 Hz, 1H), 6.88 (d, J=7.3 Hz, 1H), 6.72 (s,
1H), 5.69 (s, 2H), 4.35 (s, 2H), 2.88 (q, J=7.6 Hz, 2H), 1.29 (t,
J=7.6 Hz, 3H); MS m/z: 305 [M-NH.sub.2].sup.+.
Example 65
9-{[2-(aminomethyl)-4-(prop-1-en-2-yl)-1H-indol-7-yl]methyl}-9H-purin-6-am-
ine
[0718] Example 65 was prepared according to the procedure used for
the preparation of Example 10, substituting Example 62j for Example
9b, and 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane
for 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane. 1H NMR (400
MHz, CD.sub.3OD) .delta. 8.40 (s, 1H), 8.26 (s, 1H), 7.07 (d, J=7.6
Hz, 1H), 7.02 (d, J=7.6 Hz, 1H), 6.84 (s, 1H), 5.74 (s, 2H), 5.30
(s, 2H), 4.36 (s, 2H), 2.20 (t, J=1.1 Hz, 3H); MS m/z: 317
[M-NH.sub.2].sup.+.
Example 66
9-{[2-(aminomethyl)-4-(propan-2-yl)-1H-indol-7-yl]methyl}-9H-purin-6-amine
[0719] Example 66 was prepared according to the procedure used for
the preparation of Example 64, substituting Example 65 for Example
63. .sup.1H NMR (500 MHz, CD.sub.3OD) .delta. 8.41 (s, 1H), 8.23
(s, 1H), 7.06 (d, J=7.5 Hz, 1H), 6.93 (d, J=7.6 Hz, 1H), 6.76 (s,
1H), 5.70 (s, 2H), 4.35 (s, 2H), 3.33 (sep, J=6.8 Hz, 1H), 1.33 (d,
J=6.8 Hz, 6H); MS m/z: 319 [M-NH.sub.2].sup.+.
Example 67
9-{[2-(aminomethyl)-4-(cyclopent-1-en-1-yl)-1H-indol-7-yl]methyl}-9H-purin-
-6-amine
[0720] Example 67 was prepared according to the procedure used for
the preparation of Example 10, substituting Example 62j for Example
9b, and substituting
2-(cyclopent-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane for
4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 11.62 (s, 1H), 8.39-8.30 (m, 4H), 8.09
(s, 2H), 6.95 (d, J=7.6 Hz, 1H), 6.92 (s, 1H), 6.85 (d, J=7.6 Hz,
1H), 6.31 (t, J=2.4 Hz, 1H), 5.64 (s, 2H), 4.36-4.21 (m, 2H), 2.76
(dt, J=7.6, 3.8 Hz, 2H), 2.60-2.53 (m, 2H), 1.95 (q, J=7.5 Hz, 2H);
MS m/z: 343 [M-NH.sub.2].sup.+.
Example 68
9-{[2-(aminomethyl)-4-(1-methyl-1H-pyrazol-4-yl)-1H-indol-7-yl]methyl}-9H--
purin-6-amine
[0721] Example 68 was prepared according to the procedure used for
the preparation of Example 85, substituting
1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole
for (4-(methylsulfonamido)phenyl)boronic acid. .sup.1H NMR
(DMSO-d.sub.6) .delta. 3.92 (s, 3H), 4.30 (s, 2H), 5.73 (s, 2H),
6.92-6.96 (m, 2H), 7.17 (d, J=7.6 Hz, 1H), 7.89 (s, 1H), 8.13 (s,
1H), 8.49 (s, 1H), 8.56 (s, 1H); (ESI) m/z 357
(M-NH.sub.2).sup.+.
Example 69
9-{[2-(aminomethyl)-4-(pyridin-3-yl)-1H-indol-7-yl]methyl}-9H-purin-6-amin-
e
[0722] Example 69 was prepared according to the procedure used for
the preparation of Example 85, substituting pyridin-3-ylboronic
acid for (4-(methylsulfonamido)phenyl)boronic acid. MS (ESI) m/z
371 (M+H).sup.+.
Example 70
9-{[2-(aminomethyl)-4-phenyl-1H-indol-7-yl]methyl}-9H-purin-6-amine
[0723] Example 70 was prepared according to the procedure used for
the preparation of Example 10, substituting Example 62j for Example
9b, and substituting phenylboronic acid for
4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 11.75 (s, 1H), 8.45 (s, 1H), 8.42-8.27
(m, 3H), 8.24-7.99 (m, 2H), 7.67-7.54 (m, 2H), 7.50 (t, J=7.6 Hz,
2H), 7.44-7.34 (m, 1H), 7.07 (d, J=7.4 Hz, 1H), 6.97 (d, J=7.6 Hz,
1H), 6.77 (s, 1H), 5.71 (s, 2H), 4.30 (q, J=5.7 Hz, 2H); MS m/z:
353 [M-NH.sub.2].sup.+.
Example 71
9-{[2-(aminomethyl)-4-(3-chlorophenyl)-1H-indol-7-yl]methyl}-9H-purin-6-am-
ine
[0724] Example 71 was prepared according to the procedure used for
the preparation of Example 85, substituting (3-chlorophenyl)boronic
acid for (4-(methylsulfonamido)phenyl)boronic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.29 (s, 2H), 5.68 (s, 2H), 6.77
(s, 1H), 6.98 (d, J=7.6 Hz, 1H), 7.12 (d, J=7.5 Hz, 1H), 7.47 (d,
J=7.7 Hz, 1H), 7.51-7.60 (m, 2H), 7.62 (s, 1H), 8.25 (s, 1H), 8.34
(s, 1H); (ESI) m/z (M+H).sup.+.
Example 72
9-{[2-(aminomethyl)-4-(2-chlorophenyl)-1H-indol-7-yl]methyl}-9H-purin-6-am-
ine
[0725] Example 72 was prepared according to the procedure used for
the preparation of Example 85, substituting (2-chlorophenyl)boronic
acid for (4-(methylsulfonamido)phenyl)boronic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.25 (s, 2H), 5.77 (s, 2H), 6.34
(s, 1H), 6.94 (q, J=7.5 Hz, 2H), 7.35-7.42 (m, 1H), 7.42-7.49 (m,
2H), 7.55-7.63 (m, 1H), 8.45 (s, 1H), 8.60 (s, 1H); (ESI) m/z 387
(M-NH.sub.2).sup.+.
Example 73
9-{[2-(aminomethyl)-4-(4-fluorophenyl)-1H-indol-7-yl]methyl}-9H-purin-6-am-
ine
[0726] Example 73 was prepared according to the procedure used for
the preparation of Example 85, substituting (4-fluorophenyl)boronic
acid for (4-(methylsulfonamido)phenyl)boronic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.29 (s, 2H), 5.75 (s, 2H), 6.76
(s, 1H), 6.96 (d, J=7.6 Hz, 1H), 7.07 (d, J=7.5 Hz, 1H), 7.28-7.38
(m, 2H), 7.59-7.69 (m, 2H), 8.44 (s, 1H), 8.56 (s, 1H); (ESI) m/z
371 (M-NH.sub.2).sup.+.
Example 74
9-{[2-(aminomethyl)-4-(2-fluorophenyl)-1H-indol-7-yl]methyl}-9H-purin-6-am-
ine
[0727] Example 74 was prepared according to the procedure used for
the preparation of Example 85, substituting (2-fluorophenyl)boronic
acid for (4-(methylsulfonamido)phenyl)boronic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.28 (s, 2H), 5.79 (s, 2H), 6.51
(d, J=2.0 Hz, 1H), 6.96 (d, J=7.6 Hz, 1H), 7.04 (d, J=7.6 Hz, 1H),
7.31-7.38 (m, 2H), 7.44-7.52 (m, 2H), 8.48 (s, 1H), 8.62 (s, 1H);
(ESI) m/z 371 (M-NH.sub.2).sup.+.
Example 75
9-{[2-(aminomethyl)-4-(4-methylphenyl)-1H-indol-7-yl]methyl}-9H-purin-6-am-
ine
[0728] Example 75 was prepared according to the procedure used for
the preparation of Example 85, substituting p-tolylboronic acid for
(4-(methylsulfonamido)phenyl)boronic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 2.37 (s, 3H), 4.28 (s, 2H), 5.71
(s, 2H), 6.77 (s, 1H), 6.96 (d, J=7.6 Hz, 1H), 7.06 (d, J=7.6 Hz,
1H), 7.32 (d, J=7.9 Hz, 2H), 7.50 (d, 2H), 8.35 (s, 1H), 8.45 (s,
1H); (ESI) m/z 367 (M-NH.sub.2).sup.+
Example 76
9-{[2-(aminomethyl)-4-(3-methylphenyl)-1H-indol-7-yl]methyl}-9H-purin-6-am-
ine
[0729] Example 76 was prepared according to the procedure used for
the preparation of Example 85, substituting m-tolylboronic acid for
(4-(methylsulfonamido)phenyl)boronic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 2.39 (s, 3H), 4.29 (s, 2H), 5.75
(s, 2H), 6.78 (s, 1H), 6.96 (d, J=7.6 Hz, 1H), 7.07 (d, J=7.6 Hz,
1H), 7.19-7.25 (m, 1H), 7.35-7.44 (m, 3H), 8.45 (s, 1H), 8.56 (s,
1H); (ESI) m/z 367 (M-NH.sub.2).sup.+.
Example 77
9-{[2-(aminomethyl)-4-(2-methylphenyl)-1H-indol-7-yl]methyl}-9H-purin-6-am-
ine
[0730] Example 77 was prepared according to the procedure used for
the preparation of Example 85, substituting o-tolylboronic acid for
(4-(methylsulfonamido)phenyl)boronic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 2.09 (s, 3H), 4.24 (s, 2H), 5.75
(s, 2H), 6.28 (s, 1H), 6.87 (d, J=7.4 Hz, 1H), 6.92 (d, J=7.6 Hz,
1H), 7.18 (dd, J=7.4, 1.5 Hz, 1H), 7.24-7.31 (m, 1H), 7.31-7.38 (m,
2H), 8.44 (s, 1H), 8.56 (s, 1H); (ESI) m/z 367
(M-NH.sub.2).sup.+.
Example 78
9-{[2-(aminomethyl)-4-(4-methoxyphenyl)-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine
[0731] Example 78 was prepared according to the procedure used for
the preparation of Example 85, substituting
(4-methoxyphenyl)boronic acid for
(4-(methylsulfonamido)phenyl)boronic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 3.81 (s, 3H), 4.28 (s, 2H), 5.73
(s, 2H), 6.67-6.71 (m, 1H), 6.73-6.80 (m, 2H), 6.96 (d, J=7.6 Hz,
1H), 7.04 (d, J=7.5 Hz, 1H), 7.05-7.11 (m, 2H), 7.52-7.59 (m, 2H),
8.43 (s, 1H), 8.53 (s, 1H); (ESI) m/z 383 (M-NH.sub.2).sup.+.
Example 79
9-{[2-(aminomethyl)-4-(3-methoxyphenyl)-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine
[0732] Example 79 was prepared according to the procedure used for
the preparation of Example 85, substituting
(3-methoxyphenyl)boronic acid for
(4-(methylsulfonamido)phenyl)boronic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 3.82 (s, 3H), 4.29 (s, 2H), 5.77
(s, 2H), 6.81 (s, 1H), 6.94-7.01 (m, 2H), 7.10 (d, J=7.5 Hz, 1H),
7.13 (t, J=2.0 Hz, 1H), 7.16-7.22 (m, 1H), 7.43 (t, J=7.9 Hz, 1H),
8.48 (s, 1H), 8.60 (s, 1H); (ESI) m/z 383 (M-NH.sub.2).sup.+.
Example 80
9-{[2-(aminomethyl)-4-(2-methoxyphenyl)-1H-indol-7-yl]methyl}-9H-purin-6-a-
mine
[0733] Example 80 was prepared according to the procedure used for
the preparation of Example 85, substituting
(2-methoxyphenyl)boronic acid for
(4-(methylsulfonamido)phenyl)boronic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 3.68 (s, 3H), 4.25 (s, 2H), 5.76
(s, 2H), 6.37 (s, 1H), 6.90-6.97 (m, 2H), 7.05 (td, J=7.4, 1.0 Hz,
1H), 7.15 (d, J=8.2 Hz, 1H), 7.25 (dd, J=7.5, 1.7 Hz, 1H), 7.40
(ddd, J=8.8, 7.5, 1.8 Hz, 1H), 8.49 (s, 1H), 8.63 (s, 1H); (ESI)
m/z 383 (M-NH.sub.2).sup.+.
Example 81
9-({2-(aminomethyl)-4-[4-(methylsulfonyl)phenyl]-1H-indol-7-yl}methyl)-9H--
purin-6-amine
[0734] Example 81 was prepared according to the procedure used for
the preparation of Example 85, substituting
(4-(methylsulfonyl)phenyl)boronic acid for
(4-(methylsulfonamido)phenyl)boronic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 3.11 (s, 2H), 3.27 (s, 3H), 4.32
(s, 2H), 5.80 (s, 2H), 6.83 (s, 1H), 6.99 (t, J=8.0 Hz, 2H), 7.19
(d, J=7.5 Hz, 1H), 7.65-7.79 (m, 1H), 7.85-7.95 (m, 2H), 8.00-8.10
(m, 2H), 8.48 (s, 1H), 8.62 (s, 1H); (ESI) m/z 431
(M-NH.sub.2).sup.+.
Example 82
4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-4-yl}benzoni-
trile
[0735] Example 82 was prepared according to the procedure used for
the preparation of Example 85, substituting (4-cyanophenyl)boronic
acid for (4-(methylsulfonamido)phenyl)boronic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.29 (s, 2H), 5.74 (s, 2H), 6.79
(s, 1H), 6.98 (d, J=7.6 Hz, 1H), 7.17 (d, J=7.5 Hz, 1H), 7.79-7.86
(m, 2H), 7.94-7.99 (m, 2H), 8.35 (s, 1H), 8.47 (s, 1H); (ESI) m/z
378 (M-NH.sub.2).sup.+.
Example 83
3-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-4-yl}benzoni-
trile
[0736] Example 83 was prepared according to the procedure used for
the preparation of Example 85, substituting (3-cyanophenyl)boronic
acid for (4-(methylsulfonamido)phenyl)boronic acid. 1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.31 (s, 2H), 5.78 (s, 2H), 6.80
(s, 1H), 6.98 (d, J=7.6 Hz, 1H), 7.17 (d, J=7.5 Hz, 1H), 7.74 (t,
J=7.8 Hz, 1H), 7.87 (dt, J=7.8, 1.3 Hz, 1H), 7.96 (dt, J=7.9, 1.4
Hz, 1H), 8.01 (t, J=1.7 Hz, 1H), 8.46 (s, 1H), 8.59 (s, 1H); (ESI)
m/z 378 (M-NH.sub.2).sup.+.
Example 84
3-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-4-yl}benzami-
de
[0737] Example 84 was prepared according to the procedure used for
the preparation of Example 85, substituting
(3-carbamoylphenyl)boronic acid for
(4-(methylsulfonamido)phenyl)boronic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.30 (s, 2H), 5.76 (s, 2H), 6.78
(s, 1H), 7.00 (d, J=7.6 Hz, 1H), 7.15 (d, J=7.5 Hz, 1H), 7.43-7.56
(m, 1H), 7.60 (t, J=7.8 Hz, 1H), 7.77 (dt, J=7.6, 1.4 Hz, 1H),
7.84-7.92 (m, 2H), 8.09 (t, J=1.8 Hz, 1H), 8.43 (s, 1H), 8.55 (s,
1H); (ESI) m/z 396 (M-NH.sub.2).sup.+.
Example 85
N-(4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-4-yl}phen-
yl)methanesulfonamide
[0738] A microwave vial was charged with
tris(dibenzylideneacetone)dipalladium(0) (25 mg, 0.027 mmol),
potassium phosphate (70 mg, 0.33 mmol) and tricyclohexylphosphine
(20 mg, 0.071 mmol). Then a solution of Example 62j (27 mg, 0.08
mmol) in dioxane (1.0 mL) was added, followed by
(4-(methylsulfonamido)phenyl)boronic acid (0.16 mmol) in dioxane
(0.4 mL) and water (200 .mu.L). The resulting mixture was heated in
the microwave oven (Biotage Initiator, Power range 0-400 W from
magnetron at 2.45 GHz) for 20 minutes at 140.degree. C. The
reaction was filtered, and purified by reverse phase HPLC on a
Phenomenex Luna C8 (2) 5 .mu.m 100 .ANG. AXIA column (30
mm.times.150 mm): A gradient of acetonitrile (A) and 0.1%
trifluoroacetic acid in water (B) was used, at a flow rate of 50
mL/min (0-0.5 minutes 10% A, 0.5-6.0 minutes linear gradient
10-100% A, 6.0-7.0 minutes 100% A, 7.0-8.0 minutes linear gradient
100-10% A). An Agilent 1100 Series Purification system was used,
consisting of the following modules: Agilent 1100 Series LC/MSD SL
mass spectrometer with API-electrospray source; two Agilent 1100
Series preparative pumps; Agilent 1100 Series isocratic pump;
Agilent 1100 Series diode array detector with preparative (0.3 mm)
flow cell; Agilent active-splitter, IFC-PAL fraction
collector/autosampler. The make-up pump for the mass spectrometer
used 3:1 methanol:water with 0.1% formic acid at a flow rate of 1
mL/min. Fraction collection was automatically triggered when the
extracted ion chromatogram (EIC) for the target mass exceeded the
threshold specified in the method. The system was controlled using
Agilent Chemstation (Rev B.10.03), Agilent A2Prep, and Leap
FractPal software, with custom Chemstation macros for data export.
.sup.1H NMR (DMSO/D.sub.2O-d.sub.6) .delta. 3.05 (s, 3H), 4.31 (s,
2H), 5.77 (s, 2H), 6.73-6.80 (m, 1H), 6.81 (s, 1H), 6.98 (d, J=7.5
Hz, 1H), 7.07 (t, J=8.6 Hz, 2H), 7.32-7.39 (m, 2H), 7.58-7.65 (m,
2H), 8.49 (s, 1H), 8.60 (s, 1H); (ESI) m/z 446
(M-NH.sub.2).sup.+.
Example 86
4-{2-(aminomethyl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol-4-yl}-N,N-di-
methylbenzamide
[0739] Example 86 was prepared according to the procedure used for
the preparation of Example 85, substituting
(4-(dimethylcarbamoyl)phenyl)boronic acid for
(4-(methylsulfonamido)phenyl)boronic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 2.97-3.09 (m, 6H), 4.31 (s, 2H),
5.79 (s, 2H), 6.83 (s, 1H), 6.98 (d, J=7.6 Hz, 1H), 7.15 (d, J=7.5
Hz, 1H), 7.50-7.61 (m, 2H), 7.65-7.74 (m, 2H), 8.49 (s, 1H), 8.62
(s, 1H); (ESI) m/z 424 (M-NH.sub.2).sup.+.
Example 87
1-{7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}ethanone
Example 87a
7-((6-amino-9H-purin-9-yl)methyl)-5-chloro-1H-indole-2-carboxylic
acid
[0740] Example 7e (2.31 g, 4.91 mmol) was suspended in ethanol (25
mL) and treated with aqueous sodium hydroxide (15 mL, 30.0 mmol).
The mixture was stirred for about 16 hours at 85.degree. C. The
reaction was cooled to ambient temperature and acidified using 1N
HCl. The precipitate was collected by filtration, washed with
water, and dried under vacuum to give the crude title compound (1.8
g, 107%), which was used in the next step without further
purification. MS m/z: 207 [M-adenine and --H].sup.+.
Example 87b
7-((6-amino-9H-purin-9-yl)methyl)-5-chloro-N-methoxy-N-methyl-1H-indole-2--
carboxamide
[0741] To a mixture of Example 87a (1 g, 2.92 mmol),
2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium
hexafluorophosphate(V) (1.22 g, 3.21 mmol), and triethylamine (3.25
mL, 23.34 mmol) in N,N-dimethylacetamide (50 mL) was added
N,O-dimethylhydroxylamine hydrochloride (1.138 g, 11.67 mmol). The
mixture was stirred for 6 hours at room temperature, diluted with
ethyl acetate, washed sequentially with water (3 times) and brine,
and dried over magnesium sulfate to give the title compound (0.82
g, 2.125 mmol, 72.8% yield). .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 12.23 (s, 1H), 8.32 (s, 1H), 8.24 (s, 1H), 7.72 (d, J=1.9
Hz, 1H), 7.37 (s, 2H), 7.18 (dd, J=4.6, 1.9 Hz, 2H), 5.68 (s, 2H),
3.78 (s, 3H), 1.08 (t, J=7.0 Hz, 3H); MS m/z: 251
[M-adenine].sup.+.
Example 87c
1-{7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}ethanone
[0742] To a chilled (0.degree. C.) suspension of Example 87b (0.1
g, 0.259 mmol) in tetrahydrofuran (3 mL) was slowly added
methylmagnesium bromide (0.926 mL, 1.296 mmol) under nitrogen
atmosphere. The reaction was slowly warmed to room temperature and
stirred for about 16 hours. The reaction was quenched with 0.5 M
HCl. Ethyl acetate was added and the suspension was collected by
filtration, washed with 0.5 M HCl and ethyl acetate, and dried
under vacuum to give the title compound (0.0855 g, 97%). .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. 8.46 (d, J=17.9 Hz, 2H), 7.73 (d,
J=1.9 Hz, 1H), 7.34 (s, 1H), 7.28 (d, J=1.9 Hz, 1H), 5.79 (s, 2H),
2.60 (s, 3H); MS m/z: 341 [M+H].sup.+.
Example 88
9-{[2-(1-aminoethyl)-5-chloro-1H-indol-7-yl]methyl}-9H-purin-6-amine
[0743] A suspension of Example 87c (0.075 g, 0.220 mmol,) and
ammonium acetate (0.170 g, 2.201 mmol) in methanol (3 mL) was
treated with sodium cyanotrihydroborate (0.042 g, 0.668 mmol) and
heated for 30 minutes at 125.degree. C. in the microwave (Biotage,
Initiator). The cooled mixture was concentrated to dryness. The
residue was suspended in water and sonicated for about 5 minutes,
filtered, washed with water and dried under vacuum. The filter cake
was purified by preparative HPLC (Waters Sunfire C8, 10-40%
acetonitrile/water; 1% TFA) to give the title compound (0.043 g,
42.9%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.35 (s, 1H),
8.27 (s, 1H), 7.56 (d, J=1.9 Hz, 1H), 7.05 (s, 1H), 6.60 (s, 1H),
5.69 (s, 2H), 1.77 (d, J=6.9 Hz, 3H); MS m/z: 325
[M-NH.sub.2].sup.+.
Example 89
9-({5-chloro-2-[(methylamino)methyl]-1H-indol-7-yl}methyl)-9H-purin-6-amin-
e
Example 89a
7-((6-amino-9H-purin-9-yl)methyl)-5-chloro-1H-indole-2-carbaldehyde
[0744] Example 7g (0.22 g, 0.669 mmol) was added to a solution of
2-iodoxybenzoic acid (0.375 g, 1.338 mmol) and
2,2,2-trifluoroacetic acid (0.103 mL, 1.338 mmol) in
dimethylsulfoxide (6 mL). The solution was stirred overnight at
room temperature. The solution was diluted with aqueous sodium
bicarbonate (2.5%), and extracted with ethyl acetate. The combined
organic layers were washed with water, dried over sodium sulfate,
and concentrated to dryness under vacuum to give the crude title
compound (0.13 g, 59.5%). .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 12.54 (s, 1H), 9.93 (s, 1H), 8.31 (s, 1H), 8.21 (s, 1H),
7.82 (s, 1H), 7.45 (s, 1H), 7.34 (s, 2H), 7.10 (s, 1H), 5.71 (s,
2H); MS m/z: 327 [M+H].sup.+.
Example 89b
9-({5-chloro-2-[(methylamino)methyl]-1H-indol-7-yl}methyl)-9H-purin-6-amin-
e
[0745] To a stirring suspension of Example 89a (0.12 g, 0.367 mmol)
and methanamine in methanol (0.735 mL, 1.469 mmol) was added
N,N,N-trimethyl-1-(p-tolyl)methanaminium cyanotrihydroborate (0.671
g, 1.469 mmol) and acetic acid (0.084 mL, 1.469 mmol). The mixture
was stirred overnight at 50.degree. C. The reaction was cooled to
room temperature, filtered and the resin washed with methanol and
dichloromethane. The filtrate was concentrated and the residue
purified by preparative HPLC (Waters Sunfire C8, 0-100%
methanol/water; 0.1 M ammonium acetate) to give the title compound
(0.03 g, 20.33%). .sup.1H NMR (501 MHz, DMSO-d.sub.6) .delta. 11.73
(s, 1H), 8.36 (s, 1H), 8.26 (s, 1H), 7.51 (s, 1H), 7.35 (s, 2H),
6.86 (d, J=2.0 Hz, 1H), 6.40 (s, 1H), 5.67 (s, 2H), 3.91 (s, 2H),
2.37 (s, 3H), 1.95 (s, 3H); MS m/z: 311 [M-NHCH.sub.3].sup.+.
Example 90
1-{7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}propan-1-one
[0746] Example 90 was prepared according to the procedure used for
the preparation of Example 87c, substituting ethylmagnesium bromide
for methylmagnesium bromide. 1H NMR (400 MHz, CD.sub.3OD) .delta.
8.46 (s, 1H), 8.33 (s, 1H), 7.71 (d, J=1.9 Hz, 1H), 7.32 (s, 2H),
5.73 (s, 2H), 3.03 (q, J=7.4 Hz, 2H), 1.23 (t, J=7.3 Hz, 3H); MS
m/z: 220 [M-adenine].sup.+.
Example 91
9-{[2-(1-aminopropyl)-5-chloro-1H-indol-7-yl]methyl}-9H-purin-6-amine
[0747] A suspension of Example 90 (0.055 g, 0.155 mmol) and
ammonium acetate (0.119 g, 1.550 mmol) in methanol (5 mL) was
treated with sodium cyanotrihydroborate (0.029 g, 0.465 mmol). The
mixture was stirred at room temperature for 3 hours. The mixture
was transferred equally between two microwave vials. The first vial
was heated in the microwave for 15 minutes at 125.degree. C. then
again at 110.degree. C. for 30 minutes. Vial two was heated in the
microwave for 30 minutes at 110.degree. C. The contents were
combined and concentrated to dryness. The crude material was
suspended in water and sonicated for about 5 minutes, filtered,
washed with water and dried overnight. The solid was purified by
preparative HPLC (Waters Sunfire C8, 0-80% methanol/water; 1% TFA)
to give the title compound (0.017 g, 23.3%). .sup.1H NMR (400 MHz,
CD.sub.3OD) .delta. 8.37 (s, 1H), 8.32 (s, 1H), 7.57 (d, J=1.8 Hz,
1H), 7.06 (d, J=1.8 Hz, 1H), 6.63 (s, 1H), 5.73 (s, 2H), 4.47 (t,
J=7.4 Hz, 1H), 2.14 (p, J=7.2 Hz, 2H), 0.96 (t, J=7.4 Hz, 3H); MS
m/z: 204 [M-adenine and NH.sub.2].sup.+.
Example 92
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)acetam-
ide
[0748] To a suspension of Example 9b (0.05 g, 0.153 mmol) and
triethylamine (0.064 mL, 0.458 mmol) in THF (5 mL) was added acetyl
chloride (10.85 .mu.L, 0.153 mmol). The resulting mixture was
stirred at ambient temperature for 2 hours. The mixture was
concentrated and the residue was purified by reverse phase HPLC
(C18, 35-70% acetonitrile/water, 0.05% ammonium hydroxide) to give
the title compound (0.02 g, 0.054 mmol, 35.5% yield). MS (ESI+):
m/z 370 (M+H)+; .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 11.49
(s, 1H), 8.39 (s, 1H), 8.29 (s, 1H), 8.22 (s, 1H), 7.48 (d, J=1.6
Hz, 1H), 7.32 (s, 1H), 6.83 (d, J=2.0 Hz, 1H), 6.34 (s, 1H), 5.59
(s, 1H), 4.46 (d, J=6.4 Hz, 2H), 1.90 (s, 3H).
Example 93
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)prop-2-
-enamide
[0749] Acryloyl chloride (12.39 .mu.L, 0.153 mmol) was added to a
suspension of Example 9b (50 mg, 0.153 mmol) in triethylamine (45
.mu.L, 0.323 mmol) and dichloromethane (1.5 mL) at 0.degree. C. The
reaction mixture was stirred at 0.degree. C. for 1.5 hours and at
room temperature for 2 hours. Water was added to the reaction
mixture to afford a solid which was collected by filtration, rinsed
with water, and dried (in-vacuo). The solid was absorbed onto
silica gel and was flash chromatographed (Biotage 10 g HP Snap
Cartridge, eluting with heptane containing a gradient (20% to 90%)
with a solution of 3:1 ethyl acetate:ethanol) to provide the title
compound. .sup.1H NMR (500 MHz, DMSO-d.sub.6) .delta. 11.67-11.47
(m, 1H), 8.67 (t, J=5.6 Hz, 1H), 8.30 (s, 1H), 8.20 (s, 1H), 7.49
(d, J=2.0 Hz, 1H), 7.32 (s, 2H), 6.84 (d, J=1.9 Hz, 1H), 6.36 (d,
J=1.9 Hz, 1H), 6.32 (dd, J=17.1, 10.2 Hz, 1H), 6.18 (dd, J=17.1,
2.2 Hz, 1H), 5.67 (dd, J=10.2, 2.2 Hz, 1H), 5.59 (s, 2H), 4.56 (d,
J=5.5 Hz, 2H). MS ESI.sup.+ 382.0 (M+H).sup.+.
Example 94
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)propan-
amide
[0750] Example 94 was prepared according to the procedure used for
the preparation of Example 92, substituting propionyl chloride for
acetyl chloride. MS (ESI+): m/z 384 (M+H).sup.+; .sup.1H NMR (400
MHz, DMSO-d.sub.6): .delta. 11.50 (s, 1H), 8.33 (s, 1H), 8.29 (s,
1H), 8.21 (s, 1H), 7.48 (d, J=1.6 Hz, 1H), 7.33 (s, 1H), 6.83 (d
J=2.0 Hz, 1H), 6.33 (d J=1.6 Hz, 1H), 5.59 (s, 2H), 4.46 (d, J=6.4
Hz, 2H), 2.15-2.21 (q, J=7.6 Hz, 2H), 1.05 (t, J=7.6 Hz, 3H).
Example 95
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-met-
hoxyacetamide
[0751] Example 95 was prepared according to the procedure used for
the preparation of Example 232, substituting 2-methoxyacetic acid
for 2-(pyridin-4-yl)acetic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 3.35 (s, 3H), 3.90 (s, 3H), 4.51 (d, J=6.0
Hz, 2H), 5.66 (s, 2H), 6.32 (d, J=1.9 Hz, 1H), 6.82 (d, J=2.0 Hz,
1H), 7.49 (d, J=2.0 Hz, 1H), 8.37 (d, J=7.6 Hz, 3H), 8.47 (s, 1H),
11.42 (d, J=2.2 Hz, 1H). MS (APCI) m/z 400.1 [M+H].sup.+.
Example 96
3-[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)amino-
]propanoic acid
[0752] Acrylic acid (0.023 mL, 0.336 mmol) was added to Example 9b
(0.1 g, 0.305 mmol) in pyridine (1 mL) and the mixture stirred
overnight at room temperature. The solvent was removed and the
residue was purified by preparative HPLC (Waters Sunfire C8, 0-80%
methanol/water; 1% TFA) to give the title compound (0.07 g, 44.7%).
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.32 (s, 1H), 8.21 (s,
1H), 7.58 (s, 1H), 7.06 (s, 1H), 6.71 (s, 1H), 5.66 (s, 2H), 4.47
(s, 2H), 3.37-3.32 (m, 2H), 2.76 (t, J=6.5 Hz, 2H); MS m/z: 400
[M+H].sup.+.
Example 97
9-({5-chloro-2-[(diethylamino)methyl]-1H-indol-7-yl}methyl)-9H-purin-6-ami-
ne
[0753] To a stirring solution of Example 9b (0.05 g, 0.153 mmol)
and acetaldehyde (10 .mu.L, 0.178 mmol) was added
MP-cyanoborohydride (0.271 g, 0.610 mmol) and acetic acid (35
.mu.L, 0.611 mmol). The slurry was stirred at room temperature for
about 64 hours. The mixture was filtered and the resin washed
sequentially with methanol (2.times.25 mL) and dichloromethane (25
mL). The filtrate was concentrated in vacuo and the residue
purified by preparative HPLC (Waters Sunfire C8, 20-80%
methanol/water; 1% TFA). The product was dissolved in
dicholormethane and washed with saturated sodium bicarbonate,
filter through a phase separator, and concentrated to give the
title compound (0.0299 g, 51.1%). 1H NMR (500 MHz, CD.sub.3OD/trace
trifluoroacetic acid) .delta. 8.41 (d, J=4.0 Hz, 2H), 7.60 (d,
J=2.0 Hz, 1H), 7.10 (d, J=1.9 Hz, 1H), 6.78 (s, 1H), 5.78 (s, 2H),
4.57 (s, 2H), 3.26 (dt, J=11.5, 7.2 Hz, 2H), 1.37 (t, J=7.3 Hz,
3H); MS m/z: 311 [M-diethylamine].sup.+.
Example 98
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)butana-
mide
[0754] Example 98 was prepared according to the procedure used for
the preparation of Example 232, substituting butyric acid for
2-(pyridin-4-yl)acetic acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 0.89 (t, J=7.4 Hz, 3H), 1.57 (h, J=7.4 Hz, 2H), 2.15 (t,
J=7.3 Hz, 2H), 4.46 (d, J=5.6 Hz, 2H), 5.65 (s, 2H), 6.33 (d, J=1.9
Hz, 1H), 6.83 (d, J=2.0 Hz, 1H), 7.49 (d, J=2.0 Hz, 1H), 7.97-8.41
(m, 4H), 8.45 (s, 1H), 11.45 (d, J=2.2 Hz, 1H). MS (APCI) m/z 398.1
[M+H].sup.+.
Example 99
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-met-
hylpropanamide
[0755] Example 99 was prepared according to the procedure used for
the preparation of Example 232, substituting isobutyric acid for
2-(pyridin-4-yl)acetic acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 1.06 (d, J=6.8 Hz, 6H), 4.45 (d, J=5.5 Hz, 2H), 5.67 (s,
2H), 6.32 (d, J=1.8 Hz, 1H), 6.83 (d, J=2.0 Hz, 1H), 7.50 (d, J=2.0
Hz, 1H), 8.26-8.61 (m, 4H), 11.45 (d, J=2.3 Hz, 1H). MS (APCI) m/z
398.1 [M+H].sup.+.
Example 100
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-met-
hoxypropanamide
[0756] To a solution of 3-methoxypropanoic acid (0.016 mL, 0.168
mmol) in N,N-dimethylacetamide (1.525 mL) and
N-ethyl-N-isopropylpropan-2-amine (0.030 mL, 0.183 mmol) was added
2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium
hexafluorophosphate(V) (0.070 g, 0.183 mmol). The mixture was
stirred at room temperature for 5 minutes followed by the addition
of Example 9b (0.05 g, 0.153 mmol) and the mixture was stirred at
room temperature for 4 hours. Water and ethyl acetate were added to
the reaction and the organics were separated, concentrated, and
purified by preparative HPLC (Waters Sunfire C8, 20-80%
methanol/water; 1% TFA) to give the title compound (0.029 g,
45.9%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.46 (s, 1H),
8.32 (s, 1H), 7.47 (d, J=1.9 Hz, 1H), 7.05 (d, J=1.9 Hz, 1H), 6.38
(s, 1H), 5.69 (s, 2H), 4.54 (s, 2H), 3.68 (t, J=6.0 Hz, 2H), 3.33
(s, 3H), 2.50 (t, J=6.0 Hz, 2H); MS m/z: 279 [M-adenine].sup.+.
Example 101
2,2'-[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)im-
ino]diacetic acid
Example 101a
tert-butyl
2-(((7-((6-amino-9H-purin-9-yl)methyl)-5-chloro-1H-indol-2-yl)m-
ethyl)(tert-butoxycarbonyl)amino)acetate
[0757] tert-butyl 2-bromoacetate (0.030 mL, 0.201 mmol) was added
to Example 9b (0.06 g, 0.183 mmol) in N,N-dimethylformamide (1 mL).
The reaction was stirred at room temperature for about 1 hour. The
reaction was diluted with water and extracted 2 times with
dichloromethane; the organics were combined, passed through a phase
separator, and concentrated. The residue was purified by
preparative HPLC (Waters Sunfire C8, 45-95% methanol/water; 0.1 M
ammonium acetate) to afford the title compound (0.021 g, 21.16%)
and Example 106. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.37 (s,
1H), 8.18 (s, 1H), 7.45 (d, J=1.8 Hz, 1H), 7.05 (d, J=1.8 Hz, 1H),
6.32 (s, 1H), 5.63 (s, 2H), 4.60 (s, 2H), 4.04 (s, 2H), 1.95 (d,
J=3.9 Hz, 1H), 1.43 (s, 18H); MS (APCI+): m/z 556 [M+H].sup.+.
Example 101b
2,2'-[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)im-
ino]diacetic acid
[0758] A round bottom flask was charged with Example 101a (0.037 g,
0.067 mmol) and 0.5 mL of 1M HCl in diethyl ether. The reaction
mixture was stirred for 4 hours at room temperature. The solvent
was removed under reduced pressure and the residue was precipitated
from methanol to give the title compound (0.0057 g, 19.3%). .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 11.63 (s, 1H), 8.59 (s, 1H),
8.45 (s, 1H), 7.54 (d, J=1.9 Hz, 1H), 6.88 (d, J=1.9 Hz, 1H), 6.47
(s, 1H), 5.72 (s, 2H), 4.20 (s, 2H), 3.64 (s, 2H); MS m/z: 444
[M+H].sup.+.
Example 102
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-met-
hylbutanamide
[0759] Example 102 was prepared according to the procedure used for
the preparation of Example 232, substituting 3-methylbutanoic acid
for 2-(pyridin-4-yl)acetic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 0.85-0.97 (m, 6H), 1.99-2.06 (m, 3H), 4.46
(d, J=5.7 Hz, 2H), 5.64 (s, 2H), 6.32 (d, J=1.9 Hz, 1H), 6.83 (d,
J=2.0 Hz, 1H), 7.49 (d, J=2.0 Hz, 1H), 8.09 (s, 2H), 8.35 (d, J=3.3
Hz, 2H), 8.43 (s, 1H), 11.46 (d, J=2.2 Hz, 1H). MS (APCI) m/z 412.1
[M+H].sup.+.
Example 103
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-hyd-
roxy-3-methylbutanamide
[0760] A mixture of 3-hydroxy-3-methylbutanoic acid (13.11 .mu.L,
0.122 mmol), HATU (46.4 mg, 0.122 mmol) and
N-ethyl-N-isopropylpropan-2-amine (63.9 .mu.L, 0.366 mmol) in
N,N-dimethylformamide (0.5 mL) was stirred at ambient temperature
for 5 minutes and then treated with Example 9b (40 mg, 0.122 mmol)
and stirred at ambient temperature overnight. The mixture was
diluted with ethyl acetate (30 mL), washed sequentially with water
(2.times.) and brine, dried over MgSO.sub.4, and filtered. The
filtrate was concentrated and the residue was purified by column
chromatography on silica gel (1-10% methanol in dichloromethane) to
give the title compound (37 mg, 0.086 mmol, 70.9% yield). .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 11.51 (s, 1H), 8.38 (t, J=5.6
Hz, 1H), 8.29 (s, 1H), 8.22 (s, 1H), 7.48 (d, J=1.8 Hz, 1H), 7.30
(s, 2H), 6.82 (d, J=1.9 Hz, 1H), 6.35 (d, J=1.5 Hz, 1H), 5.59 (s,
2H), 4.83 (s, 1H), 4.49 (d, J=5.6 Hz, 2H), 2.31 (s, 2H), 1.19 (s,
6H). MS (ESI+) m/z 428.0 (M+H).sup.+.
Example 104
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3,3-d-
imethylbutanamide
[0761] Example 104 was prepared according to the procedure used for
the preparation of Example 103, substituting 3,3-dimethylbutanoic
acid for 3-hydroxy-3-methylbutanoic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 11.54 (s, 1H), 8.35-8.29 (m, 2H), 8.26 (s,
1H), 7.52 (d, J=1.9 Hz, 1H), 7.34 (s, 2H), 6.87 (d, J=1.9 Hz, 1H),
6.36 (d, J=1.6 Hz, 1H), 5.62 (s, 2H), 4.49 (d, J=5.6 Hz, 2H), 2.11
(d, J=7.3 Hz, 2H), 1.03 (s, 9H). MS (ESI+) m/z 426.0
(M+H).sup.+.
Example 105
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-met-
hylpentanamide
[0762] A stock solution of Example 9b (0.18 M in
N,N-dimethylacetamide, 297 .mu.L, 0.055 mmol), diisopropylethyl
amine (0.21 M in N,N-dimethylacetamide, 0.066 mmol), HATU (0.20 M
in N,N-dimethylacetamide, 297 .mu.L, 0.060 mmol), and
4-methy-pentanoic acid (0.40 M in N,N-dimethylacetamide, 151 .mu.L,
0.06 mmol) were aspirated from their respective source vials, mixed
through a perfluoroalkoxy mixing tube (0.2 mm inner diameter), and
loaded into an injection loop. The reaction segment was injected
into the flow reactor (Hastelloy coil, 0.75 mm inner diameter, 1.8
mL internal volume) set at 100.degree. C., and passed through the
reactor at 180 .mu.L min.sup.-1 (10 minute residence time). Upon
exiting the reactor, the reaction was loaded directly into an
injection loop and purified by preparative HPLC on a Phenomenex
Luna C8 (2) 5 .mu.m 100 .ANG. AXIA column (50 mm.times.21.2 mm). A
gradient of acetonitrile (A) and 0.1% trifluoroacetic acid in water
(B) was used, at a flow rate of 30 mL/min (0-0.5 minutes 5% A,
0.5-6.5 minutes linear gradient 5-60% A, 6.5-7.0 minutes 60-100% A,
7.0-8.9 minutes 100% A, 8.9-9.0 minutes linear gradient 100-5% A,
9.0-10 minutes 5% A). A sample volume of 1.0 mL was injected
directly from the flow reactor stream to the HPLC system. A custom
purification system was used, consisting of the following modules:
Gilson 305 and 306 pumps; Gilson 806 Manometric module; Gilson
UV/Vis 155 detector; Gilson 506C interface box; Gilson FC204
fraction collector; Agilent G1968D Active Splitter; Thermo MSQ Plus
mass spectrometer. The system was controlled through a combination
of Thermo Xcalibur 2.0.7 software and a custom application written
in-house using Microsoft Visual Basic 6.0. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 11.45 (s, 1H), 8.45 (s, 1H), 8.37 (s, 2H),
8.24 (s, 2H), 7.49 (d, J=2.2 Hz, 1H), 6.82 (d, J=2.0 Hz, 1H), 6.32
(d, J=1.9 Hz, 1H), 5.65 (s, 2H), 4.45 (d, J=5.6 Hz, 2H), 2.22-2.13
(m, 2H), 1.61-1.48 (m, 1H), 1.48-1.40 (m, 2H), 0.88 (d, J=6.6 Hz,
6H). MS (APCI+) m/z 426.1 (M+H).sup.+.
Example 106
tert-butyl
[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}met-
hyl)amino]acetate
[0763] tert-butyl 2-bromoacetate (0.030 mL, 0.201 mmol) was added
to Example 9b (0.06 g, 0.183 mmol) in N,N-dimethylformamide (1 mL).
The reaction was stirred at room temperature for about 1 hour. The
reaction was diluted with water and extracted 2 times with
dichloromethane; the organics were combined, passed through a phase
separator, and concentrated. The residue was purified by
preparative HPLC (Waters Sunfire C8, 45-95% methanol/water; 0.1 M
ammonium acetate) to afford the title compound (0.042 g, 48.6%) and
Example 101a. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.55 (s,
1H), 8.30 (s, 1H), 8.20 (s, 1H), 7.46 (d, J=2.0 Hz, 1H), 7.32 (s,
2H), 6.80 (d, J=2.0 Hz, 1H), 6.32 (d, J=1.6 Hz, 1H), 5.60 (s, 2H),
4.05 (s, 1H), 3.91 (s, 2H), 3.24 (s, 2H), 1.42 (s, 9H)); MS m/z:
442 [M+H].sup.+.
Example 107
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)cyclop-
ropanecarboxamide
[0764] Example 107 was prepared according to the procedure used for
the preparation of Example 92, substituting cyclopropanecarbonyl
chloride for acetyl chloride. MS (ESI+): m/z 396 (M+H)+; .sup.1H
NMR (400 MHz, DMSO-d.sub.6): .delta. 11.52 (s, 1H), 8.61 (s, 1H),
8.32 (s, 1H), 8.24 (s, 1H), 7.50-7.48 (m, 3H), 6.84 (d, J=2.0 Hz,
1H), 6.35 (s, 1H), 5.60 (s, 2H), 4.49 (d, J=5.2 Hz, 2H), 1.60-1.68
(m, 1H), 0.75-0.68 (m, 4H).
Example 108
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-met-
hylcyclopropanecarboxamide
[0765] Example 108 was prepared according to the procedure used for
the preparation of Example 105, substituting
1-methyl-cyclopropanecarboxylic acid for 4-methyl-pentanoic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.35 (s, 1H), 8.72 (s,
2H), 8.55 (s, 1H), 8.44 (s, 1H), 8.10 (t, J=5.8 Hz, 1H), 7.50 (d,
J=2.0 Hz, 1H), 6.84 (d, J=2.0 Hz, 1H), 6.29 (d, J=1.8 Hz, 1H), 5.69
(s, 2H), 4.46 (d, J=5.7 Hz, 2H), 1.31 (s, 3H), 1.01 (q, J=3.5 Hz,
2H), 0.56 (q, J=3.6 Hz, 2H). MS (APCI+) m/z 410.0 (M+H).sup.+.
Example 109
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-met-
hylcyclopropanecarboxamide
[0766] Example 109 was prepared according to the procedure used for
the preparation of Example 105, substituting
2-methyl-cyclopropanecarboxylic acid for 4-methyl-pentanoic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.47 (d, J=2.0 Hz,
1H), 8.54 (t, J=5.6 Hz, 1H), 8.44 (s, 1H), 8.35 (s, 1H), 8.16 (s,
2H), 7.50 (d, J=2.0 Hz, 1H), 6.84 (d, J=2.1 Hz, 1H), 6.34 (dd,
J=5.2, 2.0 Hz, 1H), 5.65 (s, 2H), 4.58-4.39 (m, 2H), 1.39 (dt,
J=8.2, 4.3 Hz, 1H), 1.22-1.03 (m, 4H), 0.98-0.83 (m, 1H), 0.54
(ddd, J=9.0, 5.9, 3.4 Hz, 1H). MS (APCI+) m/z 410.1
(M+H).sup.+.
Example 110
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-cyc-
lopropylacetamide
[0767] Example 110 was prepared according to the procedure used for
the preparation of Example 232, substituting 2-cyclopropylacetic
acid for 2-(pyridin-4-yl)acetic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 0.10-0.35 (m, 2H), 0.36-0.57 (m, 2H), 1.01
(dddd, J=12.2, 7.2, 5.2, 2.5 Hz, 2H), 2.08 (d, J=7.0 Hz, 2H), 4.47
(d, J=5.6 Hz, 2H), 5.66 (s, 2H), 6.34 (d, J=1.9 Hz, 1H), 6.83 (d,
J=2.0 Hz, 1H), 7.50 (d, J=2.0 Hz, 1H), 8.33 (d, J=28.2 Hz, 4H),
8.46 (s, 1H), 11.46 (d, J=2.3 Hz, 1H). MS (APCI) m/z 410.1.1
[M+H].sup.+.
Example 111
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)cyclob-
utanecarboxamide
[0768] Example 111 was prepared according to the procedure used for
the preparation of Example 105, substituting cyclobutanecarboxylic
acid for 4-methyl-pentanoic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 11.42 (d, J=2.0 Hz, 1H), 8.47 (s, 1H), 8.38
(s, 3H), 8.21 (t, J=5.6 Hz, 1H), 7.48 (d, J=2.0 Hz, 1H), 6.82 (d,
J=2.1 Hz, 1H), 6.30 (d, J=1.8 Hz, 1H), 5.65 (s, 2H), 4.44 (d, J=5.5
Hz, 2H), 3.08 (p, J=8.6 Hz, 1H), 2.17 (dq, J=11.2, 9.0 Hz, 2H),
2.04 (dtt, J=11.8, 8.6, 2.6 Hz, 2H), 1.94-1.83 (m, 1H), 1.82-1.71
(m, 1H). MS (APCI+) m/z 410.0 (M+H).sup.+.
Example 112
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-hyd-
roxycyclobutanecarboxamide
[0769] Example 112 was prepared according to the procedure used for
the preparation of Example 100, substituting
1-hydroxycyclobutanecarboxylic acid for 3-methoxypropanoic acid.
.sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.49 (s, 1H), 8.32 (s,
1H), 7.46 (d, J=1.9 Hz, 1H), 7.05 (d, J=1.9 Hz, 1H), 6.35 (s, 1H),
5.68 (s, 2H), 4.55 (s, 2H), 2.63-2.47 (m, 2H), 2.23-2.07 (m, 2H),
1.93 (h, J=9.3, 8.8 Hz, 2H). MS m/z: 291 [M-adenine].sup.+.
Example 113
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)tetrah-
ydrofuran-2-carboxamide
[0770] Example 113 was prepared according to the procedure used for
the preparation of Example 232, substituting
tetrahydrofuran-2-carboxylic acid for 2-(pyridin-4-yl)acetic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 1.74-1.96 (m, 4H), 2.16
(dq, J=11.6, 7.5 Hz, 1H), 3.79 (dt, J=8.0, 6.7 Hz, 1H), 3.93 (dt,
J=7.9, 6.5 Hz, 1H), 4.29 (dd, J=8.2, 5.3 Hz, 1H), 4.38-4.57 (m,
2H), 5.66 (s, 2H), 6.29 (d, J=1.8 Hz, 1H), 6.83 (d, J=2.0 Hz, 1H),
7.50 (d, J=2.0 Hz, 1H), 8.23-8.53 (m, 4H), 11.42 (d, J=2.1 Hz, 1H).
MS (APCI) m/z 426.1 [M+H].sup.+.
Example 114
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)tetrah-
ydrofuran-3-carboxamide
[0771] Example 114 was prepared according to the procedure used for
the preparation of Example 232, substituting
tetrahydrofuran-3-carboxylic acid for 2-(pyridin-4-yl)acetic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 1.98-2.13 (m, 2H),
2.93-3.08 (m, 1H), 3.70-3.82 (m, 2H), 3.88 (t, J=8.2 Hz, 2H), 4.48
(d, J=5.5 Hz, 2H), 5.66 (s, 2H), 6.34 (d, J=1.9 Hz, 1H), 6.82 (d,
J=2.0 Hz, 1H), 7.50 (d, J=1.9 Hz, 1H), 8.16-8.57 (m, 5H), 11.49 (d,
J=2.1 Hz, 1H). MS (APCI) m/z 426.1 [M+H].sup.+.
Example 115
(2S)--N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-
pyrrolidine-2-carboxamide
[0772] Example 123 (72 mg, 0.137 mmol) was treated with
dichloromethane (2 mL) and trifluoroacetic acid (1 mL) and stirred
at ambient temperature for 2.5 hours. The solvent was removed and
the residue was triturated in diethyl ether to give the title
compound as a trifluoroacetic acid salt (74 mg, 0.113 mmol, 83%
yield). 1H NMR (400 MHz, DMSO-d.sub.6, 90.degree. C.) .delta. 11.33
(bs, 1H), 8.82 (bs, 1H), 8.28 (s, 1H), 8.24 (s, 1H), 7.47 (d, J=2.0
Hz, 1H), 7.26 (bs, 1H), 6.92 (d, J=1.9 Hz, 1H), 6.38 (d, J=2.1 Hz,
1H), 5.61 (s, 2H), 4.56 (dd, J=5.5, 2.8 Hz, 2H), 4.27-4.19 (m, 1H),
3.43-3.28 (m, 1H), 3.24 (dt, J=11.2, 6.8 Hz, 1H), 2.42-2.26 (m,
1H), 2.00-1.87 (m, 3H). ms (ESI+) m/z 425.1 (M+H).sup.+.
Example 116
(2R)--N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-
pyrrolidine-2-carboxamide
[0773] Example 116 was prepared according to the procedure used for
the preparation of Example 115, substituting Example 124 for
Example 123. 1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.53 (s, 1H),
8.45 (t, J=6.0 Hz, 1H), 8.28 (s, 1H), 8.22 (s, 1H), 7.53-7.42 (m,
1H), 7.30 (s, 2H), 6.81 (d, J=2.0 Hz, 1H), 6.29 (d, J=1.6 Hz, 1H),
5.59 (s, 2H), 4.55-4.41 (m, 2H), 3.61 (dd, J=8.8, 5.6 Hz, 1H),
2.95-2.75 (m, 2H), 2.06-1.91 (m, 1H), 1.78-1.68 (m, 1H), 1.66-1.58
(m, 2H). ms (ESI+) m/z 425.1 (M+H).sup.+.
Example 117
(2S)--N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-
-5-oxopyrrolidine-2-carboxamide
[0774] Example 117 was prepared according to the procedure used for
the preparation of Example 105, substituting
(2S)-5-oxopyrrolidine-2-carboxylic acid for 4-methyl-pentanoic
acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.48 (s, 1H),
8.77 (bs, 2H), 9.24-8.51 (m, 2H), 8.44 (s, 1H), 7.85 (s, 1H), 7.50
(d, J=2.0 Hz, 1H), 6.82 (d, J=2.0 Hz, 1H), 6.37 (d, J=1.9 Hz, 1H),
5.69 (s, 2H), 4.50 (qd, J=15.8, 5.7 Hz, 2H), 4.08 (dd, J=8.5, 4.5
Hz, 1H), 2.38-2.05 (m, 3H), 2.02-1.89 (m, 1H). MS (APCI+) m/z 439.1
(M+H).sup.+.
Example 118
(2R)--N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-
-5-oxopyrrolidine-2-carboxamide
[0775] Example 118 was prepared according to the procedure used for
the preparation of Example 105, substituting
(R)-5-oxo-pyrrolidine-2-carboxylic acid for 4-methyl-pentanoic
acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.48 (s, 1H),
8.74 (bs, 2H), 8.60-8.50 (m, 2H), 8.43 (s, 1H), 7.85 (s, 1H), 7.50
(d, J=2.0 Hz, 1H), 6.82 (d, J=2.0 Hz, 1H), 6.37 (d, J=1.8 Hz, 1H),
5.69 (s, 2H), 4.50 (qd, J=15.7, 5.7 Hz, 2H), 4.08 (dd, J=9.8, 4.7
Hz, 1H), 2.38-2.05 (m, 3H), 2.02-1.89 (m, 1H). MS (APCI+) m/z 439.1
(M+H).sup.+.
Example 119
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)cyclop-
entanecarboxamide
[0776] Example 119 was prepared according to the procedure used for
the preparation of Example 232, substituting cyclopentanecarboxylic
acid for 2-(pyridin-4-yl)acetic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 1.46-1.85 (m, 9H), 2.65 (p, J=7.6 Hz, 1H),
4.46 (d, J=5.6 Hz, 2H), 5.66 (s, 2H), 6.32 (d, J=1.9 Hz, 1H), 6.83
(d, J=2.0 Hz, 1H), 7.50 (d, J=2.0 Hz, 1H), 7.78-8.42 (m, 4H), 8.46
(s, 1H), 11.46 (d, J=2.2 Hz, 1H). MS (APCI) m/z 424.1
[M+H].sup.+.
Example 120
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(py-
rrolidin-1-yl)acetamide
[0777] A mixture of Example 9b (50 mg, 0.153 mmol),
2-(pyrrolidin-1-yl)acetic acid (19.70 mg, 0.153 mmol),
1H-benzo[d][1,2,3]triazol-1-ol hydrate (28.0 mg, 0.183 mmol),
N.sup.1-((ethylimino)methylene)-N.sup.3,N.sup.3-dimethylpropane-1,3-diami-
ne hydrochloride (35.1 mg, 0.183 mmol),
N-ethyl-N-isopropylpropan-2-amine (80 .mu.L, 0.458 mmol) in
dimethylsulfoxide (0.5 mL) was stirred overnight at ambient
temperature. The mixture was purified by reverse phase HPLC (C18,
35-70% acetonitrile/water, 0.05% ammonium hydroxide) to give the
title compound (16 mg, 0.036 mmol, 23.90% yield). .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 11.49 (s, 1H), 8.28 (s, 1H), 8.26-8.20
(m, 2H), 7.48 (d, J=1.9 Hz, 1H), 7.29 (s, 2H), 6.84 (d, J=1.9 Hz,
1H), 6.30 (d, J=1.6 Hz, 1H), 5.58 (s, 2H), 4.50 (d, J=6.0 Hz, 2H),
3.12 (s, 2H), 2.58-2.52 (m, 4H), 1.76-1.68 (m, 4H). MS (ESI+) m/z
439.1 (M+H).sup.+.
Example 121
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-cyc-
lopentylacetamide
[0778] Example 121 was prepared according to the procedure used for
the preparation of Example 105, substituting cyclopentylacetic acid
for 4-methyl-pentanoic acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 11.44 (d, J=2.0 Hz, 1H), 8.46 (s, 1H), 8.40-8.31 (m, 2H),
8.26 (bs, 2H), 7.50 (d, J=2.1 Hz, 1H), 6.83 (d, J=2.0 Hz, 1H), 6.32
(d, J=1.8 Hz, 1H), 5.65 (s, 2H), 4.46 (d, J=5.6 Hz, 2H), 2.25-2.12
(m, 3H), 1.71 (ddd, J=11.9, 8.1, 5.7 Hz, 2H), 1.65-1.41 (m, 4H),
1.15 (dq, J=11.5, 7.3 Hz, 2H). MS (APCI+) m/z 438.1
(M+H).sup.+.
Example 122
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-(py-
rrolidin-1-yl)propanamide
[0779] Example 122 was prepared according to the procedure used for
the preparation of Example 105, substituting
3-(pyrrolidin-1-yl)propanoic acid hydrochloride for
4-methyl-pentanoic acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 11.51 (s, 1H), 9.46 (s, 1H), 8.71 (t, J=5.6 Hz, 1H), 8.48
(s, 1H), 8.38 (s, 4H), 7.50 (d, J=2.0 Hz, 1H), 6.81 (d, J=2.1 Hz,
1H), 6.38 (d, J=1.8 Hz, 1H), 5.66 (s, 2H), 4.51 (d, J=5.6 Hz, 2H),
3.40 (s, 2H), 3.04 (s, 2H), 2.67 (t, J=7.3 Hz, 2H), 2.00 (d, J=7.2
Hz, 2H), 1.93-1.82 (m, 2H). MS (APCI+) m/z 453.1 (M+H).sup.+.
Example 123
tert-butyl
(2S)-2-[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-
-yl}methyl)carbamoyl]pyrrolidine-1-carboxylate
[0780] A mixture of Example 9b (100 mg, 0.305 mmol),
(S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid (65.7 mg,
0.305 mmol), 1H-benzo[d][1,2,3]triazol-1-ol hydrate (56.1 mg, 0.366
mmol),
N.sup.1-((ethylimino)methylene)-N.sup.3,N.sup.3-dimethylpropane-1,3-diami-
ne hydrochloride (70.2 mg, 0.366 mmol), and
N-ethyl-N-isopropylpropan-2-amine (160 .mu.l, 0.915 mmol) in
N,N-dimethylformamide (1.5 mL) was stirred overnight at ambient
temperature. Water was added. The mixture was extracted with ethyl
acetate (2.times.), washed sequentially with water (2.times.) and
brine, dried over anhydrous magnesium sulfate, filtered, and
concentrated to give the title compound (83 mg, 0.158 mmol, 51.8%
yield). .sup.1H NMR (400 MHz, DMSO-d.sub.6, 90.degree. C.) .delta.
11.20 (s, 1H), 8.24 (s, 1H), 8.18 (s, 1H), 8.08 (s, 1H), 7.42 (d,
J=1.8 Hz, 1H), 6.94 (s, 2H), 6.89 (s, 1H), 6.33 (d, J=1.0 Hz, 1H),
5.58 (s, 2H), 4.52 (dd, J=15.6, 6.0 Hz, 1H), 4.42 (dd, J=15.6, 5.5
Hz, 1H), 4.15 (dd, J=8.4, 3.1 Hz, 1H), 3.37 (dtd, J=13.7, 10.3, 6.4
Hz, 2H), 2.11 (dt, J=18.3, 6.8 Hz, 1H), 1.92-1.72 (m, 3H), 1.33 (s,
9H). MS (ESI-) 523.2 (M-H).sup.-.
Example 124
tert-butyl
(2R)-2-[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-
-yl}methyl)carbamoyl]pyrrolidine-1-carboxylate
[0781] Example 124 was prepared according to the procedure used for
the preparation of Example 123, substituting
(R)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid for
(S)-1-(tert-butoxycarbonyl)pyrrolidine-2-carboxylic acid. .sup.1H
NMR (400 MHz, DMSO-d.sub.6, 90.degree. C.) .delta. 11.24 (bs, 1H),
8.30 (s, 1H), 8.28 (s, 1H), 8.10 (bs, 1H), 7.45-7.40 (m, 1H), 6.89
(bs, 1H), 6.33 (d, J=1.8 Hz, 1H), 5.61 (s, 2H), 4.52 (dd, J=15.5,
6.0 Hz, 1H), 4.42 (dd, J=15.7, 5.6 Hz, 1H), 4.15 (dd, J=8.4, 3.3
Hz, 1H), 3.68-3.26 (m, 4H), 2.20-2.07 (m, 1H), 1.50-1.23 (m, 10H).
MS (ESI-) m/z 523.2 (M-H).sup.-.
Example 125
9-({5-chloro-2-[(1,1-dioxidothiomorpholin-4-yl)methyl]-1H-indol-7-yl}methy-
l)-9H-purin-6-amine
[0782] In a microwave vial was added Example 9b (30 mg, 0.092
mmol), THF (1 mL), N,N-diisopropylethylamine (0.064 mL, 0.366
mmol), and (vinylsulfonyl)ethene (32.4 mg, 0.275 mmol). The
contents were heated at 130.degree. C. for 20 minutes. An
additional 0.5 mL DMSO was added to the mixture, filtered, and the
filtrate was purified by reverse phase preparative HPLC to provide
the title compound. Preparate HPLC method: Sample was purified by
preparative HPLC on a Phenomenex Luna C8 (2) 5 .mu.m 100 .ANG. AXIA
column (30 mm.times.150 mm). A gradient of acetonitrile (A) and
0.1% trifluoroacetic acid in water (B) was used, at a flow rate of
50 mL/min (0-0.5 minutes 10% A, 0.5-6.0 minutes linear gradient
10-100% A, 6.0-7.0 minutes 100% A, 7.0-8.0 minutes linear gradient
100-10% A). An Agilent 1100 Series Purification system was used,
consisting of the following modules: Agilent 1100 Series LC/MSD SL
mass spectrometer with API-electrospray source; two Agilent 1100
Series preparative pumps; Agilent 1100 Series isocratic pump;
Agilent 1100 Series diode array detector with preparative (0.3 mm)
flow cell; Agilent active-splitter, IFC-PAL fraction
collector/autosampler. The make-up pump for the mass spectrometer
used 3:1 methanol:water with 0.1% formic acid at a flow rate of 1
mL/min. Fraction collection was automatically triggered when the
extracted ion chromatogram (EIC) for the target mass exceeded the
threshold specified in the method. The system was controlled using
Agilent Chemstation (Rev B.10.03), Agilent A2Prep, and Leap
FractPal software, with custom Chemstation macros for data export.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.62 (s, 1H),
11.07-10.77 (m, 1H), 8.79 (d, J=48.0 Hz, 2H), 8.58 (s, 1H), 8.47
(s, 1H), 7.54 (d, J=1.9 Hz, 1H), 6.82 (d, J=1.9 Hz, 1H), 6.50 (d,
J=1.7 Hz, 1H), 5.74 (s, 2H), 4.05 (s, 2H), 3.23 (d, J=5.0 Hz, 4H),
3.13 (dd, J=9.9, 3.1 Hz, 4H). MS (ESI) m/z: 446 (M+H).sup.+.
Example 126
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)tetrah-
ydro-2H-pyran-4-carboxamide
[0783] A mixture of tetrahydro-2H-pyran-4-carboxylic acid (11.91
mg, 0.092 mmol), HATU (48.7 mg, 0.128 mmol) and
N-ethyl-N-isopropylpropan-2-amine (48.0 .mu.L, 0.275 mmol) in
N,N-dimethylformamide (0.5 mL) was stirred for 10 minutes and then
treated with Example 9b (30 mg, 0.092 mmol). The mixture was
stirred at ambient temperature overnight. The mixture was diluted
with 30 mL ethyl acetate, washed sequentially with water (2.times.)
and brine, dried over anhydrous magnesium sulfate, and filtered.
The filtrated was concentrated and the residue was purified by
column chromatograph on flash silica gel (eluent: 1-10% methanol in
dichloromethane) to give the title compound (22 mg, 0.050 mmol,
54.6% yield). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.49 (s,
1H), 8.36 (t, J=5.5 Hz, 1H), 8.28 (s, 1H), 8.22 (s, 1H), 7.48 (d,
J=1.9 Hz, 1H), 7.30 (s, 2H), 6.83 (d, J=1.9 Hz, 1H), 6.31 (d, J=1.6
Hz, 1H), 5.59 (s, 2H), 4.46 (d, J=5.5 Hz, 2H), 3.88 (dt, J=11.1,
3.2 Hz, 2H), 3.28-3.40 (m, 2H), 2.45 (dd, J=15.3, 7.7 Hz, 1H),
1.71-1.57 (m, 4H). MS (ESI+) m/z 440.1 (M+H).sup.+.
Example 127
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(mo-
rpholin-4-yl)acetamide
[0784] Example 127 was prepared according to the procedure used for
the preparation of Example 105, substituting 2-morpholinoacetic
acid hydrochloride for 4-methyl-pentanoic acid. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 11.61 (s, 1H), 9.14 (t, J=5.6 Hz, 1H),
8.45 (s, 1H), 8.36 (s, 1H), 8.22 (bs, 2H), 7.51 (d, J=1.8 Hz, 1H),
6.82 (d, J=2.0 Hz, 1H), 6.39 (d, J=1.8 Hz, 1H), 5.65 (s, 2H), 4.57
(d, J=5.6 Hz, 2H), 4.04 (s, 2H), 3.86 (bs, 4H), 3.31 (bs, 4H). MS
(APCI+) m/z 455.1 (M+H).sup.+.
Example 128
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)cycloh-
exanecarboxamide
[0785] Example 128 was prepared according to the procedure used for
the preparation of Example 232, substituting cyclohexanecarboxylic
acid for 2-(pyridin-4-yl)acetic acid. 1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 0.79-1.46 (m, 6H), 1.57-1.79 (m, 5H), 2.20
(tt, J=11.6, 3.3 Hz, 2H), 4.44 (d, J=5.6 Hz, 2H), 5.65 (s, 2H),
6.30 (d, J=1.9 Hz, 1H), 6.82 (d, J=2.0 Hz, 1H), 7.49 (d, J=2.0 Hz,
1H), 8.06-8.41 (m, 4H), 8.45 (s, 1H), 11.43 (d, J=2.1 Hz, 1H). MS
(APCI) m/z 438.2 [M+H].sup.+.
Example 129
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-met-
hylcyclohexanecarboxamide
[0786] Example 129 was prepared according to the procedure used for
the preparation of Example 105, substituting
1-methyl-cyclohexanecarboxylic acid for 4-methyl-pentanoic acid.
.sup.1H NMR (400 MHz, DMSO-D.sub.2O-d.sub.6) .delta. 11.33 (s, 1H),
8.57 (s, 1H), 8.48 (s, 1H), 7.52 (d, J=1.9 Hz, 1H), 6.85 (d, J=1.9
Hz, 1H), 6.29 (s, 1H), 5.70 (s, 2H), 4.47 (s, 2H), 1.95 (dd,
J=12.1, 5.5 Hz, 2H), 1.53-1.18 (m, 8H), 1.09 (s, 3H). MS (APCI+)
m/z 452.1 (M+H).sup.+.
Example 130
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-met-
hylcyclohexanecarboxamide
[0787] Example 130 was prepared according to the procedure used for
the preparation of Example 232, substituting
4-methylcyclohexanecarboxylic acid for 2-(pyridin-4-yl)acetic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 0.89 (dd, J=16.5, 6.7
Hz, 4H), 1.30-1.56 (m, 6H), 1.60-1.86 (m, 4H), 2.30 (dt, J=8.2, 4.0
Hz, 1H), 4.45 (t, J=5.9 Hz, 2H), 5.65 (s, 2H), 6.30 (d, J=1.8 Hz,
1H), 6.82 (d, J=2.0 Hz, 1H), 7.49 (d, J=2.0 Hz, 1H), 8.08-8.42 (m,
4H), 8.46 (s, 1H), 11.44 (dd, J=5.9, 2.0 Hz, 1H). MS (APCI) m/z
452.2 [M+H].sup.+.
Example 131
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-met-
hylcyclohexanecarboxamide
[0788] Example 131 was prepared according to the procedure used for
the preparation of Example 105, substituting
3-methyl-cyclohexanecarboxylic acid for 4-methyl-pentanoic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.44 (s, 1H), 8.45 (s,
1H), 8.37 (s, 1H), 8.32-8.13 (m, 3H), 7.49 (d, J=1.9 Hz, 1H), 6.82
(d, J=1.9 Hz, 1H), 6.30 (s, 1H), 5.65 (s, 2H), 4.44 (dd, J=5.7, 2.9
Hz, 2H), 2.28-2.16 (m, 1H), 1.94-1.68 (m, 3H), 1.65-1.45 (m, 2H),
1.43-1.12 (m, 2H), 1.04 (q, J=12.2 Hz, 1H), 0.90 (dd, J=13.1, 6.7
Hz, 4H). MS (APCI+) m/z 452.1 (M+H).sup.+.
Example 132
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-met-
hylcyclohexanecarboxamide
[0789] Example 132 was prepared according to the procedure used for
the preparation of Example 232, substituting
2-methylcyclohexanecarboxylic acid for 2-(pyridin-4-yl)acetic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 0.73-1.05 (m, 3H),
1.07-1.93 (m, 9H), 2.03 (d, J=8.6 Hz, 1H), 2.39 (dt, J=8.9, 4.2 Hz,
1H), 4.38-4.54 (m, 2H), 5.67 (s, 2H), 6.30 (d, J=1.9 Hz, 1H), 6.83
(d, J=2.0 Hz, 1H), 7.50 (d, J=2.0 Hz, 1H), 8.22 (t, J=5.8 Hz, 1H),
8.46 (d, J=31.2 Hz, 4H), 11.42 (d, J=2.2 Hz, 1H). MS (APCI) m/z
452.2 [M+H].sup.+.
Example 133
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-cyc-
lohexylacetamide
[0790] Example 133 was prepared according to the procedure used for
the preparation of Example 232, substituting 2-cyclohexylacetic
acid for 2-(pyridin-4-yl)acetic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 0.81-1.01 (m, 2H), 1.05-1.28 (m, 4H),
1.56-1.74 (m, 7H), 2.05 (d, J=6.8 Hz, 2H), 4.46 (d, J=5.5 Hz, 2H),
5.63 (s, 2H), 6.31 (d, J=1.9 Hz, 1H), 6.83 (d, J=2.0 Hz, 1H), 7.49
(d, J=2.0 Hz, 1H), 7.92 (s, 2H), 8.28-8.44 (m, 3H), 11.46 (d, J=2.2
Hz, 1H). MS (APCI) m/z 452.2 [M+H].sup.+.
Example 134
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-met-
hoxycyclohexanecarboxamide
[0791] Example 134 was prepared according to the procedure used for
the preparation of Example 105, substituting
4-methoxy-cyclohexanecarboxylic acid for 4-methyl-pentanoic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.57-11.22 (m, 1H),
8.72 (bs, 2H), 8.54 (d, J=1.9 Hz, 1H), 8.44 (s, 1H), 8.37-8.24 (m,
1H), 7.50 (d, J=2.1 Hz, 1H), 6.81 (dd, J=3.4, 2.0 Hz, 1H), 6.30 (d,
J=2.1 Hz, 1H), 5.69 (s, 2H), 4.44 (d, J=5.5 Hz, 2H), 3.38 (dq,
J=6.8, 3.2 Hz, 1H), 3.22 (d, J=11.3 Hz, 3H), 2.30-2.11 (m, 1H),
2.09-1.80 (m, 2H), 1.81-1.62 (m, 2H), 1.55-1.00 (m, 4H). MS (APCI+)
m/z 468.0 (M+H).sup.+.
Example 135
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-(pi-
peridin-1-yl)propanamide
[0792] Example 135 was prepared according to the procedure used for
the preparation of Example 232, substituting
3-(piperidin-1-yl)propanoic acid for 2-(pyridin-4-yl)acetic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 1.24-1.87 (m, 7H), 2.68
(t, J=7.4 Hz, 2H), 2.84-2.99 (m, 4H), 3.03-3.34 (m, 2H), 4.50 (d,
J=5.6 Hz, 2H), 5.63 (s, 2H), 6.36 (d, J=1.9 Hz, 1H), 6.78-6.88 (m,
1H), 7.49 (d, J=1.9 Hz, 1H), 7.92 (s, 2H), 8.36 (d, J=34.8 Hz, 2H),
8.71 (t, J=5.6 Hz, 1H), 9.09 (s, 1H), 11.53 (d, J=2.2 Hz, 1H). MS
(APCI) m/z 467.2 [M+H].sup.+.
Example 136
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)tricyc-
lo[3.3.1.1.sup.3,7]decane-1-carboxamide
[0793] Example 136 was prepared according to the procedure used for
the preparation of Example 126, substituting
adamantane-1-carboxylic acid for tetrahydro-2H-pyran-4-carboxylic
acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.44 (s, 1H),
8.28 (s, 1H), 8.23 (s, 1H), 7.98 (t, J=5.8 Hz, 1H), 7.47 (d, J=1.7
Hz, 1H), 7.29 (s, 2H), 6.82 (d, J=1.8 Hz, 1H), 6.24 (s, 1H), 5.58
(s, 2H), 4.45 (d, J=5.7 Hz, 2H), 1.99 (s, 3H), 1.84 (d, J=2.5 Hz,
6H), 1.76-1.56 (m, 6H). MS (ESI+) m/z 490.1 (M+H).sup.+.
Example 137
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,2-t-
hiazole-5-carboxamide
[0794] Example 137 was prepared according to the procedure used for
the preparation of Example 139, substituting
isothiazole-5-carboxylic acid for isothiazole-4-carboxylic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 4.71 (s, 2H), 5.63 (s,
2H), 6.46 (s, 1H), 6.86 (d, J=2.0 Hz, 1H), 7.53 (d, J=2.0 Hz, 1H),
7.96 (d, J=1.8 Hz, 1H), 8.20 (s, 1H), 8.34 (s, 1H), 8.70 (d, J=1.8
Hz, 1H). MS (APCI) m/z 439.1 [M+H].sup.+.
Example 138
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,3-t-
hiazole-5-carboxamide
[0795] Example 138 was prepared according to the procedure used for
the preparation of Example 105, substituting thiazole-5-carboxylic
acid for 4-methyl-pentanoic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 11.53 (s, 1H), 9.30 (t, J=5.6 Hz, 1H), 9.26
(s, 1H), 8.58-8.46 (m, 4H), 8.37 (s, 1H), 7.51 (d, J=2.0 Hz, 1H),
6.82 (d, J=2.0 Hz, 1H), 6.42 (d, J=1.9 Hz, 1H), 5.69 (s, 2H), 4.68
(d, J=5.5 Hz, 2H). MS (APCI+) m/z 439.0 (M+H).sup.+.
Example 139
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,2-t-
hiazole-4-carboxamide
[0796] A solution of Example 9b (0.19 M in N,N-dimethylacetamide,
237 .mu.L, 0.045 mmol), N,N-diisopropylethylamine (0.21 M in
N,N-dimethylacetamide, 262 .mu.L, 0.055 mmol), HATU (0.21 M in
N,N-dimethylacetamide, 238 .mu.L, 0.05 mmol), and
isothiazole-4-carboxylic acid (0.4M in N,N-dimethylacetamide, 125
.mu.L, 0.05 mmol) were aspirated from their respective source
vials, mixed through a perfluoroalkoxy alkanes mixing tube (0.2 mm
inner diameter), and loaded into an injection loop. The reaction
segment was injected into the flow reactor (Hastelloy coil, 0.75 mm
inner diameter, 1.8 mL internal volume) set at 100.degree. C., and
passed through the reactor at 180 .mu.L min.sup.-1 (10 minute
residence time). Upon exiting the reactor, the reaction was loaded
directly into an injection loop and purified using preparative HPLC
to yield the title compound (9.95 mg, 49.50% yield). Samples were
purified by preparative HPLC on a Phenomenex Luna C8 (2) 5 .mu.m
100 .ANG. AXIA column (50 mm.times.21.2 mm). A gradient of
acetonitrile (A) and 0.1% trifluoroacetic acid in water (B) was
used, at a flow rate of 30 mL/min (0-0.5 minutes 5% A, 0.5-6.5
minutes linear gradient 5-60% A, 6.5-7.0 minutes linear gradient
60-100% A, 7.0-8.9 minutes 100% A, 8.9-9.0 minutes linear gradient
100-5% A, 9.0-10 minutes 5% A). A sample volume of 1.0 mL was
injected directly from the flow reactor stream to the HPLC system.
A custom purification system was used, consisting of the following
modules: Gilson 305 and 306 pumps; Gilson 806 Manometric module;
Gilson UV/Vis 155 detector; Gilson 506C interface box; Gilson FC204
fraction collector; Agilent G1968D Active Splitter; Thermo MSQ Plus
mass spectrometer. The system was controlled through a combination
of Thermo Xcalibur 2.0.7 software and a custom application written
in-house using Microsoft Visual Basic 6.0. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 4.69 (d, J=3.9 Hz, 2H), 5.62 (s, 2H), 6.43
(s, 1H), 6.84 (d, J=2.0 Hz, 1H), 7.51 (d, J=2.0 Hz, 1H), 8.18 (s,
1H), 8.32 (s, 1H), 8.96 (s, 1H), 9.59 (s, 1H). MS (APCI) m/z 439.1
[M+H].sup.+.
Example 140
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,3-t-
hiazole-4-carboxamide
[0797] Example 140 was prepared according to the procedure used for
the preparation of Example 105, substituting thiazole-4-carboxylic
acid for 4-methyl-pentanoic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 11.46 (s, 1H), 9.22 (d, J=1.9 Hz, 1H), 9.02
(t, J=6.2 Hz, 1H), 8.49 (s, 1H), 8.42-8.34 (m, 4H), 7.49 (d, J=2.0
Hz, 1H), 6.82 (d, J=2.1 Hz, 1H), 6.35 (d, J=1.8 Hz, 1H), 5.67 (s,
2H), 4.68 (d, J=6.1 Hz, 2H). MS (APCI+) m/z 439.0 (M+H).sup.+.
Example 141
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,2-o-
xazole-4-carboxamide
[0798] Example 141 was prepared according to the procedure used for
the preparation of Example 139, substituting isoxazole-4-carboxylic
acid for isothiazole-4-carboxylic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 4.66 (d, J=4.1 Hz, 2H), 5.62 (s, 2H), 6.43
(s, 1H), 6.84 (d, J=2.0 Hz, 1H), 7.45-7.55 (m, 1H), 8.20 (s, 1H),
8.33 (s, 1H), 8.98 (s, 1H), 9.43 (d, J=0.7 Hz, 1H). MS (APCI) m/z
423.1 [M+H].sup.+.
Example 142
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-py-
razole-5-carboxamide
[0799] Example 142 was prepared according to the procedure used for
the preparation of Example 105, substituting
2H-pyrazole-3-carboxylic acid for 4-methyl-pentanoic acid. .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 11.47 (s, 1H), 8.71 (s, 1H),
8.45 (s, 1H), 8.33 (s, 1H), 8.15 (bs, 3H), 7.80 (s, 1H), 7.49 (d,
J=2.0 Hz, 1H), 6.82 (d, J=2.0 Hz, 1H), 6.73 (d, J=2.4 Hz, 1H), 6.35
(d, J=1.8 Hz, 1H), 5.65 (s, 2H), 4.64 (d, J=6.1 Hz, 2H). MS (APCI+)
m/z 422.1 (M+H).sup.+.
Example 143
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-py-
razole-4-carboxamide
[0800] Example 143 was prepared according to the procedure used for
the preparation of Example 105, substituting
1H-pyrazole-4-carboxylic acid for 4-methyl-pentanoic acid. .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 11.45 (d, J=2.2 Hz, 1H),
9.49-8.25 (m, 6H), 8.10 (s, 2H), 7.50 (d, J=2.0 Hz, 1H), 6.83 (d,
J=2.1 Hz, 1H), 6.38 (d, J=1.8 Hz, 1H), 5.71 (s, 2H), 4.62 (d, J=5.7
Hz, 2H). MS (APCI+) m/z 422.0 (M+H).sup.+.
Example 144
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)thioph-
ene-2-carboxamide
[0801] Example 144 was prepared according to the procedure used for
the preparation of Example 139, substituting thiophene-2-carboxylic
acid for isothiazole-4-carboxylic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 4.66 (s, 2H), 5.61 (s, 2H), 6.40 (s, 1H),
6.85 (d, J=2.0 Hz, 1H), 7.19 (dd, J=5.0, 3.8 Hz, 1H), 7.50 (d,
J=1.9 Hz, 1H), 7.69-7.88 (m, 2H), 8.18 (s, 1H), 8.33 (s, 1H). MS
(APCI) m/z 438.1 [M+H].sup.+.
Example 145
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)thioph-
ene-3-carboxamide
[0802] Example 145 was prepared according to the procedure used for
the preparation of Example 139, substituting thiophene-3-carboxylic
acid for isothiazole-4-carboxylic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 4.65 (s, 2H), 5.61 (s, 2H), 6.39 (s, 1H),
6.85 (d, J=2.0 Hz, 1H), 7.44-7.54 (m, 1H), 7.54-7.67 (m, 2H),
8.08-8.25 (m, 2H), 8.33 (s, 1H). MS (APCI) m/z 438.1
[M+H].sup.+.
Example 146
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-py-
rrole-2-carboxamide
[0803] Example 146 was prepared according to the procedure used for
the preparation of Example 105, substituting
1H-pyrrole-2-carboxylic acid for 4-methyl-pentanoic acid. .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 11.49 (s, 1H), 8.55 (t, J=5.8
Hz, 1H), 8.47 (s, 1H), 8.33 (s, 1H), 8.19 (bs, 3H), 7.49 (d, J=2.0
Hz, 1H), 6.93-6.88 (m, 1H), 6.88-6.84 (m, 1H), 6.83 (d, J=2.0 Hz,
1H), 6.36 (d, J=1.8 Hz, 1H), 6.15-6.08 (m, 1H), 5.66 (s, 2H), 4.64
(d, J=5.7 Hz, 2H). MS (APCI+) m/z 421.0 (M+H).sup.+.
Example 147
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-5-met-
hyl-1,3-thiazole-4-carboxamide
[0804] Example 147 was prepared according to the procedure used for
the preparation of Example 139, substituting
5-methylthiazole-4-carboxylic acid for isothiazole-4-carboxylic
acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 2.80 (s, 3H),
4.67 (s, 2H), 5.62 (s, 2H), 6.39 (s, 1H), 6.85 (d, J=2.0 Hz, 1H),
7.51 (d, J=2.0 Hz, 1H), 8.20 (s, 1H), 8.34 (s, 1H), 8.93 (s, 1H).
MS (APCI) m/z 452.1 [M+H].sup.+.
Example 148
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-met-
hyl-1,3-thiazole-5-carboxamide
[0805] Example 148 was prepared according to the procedure used for
the preparation of Example 139, substituting
4-methylthiazole-5-carboxylic acid for isothiazole-4-carboxylic
acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 2.63 (s, 3H),
4.64 (s, 2H), 5.61 (s, 2H), 6.40 (s, 1H), 6.86 (d, J=1.9 Hz, 1H),
7.51 (d, J=2.0 Hz, 1H), 8.20 (s, 1H), 8.33 (s, 1H), 9.06 (s, 1H).
MS (APCI) m/z 453.1 [M+H].sup.+.
Example 149
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-5-met-
hyl-1,2-oxazole-4-carboxamide
[0806] Example 149 was prepared according to the procedure used for
the preparation of Example 139, substituting
5-methylisoxazole-4-carboxylic acid for isothiazole-4-carboxylic
acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 2.68 (s, 3H),
3.18 (s, 1H), 4.64 (s, 2H), 5.61 (s, 2H), 6.42 (s, 1H), 6.85 (d,
J=1.9 Hz, 1H), 7.51 (d, J=1.9 Hz, 1H), 8.19 (s, 1H), 8.32 (s, 1H),
8.90 (s, 1H). MS (APCI) m/z 437.1 [M+H].sup.+.
Example 150
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-met-
hyl-1,2-oxazole-4-carboxamide
[0807] Example 150 was prepared according to the procedure used for
the preparation of Example 139, substituting
3-methylisoxazole-4-carboxylic acid for isothiazole-4-carboxylic
acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 2.45 (s, 4H),
3.19 (s, 2H), 4.65 (s, 2H), 5.63 (s, 2H), 6.44 (s, 1H), 6.86 (d,
J=1.9 Hz, 1H), 7.52 (d, J=2.0 Hz, 1H), 8.21 (s, 1H), 8.34 (s, 1H),
9.28 (s, 1H). MS (APCI) m/z 437.1 [M+H].sup.+.
Example 151
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-met-
hyl-1H-pyrazole-3-carboxamide
[0808] Example 151 was prepared according to the procedure used for
the preparation of Example 139, substituting
1-methyl-1H-pyrazole-3-carboxylic acid for isothiazole-4-carboxylic
acid. 1H NMR (400 MHz, DMSO-d.sub.6) .delta. 3.93 (s, 3H), 4.63 (s,
2H), 5.60 (s, 2H), 6.36 (s, 1H), 6.70 (d, J=2.3 Hz, 1H), 6.84 (d,
J=2.0 Hz, 1H), 7.49 (d, J=2.0 Hz, 1H), 7.78 (d, J=2.3 Hz, 1H), 8.20
(s, 1H), 8.33 (s, 1H). MS (APCI) m/z 436.1 [M+H].sup.+.
Example 152
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-met-
hyl-1H-pyrazole-5-carboxamide
[0809] Example 152 was prepared according to the procedure used for
the preparation of Example 139, substituting
1-methyl-1H-pyrazole-5-carboxylic acid for isothiazole-4-carboxylic
acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 4.09 (s, 3H),
4.64 (s, 2H), 5.63 (s, 2H), 6.40 (s, 1H), 6.85 (d, J=2.0 Hz, 1H),
6.92 (d, J=2.1 Hz, 1H), 7.51 (d, J=2.0 Hz, 2H), 8.21 (s, 1H), 8.36
(s, 1H). MS (APCI) m/z 436.1 [M+H].sup.+.
Example 153
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-met-
hyl-1H-imidazole-5-carboxamide
[0810] Example 153 was prepared according to the procedure used for
the preparation of Example 139, substituting
1-methyl-1H-imidazole-5-carboxylic acid for
isothiazole-4-carboxylic acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 3.87 (s, 3H), 4.62 (s, 2H), 5.62 (s, 2H), 6.39 (s, 1H),
6.85 (d, J=2.0 Hz, 1H), 7.50 (d, J=1.9 Hz, 1H), 8.18 (s, 1H), 8.33
(s, 1H). MS (APCI) m/z 436.1 [M+H].sup.+.
Example 154
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-met-
hyl-1H-imidazole-2-carboxamide
[0811] Example 154 was prepared according to the procedure used for
the preparation of Example 139, substituting
1-methyl-1H-imidazole-2-carboxylic acid for
isothiazole-4-carboxylic acid. 1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 3.97 (s, 3H), 4.63 (s, 2H), 5.61 (s, 2H), 6.38 (s, 1H),
6.83 (d, J=2.0 Hz, 1H), 7.04 (d, J=1.1 Hz, 1H), 7.36 (d, J=1.0 Hz,
1H), 7.50 (d, J=2.0 Hz, 1H), 8.19 (s, 1H), 8.34 (s, 1H). MS (APCI)
m/z 436.1 [M+H].sup.+.
Example 155
5-amino-N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methy-
l)-3-methyl-1,2-oxazole-4-carboxamide
[0812] Example 155 was prepared according to the procedure used for
the preparation of Example 190, substituting
5-amino-3-methylisoxazole-4-carboxylic acid for
5-cyclopropyl-3-methylisoxazole-4-carboxylic acid. 1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 2.33 (s, 3H), 4.59 (s, 2H), 5.61 (s, 2H),
6.37 (s, 1H), 6.84 (d, J=1.9 Hz, 1H), 7.49 (d, J=2.0 Hz, 1H), 8.19
(s, 1H), 8.32 (s, 1H). MS (APCI) m/z 452.1 [M+H].sup.+.
Example 156
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-met-
hylthiophene-3-carboxamide
[0813] Example 156 was prepared according to the procedure used for
the preparation of Example 139, substituting
2-methylthiophene-3-carboxylic acid for isothiazole-4-carboxylic
acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 2.66 (s, 3H),
4.63 (s, 2H), 5.61 (s, 2H), 6.38 (s, 1H), 6.85 (d, J=2.0 Hz, 1H),
7.31 (d, J=5.4 Hz, 1H), 7.38 (d, J=5.4 Hz, 1H), 7.50 (d, J=2.0 Hz,
1H), 8.18 (s, 1H), 8.33 (s, 1H). MS (APCI) m/z 452.1
[M+H].sup.+.
Example 157
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-met-
hylthiophene-2-carboxamide
[0814] Example 157 was prepared according to the procedure used for
the preparation of Example 139, substituting
3-methylthiophene-2-carboxylic acid for isothiazole-4-carboxylic
acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 2.46 (s, 3H),
4.63 (s, 2H), 5.61 (s, 2H), 6.39 (s, 1H), 6.85 (d, J=2.0 Hz, 1H),
7.01 (d, J=5.0 Hz, 1H), 7.51 (d, J=2.0 Hz, 1H), 7.60 (d, J=5.0 Hz,
1H), 8.19 (s, 1H), 8.33 (s, 1H). MS (APCI) m/z 452.1
[M+H].sup.+.
Example 158
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-met-
hoxythiophene-3-carboxamide
[0815] Example 158 was prepared according to the procedure used for
the preparation of Example 139, substituting
4-methoxythiophene-3-carboxylic acid for isothiazole-4-carboxylic
acid. 1H NMR (400 MHz, DMSO-d.sub.6) .delta. 3.92 (s, 3H), 4.69 (s,
2H), 5.62 (s, 2H), 6.39 (s, 1H), 6.83 (dd, J=19.9, 2.8 Hz, 2H),
7.52 (d, J=2.0 Hz, 1H), 8.11 (d, J=3.6 Hz, 1H), 8.20 (s, 1H), 8.34
(s, 1H). MS (APCI) m/z 468.1 [M+H].sup.+.
Example 159
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-met-
hoxythiophene-2-carboxamide
[0816] Example 159 was prepared according to the procedure used for
the preparation of Example 139, substituting
3-methoxythiophene-2-carboxylic acid for isothiazole-4-carboxylic
acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 4.01 (s, 3H),
4.65-4.75 (m, 2H), 5.62 (s, 2H), 6.39 (s, 1H), 6.86 (d, J=2.0 Hz,
1H), 7.16 (d, J=5.6 Hz, 1H), 7.52 (d, J=2.0 Hz, 1H), 7.75 (d, J=5.5
Hz, 1H), 8.05-8.24 (m, 2H), 8.34 (s, 1H). MS (APCI) m/z 468.1
[M+H].sup.+.
Example 160
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-met-
hyl-1H-pyrrole-2-carboxamide
[0817] Example 160 was prepared according to the procedure used for
the preparation of Example 232, substituting
1-methyl-1H-pyrrole-2-carboxylic acid for 2-(pyridin-4-yl)acetic
acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 3.88 (s, 4H),
4.59 (d, J=5.8 Hz, 2H), 5.66 (s, 2H), 6.04 (dd, J=3.9, 2.5 Hz, 1H),
6.35 (d, J=1.8 Hz, 1H), 6.79-6.98 (m, 3H), 7.49 (d, J=2.0 Hz, 1H),
8.31 (s, 3H), 8.42-8.61 (m, 2H), 11.45 (d, J=2.0 Hz, 1H). MS (APCI)
m/z 435.1 [M+H].sup.+.
Example 161
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2,4-d-
imethyl-1,3-thiazole-5-carboxamide
[0818] Example 161 was prepared according to the procedure used for
the preparation of Example 139, substituting
2,4-dimethylthiazole-5-carboxylic acid for isothiazole-4-carboxylic
acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 2.54 (d, J=1.4
Hz, 4H), 4.61 (s, 2H), 5.61 (s, 2H), 6.38 (s, 1H), 6.85 (d, J=2.0
Hz, 1H), 7.51 (d, J=1.9 Hz, 1H), 8.20 (s, 1H), 8.32 (s, 1H). MS
(APCI) m/z 467.1 [M+H].sup.+.
Example 162
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3,5-d-
imethyl-1,2-oxazole-4-carboxamide
[0819] Example 162 was prepared according to the procedure used for
the preparation of Example 105, substituting
3,5-dimethyl-isoxazole-4-carboxylic acid for 4-methyl-pentanoic
acid. .sup.1H NMR (400 MHz, DMSO-D.sub.2O-d.sub.6) .delta. 11.48
(s, 1H), 8.57 (s, 1H), 8.45 (s, 1H), 7.54 (d, J=2.0 Hz, 1H), 6.85
(d, J=1.9 Hz, 1H), 6.43 (s, 1H), 5.72 (s, 2H), 4.64 (s, 2H), 2.54
(s, 3H), 2.33 (s, 3H). MS (APCI+) m/z 451.0 (M+H).sup.+.
Example 163
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(1,2,5,6-tetrahydropyridin-3-yl)-1-
H-indol-2-yl}methyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide
[0820] To a mixture of Example 162 (200 mg, 0.444 mmol), tert-butyl
3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-
-carboxylate (165 mg, 0.532 mmol), potassium phosphate tribasic
(0.094 g, 0.444 mmol) in 1,4-dioxane (2 mL) and water (0.111 mL)
was added tris(dibenzylideneacetone)dipalladium(0) (0.0406 g, 0.044
mmol) and tricyclohexylphosphine (0.009 g, 0.032 mmol). The vessel
was sealed and heated at 125.degree. C. for 30 minutes in a
microwave (Biotage, Initiator). The cooled solution was filtered
through Celite.RTM. and the filtrated concentrated under reduced
pressure. The crude intermediate was added to a silica gel column
and was eluted with methanol/dichloromethane (0-20%). The
intermediate was treated with 20% trifluoroacetic acid in
dichloromethane (3 mL) for 3 days with stirring at room
temperature. The mixture was concentrated to dryness and purified
by preparative HPLC (Waters Sunfire C8, 15-45% acetonitrile/water;
1% TFA) to give the title compound (0.023 g, 8.48%). .sup.1H NMR
(400 MHz, CD.sub.3OD) .delta. 8.43 (s, 1H), 8.23 (s, 1H), 7.55 (d,
J=1.6 Hz, 1H), 7.25 (d, J=1.6 Hz, 1H), 6.47 (s, 1H), 5.71 (s, 2H),
4.68 (d, J=4.3 Hz, 2H), 4.09 (d, J=2.4 Hz, 2H), 2.58 (d, J=4.9 Hz,
2H), 2.51 (s, 3H), 2.34 (s, 3H); MS m/z: 363 [M-adinine].sup.+.
Example 164
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-phenyl-1H-indol-2-yl}methyl)-3,
5-dimethyl-1,2-oxazole-4-carboxamide
[0821] Example 164 was prepared according to the procedure used for
the preparation of Example 177, substituting phenylboronic acid for
N-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide.
.sup.1H NMR (DMSO/D.sub.2O-d.sub.6) .delta. 2.32 (s, 3H), 4.65 (s,
2H), 5.68 (s, 2H), 7.27 (t, J=7.0 Hz, 1H), 7.31-7.33 (m, 1H),
7.37-7.44 (m, 2H), 7.51-7.62 (m, 2H), 7.68-7.76 (m, 1H), 8.27 (s,
2H); (ESI) m/z 493 (M+H).sup.+.
Example 165
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4-fluorophenyl)-1H-indol-2-yl}met-
hyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide
[0822] Example 165 was prepared according to the procedure used for
the preparation of Example 177, substituting
(4-fluorophenyl)boronic acid for
N,N-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide.
.sup.1H NMR (DMSO/D.sub.2O-d.sub.6) .delta. 2.32 (s, 3H), 4.65 (s,
2H), 5.67 (s, 2H), 7.13-7.26 (m, 2H), 7.26-7.35 (m, 1H), 7.53-7.64
(m, 2H), 7.64-7.74 (m, 1H), 8.23-8.32 (m, 2H); (ESI) m/z 511
(M+H).sup.+.
Example 166
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4-sulfamoylphenyl)-1H-indol-2-yl}-
methyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide
[0823] Example 166 was prepared according to the procedure used for
the preparation of Example 180, substituting
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide
for (3-(morpholine-4-carbonyl)phenyl)boronic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 2.33 (s, 3H), 4.66 (s, 2H), 5.67
(s, 2H), 6.50 (s, 1H), 7.41 (s, 1H), 7.70-7.77 (m, 2H), 7.79-7.82
(m, 1H), 7.83-7.92 (m, 2H), 8.24 (s, 2H) (ESI) m/z 572
(M+H).sup.+.
Example 167
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4-methylphenyl)-1H-indol-2-yl}met-
hyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide
[0824] Example 167 was prepared according to the procedure used for
the preparation of Example 177, substituting p-tolylboronic acid
for
N,N-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide.
.sup.1H NMR (DMSO/D.sub.2O-d.sub.6) .delta. 2.30-2.33 (m, 6H), 4.64
(s, 2H), 5.66 (s, 2H), 6.45 (s, 1H), 7.16-7.26 (m, 2H), 7.26-7.34
(m, 1H), 7.42-7.47 (m, 2H), 7.67-7.69 (m, 1H), 8.23-8.26 (m, 2H).
(ESI) m/z 507 (M+H).sup.+.
Example 168
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4-methoxyphenyl)-1H-indol-2-yl}me-
thyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide
[0825] Example 168 was prepared according to the procedure used for
the preparation of Example 177, substituting
(4-methoxyphenyl)boronic acid for
N,N-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide-
. .sup.1H NMR (DMSO/D.sub.2O-d.sub.6) .delta. 2.32 (s, 3H), 3.78
(s, 3H), 4.64 (s, 2H), 5.66 (s, 2H), 6.95-6.99 (m, 2H), 7.23-7.32
(m, 1H), 7.43-7.51 (m, 2H), 7.60-7.69 (m, 1H), 8.21-8.28 (m, 2H);
(ESI) m/z 523 (M+H).sup.+.
Example 169
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(3-methoxyphenyl)-1H-indol-2-yl}me-
thyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide
[0826] Example 169 was prepared according to the procedure used for
the preparation of Example 177, substituting
(3-methoxyphenyl)boronic acid for
N,N-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide-
. .sup.1H NMR (DMSO/D.sub.2O-d.sub.6) .delta. 2.32 (s, 3H), 3.80
(s, 3H), 4.65 (s, 2H), 5.68 (s, 2H), 6.80-6.91 (m, 1H), 7.06-7.11
(m, 1H), 7.11-7.20 (m, 1H), 7.26-7.38 (m, 2H), 7.70-7.73 (m, 1H),
8.24-8.34 (m, 2H); (ESI) m/z 523 (M+H).sup.+.
Example 170
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-[4-(methylsulfonyl)phenyl]-1H-indo-
l-2-yl}methyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide
[0827] Example 170 was prepared according to the procedure used for
the preparation of Example 177, substituting
(4-(methylsulfonyl)phenyl)boronic acid for
N,N-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide.
.sup.1H NMR (DMSO/D.sub.2O-d.sub.6) .delta. 2.32 (s, 3H), 3.17 (s,
3H), 4.66 (s, 2H), 5.72 (s, 2H), 7.38-7.47 (m, 1H), 7.82-7.87 (m,
3H), 7.91-7.96 (m, 2H), 8.29-8.35 (m, 2H); (ESI) m/z 571
(M+H).sup.+.
Example 171
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4-cyanophenyl)-1H-indol-2-yl}meth-
yl)-3,5-dimethyl-1,2-oxazole-4-carboxamide
[0828] Example 171 was prepared according to the procedure used for
the preparation of Example 177, substituting (4-cyanophenyl)boronic
acid for
N,N-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide.
.sup.1H NMR (DMSO/D.sub.2O-d.sub.6) .delta. 2.32 (s, 3H), 4.65 (s,
2H), 5.69 (s, 2H), 6.51 (s, 1H), 7.38-7.47 (m, 1H), 7.76-7.82 (m,
4H), 7.83-7.88 (m, 1H), 8.27 (s, 2H); (ESI) m/z 518
(M+H).sup.+.
Example 172
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(3-cyanophenyl)-H-indol-2-yl}methy-
l)-3,5-dimethyl-1,2-oxazole-4-carboxamide
[0829] Example 172 was prepared according to the procedure used for
the preparation of Example 177, substituting (3-cyanophenyl)boronic
acid for
N,N-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide.
.sup.1H NMR (DMSO/D.sub.2O-d.sub.6) .delta. 2.32 (s, 3H), 4.65 (s,
2H), 5.67 (s, 2H), 6.50 (s, 1H), 7.41-7.44 (m, 1H), 7.58-7.70 (m,
2H), 7.77-7.86 (m, 1H), 7.89-7.96 (m, 1H), 7.96-8.02 (m, 1H),
8.21-8.30 (m, 2H); MS (ESI) m/z 518 (M+H).sup.+.
Example 173
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(3-carbamoylphenyl)-1H-indol-2-yl}-
methyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide
[0830] Example 173 was prepared according to the procedure used for
the preparation of Example 177, substituting
(3-carbamoylphenyl)boronic acid for
N,N-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide-
. .sup.1H NMR (DMSO/D.sub.2O-d.sub.6) .delta. 2.32 (s, 3H), 4.65
(s, 2H), 5.69 (s, 2H), 7.38-7.55 (m, 2H), 7.67-7.85 (m, 3H),
8.04-8.13 (m, 1H), 8.24-8.33 (m, 2H); MS (ESI) m/z 536
(M+H).sup.+.
Example 174
N-[(7-[(6-amino-9H-purin-9-yl)methyl]-5-{4-[(methyl
sulfonyl)amino]phenyl}-1H-indol-2-yl)methyl]-3,5-dimethyl-1,2-oxazole-4-c-
arboxamide
[0831] Example 174 was prepared according to the procedure used for
the preparation of Example 177, substituting
N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanesulfonami-
de for
N,N-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzami-
de. .sup.1H NMR (DMSO/D.sub.2O-d.sub.6) .delta. 2.32 (s, 3H), 2.98
(s, 3H), 4.64 (s, 2H), 5.67 (s, 2H), 7.23-7.29 (m, 2H), 7.29-7.36
(m, 1H), 7.49-7.60 (m, 2H), 7.66-7.75 (m, 1H), 8.23-8.32 (m, 2H);
MS (ESI) m/z 586 (M+H).sup.+.
Example 175
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-[4-(cyanomethyl)phenyl]-1H-indol-2-
-yl}methyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide
[0832] Example 175 was prepared according to the procedure used for
the preparation of Example 177, substituting
(4-(cyanomethyl)phenyl)boronic acid for
N,N-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benz-
amide. .sup.1H NMR (DMSO/D.sub.2O-d.sub.6) .delta. 2.32 (s, 3H),
3.96 (s, 2H), 4.65 (s, 2H), 5.69 (s, 2H), 7.31-7.35 (m, 1H),
7.37-7.42 (m, 2H), 7.54-7.66 (m, 2H), 7.68-7.79 (m, 1H), 8.19-8.39
(m, 2H); MS (ESI) m/z 532 (M+H).sup.+.
Example 176
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-[4-(dimethylcarbamoyl)phenyl]-1H-i-
ndol-2-yl}methyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide
[0833] Example 176 was prepared according to the procedure used for
the preparation of Example 177, substituting
N,N-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide
for
N,N-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide.
.sup.1H NMR (DMSO/D.sub.2O-d.sub.6) .delta. 2.32 (s, 3H), 2.98 (s,
6H), 4.65 (s, 2H), 5.68 (s, 2H), 7.38-7.39 (m, 1H), 7.41-7.45 (m,
3H), 7.62-7.66 (m, 2H), 7.76-7.79 (m, 1H), 8.27 (s, 2H); MS (ESI)
m/z 564 (M+H).sup.+.
Example 177
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-[3-(dimethylcarbamoyl)phenyl]-1H-i-
ndol-2-yl}methyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide
[0834] A microwave vial was charged with 32 mg of SiliaCat DPP-Pd
(diphenylphosphine palladium (II)). Then a solution Example 162 (24
mg, 0.05 mmol) in dioxane (1.0 mL) was added, followed by the
addition of
N,N-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide
(0.1 mmol) in dioxane (0.4 mL) and an aqueous solution of
Cs.sub.2CO.sub.3 (160 .mu.L, 1M).
[0835] The resulting mixture was heated in the microwave oven
(Biotage, Initiator, Power range 0-400 W from magnetron at 2.45
GHz) for 20 minutes at 120.degree. C. The reaction was filtered,
and the filtrate was purified by preparative HPLC on a Phenomenex
Luna C8 (2) 5 .mu.m 100 .ANG. AXIA column (30 mm.times.150 mm). A
gradient of acetonitrile (A) and 0.1% trifluoroacetic acid in water
(B) was used, at a flow rate of 50 mL/min (0-0.5 minutes 10% A,
0.5-6.0 minutes linear gradient 10-100% A, 6.0-7.0 minutes 100% A,
7.0-8.0 minutes linear gradient 100-10% A). An Agilent 1100 Series
Purification system was used, consisting of the following modules:
Agilent 1100 Series LC/MSD SL mass spectrometer with
API-electrospray source; two Agilent 1100 Series preparative pumps;
Agilent 1100 Series isocratic pump; Agilent 1100 Series diode array
detector with preparative (0.3 mm) flow cell; Agilent
active-splitter, IFC-PAL fraction collector/autosampler. The
make-up pump for the mass spectrometer used 3:1 methanol:water with
0.1% formic acid at a flow rate of 1 mL/min. Fraction collection
was automatically triggered when the extracted ion chromatogram
(EIC) for the target mass exceeded the threshold specified in the
method. The system was controlled using Agilent Chemstation (Rev B.
10.03), Agilent A2Prep, and Leap FractPal software, with custom
Chemstation macros for data export. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 2.32 (s, 3H), 2.98 (s, 6H), 4.65
(s, 2H), 5.71 (s, 2H), 7.26-7.30 (m, 1H), 7.34-7.37 (m, 1H),
7.39-7.51 (m, 2H), 7.54-7.57 (m, 1H), 7.62-7.67 (m, 1H), 7.74-7.79
(m, 1H), 8.28-8.35 (m, 2H); MS (ESI) m/z 564 (M+H).sup.+.
Example 178
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-[3-(cyclopropylcarbamoyl)phenyl]-1-
H-indol-2-yl}methyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide
[0836] Example 178 was prepared according to the procedure used for
the preparation of Example 180, substituting
(3-cyclopropylcarbamoyl)phenyl)boronic acid for
(3-(morpholine-4-carbonyl)phenyl)boronic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 0.61 (d, J=8.0, 4.4 Hz, 2H),
0.67-0.80 (m, 2H), 2.33 (s, 3H), 2.81-2.94 (m, 1H), 4.65 (s, 2H),
5.67 (s, 2H), 6.48 (s, 1H), 7.39-7.44 (m, 1H), 7.47 (t, J=7.7 Hz,
1H), 7.64-7.74 (m, 2H), 7.74-7.83 (m, 1H), 7.96-8.04 (m, 1H),
8.18-8.28 (m, 2H); MS (ESI) m/z 576 (M+H).sup.+.
Example 179
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-[3-(morpholin-4-yl)phenyl]-1H-indo-
l-2-yl}methyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide
[0837] Example 179 was prepared according to the procedure used for
the preparation of Example 177, substituting
(3-morpholinophenyl)boronic acid hydrochloride for
N,N-dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide.
.sup.1H NMR (DMSO/D.sub.2O-d.sub.6) .delta. 2.32 (s, 3H), 3.12-3.16
(m, 4H), 3.75-3.80 (m, 4H), 4.65 (s, 2H), 5.70 (s, 2H), 6.80-6.91
(m, 1H), 6.97-7.08 (m, 2H), 7.20-7.33 (m, 2H), 7.66-7.75 (m, 1H),
8.26-8.36 (m, 2H); MS (ESI) m/z 578 (M+H).sup.+.
Example 180
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-[3-(morpholin-4-ylcarbonyl)phenyl]-
-1H-indol-2-yl}methyl)-3,5-dimethyl-1,2-oxazole-4-carboxamide
[0838] A microwave vial was charged with 32 mg of SiliaCat DPP-Pd
(diphenylphosphine palladium (II)). Then a solution of Example 162
(24 mg, 0.05 mmol) in dioxane (1.0 mL) was added, followed by
(3-(morpholine-4-carbonyl)phenyl)boronic acid (0.1 mmol) in dioxane
(0.4 mL) and an aqueous solution of Cs.sub.2CO.sub.3 (160 .mu.L,
1M). The resulting mixture was heated in the microwave oven
(Biotage Initiator, Power range 0-400 W from magnetron at 2.45 GHz)
for 20 minutes at 120.degree. C. The reaction was filtered, and the
filtrate was purified by preparative HPLC on a Phenomenex Luna C8
(2) 5 .mu.m 100 .ANG. AXIA column (30 mm.times.150 mm). A gradient
of acetonitrile (A) and 0.05% ammonium acetate in water (B) was
used, at a flow rate of 50 mL/min (0-0.5 minutes 10% A, 0.5-6.0
minutes linear gradient 10-100% A, 6.0-7.0 minutes 100% A, 7.0-8.0
minutes linear gradient 100-10% A). An Agilent 1100 Series
Purification system was used, consisting of the following modules:
Agilent 1100 Series LC/MSD SL mass spectrometer with
API-electrospray source; two Agilent 1100 Series preparative pumps;
Agilent 1100 Series isocratic pump; Agilent 1100 Series diode array
detector with preparative (0.3 mm) flow cell; Agilent
active-splitter, IFC-PAL fraction collector/autosampler. The
make-up pump for the mass spectrometer used 3:1 methanol:water with
0.1% formic acid at a flow rate of 1 mL/min. Fraction collection
was automatically triggered when the extracted ion chromatogram
(EIC) for the target mass exceeded the threshold specified in the
method. The system was controlled using Agilent Chemstation (Rev
B.10.03), Agilent A2Prep, and Leap FractPal software, with custom
Chemstation macros for data export. .sup.1H NMR (DMSO-d.sub.6)
.delta. 2.32 (s, 3H), 3.47-3.56 (m, 4H), 3.57-3.67 (m, 4H), 4.65
(s, 2H), 5.67 (s, 2H), 6.48 (s, 1H), 7.24-7.33 (m, 1H), 7.36 (s,
1H), 7.49 (t, J=7.7 Hz, 1H), 7.56 (s, 1H), 7.61-7.69 (m, 1H),
7.74-7.80 (m, 1H), 8.22-8.26 (m, 2H); (ESI) m/z 606
(M+H).sup.+.
Example 181
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-5-eth-
yl-1,2-oxazole-4-carboxamide
[0839] Example 181 was prepared according to the procedure used for
the preparation of Example 139, substituting
5-ethylisoxazole-4-carboxylic acid for isothiazole-4-carboxylic
acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 1.26 (t, J=7.5
Hz, 3H), 3.08-3.25 (m, 2H), 4.65 (s, 2H), 5.63 (s, 2H), 6.43 (s,
1H), 6.87 (d, J=2.0 Hz, 1H), 7.52 (d, J=2.0 Hz, 1H), 8.20 (s, 1H),
8.34 (s, 1H), 8.92 (s, 1H). MS (APCI) m/z 451.1 [M+H].sup.+.
Example 182
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,5-d-
imethyl-1H-pyrazole-3-carboxamide
[0840] Example 182 was prepared according to the procedure used for
the preparation of Example 139, substituting
1,5-dimethyl-1H-pyrazole-3-carboxylic acid for
isothiazole-4-carboxylic acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 2.29 (s, 3H), 3.80 (s, 3H), 4.61 (s, 2H), 5.60 (s, 2H),
6.34 (s, 1H), 6.49 (d, J=1.0 Hz, 1H), 6.83 (d, J=2.0 Hz, 1H), 7.49
(d, J=2.0 Hz, 1H), 8.21 (s, 1H), 8.33 (s, 1H). MS (APCI) m/z 450.1
[M+H].sup.+.
Example 183
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,3-d-
imethyl-1H-pyrazole-5-carboxamide
[0841] Example 183 was prepared according to the procedure used for
the preparation of Example 139, substituting
1,3-dimethyl-1H-pyrazole-5-carboxylic acid for
isothiazole-4-carboxylic acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 2.19 (s, 3H), 4.02 (s, 3H), 4.64 (s, 2H), 5.64 (s, 2H),
6.40 (s, 1H), 6.69 (s, 1H), 6.85 (d, J=1.9 Hz, 1H), 7.52 (d, J=2.0
Hz, 1H), 8.23 (s, 1H), 8.37 (s, 1H). MS (APCI) m/z 450.1
[M+H].sup.+.
Example 184
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,3-d-
imethyl-1H-pyrazole-4-carboxamide
[0842] Example 184 was prepared according to the procedure used for
the preparation of Example 139, substituting
1,3-dimethyl-1H-pyrazole-4-carboxylic acid for
isothiazole-4-carboxylic acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 2.36 (s, 3H), 3.79 (s, 3H), 4.59 (s, 2H), 5.61 (s, 2H),
6.37 (s, 1H), 6.85 (d, J=1.9 Hz, 1H), 7.49 (d, J=1.9 Hz, 1H), 8.08
(s, 1H), 8.18 (s, 1H), 8.32 (s, 1H). MS (APCI) m/z 450.1
[M+H].sup.+.
Example 185
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-5-eth-
yl-3-methyl-1,2-oxazole-4-carboxamide
[0843] Example 185 was prepared according to the procedure used for
the preparation of Example 190, substituting
5-ethyl-3-methylisoxazole-4-carboxylic acid for
5-cyclopropyl-3-methylisoxazole-4-carboxylic acid. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 1.20 (t, J=7.6 Hz, 3H), 2.33 (s, 3H),
2.93 (q, J=7.6 Hz, 2H), 4.64 (s, 2H), 5.61 (s, 2H), 6.40 (s, 1H),
6.86 (d, J=2.0 Hz, 1H), 7.52 (d, J=2.0 Hz, 1H), 8.21 (s, 1H), 8.31
(s, 1H). MS (APCI) m/z 465.1 [M+H].sup.+.
Example 186
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-eth-
yl-5-methyl-1,2-oxazole-4-carboxamide
[0844] Example 186 was prepared according to the procedure used for
the preparation of Example 139, substituting
3-ethyl-5-methylisoxazole-4-carboxylic acid for
isothiazole-4-carboxylic acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 1.26 (t, J=7.5 Hz, 3H), 2.62 (s, 3H), 2.86 (q, J=7.5 Hz,
2H), 4.74 (s, 2H), 5.71 (s, 2H), 6.51 (s, 1H), 6.96 (d, J=1.9 Hz,
1H), 7.62 (d, J=2.0 Hz, 1H), 8.31 (s, 1H), 8.41 (s, 1H). MS (APCI)
m/z 465.1 [M+H].sup.+.
Example 187
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-5-(pr-
opan-2-yl)-1,2-oxazole-4-carboxamide
[0845] Example 187 was prepared according to the procedure used for
the preparation of Example 139, substituting
5-isopropylisoxazole-4-carboxylic acid for isothiazole-4-carboxylic
acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 1.29 (d, J=7.0
Hz, 6H), 3.88 (p, J=7.0 Hz, 1H), 4.64 (d, J=4.1 Hz, 2H), 5.61 (s,
2H), 6.42 (s, 1H), 6.85 (d, J=2.0 Hz, 1H), 7.51 (d, J=2.0 Hz, 1H),
8.19 (s, 1H), 8.33 (s, 1H), 8.90 (s, 1H). MS (APCI) m/z 465.1
[M+H].sup.+.
Example 188
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-eth-
yl-3,5-dimethyl-1H-pyrazole-4-carboxamide
[0846] Example 188 was prepared according to the procedure used for
the preparation of Example 139, substituting
1-ethyl-3,5-dimethyl-1H-pyrazole-4-carboxylic acid for
isothiazole-4-carboxylic acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 1.27 (t, J=7.2 Hz, 3H), 2.28 (s, 3H), 2.37 (s, 3H), 4.00
(q, J=7.2 Hz, 2H), 4.61 (s, 2H), 5.61 (s, 2H), 6.38 (s, 1H), 6.85
(d, J=2.0 Hz, 1H), 7.50 (d, J=1.9 Hz, 1H), 8.19 (s, 1H), 8.31 (s,
1H). MS (APCI) m/z 478.1 [M+H].sup.+.
Example 189
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-5-cyc-
lopropyl-1,2-oxazole-4-carboxamide
[0847] Example 189 was prepared according to the procedure used for
the preparation of Example 139, substituting
5-cyclopropylisoxazole-4-carboxylic acid for
isothiazole-4-carboxylic acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 1.08-1.30 (m, 4H), 2.96 (ddd, J=8.3, 5.1, 3.3 Hz, 1H), 4.66
(s, 2H), 5.63 (s, 2H), 6.44 (s, 1H), 6.87 (d, J=1.9 Hz, 1H), 7.53
(d, J=2.0 Hz, 1H), 8.21 (s, 1H), 8.34 (s, 1H), 8.89 (s, 1H). MS
(APCI) m/z 463.1 [M+H].sup.+.
Example 190
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-5-cyc-
lopropyl-3-methyl-1,2-oxazole-4-carboxamide
[0848] A solution of Example 9b (0.14 M in N,N-dimethylacetamide,
329 .mu.L, 0.046 mmol and N,N-diisopropylethylamine (0.14 M in
N,N-dimethylacetamide, 329 .mu.L, 0.046 mmol), HATU (0.15 M in
N,N-dimethylacetamide, 333 .mu.L, 0.05 mmol), and
5-cyclopropyl-3-methylisoxazole-4-carboxylic acid (0.4M in
N,N-dimethylacetamide, 125 .mu.L, 0.05 mmol) were aspirated from
their respective source vials, mixed through a perfluoroalkoxy
alkanes mixing tube (0.2 mm inner diameter), and loaded into an
injection loop. The reaction segment was injected into the flow
reactor (Hastelloy coil, 0.75 mm inner diameter, 1.8 mL internal
volume) set at 100.degree. C., and passed through the reactor at
180 .mu.L min.sup.-1 (10 minute residence time). Upon exiting the
reactor, the reaction was loaded directly into an injection loop
and purified using preparative HPLC to yield the title compound
(12.49 mg, 57.18% yield). Samples were purified by preparative HPLC
on a Phenomenex Luna C8 (2) 5 .mu.m 100 .ANG. AXIA column (50
mm.times.21.2 mm). A gradient of acetonitrile (A) and 0.1% ammonium
acetate in water (B) was used, at a flow rate of 30 mL/min (0-0.5
minutes 5% A, 0.5-6.5 minutes linear gradient 5-60% A, 6.5-7.0
minutes linear gradient 60-100% A, 7.0-8.9 minutes 100% A, 8.9-9.0
minutes linear gradient 100-5% A, 9.0-10 minutes 5% A). A sample
volume of 1.0 mL was injected directly from the flow reactor stream
to the HPLC system. A custom purification system was used,
consisting of the following modules: Gilson 305 and 306 pumps;
Gilson 806 Manometric module; Gilson UV/Vis 155 detector; Gilson
506C interface box; Gilson FC204 fraction collector; Agilent G1968D
Active Splitter; Thermo MSQ Plus mass spectrometer. The system was
controlled through a combination of Thermo Xcalibur 2.0.7 software
and a custom application written in-house using Microsoft Visual
Basic 6.0. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 0.97-1.08
(m, 2H), 1.13 (dt, J=8.2, 3.3 Hz, 2H), 2.31 (s, 3H), 2.37-2.47 (m,
1H), 4.65 (s, 2H), 5.61 (s, 2H), 6.42 (s, 1H), 6.86 (d, J=1.9 Hz,
1H), 7.52 (d, J=2.0 Hz, 1H), 8.21 (s, 1H), 8.31 (s, 1H). MS (APCI)
m/z 477.1.1 [M+H].sup.+.
Example 191
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-met-
hyl-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carboxamide
[0849] Example 191 was prepared according to the procedure used for
the preparation of Example 139, substituting
1-methyl-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carboxylic acid
for isothiazole-4-carboxylic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 2.44-2.52 (m, 2H), 2.71 (q, J=7.6 Hz, 5H),
3.78 (s, 3H), 4.55-4.65 (m, 2H), 5.61 (s, 2H), 6.35 (s, 1H), 6.85
(d, J=2.0 Hz, 1H), 7.50 (d, J=2.0 Hz, 1H), 8.22 (s, 1H), 8.33 (s,
1H). MS (APCI) m/z 476.1 [M+H].sup.+.
Example 192
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4,
5,6,7-tetrahydropyrazolo[1,5-a]pyridine-3-carboxamide
[0850] Example 192 was prepared according to the procedure used for
the preparation of Example 139, substituting
4,5,6,7-tetrahydropyrazolo[1,5-a]pyridine-3-carboxylic acid for
isothiazole-4-carboxylic acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 1.76-1.85 (m, 3H), 1.98 (tt, J=6.1, 2.9 Hz, 2H), 3.02 (t,
J=6.4 Hz, 2H), 4.08 (q, J=6.0 Hz, 3H), 4.61 (s, 2H), 5.62 (s, 2H),
6.38 (s, 1H), 6.86 (d, J=2.0 Hz, 1H), 7.51 (d, J=2.1 Hz, 1H), 7.91
(d, J=33.1 Hz, 1H), 8.20 (s, 1H), 8.34 (s, 1H). MS (APCI) m/z 476.1
[M+H].sup.+.
Example 193
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)pyrazi-
ne-2-carboxamide
[0851] Example 193 was prepared according to the procedure used for
the preparation of Example 232, substituting pyrazine-2-carboxylic
acid for 2-(pyridin-4-yl)acetic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 4.73 (d, J=6.1 Hz, 2H), 5.63 (s, 2H), 6.37
(d, J=1.9 Hz, 1H), 6.81 (d, J=2.0 Hz, 1H), 7.48 (d, J=1.9 Hz, 1H),
7.82 (s, 2H), 8.27 (s, 1H), 8.39 (s, 1H), 8.73-8.82 (m, 1H), 9.24
(d, J=1.5 Hz, 1H), 9.46 (t, J=6.1 Hz, 1H), 11.51 (d, J=2.2 Hz, 1H).
MS (APCI) m/z 434.1 [M+H].sup.+.
Example 194
9-({2-[amino(phenyl)methyl]-5-chloro-1H-indol-7-yl}methyl)-9H-purin-6-amin-
e
[0852] Example 194 was according to the procedure used for the
preparation of Example 87C, substituting phenylmagnesium bromide
for methylmagnesium bromide. .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.27 (d, J=2.0 Hz, 1H), 8.00 (d, J=3.4 Hz, 1H), 7.61 (d,
J=1.9 Hz, 1H), 7.54-7.39 (m, 5H), 7.10 (d, J=1.8 Hz, 1H), 6.69 (s,
1H), 5.87 (s, 1H), 5.73-5.55 (m, 2H), 2.65 (s, 1H). MS m/z: 387
[M-NH.sub.2].sup.+.
Example 195
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)pyridi-
ne-2-carboxamide
[0853] Example 195 was prepared according to the procedure used for
the preparation of Example 232, substituting picolinic acid for
2-(pyridin-4-yl)acetic acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 4.72 (d, J=6.2 Hz, 2H), 5.65 (s, 2H), 6.36 (d, J=1.9 Hz,
1H), 6.81 (d, J=2.0 Hz, 1H), 7.48 (d, J=2.0 Hz, 1H), 7.58-7.70 (m,
1H), 7.91-8.18 (m, 4H), 8.31 (s, 1H), 8.44 (s, 1H), 8.64-8.74 (m,
1H), 9.31 (t, J=6.2 Hz, 1H), 11.50 (d, J=2.2 Hz, 1H). MS (APCI) m/z
433.1 [M+H].sup.+.
Example 196
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)pyridi-
ne-3-carboxamide
[0854] Example 196 was prepared according to the procedure used for
the preparation of Example 232, substituting nicotinic acid for
2-(pyridin-4-yl)acetic acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 2.94 (s, 1H), 4.72 (d, J=5.5 Hz, 2H), 5.71 (s, 2H), 6.43
(d, J=1.8 Hz, 1H), 6.81 (d, J=2.0 Hz, 1H), 7.46-7.64 (m, 2H), 8.31
(dt, J=8.0, 1.9 Hz, 1H), 8.42 (s, 1H), 8.66 (d, J=88.6 Hz, 3H),
9.11 (s, 1H), 9.31 (t, J=5.7 Hz, 1H), 11.53 (d, J=2.2 Hz, 1H). MS
(APCI) m/z 433.1 [M+H].sup.+.
Example 197
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-6-hyd-
roxypyridine-2-carboxamide
[0855] Example 197 was prepared according to the procedure used for
the preparation of Example 105, substituting
6-hydroxy-pyridine-2-carboxylic acid for 4-methyl-pentanoic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.51 (s, 1H), 8.91 (s,
1H), 8.54 (s, 1H), 8.38 (s, 1H), 7.78-7.71 (m, 1H), 7.54-7.46 (m,
1H), 7.36 (s, 2H), 6.80 (t, J=3.6 Hz, 2H), 6.40 (d, J=1.9 Hz, 1H),
5.69 (s, 2H), 4.69 (d, J=5.8 Hz, 2H). MS (APCI+) m/z 449.0
(M+H).sup.+.
Example 198
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-oxo-
-1,2-dihydropyridine-3-carboxamide
[0856] Example 198 was prepared according to the procedure used for
the preparation of Example 105, substituting
2-oxo-1,2-dihydro-pyridine-3-carboxylic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 12.54 (s, 1H), 11.56 (d, J=2.0 Hz, 1H), 10.24
(t, J=5.7 Hz, 1H), 8.57 (s, 1H), 8.46-8.34 (m, 3H), 7.74 (td,
J=6.3, 2.3 Hz, 1H), 7.51 (d, J=2.1 Hz, 1H), 6.88-6.76 (m, 1H),
6.57-6.48 (m, 1H), 6.39 (d, J=1.8 Hz, 1H), 5.73-5.66 (m, 3H), 4.72
(d, J=5.8 Hz, 2H). MS (APCI+) m/z 449.0 (M+H).sup.+.
Example 199
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-met-
hylpyridazine-4-carboxamide
[0857] A solution of Example 9b (0.1 M in N,N-dimethylacetamide,
360 .mu.L, 0.036 mmol), N,N-diisopropylethylamine (0.3 M in
N,N-dimethylacetamide, 360 .mu.L, 0.108 mmol), HATU (0.12 M in
N,N-dimethylacetamide, 375 .mu.L, 0.0432 mmol), and
3-methylpyridazine-4-carboxylic acid (0.4M in
N,N-dimethylacetamide, 110 .mu.L, 0.0432 mmol) were aspirated from
their respective source vials, mixed through a perfluoroalkoxy
alkanes mixing tube (0.2 mm inner diameter), and loaded into an
injection loop. The reaction segment was injected into the flow
reactor (Hastelloy coil, 0.75 mm inner diameter, 1.8 mL internal
volume) set at 100.degree. C., and passed through the reactor at
180 .mu.L min.sup.-1 (10 minute residence time). Upon exiting the
reactor, the reaction was loaded directly into an injection loop
and purified using preparative HPLC to yield the title compound
(11.38 mg, 55.3% yield). Samples were purified by preparative HPLC
on a Phenomenex Luna C8 (2) 5 .mu.m 100 .ANG. AXIA column (50
mm.times.21.2 mm). A gradient of acetonitrile (A) and 0.1%
trifluoroacetic acid in water (B) was used, at a flow rate of 30
mL/min (0-0.5 minutes 5% A, 0.5-6.5 minutes linear gradient 5-40%
A, 6.5-7.0 minutes linear gradient 40-100% A, 7.0-8.5 minutes 100%
A, 8.5-9.0 minutes linear gradient 100-5% A, 9.0-10 minutes 5% A).
A sample volume of 1.0 mL was injected directly from the flow
reactor stream to the HPLC system. A custom purification system was
used, consisting of the following modules: Gilson 305 and 306
pumps; Gilson 806 Manometric module; Gilson UV/Vis 155 detector;
Gilson 506C interface box; Gilson FC204 fraction collector; Agilent
G1968D Active Splitter; Thermo MSQ Plus mass spectrometer. The
system was controlled through a combination of Thermo Xcalibur
2.0.7 software and a custom application written in-house using
Microsoft Visual Basic 6.0. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 2.69 (s, 3H), 4.70 (s, 2H), 5.73 (s, 2H), 6.49 (s, 1H),
6.84 (d, J=1.9 Hz, 1H), 7.55 (d, J=2.0 Hz, 1H), 7.69 (d, J=5.1 Hz,
1H), 8.45 (s, 1H), 8.58 (s, 1H), 9.25 (d, J=5.1 Hz, 1H). MS (APCI)
m/z 448.2 [M+H].sup.+.
Example 200
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(1,2,3,6-tetrahydropyridin-4-yl)-1-
H-indol-2-yl}methyl)-3-methylpyridazine-4-carboxamide
[0858] Example 204 (10 mg, 0.017 mmol) in 0.6 mL dichloromethane
was treated with trifluoroacetic acid (0.3 mL). The mixture was
stirred at ambient temperature for 2 hours and concentrated. To the
residue was added 4N HCl dioxane solution (1 mL) and concentrated
again. The solid residue was triturated in 1 mL diethyl ether to
afford the title compound as hydrochloric acid salt (9 mg, 0.015
mmol, 89% yield). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.70
(s, 1H), 9.38 (t, J=5.6 Hz, 1H), 9.25 (d, J=5.0 Hz, 1H), 9.18 (s,
2H), 8.71 (s, 1H), 8.53 (d, J=21.7 Hz, 1H), 7.71 (d, J=5.1 Hz, 1H),
7.63-7.46 (m, 1H), 7.12 (s, 1H), 6.46 (s, 1H), 5.98 (s, 1H), 5.76
(s, 2H), 4.70 (d, J=5.6 Hz, 2H), 3.28 (s, 2H), 2.67 (s, 2H). MS
(ESI-) m/z 493.3 (M-H).
Example 201
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4,4-difluorocyclohex-1-en-1-yl)-1-
H-indol-2-yl}methyl)-3-methylpyridazine-4-carboxamide
[0859] A mixture of Example 199 (16 mg, 0.036 mmol),
2-(4,4-difluorocyclohex-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
e (13.08 mg, 0.054 mmol) and
phenylallylchloro[1,3-bis(diisopropylphenyl)-2-imidazol-2-ylidene]palladi-
um (II) (3.47 mg, 5.36 .mu.mol), potassium phosphate (22.75 mg,
0.107 mmol) in 1 mL dioxane and 0.3 mL water was purged with
nitrogen and heated at 130.degree. C. in microwave oven (Biotage
Initiator) for 1 hour. The reaction mixture was diluted with ethyl
acetate, washed with brine, dried over anhydrous magnesium sulfate,
and filtered. The filtrate was concentrated and the residue was
first purified by column chromatography on silica gel (2-14%
methanol in dichloromethane with 1% NH.sub.4OH), and then
triturated in diethyl ether to give the title compound. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 11.40 (s, 1H), 9.27 (t, J=5.6 Hz,
1H), 9.23 (d, J=5.0 Hz, 1H), 8.27 (s, 1H), 8.21 (s, 1H), 7.64 (d,
J=5.1 Hz, 1H), 7.51 (s, 1H), 7.27 (s, 2H), 7.12 (d, J=1.4 Hz, 1H),
6.44 (d, J=1.5 Hz, 1H), 5.81 (s, 1H), 5.60 (s, 2H), 4.68 (d, J=5.6
Hz, 2H), 2.71-2.61 (m, 6H), 2.22-2.08 (m, 2H), 1.26 (d, J=6.8 Hz,
1H), 1.16 (d, J=6.9 Hz, 1H). MS (ESI+) m/z 530.1 (M+H).sup.+.
Example 202
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-[1-(methylsulfonyl)-1,2,3,6-tetrah-
ydropyridin-4-yl]-1H-indol-2-yl}methyl)-3-methylpyridazine-4-carboxamide
[0860] Example 202 was prepared according to the procedure used for
the preparation of Example 201, substituting
1-(methylsulfonyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,2,3,-
6-tetrahydropyridine for
2-(4,4-difluorocyclohex-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
e. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.42 (s, 1H), 9.27
(dd, J=12.4, 6.9 Hz, 1H), 9.23 (d, J=5.1 Hz, 1H), 8.26 (s, 1H),
8.21 (s, 1H), 7.64 (d, J=5.1 Hz, 1H), 7.51 (s, 1H), 7.28 (s, 2H),
7.16 (d, J=1.3 Hz, 1H), 6.44 (d, J=1.5 Hz, 1H), 5.99 (s, 1H), 5.60
(s, 2H), 4.68 (d, J=5.5 Hz, 2H), 3.80 (dd, J=19.1, 4.9 Hz, 2H),
2.91 (s, 3H), 2.70 (s, 3H), 2.59 (s, 2H). MS (ESI+) m/z 573.1
(M+H).sup.+.
Example 203
N-({5-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-7-[(6-amino-9H-purin-9-yl)-
methyl]-1H-indol-2-yl}methyl)-3-methylpyridazine-4-carboxamide
[0861] Example 203 was prepared according to the procedure used for
the preparation of Example 201, substituting
1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridin-1(2-
H)-yl)ethanone (33.6 mg, 0.134 mmol) for
2-(4,4-difluorocyclohex-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
e. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.40 (s, 1H),
9.34-9.15 (m, 2H), 8.26 (s, 1H), 8.21 (s, 1H), 7.64 (d, J=5.1 Hz,
1H), 7.49 (d, J=3.1 Hz, 1H), 7.27 (s, 2H), 7.14 (s, 1H), 6.44 (s,
1H), 5.96 (d, J=11.1 Hz, 1H), 5.60 (s, 2H), 4.68 (d, J=5.5 Hz, 2H),
4.08 (d, J=21.9 Hz, 2H), 3.69-3.54 (m, 2H), 2.70 (s, 3H), 2.55-2.39
(m, 2H), 2.06 (s, 1.5H), 2.02 (s, 1.5H). MS (ESI+) m/z 537.1
(M+H).sup.+.
Example 204
tert-butyl
4-{7-[(6-amino-9H-purin-9-yl)methyl]-2-({[(3-methylpyridazin-4--
yl)carbonyl]amino}methyl)-1H-indol-5-yl}-3,6-dihydropyridine-1
(2H)-carboxylate
[0862] Example 204 was prepared according to the procedure used for
the preparation of Example 201, substituting tert-butyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-
-carboxylate for
2-(4,4-difluorocyclohex-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
e. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.41 (s, 1H), 9.28
(t, J=5.6 Hz, 1H), 9.23 (d, J=5.0 Hz, 1H), 8.26 (s, 1H), 8.21 (s,
1H), 7.64 (d, J=5.0 Hz, 1H), 7.49 (s, 1H), 7.27 (s, 2H), 7.14 (d,
J=1.2 Hz, 1H), 6.43 (d, J=1.5 Hz, 1H), 5.94 (s, 1H), 5.59 (s, 2H),
4.68 (d, J=5.5 Hz, 2H), 3.96 (s, 2H), 3.52 (t, J=5.5 Hz, 2H), 2.70
(s, 3H), 2.45 (s, 2H), 1.42 (s, 9H). MS (ESI+) m/z 595.0
(M+H).sup.+.
Example 205
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-5-met-
hylpyrazine-2-carboxamide
[0863] Example 205 was prepared according to the procedure used for
the preparation of Example 232, substituting
5-methylpyrazine-2-carboxylic acid for 2-(pyridin-4-yl)acetic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 2.61 (s, 3H), 4.71 (d,
J=6.1 Hz, 2H), 5.66 (s, 2H), 6.36 (d, J=1.8 Hz, 1H), 6.81 (d, J=2.0
Hz, 1H), 7.48 (d, J=1.9 Hz, 1H), 8.34 (s, 3H), 8.46 (s, 1H), 8.66
(d, J=1.4 Hz, 1H), 9.10 (d, J=1.4 Hz, 1H), 9.38 (t, J=6.2 Hz, 1H),
11.49 (d, J=2.1 Hz, 1H). MS (APCI) m/z 448.1 [M+H].sup.+.
Example 206
9-{[2-(1-amino-2-phenylethyl)-5-chloro-1H-indol-7-yl]methyl}-9H-purin-6-am-
ine
[0864] Example 206 was according to the procedure used for the
preparation of Example 87C, substituting benzylmagnesium bromide
for methylmagnesium bromide. .sup.1H NMR (400 MHz, CD.sub.3OD)
.delta. 8.33 (s, 1H), 8.20 (d, J=1.5 Hz, 1H), 7.56 (d, J=1.9 Hz,
1H), 7.26-7.17 (m, 3H), 7.14-7.04 (m, 3H), 6.65 (s, 1H), 5.64 (s,
2H), 4.76 (t, J=7.5 Hz, 1H), 3.38 (d, J=7.5 Hz, 2H); MS m/z: 266
[M-adenine and NH.sub.3].sup.+.
Example 207
9-({2-[(benzylamino)methyl]-5-chloro-1H-indol-7-yl}methyl)-9H-purin-6-amin-
e
[0865] Example 207 was prepared according to the procedure used for
the preparation of Example 97, substituting benzaldehyde for
acetaldehyde. .sup.1H NMR (400 MHz, CDCl.sub.3 with trace
dimethylsulfoxide) .delta. 11.64 (brs, 1H), 8.37 (s, 1H), 8.01 (s,
1H), 7.48 (s, 1H), 7.40-7.34 (m, 5H), 7.17 (s, 1H), 6.38 (s, 1H),
6.03 (brs, 1H), 5.56 (s, 2H), 4.08 (s, 2H), 3.93 (s, 2H); MS m/z:
311 [M-benzylamine].sup.+.
Example 208
9-[(2-{[(2-bromobenzyl)amino]methyl}-5-chloro-1H-indol-7-yl)methyl]-9H-pur-
in-6-amine
[0866] In a 20 mL vial, a solution of the 2-bromobenzaldehyde
monomer (16 mg, 0.08 mmol) in 1:1 methanol/dichloromethane (1 mL)
was added, followed by the addition of
9-((2-(aminomethyl)-5-chloro-1H-indol-7-yl)methyl)-9H-purin-6-amine
amine core (25 mg, 0.08 mmol) in 1:1 methanol/dichloromethane (1.0
mL), and acetic acid (17.5 .mu.L, 0.30 mmol). To this mixture was
then added sodium cyanoborohydride resin (2.19 mmol/g loading, 140
mg) and was allowed to stir overnight at 50.degree. C. The reaction
was filtered and the filtrate was concentrated to dryness. The
residue was reconstituted in 1:1 DMSO/methanol and by reverse phase
HPLC on a Phenomenex Luna C8 (2) 5 .mu.m 100 .ANG. AXIA column (30
mm.times.150 mm). A gradient of acetonitrile (A) and 0.1%
trifluoroacetic acid in water (B) was used, at a flow rate of 50
mL/min (0-0.5 minutes 10% A, 0.5-6.0 minutes linear gradient
10-100% A, 6.0-7.0 minutes 100% A, 7.0-8.0 minutes linear gradient
100-10% A). An Agilent 1100 Series Purification system was used,
consisting of the following modules: Agilent 1100 Series LC/MSD SL
mass spectrometer with API-electrospray source; two Agilent 1100
Series preparative pumps; Agilent 1100 Series isocratic pump;
Agilent 1100 Series diode array detector with preparative (0.3 mm)
flow cell; Agilent active-splitter, IFC-PAL fraction
collector/autosampler. The make-up pump for the mass spectrometer
used 3:1 methanol:water with 0.1% formic acid at a flow rate of 1
mL/min. Fraction collection was automatically triggered when the
extracted ion chromatogram (EIC) for the target mass exceeded the
threshold specified in the method. The system was controlled using
Agilent Chemstation (Rev B.10.03), Agilent A2Prep, and Leap
FractPal software, with custom Chemstation macros for data export.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.47 (s, 1H), 8.34 (s,
1H), 7.74 (dd, J=8.0, 1.2 Hz, 1H), 7.71-7.56 (m, 2H), 7.51 (td,
J=7.6, 1.2 Hz, 1H), 7.41 (td, J=7.7, 1.7 Hz, 1H), 6.90 (d, J=2.0
Hz, 1H), 6.80 (s, 1H), 5.69 (s, 2H), 4.51 (s, 2H), 4.37 (s, 2H). MS
(ESI+) m/z 496 (M+H).sup.+.
Example 209
9-[(5-chloro-2-{[(3-chlorobenzyl)amino]methyl}-1H-indol-7-yl)methyl]-9H-pu-
rin-6-amine
[0867] Example 209 was prepared according to the procedure used for
the preparation of Example 208, substituting 3-chlorobenzaldehyde
for 2-bromobenzaldehyde. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 8.45 (s, 1H), 8.32 (s, 1H), 7.64 (dd, J=13.2, 2.0 Hz, 2H),
7.56-7.42 (m, 3H), 6.88 (d, J=1.9 Hz, 1H), 6.74 (s, 1H), 5.67 (s,
2H), 4.41 (s, 2H), 4.28 (s, 2H). MS (ESI+) m/z 452.1
(M+H).sup.+.
Example 210
9-[(5-chloro-2-{[(2-chlorobenzyl)amino]methyl}-1H-indol-7-yl)methyl]-9H-pu-
rin-6-amine
[0868] Example 210 was prepared according to the procedure used for
the preparation of Example 208, substituting 2-chlorobenzaldehyde
for 2-bromobenzaldehyde. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 8.46 (s, 1H), 8.33 (s, 1H), 7.67 (d, J=1.9 Hz, 1H), 7.60
(ddd, J=16.7, 7.5, 1.9 Hz, 2H), 7.55-7.42 (m, 2H), 6.90 (d, J=2.0
Hz, 1H), 6.79 (s, 1H), 5.68 (s, 2H), 4.50 (s, 2H), 4.37 (s, 2H). MS
(ESI+) m/z 452.1 (M+H).sup.+.
Example 211
9-[(5-chloro-2-{[(2,6-dichlorobenzyl)amino]methyl}-1H-indol-7-yl)methyl]-9-
H-purin-6-amine
[0869] Example 211 was prepared according to the procedure used for
the preparation of Example 208, substituting
2,6-dichlorobenzaldehyde for 2-bromobenzaldehyde. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 8.47 (s, 1H), 8.34 (s, 1H), 7.67 (d,
J=1.9 Hz, 1H), 7.63-7.46 (m, 3H), 6.92 (d, J=1.8 Hz, 1H), 6.83 (s,
1H), 5.70 (s, 2H), 4.55 (s, 2H), 4.48 (s, 2H). MS (ESI+) m/z 486
(M+H).sup.+.
Example 212
9-[(5-chloro-2-{[(3,
5-dichlorobenzyl)amino]methyl}-1H-indol-7-yl)methyl]-9H-purin-6-amine
[0870] Example 212 was prepared according to the procedure used for
the preparation of Example 208, substituting
3,5-dichlorobenzaldehyde for 2-bromobenzaldehyde. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 8.46 (s, 1H), 8.34 (s, 1H), 7.70 (t,
J=1.9 Hz, 1H), 7.65 (d, J=1.9 Hz, 1H), 7.60 (d, J=1.9 Hz, 2H), 6.88
(d, J=1.9 Hz, 1H), 6.74 (s, 1H), 5.68 (s, 2H), 4.43 (s, 2H), 4.30
(s, 2H). MS (ESI+) m/z 486 (M+H).sup.+.
Example 213
9-[(5-chloro-2-{[(3,4-dichlorobenzyl)amino]methyl}-1H-indol-7-yl)methyl]-9-
H-purin-6-amine
[0871] Example 213 was prepared according to the procedure used for
the preparation of Example 208, substituting
3,4-dichlorobenzaldehyde for 2-bromobenzaldehyde. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 8.45 (s, 1H), 8.33 (s, 1H), 7.80 (d,
J=2.0 Hz, 1H), 7.73 (d, J=8.2 Hz, 1H), 7.65 (d, J=1.9 Hz, 1H), 7.50
(dd, J=8.4, 2.1 Hz, 1H), 6.87 (d, J=2.0 Hz, 1H), 6.73 (s, 1H), 5.67
(s, 2H), 4.41 (s, 2H), 4.28 (s, 2H). MS (ESI+) m/z 488
(M+H).sup.+.
Example 214
9-[(5-chloro-2-{[(2-fluorobenzyl)amino]methyl}-1H-indol-7-yl)methyl]-9H-pu-
rin-6-amine
[0872] Example 214 was prepared according to the procedure used for
the preparation of Example 208, substituting 2-fluorobenzaldehyde
for 2-bromobenzaldehyde. 1H NMR (400 MHz, DMSO-d.sub.6) .delta.
8.44 (s, 1H), 8.31 (s, 1H), 7.66 (d, J=1.9 Hz, 1H), 7.61-7.47 (m,
2H), 7.39-7.26 (m, 2H), 6.88 (d, J=2.0 Hz, 1H), 6.76 (s, 1H), 5.67
(s, 2H), 4.46 (s, 2H), 4.31 (s, 2H). MS (ESI+) m/z 436.1
(M+H).sup.+.
Example 215
9-[(5-chloro-2-{[(2-chloro-6-fluorobenzyl)amino]methyl}-1H-indol-7-yl)meth-
yl]-9H-purin-6-amine
[0873] Example 215 was prepared according to the procedure used for
the preparation of Example 208, substituting
2-chloro-6-fluorobenzaldehyde for 2-bromobenzaldehyde. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 8.47 (s, 1H), 8.34 (s, 1H), 7.67
(d, J=1.9 Hz, 1H), 7.57 (td, J=8.3, 6.2 Hz, 1H), 7.46 (d, J=8.1 Hz,
1H), 7.41-7.30 (m, 1H), 6.90 (d, J=1.9 Hz, 1H), 6.80 (s, 1H), 5.69
(s, 2H), 4.52 (s, 2H), 4.39 (d, J=2.0 Hz, 2H). MS (ESI+) m/z 470
(M+H).sup.+.
Example 216
9-[(5-chloro-2-{[(3-chloro-5-fluorobenzyl)amino]methyl}-1H-indol-7-yl)meth-
yl]-9H-purin-6-amine
[0874] Example 216 was prepared according to the procedure used for
the preparation of Example 208, substituting
3-chloro-5-fluorobenzaldehyde for 2-bromobenzaldehyde. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 8.48 (s, 1H), 8.36 (s, 1H), 7.65
(d, J=1.9 Hz, 1H), 7.52 (dt, J=8.7, 2.1 Hz, 1H), 7.49 (t, J=1.6 Hz,
1H), 7.39 (dt, J=9.3, 1.9 Hz, 1H), 6.88 (d, J=1.9 Hz, 1H), 6.74 (s,
1H), 5.69 (s, 2H), 4.43 (s, 2H), 4.30 (s, 2H). MS (ESI+) m/z 470.2
(M+H).sup.+.
Example 217
9-[(5-chloro-2-{[(2-chloro-5-fluorobenzyl)amino]methyl}-1H-indol-7-yl)meth-
yl]-9H-purin-6-amine
[0875] Example 217 was prepared according to the procedure used for
the preparation of Example 208, substituting
2-chloro-5-fluorobenzaldehyde for 2-bromobenzaldehyde. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 8.47 (s, 1H), 8.34 (s, 1H), 7.67
(d, J=2.0 Hz, 1H), 7.63 (dd, J=8.9, 5.1 Hz, 1H), 7.52 (dd, J=9.3,
3.1 Hz, 1H), 7.37 (td, J=8.5, 3.1 Hz, 1H), 6.90 (d, J=2.0 Hz, 1H),
6.78 (s, 1H), 5.69 (s, 2H), 4.51 (s, 2H), 4.38 (s, 2H). MS (ESI+)
m/z 470.1 (M+H).sup.+.
Example 218
9-[(5-chloro-2-{[(3-chloro-2-fluorobenzyl)amino]methyl}-1H-indol-7-yl)meth-
yl]-9H-purin-6-amine
[0876] Example 218 was prepared according to the procedure used for
the preparation of Example 208, substituting
3-chloro-2-fluorobenzaldehyde for 2-bromobenzaldehyde. 1H NMR (400
MHz, DMSO-d.sub.6) .delta. 8.43 (s, 1H), 8.30 (s, 1H), 7.77-7.67
(m, 1H), 7.65 (d, J=1.9 Hz, 1H), 7.56 (td, J=7.3, 6.6, 1.6 Hz, 1H),
7.34 (dd, J=8.5, 7.5 Hz, 1H), 6.87 (d, J=1.9 Hz, 1H), 6.75 (s, 1H),
5.67 (s, 2H), 4.47 (s, 2H), 4.36 (s, 2H). MS (ESI+) m/z 470.1
(M+H).sup.+.
Example 219
9-[(5-chloro-2-{[(2,6-difluorobenzyl)amino]methyl}-1H-indol-7-yl)methyl]-9-
H-purin-6-amine
[0877] Example 219 was prepared according to the procedure used for
the preparation of Example 208, substituting
2,6-difluorobenzaldehyde for 2-bromobenzaldehyde. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 8.45 (s, 1H), 8.32 (s, 1H), 7.66 (d,
J=2.0 Hz, 1H), 7.60 (tt, J=8.4, 6.7 Hz, 1H), 7.23 (t, J=8.1 Hz,
2H), 6.88 (d, J=1.9 Hz, 1H), 6.77 (s, 1H), 5.68 (s, 2H), 4.49 (s,
2H), 4.32 (s, 2H). MS (ESI+) m/z 454 (M+H).sup.+.
Example 220
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)benzam-
ide
[0878] To a suspension of Example 9b (0.05 g, 0.153 mmol) and
triethylamine (0.021 mL, 0.153 mmol) in THF (5 mL) were added
benzoyl chloride (0.018 mL, 0.153 mmol). The resulting mixture was
stirred at ambient temperature for 1 hour. The mixture was
concentrated. The residue was purified by reverse phase HPLC (C18,
35-70% acetonitrile/water, 0.05% ammonium hydroxide) to give the
title compound (0.02 g, 0.046 mmol, 30.4% yield). MS (ESI+): m/z
432 (M+H).sup.+; .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta. 11.55
(s, 1H), 9.08 (brs, 1H), 8.31 (s, 1H), 8.17 (s, 1H), 7.94 (d, J=4.0
Hz, 2H), 7.58-7.48 (m, 4H), 7.32 (s, 2H), 6.84 (d, J=2.0 Hz, 1H),
6.38 (s, 1H), 5.56 (s, 2H), 4.70 (d, J=6.4 Hz, 2H).
Example 221
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-chl-
orobenzamide
[0879] Example 221 was prepared according to the procedure used for
the preparation of Example 232, substituting 4-chlorobenzoic acid
for 2-(pyridin-4-yl)acetic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 4.68 (d, J=5.5 Hz, 2H), 5.68 (s, 2H), 6.39
(d, J=1.9 Hz, 1H), 6.82 (d, J=2.0 Hz, 1H), 7.50 (d, J=2.0 Hz, 1H),
7.53-7.63 (m, 2H), 7.90-8.00 (m, 2H), 8.35 (s, 2H), 8.48 (s, 1H),
9.16 (t, J=5.7 Hz, 1H), 11.50 (d, J=2.1 Hz, 1H). MS (APCI) m/z
466.1 [M+H].sup.+.
Example 222
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-chl-
orobenzamide
[0880] Example 222 was prepared according to the procedure used for
the preparation of Example 232, substituting 3-chlorobenzoic acid
for 2-(pyridin-4-yl)acetic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 4.69 (d, J=5.5 Hz, 2H), 5.65 (s, 2H), 6.40
(d, J=1.9 Hz, 1H), 6.82 (d, J=2.0 Hz, 1H), 7.45-7.59 (m, 2H),
7.60-7.94 (m, 4H), 7.98 (t, J=1.9 Hz, 1H), 8.26 (s, 1H), 8.40 (s,
1H), 9.20 (t, J=5.6 Hz, 1H), 11.53 (d, J=2.3 Hz, 1H). MS (APCI) m/z
466.1 [M+H].sup.+.
Example 223
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-flu-
orobenzamide
[0881] Example 223 was prepared according to the procedure used for
the preparation of Example 105, substituting 4-fluorobenzoic acid
for 4-methyl-pentanoic acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 11.50 (s, 1H), 9.10 (t, J=5.7 Hz, 1H), 8.42 (s, 1H), 8.29
(s, 1H), 8.16-7.83 (m, 4H), 7.49 (d, J=2.0 Hz, 1H), 7.39-7.28 (m,
2H), 6.83 (d, J=2.0 Hz, 1H), 6.39 (d, J=1.8 Hz, 1H), 5.65 (s, 2H),
4.68 (d, J=5.6 Hz, 2H). MS (APCI+) m/z 450.0 (M+H).sup.+.
Example 224
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-flu-
orobenzamide
[0882] Example 224 was prepared according to the procedure used for
the preparation of Example 105, substituting 3-fluorobenzoic acid
for 4-methyl-pentanoic acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 11.53 (s, 1H), 9.17 (t, J=5.7 Hz, 1H), 8.39 (s, 1H), 8.26
(s, 1H), 7.89-7.69 (m, 4H), 7.56 (td, J=8.0, 5.8 Hz, 1H), 7.49 (d,
J=2.0 Hz, 1H), 7.42 (td, J=8.4, 2.6 Hz, 1H), 6.82 (d, J=2.0 Hz,
1H), 6.40 (d, J=1.8 Hz, 1H), 5.64 (s, 2H), 4.70 (d, J=5.6 Hz, 2H).
MS (APCI+) m/z 450.0 (M+H).sup.+.
Example 225
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-flu-
orobenzamide
[0883] Example 225 was prepared according to the procedure used for
the preparation of Example 105, substituting 2-fluorobenzoic acid
for 4-methyl-pentanoic acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 11.54 (s, 1H), 8.90 (td, J=5.8, 2.2 Hz, 1H), 8.42 (s, 1H),
8.30 (s, 1H), 7.94 (s, 2H), 7.70 (td, J=7.4, 1.7 Hz, 1H), 7.61-7.48
(m, 2H), 7.37-7.27 (m, 2H), 6.82 (d, J=2.0 Hz, 1H), 6.40 (d, J=1.8
Hz, 1H), 5.65 (s, 2H), 4.68 (d, J=5.8 Hz, 2H). MS (APCI+) m/z 450.0
(M+H).sup.+.
Example 226
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-bro-
mo-6-fluorobenzamide
[0884] Example 226 was prepared according to the procedure used for
the preparation of Example 229, substituting
2-bromo-6-fluorobenzoic acid for 2-fluoro-6-hydroxybenzoic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 4.67 (s, 2H), 5.64 (s,
2H), 6.48 (s, 1H), 6.93 (d, J=2.0 Hz, 1H), 7.28 (t, J=8.7 Hz, 1H),
7.35-7.54 (m, 3H), 8.31 (d, J=8.6 Hz, 2H). MS (APCI) m/z 529.9
[M+H].sup.+.
Example 227
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-chl-
oro-6-fluorobenzamide
[0885] Example 227 was prepared according to the procedure used for
the preparation of Example 229, substituting
2-chloro-6-fluorobenzoic acid for 2-fluoro-6-hydroxybenzoic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 4.67 (s, 2H), 5.64 (s,
2H), 6.46 (s, 1H), 6.94 (d, J=2.0 Hz, 1H), 7.24 (t, J=8.7 Hz, 1H),
7.34 (d, J=8.1 Hz, 1H), 7.40-7.54 (m, 2H), 8.31 (d, J=7.9 Hz, 2H).
MS (APCI) m/z 484.1 [M+H].sup.+.
Example 228
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2,6-d-
ifluorobenzamide
[0886] Example 228 was prepared according to the procedure used for
the preparation of Example 229, substituting 2,6-difluorobenzoic
acid for 2-fluoro-6-hydroxybenzoic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 4.67 (s, 2H), 5.64 (s, 2H), 6.43 (s, 1H),
6.93 (d, J=1.9 Hz, 1H), 7.12 (t, J=8.1 Hz, 2H), 7.43-7.59 (m, 2H),
8.30 (d, J=4.0 Hz, 2H). MS (APCI) m/z 468.1 [M+H].sup.+.
Example 229
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-flu-
oro-6-hydroxybenzamide
[0887] A solution of Example 9b (0.0925 M in N,N-dimethylacetamide,
329 .mu.L, 0.03 mmol) and N,N-diisopropylethylamine (0.27 M in
N,N-dimethylacetamide, 333 .mu.L 0.09 mmol), HATU (0.12 M in
N,N-dimethylacetamide, 300 .mu.L, 0.036 mmol), and
2-fluoro-6-hydroxybenzoic acid (0.4M in N,N-dimethylacetamide, 90
.mu.L, 0.036 mmol) were aspirated from their respective source
vials, mixed through a perfluoroalkoxy alkanes mixing tube (0.2 mm
inner diameter), and loaded into an injection loop. The reaction
segment was injected into the flow reactor (Hastelloy coil, 0.75 mm
inner diameter, 1.8 mL internal volume) set at 100.degree. C., and
passed through the reactor at 180 .mu.L min.sup.-1 (10 minute
residence time). Upon exiting the reactor, the reaction was loaded
directly into an injection loop and purified using preparative HPLC
to yield the title compound (2.63 mg, 14.87% yield). Samples were
purified by preparative HPLC on a Phenomenex Luna C8 (2) 5 .mu.m
100 .ANG. AXIA column (50 mm.times.21.2 mm). A gradient of
acetonitrile (A) and 0.1% trifluoroacetic acid in water (B) was
used, at a flow rate of 30 mL/min (0-0.5 minutes 5% A, 0.5-6.5
minutes linear gradient 5-40% A, 6.5-7.0 minutes linear gradient
40-100% A, 7.0-8.5 minutes 100% A, 8.5-9.0 minutes linear gradient
100-5% A, 9.0-10 minutes 5% A). A sample volume of 1.0 mL was
injected directly from the flow reactor stream to the HPLC system.
A custom purification system was used, consisting of the following
modules: Gilson 305 and 306 pumps; Gilson 806 Manometric module;
Gilson UV/Vis 155 detector; Gilson 506C interface box; Gilson FC204
fraction collector; Agilent G1968D Active Splitter; Thermo MSQ Plus
mass spectrometer. The system was controlled through a combination
of Thermo Xcalibur 2.0.7 software and a custom application written
in-house using Microsoft Visual Basic 6.0. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 4.71 (s, 2H), 5.60 (s, 2H), 6.43 (s, 1H),
6.65-6.83 (m, 2H), 6.91 (d, J=1.8 Hz, 1H), 7.28-7.40 (m, 1H), 7.47
(d, J=2.0 Hz, 1H), 8.22 (d, J=3.2 Hz, 2H). MS (APCI) m/z 466.0
[M+H].sup.+.
Example 230
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(py-
ridin-2-yl)acetamide
[0888] Example 230 was prepared according to the procedure used for
the preparation of Example 232, substituting 2-(pyridin-2-yl)acetic
acid for 2-(pyridin-4-yl)acetic acid. 1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 0.73-2.40 (m, 5H), 2.63-2.83 (m, 1H),
2.87-3.58 (m, 18H), 3.86 (s, 5H), 4.51 (d, J=5.5 Hz, 2H), 5.67 (s,
2H), 6.38 (d, J=1.9 Hz, 1H), 6.82 (d, J=2.0 Hz, 1H), 7.46-7.58 (m,
2H), 7.62 (d, J=7.9 Hz, 1H), 8.06 (t, J=7.7 Hz, 1H), 8.28-8.83 (m,
6H), 11.51 (s, 1H). MS (APCI) m/z 447.1 [M+H].sup.+.
Example 231
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(py-
ridin-3-yl)acetamide
[0889] Example 231 was prepared according to the procedure used for
the preparation of Example 105, substituting pyridin-3-yl-acetic
acid for 4-methyl-pentanoic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 11.51 (d, J=2.0 Hz, 1H), 8.83-8.67 (m, 3H),
8.46 (d, J=46.1 Hz, 4H), 8.22 (dt, J=8.1, 1.8 Hz, 1H), 7.79 (dd,
J=7.9, 5.3 Hz, 1H), 7.50 (d, J=2.0 Hz, 1H), 6.81 (d, J=2.0 Hz, 1H),
6.37 (d, J=1.9 Hz, 1H), 5.68 (s, 2H), 4.51 (d, J=5.5 Hz, 2H), 3.75
(s, 2H). MS (APCI+) m/z 447.1 (M+H).sup.+.
Example 232
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(py-
ridin-4-yl)acetamide
[0890] A solution of Example 9b (0.136 M in N,N-dimethylacetamide,
337 .mu.L, 0.046 mmol), N,N-diisopropylethylamine (0.157 M in
N,N-dimethylacetamide, 350 .mu.L, 0.055 mmol), HATU (0.15 M in
N,N-diemtheylacetimide, 337 .mu.L, 0.05 mmol), and
2-(pyridin-4-yl)acetic acid (0.4 M in N,N-diemtheylacetimide, 125
.mu.L, 0.05 mmol) were aspirated from their respective source
vials, mixed through a perfluoroalkoxy alkanes mixing tube (0.2 mm
inner diameter), and loaded into an injection loop. The reaction
segment was injected into the flow reactor (Hastelloy coil, 0.75 mm
inner diameter, 1.8 mL internal volume) set at 100.degree. C., and
passed through the reactor at 180 .mu.L min.sup.-1 (10 minute
residence time). Upon exiting the reactor, the reaction was loaded
directly into an injection loop and purified using preparative HPLC
to yield the title compound (6.21 mg, 24.17% yield). Samples were
purified by preparative HPLC on a Phenomenex Luna C8 (2) 5 .mu.m
100 .ANG. AXIA column (50 mm.times.21.2 mm). A gradient of
acetonitrile (A) and 0.1% trifluoroacetic acid in water (B) was
used, at a flow rate of 30 mL/min (0-0.5 minutes 5% A, 0.5-6.5
minutes linear gradient 5-60% A, 6.5-7.0 minutes linear gradient
60-100% A, 7.0-8.9 minutes 100% A, 8.9-9.0 minutes linear gradient
100-5% A, 9.0-10 minutes 5% A). A sample volume of 1.0 mL was
injected directly from the flow reactor stream to the HPLC system.
A custom purification system was used, consisting of the following
modules: Gilson 305 and 306 pumps; Gilson 806 Manometric module;
Gilson UV/Vis 155 detector; Gilson 506C interface box; Gilson FC204
fraction collector; Agilent G1968D Active Splitter; Thermo MSQ Plus
mass spectrometer. The system was controlled through a combination
of Thermo Xcalibur 2.0.7 software and a custom application written
in-house using Microsoft Visual Basic 6.0. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 1.96 (s, 5H), 2.78 (s, 1H), 2.87-3.58 (m,
18H), 3.86 (s, 5H), 4.51 (d, J=5.5 Hz, 2H), 5.67 (s, 2H), 6.38 (d,
J=1.9 Hz, 1H), 6.82 (d, J=2.0 Hz, 1H), 7.46-7.58 (m, 2H), 7.62 (d,
J=7.9 Hz, 1H), 8.06 (t, J=7.7 Hz, 1H), 8.28-8.83 (m, 6H), 11.51 (s,
1H). MS (APCI) m/z 447.1 [M+H].sup.+.
Example 233
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-met-
hylpyridine-3-carboxamide
[0891] Example 233 was prepared according to the procedure used for
the preparation of Example 229, substituting 2-methylnicotinic acid
for 2-fluoro-6-hydroxybenzoic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 4.67 (s, 2H), 5.64 (s, 2H), 6.45 (s, 1H),
6.94 (s, 1H), 7.30-7.42 (m, 1H), 7.49 (d, J=2.1 Hz, 1H), 7.85 (d,
J=7.5 Hz, 1H), 8.29 (s, 2H), 8.53 (dd, J=4.9, 1.8 Hz, 1H). MS
(APCI) m/z 447.1 [M+H].sup.+.
Example 234
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3,6-d-
imethylpyridazine-4-carboxamide
[0892] Example 234 was prepared according to the procedure used for
the preparation of Example 199, substituting
3,6-dimethylpyridazine-4-carboxylic acid for
3-methylpyridazine-4-carboxylic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 2.66 (d, J=4.1 Hz, 6H), 4.69 (s, 2H), 5.73
(s, 2H), 6.49 (s, 1H), 6.84 (d, J=1.9 Hz, 1H), 7.55 (d, J=2.0 Hz,
1H), 7.69 (s, 1H), 8.46 (s, 1H), 8.59 (s, 1H). MS (APCI) m/z 462.2
[M+H].sup.+.
Example 235
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(1,2,3,6-tetrahydropyridin-4-yl)-1-
H-indol-2-yl}methyl)-3,6-dimethylpyridazine-4-carboxamide
Example 235a
tert-butyl
4-(7-((6-amino-9H-purin-9-yl)methyl)-2-(aminomethyl)-1H-indol-5-
-yl)-5,6-dihydropyridine-1 (2H)-carboxylate
[0893] Example 235a was prepared according to the procedure used
for the preparation of Example 10, substituting tert-butyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-
-carboxylate [Frontier] for
4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane. MS m/z: 475
[M+H].sup.+.
Example 235b
tert-butyl
4-(7-((6-amino-9H-purin-9-yl)methyl)-2-((3,6-dimethylpyridazine-
-4-carboxamido)methyl)-1H-indol-5-yl)-5, 6-dihydropyridine-1
(2H)-carboxylate
[0894] Example 235b was prepared according to the procedure used
for the preparation of Example 100, substituting
3,6-dimethylpyridazine-4-carboxylic acid [Enamine] for
3-methoxypropanoic acid and N,N-dimethylformamide for
N,N-dimethylacetamide. MS m/z: 609 [M+H].sup.+.
Example 235c
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(1,2,3,6-tetrahydropyridin-4-yl)-1-
H-indol-2-yl}methyl)-3,6-dimethylpyridazine-4-carboxamide
[0895] To a flask was added Example 235b (0.074 g, 0.122 mmol),
1,4-dioxane (1 mL) and hydrogen chloride (0.365 mL, 1.459 mmol, 4 M
in 1,4-dioxane). The mixture was stirred at room temperature for
about 1 hour, and concentrated to dryness. The residue was
suspended in methanol and sonicated. The solid was collected by
filtration, washed with ether and dried to give the title compound
(0.038 g, 53.8%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.53
(s, 1H), 8.38 (s, 1H), 7.99 (s, 1H), 7.65 (d, J=1.6 Hz, 1H), 7.37
(d, J=1.6 Hz, 1H), 6.54 (s, 1H), 6.09 (s, 1H), 5.78 (s, 2H), 3.85
(d, J=3.1 Hz, 2H), 3.47 (t, J=6.1 Hz, 2H), 2.86 (s, 2H), 2.77 (s,
3H), 2.75 (s, 3H); MS m/z: 509 [M+H].sup.+.
Example 236
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4,4-difluorocyclohex-1-en-1-yl)-1-
H-indol-2-yl}methyl)-3,6-dimethylpyridazine-4-carboxamide
[0896] Example 236 was prepared according to the procedure used for
the preparation of Example 100, substituting Example 14 for Example
9b, and substituting 3,6-dimethylpyridazine-4-carboxylic acid
[Enamine] for 3-methoxypropanoic acid, and N,N-dimethylformamide
for N,N-dimethylacetamide. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 11.41 (s, 1H), 9.23 (t, J=5.6 Hz, 1H), 8.28 (s, 1H), 8.20
(s, 1H), 7.51 (d, J=3.9 Hz, 2H), 7.30 (s, 2H), 7.12 (d, J=1.6 Hz,
1H), 6.43 (d, J=1.8 Hz, 1H), 5.81 (s, 1H), 5.59 (s, 2H), 4.67 (d,
J=5.7 Hz, 2H), 2.63 (m, 10H), 2.16 (tt, J=13.8, 6.4 Hz, 2H); MS
m/z: 544 [M+H].sup.+.
Example 237
N-({5-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-7-[(6-amino-9H-purin-9-yl)-
methyl]-1H-indol-2-yl}methyl)-3,6-dimethylpyridazine-4-carboxamide
[0897] Example 237 was prepared according to the procedure used for
the preparation of Example 100, substituting Example 15b for
Example 9b, and substituting 3,6-dimethylpyridazine-4-carboxylic
acid [Enamine] for 3-methoxypropanoic acid, and
N,N-dimethylformamide for N,N-dimethylacetamide. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 11.42 (s, 1H), 9.24 (t, J=5.6 Hz, 1H),
8.28 (s, 1H), 8.20 (s, 1H), 7.50 (d, J=11.7 Hz, 2H), 7.30 (s, 2H),
7.15 (s, 1H), 6.44 (d, J=1.8 Hz, 1H), 5.96 (d, J=11.3 Hz, 1H), 5.60
(s, 2H), 4.67 (d, J=5.6 Hz, 2H), 4.08 (d, J=23.5 Hz, 2H), 3.62 (dt,
J=11.9, 5.7 Hz, 3H), 2.64 (s, 3H), 2.63 (s, 3H), 2.10-1.98 (m, 3H);
MS m/z: 551 [M+H].sup.+.
Example 238
N-({5-(1-acetyl-1,4,5,6-tetrahydropyridin-3-yl)-7-[(6-amino-9H-purin-9-yl)-
methyl]-1H-indol-2-yl}methyl)-3,6-dimethylpyridazine-4-carboxamide
[0898] Example 238 was prepared according to the procedure used for
the preparation of Example 100, substituting Example 16b for
Example 9b, and substituting 3,6-dimethylpyridazine-4-carboxylic
acid [Enamine] for 3-methoxypropanoic acid, and
N,N-dimethylformamide for N,N-dimethylacetamide. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 11.42 (s, 1H), 9.25 (t, J=5.6 Hz, 1H),
8.28 (s, 1H), 8.21 (s, 1H), 7.58-7.47 (m, 2H), 7.30 (s, 2H), 7.14
(d, J=11.2 Hz, 1H), 6.51-6.40 (m, 1H), 6.10 (d, J=14.1 Hz, 1H),
5.60 (s, 2H), 4.67 (d, J=5.5 Hz, 2H), 4.31 (s, 2H), 3.54 (dt,
J=10.9, 5.7 Hz, 2H), 2.64 (s, 3H), 2.63 (s, 3H), 2.36-2.16 (m, 2H),
2.10-2.04 (m, 3H); MS m/z: 551 [M+H].sup.+.
Example 239
N-({7-[(6-amino-9H-purin-9-yl)methyl]-4-chloro-1H-indol-2-yl}methyl)-3,6-d-
imethylpyridazine-4-carboxamide
[0899] Example 239 was prepared according to the procedure used for
the preparation of Example 100, substituting Example 62j for
Example 9b, and substituting 3,6-dimethylpyridazine-4-carboxylic
acid [Enamine] for 3-methoxypropanoic acid, and
N,N-dimethylformamide for N,N-dimethylacetamide. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 11.76 (s, 1H), 9.26 (t, J=5.6 Hz, 1H),
8.42 (s, 1H), 8.36-8.09 (m, 3H), 7.55 (s, 1H), 7.01 (d, J=7.9 Hz,
1H), 6.82 (d, J=7.9 Hz, 1H), 6.49 (s, 1H), 5.67 (s, 2H), 4.70 (d,
J=5.6 Hz, 2H), 2.66 (s, 3H), 2.62 (s, 3H); MS m/z: 462
[M+H].sup.+.
Example 240
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-choro-1H-indol-2-yl}methyl)-6-cyan-
opyridine-3-carboxamide
[0900] Example 240 was prepared according to the procedure used for
the preparation of Example 229, substituting 6-cyanonicotinic acid
for 2-fluoro-6-hydroxybenzoic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 4.72 (s, 2H), 5.67 (s, 2H), 6.92 (d, J=1.9
Hz, 1H), 7.49 (d, J=2.0 Hz, 1H), 8.09 (d, J=8.0 Hz, 1H), 8.29-8.47
(m, 3H), 9.14 (d, J=2.0 Hz, 1H). MS (APCI) m/z 458.1
[M+H].sup.+.
Example 241
9-[(5-chloro-2-{[(4-methylbenzyl)amino]methyl}-1H-indol-7-yl)methyl]-9H-pu-
rin-6-amine
[0901] Example 241 was prepared according to the procedure used for
the preparation of Example 208, substituting 4-methylbenzaldehyde
for 2-bromobenzaldehyde. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 8.44 (s, 1H), 8.31 (s, 1H), 7.65 (d, J=1.9 Hz, 1H), 7.39
(d, J=8.0 Hz, 2H), 7.29 (d, J=7.9 Hz, 2H), 6.88 (d, J=1.9 Hz, 1H),
6.73 (s, 1H), 5.67 (s, 2H), 4.37 (s, 2H), 4.20 (s, 2H), 2.34 (s,
3H). MS (ESI+) m/z 432.3 (M+H).sup.+.
Example 242
9-[(5-chloro-2-{[(2-methylbenzyl)amino]methyl}-1H-indol-7-yl)methyl]-9H-pu-
rin-6-amine
[0902] Example 242 was prepared according to the procedure used for
the preparation of Example 208, substituting 2-methylbenzaldehyde
for 2-bromobenzaldehyde. 1H NMR (400 MHz, DMSO-d.sub.6) .delta.
8.45 (s, 1H), 8.32 (s, 1H), 7.66 (d, J=1.9 Hz, 1H), 7.49-7.39 (m,
1H), 7.38-7.25 (m, 3H), 6.90 (d, J=1.9 Hz, 1H), 6.78 (s, 1H), 5.69
(s, 2H), 4.48 (s, 2H), 4.24 (s, 2H), 2.30 (s, 3H). MS (ESI+) m/z
432.1 (M+H).sup.+.
Example 243
9-[(5-chloro-2-{[(2-chloro-6-methylbenzyl)amino]methyl})-1H-indol-7-yl)met-
hyl]-9H-purin-6-amine
[0903] Example 243 was prepared according to the procedure used for
the preparation of Example 208, substituting
2-chloro-6-methylbenzaldehyde for 2-bromobenzaldehyde. 1H NMR (400
MHz, DMSO-d.sub.6) .delta. 8.46 (s, 1H), 8.33 (s, 1H), 7.68 (d,
J=1.9 Hz, 1H), 7.47-7.34 (m, 2H), 7.29 (dd, J=6.8, 2.1 Hz, 1H),
6.92 (d, J=1.9 Hz, 1H), 6.83 (s, 1H), 5.70 (s, 2H), 4.54 (s, 2H),
4.35 (s, 2H), 2.34 (s, 3H). MS (ESI+) m/z 466.1 (M+H).sup.+.
Example 244
9-[(5-chloro-2-{[(2-fluoro-6-methylbenzyl)amino]methyl}-1H-indol-7-yl)meth-
yl]-9H-purin-6-amine
[0904] Example 244 was prepared according to the procedure used for
the preparation of Example 208, substituting
2-fluoro-6-methylbenzaldehyde for 2-bromobenzaldehyde. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 8.46 (s, 1H), 8.33 (s, 1H), 7.67
(d, J=1.9 Hz, 1H), 7.41 (td, J=8.1, 6.2 Hz, 1H), 7.15 (t, J=8.7 Hz,
2H), 6.89 (d, J=2.0 Hz, 1H), 6.80 (s, 1H), 5.69 (s, 2H), 4.50 (s,
2H), 4.27 (d, J=1.8 Hz, 2H), 2.34 (s, 3H). MS (ESI+) m/z 450.1
(M+H).sup.+.
Example 245
9-[(5-chloro-2-{[(2-fluoro-3-methylbenzyl)amino]methyl}-1H-indol-7-yl)meth-
yl]-9H-purin-6-amine
[0905] Example 245 was prepared according to the procedure used for
the preparation of Example 208, substituting
2-fluoro-3-methylbenzaldehyde for 2-bromobenzaldehyde. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 8.47 (s, 1H), 8.33 (s, 1H), 7.66
(d, J=1.9 Hz, 1H), 7.39 (td, J=7.5, 7.0, 4.8 Hz, 2H), 7.20 (t,
J=7.6 Hz, 1H), 6.88 (d, J=1.9 Hz, 1H), 6.76 (s, 1H), 5.68 (s, 2H),
4.45 (s, 2H), 4.29 (s, 2H), 2.27 (d, J=1.9 Hz, 3H). MS (ESI+) m/z
450.1 (M+H).sup.+.
Example 246
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-met-
hylbenzamide
[0906] Example 246 was prepared according to the procedure used for
the preparation of Example 105, substituting 4-methylbenzoic acid
for 4-methyl-pentanoic acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 11.49 (s, 1H), 8.99 (t, J=5.8 Hz, 1H), 8.46 (s, 1H), 8.34
(s, 1H), 8.24 (s, 2H), 7.87-7.80 (m, 2H), 7.49 (d, J=2.0 Hz, 1H),
7.30 (d, J=8.0 Hz, 2H), 6.83 (d, J=2.0 Hz, 1H), 6.37 (d, J=1.8 Hz,
1H), 5.67 (s, 2H), 4.67 (d, J=5.7 Hz, 2H), 2.37 (s, 3H). MS (APCI+)
m/z 446.1 (M+H).sup.+.
Example 247
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-met-
hylbenzamide
[0907] Example 247 was prepared according to the procedure used for
the preparation of Example 105, substituting 3-methylbenzoic acid
for 4-methyl-pentanoic acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 11.49 (s, 1H), 9.02 (t, J=5.8 Hz, 1H), 8.48 (s, 1H),
8.37-8.15 (m, 3H), 7.77-7.68 (m, 2H), 7.50 (d, J=1.9 Hz, 1H),
7.45-7.33 (m, 2H), 6.82 (d, J=2.0 Hz, 1H), 6.38 (d, J=1.8 Hz, 1H),
5.68 (s, 2H), 4.68 (d, J=5.6 Hz, 2H), 2.37 (s, 3H). MS (APCI+) m/z
446.1 (M+H).sup.+.
Example 248
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-met-
hylbenzamide
[0908] Example 248 was prepared according to the procedure used for
the preparation of Example 105, substituting 2-methylbenzoic acid
for 4-methyl-pentanoic acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 11.54 (s, 1H), 8.84 (t, J=5.8 Hz, 1H), 8.47 (s, 1H), 8.35
(s, 1H), 8.26 (s, 2H), 7.52 (d, J=2.1 Hz, 1H), 7.42 (dd, J=8.0, 1.6
Hz, 1H), 7.37-7.31 (m, 1H), 7.30-7.19 (m, 2H), 6.84 (d, J=2.0 Hz,
1H), 6.41 (d, J=1.8 Hz, 1H), 5.68 (s, 2H), 4.65 (d, J=5.7 Hz, 2H),
2.37 (s, 3H). MS (APCI+) m/z 446.1 (M+H).sup.+.
Example 249
9-[(5-chloro-2-{[(3-methoxybenzyl)amino]methyl}-1H-indol-7-yl)methyl]-9H-p-
urin-6-amine
[0909] Example 249 was prepared according to the procedure used for
the preparation of Example 208, substituting 3-methoxybenzaldehyde
for 2-bromobenzaldehyde. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 8.45 (s, 1H), 8.32 (s, 1H), 7.65 (d, J=1.9 Hz, 1H), 7.40
(t, J=7.9 Hz, 1H), 7.15-6.98 (m, 3H), 6.88 (d, J=1.9 Hz, 1H), 6.74
(s, 1H), 5.67 (s, 2H), 4.40 (s, 2H), 4.23 (s, 2H), 3.79 (s, 3H). MS
(ESI+) m/z 448.2 (M+H).sup.+.
Example 250
9-[(5-chloro-2-{[(2-methoxybenzyl)amino]methyl}-1H-indol-7-yl)methyl]-9H-p-
urin-6-amine
[0910] Example 250 was prepared according to the procedure used for
the preparation of Example 208, substituting 2-methoxybenzaldehyde
for 2-bromobenzaldehyde. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 8.46 (s, 1H), 8.32 (s, 1H), 7.66 (d, J=1.9 Hz, 1H), 7.46
(td, J=7.9, 1.7 Hz, 1H), 7.39 (dd, J=7.6, 1.7 Hz, 1H), 7.11 (d,
J=8.3 Hz, 1H), 7.02 (t, J=7.5 Hz, 1H), 6.88 (d, J=2.0 Hz, 1H), 6.76
(s, 1H), 5.68 (s, 2H), 4.40 (s, 2H), 4.18 (s, 2H), 3.82 (s, 3H). MS
(ESI+) m/z 448.1 (M+H).sup.+.
Example 251
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(4--
chlorophenyl)acetamide
[0911] Example 251 was prepared according to the procedure used for
the preparation of Example 105, substituting (4-chlorophenyl)acetic
acid for 4-methyl-pentanoic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 11.50 (d, J=2.0 Hz, 1H), 8.64 (t, J=5.6 Hz,
1H), 8.47 (s, 1H), 8.37 (s, 3H), 7.49 (d, J=2.1 Hz, 1H), 7.42-7.19
(m, 4H), 6.82 (d, J=2.0 Hz, 1H), 6.33 (d, J=1.8 Hz, 1H), 5.66 (s,
2H), 4.47 (d, J=5.5 Hz, 2H), 3.52 (s, 2H). MS (APCI+) m/z 480.0
(M+H).sup.+.
Example 252
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(3--
chlorophenyl)acetamide
[0912] Example 252 was prepared according to the procedure used for
the preparation of Example 232, substituting
2-(3-chlorophenyl)acetic acid for 2-(pyridin-4-yl)acetic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 3.54 (s, 2H), 4.48 (d,
J=5.5 Hz, 2H), 5.64 (s, 2H), 6.33 (d, J=1.9 Hz, 1H), 6.82 (d, J=2.0
Hz, 1H), 7.12-7.43 (m, 5H), 7.48 (d, J=2.0 Hz, 1H), 8.07 (s, 2H),
8.33 (s, 1H), 8.43 (s, 1H), 8.66 (t, J=5.6 Hz, 1H), 11.52 (d, J=2.1
Hz, 1H). MS (APCI) m/z 480.1 [M+H].sup.+.
Example 253
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(2--
chlorophenyl)acetamide
[0913] Example 253 was prepared according to the procedure used for
the preparation of Example 232, substituting
2-(2-chlorophenyl)acetic acid for 2-(pyridin-4-yl)acetic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 3.70 (s, 2H), 4.51 (d,
J=5.5 Hz, 2H), 5.66 (s, 2H), 6.37 (d, J=1.9 Hz, 1H), 6.82 (d, J=2.0
Hz, 1H), 7.14-7.34 (m, 2H), 7.34-7.46 (m, 2H), 7.50 (d, J=1.9 Hz,
1H), 8.36 (s, 3H), 8.46 (s, 1H), 8.63 (t, J=5.6 Hz, 1H), 11.50 (d,
J=2.1 Hz, 1H). MS (APCI) m/z 480.1 [M+H].sup.+.
Example 254
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(4--
fluorophenyl)acetamide
[0914] Example 254 was prepared according to the procedure used for
the preparation of Example 105, substituting (4-fluorophenyl)acetic
acid for 4-methyl-pentanoic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 11.50 (s, 1H), 8.62 (t, J=5.6 Hz, 1H), 8.46
(s, 1H), 8.36 (s, 1H), 8.29 (s, 2H), 7.49 (d, J=2.0 Hz, 1H),
7.39-7.29 (m, 2H), 7.19-7.08 (m, 2H), 6.82 (d, J=2.0 Hz, 1H), 6.33
(d, J=1.8 Hz, 1H), 5.66 (s, 2H), 4.47 (d, J=5.5 Hz, 2H), 3.51 (s,
2H). MS (APCI+) m/z 464.0 (M+H).sup.+.
Example 255
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(3--
fluorophenyl)acetamide
[0915] Example 255 was prepared according to the procedure used for
the preparation of Example 105, substituting (3-fluorophenyl)acetic
acid for 4-methyl-pentanoic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 11.51 (s, 1H), 8.65 (t, J=5.6 Hz, 1H), 8.46
(s, 1H), 8.36 (s, 1H), 8.26 (s, 2H), 7.49 (d, J=2.0 Hz, 1H),
7.41-7.31 (m, 1H), 7.18-7.12 (m, 2H), 7.10-7.02 (m, 1H), 6.82 (d,
J=2.0 Hz, 1H), 6.33 (d, J=1.8 Hz, 1H), 5.66 (s, 2H), 4.48 (d, J=5.5
Hz, 2H), 3.55 (s, 2H). MS (APCI+) m/z 464.0 (M+H).sup.+.
Example 256
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(2--
fluorophenyl)acetamide
[0916] Example 256 was prepared according to the procedure used for
the preparation of Example 232, substituting
2-(2-fluorophenyl)acetic acid for 2-(pyridin-4-yl)acetic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 3.96 (s, 2H), 4.50 (d,
J=5.5 Hz, 2H), 5.66 (s, 2H), 6.36 (d, J=1.9 Hz, 1H), 6.82 (d, J=2.0
Hz, 1H), 6.85-7.24 (m, 2H), 7.24-7.44 (m, 2H), 7.50 (d, J=2.0 Hz,
1H), 8.37 (s, 3H), 8.47 (s, 1H), 8.64 (t, J=5.6 Hz, 1H), 11.51 (d,
J=2.1 Hz, 1H). MS (APCI) m/z 464.1 [M+H].sup.+.
Example 257
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(tr-
ifluoromethyl)benzamide
[0917] Example 257 was prepared according to the procedure used for
the preparation of Example 229, substituting
2-(trifluoromethyl)benzoic acid for 2-fluoro-6-hydroxybenzoic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 4.67 (s, 2H), 5.69 (s,
2H), 6.95 (d, J=2.0 Hz, 1H), 7.52 (d, J=1.9 Hz, 1H), 7.59 (d, J=7.5
Hz, 1H), 7.65-7.88 (m, 4H), 8.37 (d, J=2.0 Hz, 2H). MS (APCI) m/z
500.2 [M+H].sup.+.
Example 258
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-met-
hoxybenzamide
[0918] Example 258 was prepared according to the procedure used for
the preparation of Example 232, substituting 4-methoxybenzoic acid
for 2-(pyridin-4-yl)acetic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 3.82 (s, 3H), 4.66 (d, J=5.6 Hz, 2H), 5.67
(s, 2H), 6.37 (d, J=1.8 Hz, 1H), 6.83 (d, J=2.0 Hz, 1H), 6.97-7.08
(m, 2H), 7.49 (d, J=2.0 Hz, 1H), 7.86-7.97 (m, 2H), 8.34 (s, 3H),
8.47 (s, 1H), 8.92 (t, J=5.7 Hz, 1H), 11.43-11.51 (m, 1H). MS
(APCI) m/z 462.1 [M+H].sup.+.
Example 259
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-met-
hoxybenzamide
[0919] Example 259 was prepared according to the procedure used for
the preparation of Example 232, substituting 3-methoxybenzoic acid
for 2-(pyridin-4-yl)acetic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 3.82 (s, 4H), 4.68 (d, J=5.6 Hz, 2H), 5.67
(s, 2H), 6.38 (d, J=1.9 Hz, 1H), 6.83 (d, J=2.0 Hz, 1H), 7.12 (ddd,
J=8.2, 2.6, 1.0 Hz, 1H), 7.41 (t, J=7.9 Hz, 1H), 7.45-7.57 (m, 3H),
8.34 (s, 3H), 8.47 (s, 1H), 9.07 (t, J=5.7 Hz, 1H), 11.51 (d, J=2.1
Hz, 1H). MS (APCI) m/z 462.1 [M+H].sup.+.
Example 260
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-met-
hoxybenzamide
[0920] Example 260 was prepared according to the procedure used for
the preparation of Example 105, substituting 2-methoxybenzoic acid
for 4-methyl-pentanoic acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 11.52 (s, 1H), 8.72 (t, J=5.8 Hz, 1H), 8.40 (s, 1H), 8.27
(s, 1H), 7.89-7.78 (m, 3H), 7.55-7.46 (m, 2H), 7.17 (d, J=8.3 Hz,
1H), 7.06 (t, J=7.4 Hz, 1H), 6.83 (d, J=2.0 Hz, 1H), 6.38 (d, J=1.8
Hz, 1H), 5.64 (s, 2H), 4.70 (d, J=5.8 Hz, 2H), 3.92 (s, 3H). MS
(APCI+) m/z 462.0 (M+H).sup.+.
Example 261
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(di-
fluoromethoxy)benzamide
[0921] Example 261 was prepared according to the procedure used for
the preparation of Example 229, substituting
2-(difluoromethoxy)benzoic acid for 2-fluoro-6-hydroxybenzoic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 4.67 (s, 2H), 5.65 (s,
2H), 6.44 (s, 1H), 6.92 (d, J=1.9 Hz, 1H), 7.02 (d, J=17.3 Hz, 1H),
7.14-7.42 (m, 3H), 7.43-7.69 (m, 3H), 8.33 (d, J=2.4 Hz, 2H). MS
(APCI) m/z 498.0 [M+H].sup.+.
Example 262
9-{[5-chloro-2-({[3-(methylsulfonyl)benzyl]amino}methyl)-1H-indol-7-yl]met-
hyl}-9H-purin-6-amine
[0922] Example 262 was prepared according to the procedure used for
the preparation of Example 208, substituting
3-(methylsulfonyl)benzaldehyde for 2-bromobenzaldehyde. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 8.46 (s, 1H), 8.33 (s, 1H), 8.12
(t, J=1.8 Hz, 1H), 8.01 (dt, J=7.9, 1.4 Hz, 1H), 7.86 (dt, J=8.0,
1.4 Hz, 1H), 7.76 (t, J=7.8 Hz, 1H), 7.66 (d, J=1.9 Hz, 1H), 6.87
(d, J=2.0 Hz, 1H), 6.75 (s, 1H), 5.68 (s, 2H), 4.46 (s, 2H), 4.40
(s, 2H), 3.22 (s, 3H). MS (ESI+) m/z 496 (M+H).sup.+.
Example 263
9-{[5-chloro-2-({[4-fluoro-3-(methylsulfonyl)benzyl]amino}methyl)-1H-indol-
-7-yl]methyl}-9H-purin-6-amine
[0923] Example 263 was prepared according to the procedure used for
the preparation of Example 208, substituting 4-fluoro-3-(methyl
sulfonyl)benzaldehyde for 2-bromobenzaldehyde. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 8.46 (s, 1H), 8.34 (s, 1H), 8.10 (dd,
J=6.7, 2.4 Hz, 1H), 7.91 (ddd, J=8.6, 4.7, 2.3 Hz, 1H), 7.70-7.55
(m, 2H), 6.87 (d, J=1.9 Hz, 1H), 6.73 (s, 1H), 5.68 (s, 2H), 4.44
(s, 2H), 4.37 (s, 2H), 3.34 (s, 3H). MS (ESI+) m/z 514
(M+H).sup.+.
Example 264
9-{[5-chloro-2-({[3-fluoro-4-(methyl
sulfonyl)benzyl]amino}methyl)-1H-indol-7-yl]methyl}-9H-purin-6-amine
[0924] Example 264 was prepared according to the procedure used for
the preparation of Example 208, substituting 3-fluoro-4-(methyl
sulfonyl)benzaldehyde for 2-bromobenzaldehyde. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 8.47 (s, 1H), 8.34 (s, 1H), 7.95 (t,
J=7.7 Hz, 1H), 7.76-7.63 (m, 2H), 7.59 (dd, J=8.1, 1.6 Hz, 1H),
6.88 (d, J=2.0 Hz, 1H), 6.74 (s, 1H), 5.68 (s, 2H), 4.45 (s, 2H),
4.40 (s, 2H), 3.33 (s, 3H). MS (ESI+) m/z 514.1 (M+H).sup.+.
Example 265
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(me-
thyl sulfonyl)benzamide
[0925] Example 265 was prepared according to the procedure used for
the preparation of Example 229, substituting
2-(methylsulfonyl)benzoic acid for 2-fluoro-6-hydroxybenzoic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 3.36 (s, 3H), 4.68 (s,
2H), 5.67 (s, 2H), 6.91 (d, J=1.9 Hz, 1H), 7.49 (d, J=2.0 Hz, 1H),
7.55-7.66 (m, 1H), 7.66-7.85 (m, 2H), 8.01 (d, J=7.7 Hz, 1H), 8.32
(d, J=4.2 Hz, 2H). MS (APCI) m/z 510.1 [M+H].sup.+.
Example 266
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-chl-
oro-4-(methyl sulfonyl)benzamide
[0926] A mixture of Example 9b (30 mg, 0.092 mmol), HATU (48.7 mg,
0.128 mmol), and 2-chloro-4-(methylsulfonyl)benzoic acid (21.48 mg,
0.092 mmol) in 0.5 mL N,N-dimethylformamide was stirred at ambient
temperature for 5 minutes and then treated with
N-ethyl-N-isopropylpropan-2-amine (48.0 .mu.L, 0.275 mmol). The
mixture was stirred at ambient temperature overnight and then
diluted with ethyl acetate, washed sequentially with water
(3.times.) and brine, dried over magnesium sulfate, and filtered.
The filtrate was concentrated and the residue was purified by
column chromatography on silica gel (1-10% methanol in
dichloromethane) to give the title compound (28 mg, 0.051 mmol,
56.2% yield). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.64 (s,
1H), 9.25 (t, J=5.6 Hz, 1H), 8.30 (s, 1H), 8.21 (s, 1H), 8.07 (d,
J=1.7 Hz, 1H), 7.97 (dd, J=8.0, 1.7 Hz, 1H), 7.79 (d, J=8.0 Hz,
1H), 7.51 (d, J=1.9 Hz, 1H), 7.30 (s, 2H), 6.83 (d, J=1.9 Hz, 1H),
6.46 (d, J=1.6 Hz, 1H), 5.62 (s, 2H), 4.69 (d, J=5.5 Hz, 2H), 3.33
(s, 3H); MS(ESI+) m/z 544.0 (M+H).sup.+.
Example 267
4-{[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)amin-
o]methyl})benzonitrile
[0927] Example 267 was prepared according to the procedure used for
the preparation of Example 208, substituting 4-formylbenzonitrile
for 2-bromobenzaldehyde. 1H NMR (400 MHz, DMSO-d.sub.6) .delta.
8.46 (s, 1H), 8.34 (s, 1H), 7.99-7.88 (m, 2H), 7.76-7.67 (m, 2H),
7.65 (d, J=2.0 Hz, 1H), 6.88 (d, J=2.0 Hz, 1H), 6.74 (s, 1H), 5.68
(s, 2H), 4.43 (s, 2H), 4.36 (s, 2H). MS (ESI+) m/z 443.1
(M+H).sup.+.
Example 268
3-{[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)amin-
o]methyl})benzonitrile
[0928] Example 268 was prepared according to the procedure used for
the preparation of Example 208, substituting 3-formylbenzonitrile
for 2-bromobenzaldehyde. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 8.47 (s, 1H), 8.34 (s, 1H), 7.97 (t, J=1.7 Hz, 1H), 7.91
(dt, J=7.7, 1.4 Hz, 1H), 7.85 (dt, J=7.9, 1.4 Hz, 1H), 7.75-7.61
(m, 2H), 6.87 (d, J=1.9 Hz, 1H), 6.74 (s, 1H), 5.68 (s, 2H), 4.43
(s, 2H), 4.34 (s, 2H). MS (ESI+) m/z 443.1 (M+H).sup.+.
Example 269
2-{[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)amin-
o]methyl}benzonitrile
[0929] Example 269 was prepared according to the procedure used for
the preparation of Example 208, substituting 2-formylbenzonitrile
for 2-bromobenzaldehyde. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 8.47 (s, 1H), 8.30 (d, J=11.7 Hz, 1H), 8.23 (d, J=7.8 Hz,
1H), 7.97-7.64 (m, 3H), 7.58 (dd, J=7.5, 1.9 Hz, 1H), 6.81 (dd,
J=7.6, 1.9 Hz, 1H), 6.61 (d, J=3.4 Hz, 1H), 5.69 (s, 2H), 5.24 (s,
2H), 4.88 (s, 2H). MS (ESI+) m/z 443.1 (M+H).sup.+.
Example 270
3-{[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)amin-
o]methyl}-4-fluorobenzonitrile
[0930] Example 270 was prepared according to the procedure used for
the preparation of Example 208, substituting
4-fluoro-3-formylbenzonitrile for 2-bromobenzaldehyde. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 8.49 (s, 1H), 8.36 (s, 1H), 8.09
(dd, J=6.7, 2.1 Hz, 1H), 8.02 (ddd, J=8.7, 4.8, 2.2 Hz, 1H), 7.66
(d, J=1.9 Hz, 1H), 7.55 (t, J=9.1 Hz, 1H), 6.87 (d, J=1.9 Hz, 1H),
6.75 (s, 1H), 5.69 (s, 2H), 4.49 (s, 2H), 4.37 (s, 2H). MS (ESI+)
m/z 461.1 (M+H).sup.+.
Example 271
5-amino-N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methy-
l)-2-methylbenzamide
[0931]
N.sup.1-((ethylimino)methylene)-N.sup.3,N.sup.3-dimethylpropane-1,3-
-diamine hydrochloride (25.9 mg, 0.135 mmol) was added to a partial
solution of Example 9b (30 mg, 0.092 mmol), HOBT (18.6 mg, 0.121
mmol), 5-amino-2-methylbenzoic acid (14 mg, 0.093 mmol),
N-ethyl-N-isopropylpropan-2-amine (0.048 mL, 0.275 mmol),
tetrahydrofuran (1.0 mL), and N,N-dimethylformamide (0.2 mL). The
reaction mixture was stirred at room temperature overnight. Water
and ethyl acetate were added to the reaction mixture. The layers
were separated and the ethyl acetate layer was absorbed onto silica
gel and was flash chromatographed (Biotage 10 g HP Snap Cartridge,
eluting with heptanes containing a gradient with a solution of 3:1
ethyl acetate:ethanol, 35% to 100%) to provide the title compound.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.61-11.49 (m, 1H),
8.65 (t, J=5.8 Hz, 1H), 8.31 (s, 1H), 8.21 (s, 1H), 7.49 (d, J=2.0
Hz, 1H), 7.29 (s, 2H), 6.88 (d, J=8.1 Hz, 1H), 6.84 (d, J=2.0 Hz,
1H), 6.64 (d, J=2.4 Hz, 1H), 6.54 (dd, J=8.1, 2.5 Hz, 1H), 6.37 (d,
J=1.8 Hz, 1H), 5.60 (s, 2H), 5.00 (s, 2H), 4.60 (d, J=5.8 Hz, 2H),
2.18 (s, 3H). MS ESI.sup.+ 461.0 (M+H).sup.+.
Example 272
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-cya-
nobenzamide
[0932] Example 272 was prepared according to the procedure used for
the preparation of Example 105, substituting 4-cyanobenzoic acid
for 4-methyl-pentanoic acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 11.51 (s, 1H), 9.34 (t, J=5.6 Hz, 1H), 8.48 (s, 1H), 8.34
(s, 3H), 8.11-8.04 (m, 2H), 8.00 (d, J=8.4 Hz, 2H), 7.50 (d, J=2.0
Hz, 1H), 6.82 (d, J=2.1 Hz, 1H), 6.41 (d, J=1.9 Hz, 1H), 5.68 (s,
2H), 4.71 (d, J=5.5 Hz, 2H). MS (APCI+) m/z 457.0 (M+H).sup.+.
Example 273
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-cya-
nobenzamide
[0933] Example 273 was prepared according to the procedure used for
the preparation of Example 232, substituting 3-cyanobenzoic acid
for 2-(pyridin-4-yl)acetic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 4.71 (d, J=5.5 Hz, 2H), 5.68 (s, 2H), 6.43
(d, J=1.8 Hz, 1H), 6.81 (d, J=2.0 Hz, 1H), 7.50 (d, J=2.0 Hz, 1H),
7.74 (t, J=7.9 Hz, 1H), 8.04 (dt, J=7.8, 1.4 Hz, 1H), 8.13-8.40 (m,
4H), 8.46 (s, 1H), 9.29 (t, J=5.6 Hz, 1H), 11.54 (d, J=2.1 Hz, 1H).
MS (APCI) m/z 457.1 [M+H].sup.+.
Example 274
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-cya-
nobenzamide
[0934] Example 274 was prepared according to the procedure used for
the preparation of Example 229, substituting 2-cyanobenzoic acid
for 2-fluoro-6-hydroxybenzoic acid. 1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 4.70 (s, 2H), 5.65 (s, 2H), 6.47 (s, 1H), 6.92 (d, J=2.0
Hz, 1H), 7.48 (d, J=2.0 Hz, 1H), 7.63-7.94 (m, 4H), 8.29 (d, J=6.2
Hz, 2H). MS (APCI) m/z 457.1 [M+H].sup.+.
Example 275
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(me-
thylamino)benzamide
[0935] Example 275 was prepared according to the procedure used for
the preparation of Example 229, substituting 2-(methylamino)benzoic
acid for 2-fluoro-6-hydroxybenzoic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 2.80 (s, 3H), 4.63 (s, 2H), 5.65 (s, 2H),
6.60 (t, J=7.5 Hz, 1H), 6.69 (d, J=8.4 Hz, 1H), 6.92 (d, J=2.0 Hz,
1H), 7.26-7.38 (m, 1H), 7.47 (d, J=2.0 Hz, 1H), 7.58 (dd, J=7.7,
1.7 Hz, 1H), 8.32 (d, J=13.5 Hz, 2H). MS (APCI) m/z 461.2
[M+H].sup.+.
Example 276
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-chl-
oro-4-cyanobenzamide
[0936] Example 276 was prepared according to the procedure used for
the preparation of Example 199, substituting
2-chloro-4-cyanobenzoic acid for 3-methylpyridazine-4-carboxylic
acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 4.64-4.73 (m,
2H), 5.65 (s, 2H), 6.48 (s, 1H), 6.84 (d, J=2.0 Hz, 1H), 7.53 (d,
J=2.0 Hz, 1H), 7.69 (d, J=7.9 Hz, 1H), 7.92 (dd, J=7.9, 1.5 Hz,
1H), 8.12 (d, J=1.5 Hz, 1H), 8.29 (s, 1H), 8.40 (s, 1H), 9.28 (t,
J=5.7 Hz, 1H). MS (APCI) m/z 491.1 [M+H].sup.+.
Example 277
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(1,2,3,6-tetrahydropyridin-4-yl)-1-
H-indol-2-yl}methyl)-2-chloro-4-cyanobenzamide
[0937] Example 277 was prepared according to the procedure used for
the preparation of Example 235, substituting
2-chloro-4-cyanobenzoic acid for
3,6-dimethylpyridazine-4-carboxylic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 11.51 (s, 1H), 9.26 (t, J=5.6 Hz, 1H), 8.92
(s, 2H), 8.51 (s, 1H), 8.38 (s, 1H), 8.17 (d, J=1.5 Hz, 1H), 7.95
(dd, J=7.9, 1.6 Hz, 1H), 7.70 (d, J=7.9 Hz, 1H), 7.55 (s, 1H), 7.08
(s, 1H), 6.47 (s, 1H), 6.10-5.89 (m, 1H), 5.70 (s, 2H), 4.67 (d,
J=5.7 Hz, 2H), 3.77-3.68 (m, 3H), 2.72-2.59 (m, 2H); MS m/z: 538
[M+H].sup.+.
Example 278
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4,4-difluorocyclohex-1-en-1-yl)-1-
H-indol-2-yl}methyl)-2-chloro-4-cyanobenzamide
[0938] Example 278 was prepared according to the procedure used for
the preparation of Example 100, substituting Example 14 for Example
9b, and substituting 2-chloro-4-cyanobenzoic acid for
3-methoxypropanoic acid, and N,N-dimethylformamide for
N,N-dimethylacetamide. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
11.41 (s, 1H), 9.23 (t, J=5.6 Hz, 1H), 8.27 (s, 1H), 8.24-8.12 (m,
2H), 7.94 (dd, J=7.9, 1.5 Hz, 1H), 7.76-7.64 (m, 1H), 7.58-7.46 (m,
1H), 7.30 (s, 2H), 7.10 (s, 1H), 6.48-6.38 (m, 1H), 5.84-5.72 (m,
1H), 5.59 (s, 2H), 4.71-4.59 (m, 2H), 2.77-2.59 (m, 4H), 2.15 (dt,
J=14.2, 7.3 Hz, 2H). MS m/z: 473 [M+H]+.
Example 279
N-({5-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-7-[(6-amino-9H-purin-9-yl)-
methyl]-1H-indol-2-yl}methyl)-2-chloro-4-cyanobenzamide
[0939] Example 279 was prepared according to the procedure used for
the preparation of Example 100, substituting Example 15b for
Example 9b, and substituting 2-chloro-4-cyanobenzoic acid for
3-methoxypropanoic acid, and N,N-dimethylformamide for
N,N-dimethylacetamide. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
11.40 (s, 1H), 9.23 (t, J=5.7 Hz, 1H), 8.27 (s, 1H), 8.22 (s, 1H),
8.17 (d, J=1.5 Hz, 1H), 7.94 (dd, J=7.9, 1.5 Hz, 1H), 7.70 (d,
J=7.9 Hz, 1H), 7.51-7.45 (m, 1H), 7.32 (s, 2H), 7.12 (s, 1H), 6.44
(s, 1H), 6.01-5.90 (m, 1H), 5.60 (s, 2H), 4.66 (d, 2H), 4.15-4.01
(m, 2H), 3.69-3.52 (m, 2H), 2.04 (d, J=16.4 Hz, 3H); MS m/z: 480
[M+H].sup.+.
Example 280
N-({5-(1-acetyl-1,4,5,6-tetrahydropyridin-3-yl)-7-[(6-amino-9H-purin-9-yl)-
methyl]-1H-indol-2-yl}methyl)-2-chloro-4-cyanobenzamide
[0940] Example 280 was prepared according to the procedure used for
the preparation of Example 100, substituting Example 16b for
Example 9b, and substituting 2-chloro-4-cyanobenzoic acid for
3-methoxypropanoic acid, and N,N-dimethylformamide for
N,N-dimethylacetamide. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
11.42 (s, 1H), 9.23 (t, J=5.6 Hz, 1H), 8.29-8.25 (m, 1H), 8.23-8.12
(m, 2H), 7.94 (d, J=8.0 Hz, 1H), 7.70 (d, J=8.1 Hz, 1H), 7.58-7.43
(m, 1H), 7.30 (s, 2H), 7.12 (d, J=12.2 Hz, 1H), 6.50-6.41 (m, 1H),
6.15-6.03 (m, 1H), 5.60 (s, 2H), 4.66 (d, J=5.5 Hz, 2H), 4.35-4.26
(m, 2H), 4.05 (s, 1H), 3.61-3.47 (m, 2H), 2.34-2.15 (m, 3H), 2.07
(d, J=8.3 Hz, 3H); MS m/z: 580 [M+H].sup.+.
Example 281
N-({5-(1-acetylpiperidin-4-yl)-7-[(6-amino-9H-purin-9-yl)methyl]-1H-indol--
2-yl}methyl)-2-chloro-4-cyanobenzamide
[0941] Example 281 was prepared according to the procedure used for
the preparation of Example 100, substituting Example 17 for Example
9b, and substituting 2-chloro-4-cyanobenzoic acid for
3-methoxypropanoic acid, and N,N-dimethylformamide for
N,N-dimethylacetamide. .sup.1H NMR (400 MHz, CD.sub.3OD) .delta.
8.34 (s, 1H), 8.08 (s, 1H), 7.89 (d, J=1.4 Hz, 1H), 7.75 (dd,
J=7.9, 1.5 Hz, 1H), 7.59 (d, J=7.9 Hz, 1H), 7.37 (s, 1H), 7.05 (s,
1H), 6.43 (s, 1H), 5.60 (s, 2H), 4.74-4.60 (m, 3H), 4.56 (s, 2H),
4.08-3.96 (m, 1H), 3.28-3.14 (m, 1H), 2.92-2.77 (m, 1H), 2.77-2.63
(m, 1H), 2.13 (s, 3H), 1.97-1.81 (m, 2H), 1.79-1.50 (m, 2H); MS
m/z: 582 [M+H].sup.+.
Example 282
N-({7-[(6-amino-9H-purin-9-yl)methyl]-4-chloro-1H-indol-2-yl}methyl)-2-chl-
oro-4-cyanobenzamide
[0942] Example 282 was prepared according to the procedure used for
the preparation of Example 100, substituting Example 62j for
Example 9b, and substituting 2-chloro-4-cyanobenzoic acid for
3-methoxypropanoic acid, and N,N-dimethylformamide for
N,N-dimethylacetamide. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
11.77 (s, 1H), 9.24 (t, i=5.6 Hz, 1H), 8.24 (s, 1H), 8.21-8.10 (m,
2H), 7.93 (dd, i=7.7, 1.5 Hz, 1H), 7.69 (d, i=7.9 Hz, 1H), 7.26 (s,
2H), 7.00 (d, i=7.7 Hz, 1H), 6.82 (d, i=7.9 Hz, 1H), 6.49 (d, J=2.1
Hz, 1H), 5.60 (s, 2H), 4.69 (d, J=5.5 Hz, 2H); MS m/z: 491
[M+H].sup.+.
Example 283
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2,6-d-
ichloro-4-cyanobenzamide
[0943] Example 283 was prepared according to the procedure used for
the preparation of Example 266, substituting
2,6-dichloro-4-cyanobenzoic acid for
2-chloro-4-(methylsulfonyl)benzoic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 11.65 (s, 1H), 9.41 (t, J=5.6 Hz, 1H), 8.29
(s, 1H), 8.22 (s, 1H), 8.19 (s, 2H), 7.53 (d, J=1.8 Hz, 1H), 7.30
(s, 2H), 6.85 (d, J=1.8 Hz, 1H), 6.47 (d, J=1.4 Hz, 1H), 5.60 (s,
2H), 4.70 (d, J=5.6 Hz, 2H). MS (ESI+) m/z 524.9 (M+H).sup.+.
Example 284
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-cya-
no-2-fluorobenzamide
[0944] Example 284 was prepared according to the procedure used for
the preparation of Example 229, substituting
4-cyano-2-fluorobenzoic acid for 2-fluoro-6-hydroxybenzoic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 4.71 (s, 2H), 5.64 (s,
2H), 6.45 (s, 1H), 6.96 (d, J=1.9 Hz, 1H), 7.51 (d, J=2.0 Hz, 1H),
7.76 (dd, J=7.9, 1.6 Hz, 1H), 7.80-7.91 (m, 2H), 8.26 (d, J=2.7 Hz,
2H). MS (APCI) m/z 475.1 [M+H].sup.+.
Example 285
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(3,
6-dihydro-2H-pyran-4-yl)-1H-indol-2-yl}methyl)-4-cyano-2-fluorobenzamide
[0945] Using the procedure described for Example 4d and
substituting Example 284 for Example 4c and substituting
2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
for methylboronic acid provided the title compound. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 11.34 (d, J=2.2 Hz, 1H), 9.16 (q,
J=6.2, 5.6 Hz, 1H), 8.26 (s, 1H), 8.20 (s, 1H), 8.04-7.96 (m, 1H),
7.86-7.79 (m, 2H), 7.49 (d, J=1.8 Hz, 1H), 7.26 (s, 2H), 7.13 (d,
J=1.7 Hz, 1H), 6.43-6.38 (m, 1H), 6.02 (dq, J=3.2, 1.6 Hz, 1H),
5.59 (s, 2H), 4.67 (d, J=5.7 Hz, 2H), 4.18 (q, J=2.5 Hz, 2H), 3.80
(q, J=6.0, 5.4 Hz, 2H), 2.46-2.37 (m, 2H). MS ESI+523.0
(M+H).sup.+.
Example 286
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(1,2,3,6-tetrahydropyridin-4-yl)-1-
H-indol-2-yl}methyl)-4-cyano-2-fluorobenzamide
Example 286a
tert-butyl
4-(7-((6-amino-9H-purin-9-yl)methyl)-2-((4-cyano-2-fluorobenzam-
ido)methyl)-1H-indol-5-yl)-5,6-dihydropyridine-1(2H)-carboxylate
[0946] Using the procedure described for Example 4d and
substituting Example 284 for Example 4C and substituting tert-butyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-
-carboxylate for methylboronic acid provided the title compound. MS
ESI.sup.+ 622.0 (M+H).sup.+.
Example 286b
N-((7-((6-amino-9H-purin-9-yl)methyl)-5-(1,2,3,6-tetrahydropyridin-4-yl)-1-
H-indol-2-yl)methyl)-4-cyano-2-fluorobenzamide
[0947] A solution of Example 286a (4.2 mg, 6.76 .mu.mol),
2,2,2-trifluoroacetic acid (40 .mu.L, 0.52 mmol) and
dichloromethane (0.5 mL) was stirred at room temperature overnight.
The reaction mixture was concentrated to dryness. Methanol (10 mL)
and toluene (10 mL) were added and concentrated to dryness. The
product was dried (in-vacuo) to provide the title compound. .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 11.51-11.25 (m, 1H), 9.18 (t,
J=5.7 Hz, 1H), 8.77 (s, 2H), 8.39 (s, 1H), 8.30 (s, 1H), 8.01 (d,
J=9.9 Hz, 1H), 7.94 (s, 2H), 7.82 (d, J=3.4 Hz, 2H), 7.55 (d, J=1.7
Hz, 1H), 7.06 (d, J=1.7 Hz, 1H), 6.43 (d, J=1.8 Hz, 1H), 5.96 (d,
J=3.9 Hz, 1H), 5.66 (s, 2H), 4.68 (d, J=5.7 Hz, 2H), 3.73 (s, 2H),
3.31 (d, J=6.6 Hz, 2H), 2.65 (t, J=5.1 Hz, 2H). MS ESI.sup.+ 522.0
(M+H).sup.+.
Example 287
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4,4-difluorocyclohex-1-en-1-yl)-1-
H-indol-2-yl}methyl)-4-cyano-2-fluorobenzamide
[0948] Using the procedure described for Example 4d and
substituting Example 284 for Example 4c and substituting
2-(4,4-difluorocyclohex-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
e for methylboronic acid provided the title compound. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 11.42-11.25 (m, 1H), 9.16 (t, J=5.8
Hz, 1H), 8.26 (s, 1H), 8.20 (s, 1H), 8.05-7.95 (m, 1H), 7.86-7.75
(m, 2H), 7.50 (d, J=1.7 Hz, 1H), 7.27 (s, 2H), 7.10 (d, J=1.8 Hz,
1H), 6.40 (d, J=1.9 Hz, 1H), 5.80 (s, 1H), 5.59 (s, 2H), 4.67 (d,
J=5.6 Hz, 2H), 2.80-2.56 (m, 4H), 2.15 (tt, J=14.0, 6.6 Hz, 2H). MS
ESI.sup.+ 557.0 (M+H).sup.+.
Example 288
N-({5-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-7-[(6-amino-9H-purin-9-yl)-
methyl]-1H-indol-2-yl}methyl)-4-cyano-2-fluorobenzamide
[0949] Using the procedure described for Example 4d and
substituting Example 284 for Example 4c and substituting
1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridin-1(2-
H)-yl)ethanone for methylboronic acid provided the title compound.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.35 (s, 1H), 9.15 (t,
J=5.6 Hz, 1H), 8.26 (s, 1H), 8.20 (s, 1H), 8.07-7.94 (m, 1H),
7.88-7.72 (m, 2H), 7.49 (dd, J=4.3, 1.7 Hz, 1H), 7.27 (s, 2H), 7.13
(s, 1H), 6.41 (d, J=1.9 Hz, 1H), 5.96 (d, J=10.9 Hz, 1H), 5.59 (s,
2H), 4.67 (d, J=5.7 Hz, 2H), 4.16 3.98 (m, 2H), 3.62 (dt, J=11.9,
5.6 Hz, 2H), 2.43 (s, 1H), 2.03 (d, J=16.3 Hz, 3H). MS
ESI.sup.+564.1 (M+H).sup.+.
Example 289
tert-butyl
4-(7-[(6-amino-9H-purin-9-yl)methyl]-2-{[(4-cyano-2-fluorobenzo-
yl)amino]methyl}-1H-indol-5-yl)-3,6-dihydropyridine-1(2H)-carboxylate
Example 289a
tert-butyl
4-(7-((6-amino-9H-purin-9-yl)methyl)-2-(aminomethyl)-1H-indol-5-
-yl)-5,6-dihydropyridine-1 (2H)-carboxylate
[0950] Using the procedure described for Example 59, substituting
Example 9b for Example 58 and substituting tert-butyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-
-carboxylate for 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane
provided the title compound. MS ESI 473.2 (M-H).sup.-.
Example 289b
tert-butyl
4-(7-[(6-amino-9H-purin-9-yl)methyl]-2-{[(4-cyano-2-fluorobenzo-
yl)amino]methyl}-1H-indol-5-yl)-3,6-dihydropyridine-1(2H)-carboxylate
[0951] Using the procedure described for Example 271, substituting
Example 289a for Example 9 and substituting 4-cyano-2-fluorobenzoic
acid for 5-amino-2 methylbenzoic acid provided the title compound.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.49 (s, 1H), 9.15 (t,
J=5.7 Hz, 1H), 8.23 (d, J=21.4 Hz, 2H), 8.00 (d, J=10.1 Hz, 1H),
7.82 (d, J=3.9 Hz, 2H), 7.48 (d, J=1.5 Hz, 1H), 7.27 (s, 2H), 7.13
(d, J=1.7 Hz, 1H), 6.40 (d, J=1.7 Hz, 1H), 5.94 (s, 1H), 5.59 (s,
2H), 4.67 (d, J=5.7 Hz, 2H), 3.96 (s, 2H), 3.52 (t, J=5.8 Hz, 2H),
2.44 (s, 2H), 1.42 (s, 9H). MS ESI.sup.+622.0 (M+H).sup.+.
Example 290
9-[(5-chloro-2-{[(2,6-dimethylbenzyl)amino]methyl}-1H-indol-7-yl)methyl]-9-
H-purin-6-amine
[0952] Example 290 was prepared according to the procedure used for
the preparation of Example 208, substituting
2,6-dimethylbenzaldehyde for 2-bromobenzaldehyde. .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 8.47 (s, 1H), 8.34 (s, 1H), 7.68 (d,
J=1.9 Hz, 1H), 7.30-7.17 (m, 1H), 7.11 (d, J=7.6 Hz, 2H), 6.93 (d,
J=2.0 Hz, 1H), 6.84 (s, 1H), 5.71 (s, 2H), 4.53 (s, 2H), 4.23 (s,
2H), 2.26 (s, 6H). MS (ESI+) m/z 446.1 (M+H).sup.+.
Example 291
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-phe-
nylpropanamide
[0953] Example 291 was prepared according to the procedure used for
the preparation of Example 232, substituting 3-phenylpropanoic acid
for 2-(pyridin-4-yl)acetic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 2.74-2.99 (m, 3H), 4.46 (d, J=5.6 Hz, 2H),
5.65 (s, 2H), 6.22 (d, J=1.9 Hz, 1H), 6.82 (d, J=2.0 Hz, 1H),
7.13-7.33 (m, 5H), 7.47 (d, J=2.0 Hz, 1H), 7.98-8.49 (m, 4H), 11.45
(d, J=2.1 Hz, 1H). MS (APCI) m/z 460.2 [M+H].sup.+.
Example 292
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(4--
methylphenyl)acetamide
[0954] Example 292 was prepared according to the procedure used for
the preparation of Example 232, substituting 2-(p-tolyl)acetic acid
for 2-(pyridin-4-yl)acetic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 2.11 (s, 1H), 2.27 (s, 3H), 3.46 (s, 2H),
4.46 (d, J=5.6 Hz, 2H), 5.66 (s, 2H), 6.32 (d, J=1.8 Hz, 1H), 6.82
(d, J=2.0 Hz, 1H), 7.11 (d, J=7.9 Hz, 2H), 7.15-7.24 (m, 2H), 7.49
(d, J=1.9 Hz, 1H), 8.17-8.61 (m, 5H), 11.48 (d, J=2.2 Hz, 1H). MS
(APCI) m/z 460.2 [M+H].sup.+.
Example 293
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(3--
methylphenyl)acetamide
[0955] Example 293 was prepared according to the procedure used for
the preparation of Example 105, substituting m-tolylacetic acid for
4-methyl-pentanoic acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 11.50 (d, J=2.1 Hz, 1H), 8.59 (t, J=5.6 Hz, 1H), 8.46 (s,
1H), 8.36 (s, 1H), 8.27 (s, 2H), 7.49 (d, J=2.0 Hz, 1H), 7.19 (t,
J=7.5 Hz, 1H), 7.14-7.01 (m, 3H), 6.82 (d, J=2.1 Hz, 1H), 6.32 (d,
J=1.8 Hz, 1H), 5.66 (s, 2H), 4.47 (d, J=5.5 Hz, 2H), 3.47 (s, 2H),
2.28 (s, 3H). MS (APCI+) m/z 460.1 (M+H).sup.+.
Example 294
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(2--
methylphenyl)acetamide
[0956] Example 294 was prepared according to the procedure used for
the preparation of Example 105, substituting o-tolylacetic acid for
4-methyl-pentanoic acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 11.70 (s, 1H), 8.75 (t, J=5.6 Hz, 1H), 8.69 (s, 2H), 8.59
(s, 2H), 7.71 (d, J=2.0 Hz, 1H), 7.43 (q, J=4.1, 3.5 Hz, 1H),
7.40-7.28 (m, 2H), 7.03 (d, J=2.0 Hz, 1H), 6.93 (s, 1H), 6.54 (d,
J=1.9 Hz, 1H), 5.87 (s, 2H), 4.69 (d, J=5.6 Hz, 2H), 3.75 (s, 2H),
2.49 (s, 3H). MS (APCI+) m/z 460.1 (M+H).sup.+.
Example 295
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2,6-d-
imethylbenzamide
[0957] Example 295 was prepared according to the procedure used for
the preparation of Example 266, substituting 2,6-dimethylbenzoic
acid for 2-chloro-4-(methylsulfonyl)benzoic acid. 1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 11.55 (s, 1H), 8.88 (t, J=5.8 Hz, 1H), 8.50
(s, 1H), 8.43-8.37 (m, 1H), 7.53 (d, J=1.9 Hz, 1H), 7.22-7.11 (m,
1H), 7.06 (s, 1H), 7.04 (s, 1H), 6.86 (d, J=1.9 Hz, 1H), 6.42 (d,
J=1.7 Hz, 1H), 5.69 (s, 2H), 4.66 (d, J=5.8 Hz, 2H), 2.23 (s, 6H).
MS (ESI+) m/z 406.1 (M+H).sup.+.
Example 296
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-eth-
ylbenzamide
[0958] Example 296 was prepared according to the procedure used for
the preparation of Example 229, substituting 2-ethylbenzoic acid
for 2-fluoro-6-hydroxybenzoic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 1.13 (t, J=7.5 Hz, 3H), 2.73 (q, J=7.5 Hz,
2H), 4.64 (s, 2H), 5.64 (s, 2H), 6.42 (s, 1H), 6.93 (d, J=1.9 Hz,
1H), 7.16-7.31 (m, 2H), 7.36 (d, J=7.4 Hz, 2H), 7.49 (d, J=2.0 Hz,
1H), 8.29 (d, J=2.2 Hz, 2H). MS (APCI) m/z 474.22 [M+H].sup.+.
Example 297
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(4--
methoxyphenyl)acetamide
[0959] Example 297 was prepared according to the procedure used for
the preparation of Example 232, substituting
2-(4-methoxyphenyl)acetic acid for 2-(pyridin-4-yl)acetic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 3.44 (s, 2H), 3.73 (s,
3H), 4.46 (d, J=5.5 Hz, 2H), 5.65 (s, 2H), 6.32 (d, J=1.9 Hz, 1H),
6.78-6.93 (m, 3H), 7.17-7.27 (m, 2H), 7.49 (d, J=2.0 Hz, 1H), 8.36
(s, 3H), 8.41-8.58 (m, 2H), 11.48 (d, J=2.2 Hz, 1H). MS (APCI) m/z
476.2 [M+H].sup.+.
Example 298
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(2--
methoxyphenyl)acetamide
[0960] Example 298 was prepared according to the procedure used for
the preparation of Example 232, substituting
2-(2-methoxyphenyl)acetic acid for 2-(pyridin-4-yl)acetic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 3.76 (s, 5H), 4.48 (d,
J=5.7 Hz, 2H), 5.66 (s, 2H), 6.33 (d, J=1.9 Hz, 1H), 6.77-7.02 (m,
3H), 7.16-7.29 (m, 2H), 7.50 (d, J=2.0 Hz, 1H), 8.17-8.51 (m, 4H),
11.47 (d, J=2.1 Hz, 1H). MS (APCI) m/z 476.2 [M+H].sup.+.
Example 299
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-met-
hoxy-6-methylbenzamide
[0961] Example 299 was prepared according to the procedure used for
the preparation of Example 229, substituting
2-methoxy-6-methylbenzoic acid for 2-fluoro-6-hydroxybenzoic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 2.19 (s, 3H), 3.76 (s,
3H), 4.63 (s, 2H), 5.62 (s, 2H), 6.45 (s, 1H), 6.76-6.96 (m, 3H),
7.24 (t, J=7.9 Hz, 1H), 7.49 (d, J=2.0 Hz, 1H), 8.28 (d, J=8.9 Hz,
2H). MS (APCI) m/z 476.2 [M+H].sup.+.
Example 300
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-met-
hoxy-4-methylbenzamide
[0962] Example 300 was prepared according to the procedure used for
the preparation of Example 100, substituting
3-methoxy-4-methylbenzoic acid for 3-methoxypropanoic acid. .sup.1H
NMR (400 MHz, CD.sub.3OD) .delta. 8.40 (s, 1H), 8.34 (s, 1H), 7.48
(d, J=1.9 Hz, 1H), 7.44-7.33 (m, 2H), 7.23 (d, J=7.7 Hz, 1H), 7.07
(d, J=1.9 Hz, 1H), 6.41 (s, 1H), 5.69 (s, 2H), 3.89 (s, 3H), 2.24
(s, 3H); MS m/z: 341 [M-adenine].sup.+.
Example 301
4-(aminomethyl)-N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4,4-difluorocyclo-
hexyl)-1H-indol-2-yl}methyl)-2-methylbenzamide
[0963] A solution of Example 306 (9.3 mg, 0.017 mmol) in THF (4 mL)
was added to 20% Pd(OH).sub.2/C (wet, 4 mg, 2.91 .mu.mol) in a 50
mL pressure bottle and the suspension was shaken for 16 hours at
room temperature under 30 psi hydrogen. The reaction mixture was
filtered and was concentrated to dryness. The crude product was
purified by preparative HPLC on *2-coupled C8 5 m 100 .ANG. columns
(30 mm.times.75 mm each) with a gradient of acetonitrile (A) and
0.1% trifluoroacetic acid in water (B) was used, at a flow rate of
50 mL/min (0-0.5 minute 5% A, 0.5-8.5 minutes linear gradient
5-100% A, 8.7-10.7 minutes 100% A, 10.7-11 minutes linear gradient
100-5% A) to provide the title compound. .sup.1H NMR (500 MHz,
DMSO-d.sub.6) .delta. 11.22 (d, J=2.0 Hz, 1H), 8.86 (q, J=5.6 Hz,
1H), 8.44 (s, 1H), 8.37 (s, 1H), 8.19 (s, 4H), 7.46 (d, J=7.8 Hz,
1H), 7.41-7.29 (m, 3H), 6.84 (s, 1H), 6.35 (d, J=1.8 Hz, 1H), 5.63
(s, 2H), 4.63 (d, J=5.7 Hz, 2H), 4.04 (t, J=5.8 Hz, 2H), 2.66 (dd,
J=13.6, 9.8 Hz, 1H), 2.39 (s, 3H), 2.38-2.31 (m, 1H), 2.06 (d,
J=12.9 Hz, 2H), 2.02-1.85 (m, 2H), 1.81 (d, J=13.0 Hz, 2H),
1.70-1.56 (m, 2H), 1.17 (d, J=6.7 Hz, 1H), 0.82 (d, J=6.7 Hz, 1H).
MS ESI.sup.+ 557.3 (M+H).sup.+.
Example 302
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-(di-
methylamino)benzamide
[0964] Example 302 was prepared according to the procedure used for
the preparation of Example 232, substituting
4-(dimethylamino)benzoic acid for 2-(pyridin-4-yl)acetic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 2.81 (s, 2H), 2.98 (s,
7H), 3.15 (s, 9H), 4.64 (d, J=5.7 Hz, 2H), 5.66 (s, 2H), 6.35 (d,
J=1.9 Hz, 1H), 6.43-6.79 (m, 2H), 6.83 (d, J=2.0 Hz, 1H), 7.48 (d,
J=1.9 Hz, 1H), 7.65-7.85 (m, 2H), 8.33 (s, 3H), 8.45 (s, 1H), 8.69
(t, J=5.7 Hz, 1H), 11.45 (d, J=2.2 Hz, 1H). MS (APCI) m/z 475.2
[M+H].sup.+.
Example 303
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-cya-
no-2-methylbenzamide
[0965] Example 303 was prepared according to the procedure used for
the preparation of Example 199, substituting
4-cyano-2-methylbenzoic acid for 3-methylpyridazine-4-carboxylic
acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 2.38 (s, 3H),
4.67 (s, 2H), 5.70 (s, 2H), 6.45 (s, 1H), 6.85 (d, J=1.9 Hz, 1H),
7.50-7.62 (m, 2H), 7.69-7.84 (m, 2H), 8.39 (s, 1H), 8.52 (s, 1H).
MS (APCI) m/z 471.2 [M+H].sup.+.
Example 304
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(3,
6-dihydro-2H-pyran-4-yl)-1H-indol-2-yl}methyl)-4-cyano-2-methylbenzamide
[0966] Using the procedure described for Example 4d, substituting
Example 303 for Example 4c and substituting
2-(3,6-dihydro-2H-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
for methylboronic acid provided the title compound. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 11.42 (d, J=1.9 Hz, 1H), 9.10 (t,
J=5.7 Hz, 1H), 8.32 (s, 1H), 8.26 (s, 1H), 7.84 (s, 1H), 7.81 (dd,
J=7.6, 1.6 Hz, 1H), 7.62 (d, J=7.8 Hz, 1H), 7.55 (d, J=1.7 Hz, 1H),
7.33 (s, 2H), 7.21 (d, J=1.7 Hz, 1H), 6.47 (d, J=1.9 Hz, 1H), 6.09
(t, J=2.8 Hz, 1H), 5.65 (s, 2H), 4.71 (d, J=5.8 Hz, 2H), 4.25 (q,
J=2.7 Hz, 2H), 3.86 (t, J=5.4 Hz, 2H), 2.49 (s, 2H), 2.45 (s, 3H).
MS ESI.sup.+ 519.1 (M+H).sup.+.
Example 305
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(1,2,3,6-tetrahydropyridin-4-yl)-1-
H-indol-2-yl}methyl)-4-cyano-2-methylbenzamide
[0967] Using the procedure described for Example 286B and
substituting Example 308 for Example 286a provided the title
compound. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.43 (s,
1H), 9.06 (t, J=5.7 Hz, 1H), 8.80 (d, J=6.3 Hz, 2H), 8.40 (s, 1H),
8.31 (s, 1H), 8.00 (s, 2H), 7.84 7.71 (m, 2H), 7.57 (d, J=8.5 Hz,
2H), 7.08 (s, 1H), 6.43 (s, 1H), 5.96 (d, J=3.5 Hz, 1H), 5.67 (s,
2H), 4.66 (d, J=5.6 Hz, 2H), 3.72 (d, J=4.5 Hz, 2H), 3.31 (d, J=6.4
Hz, 2H), 2.66 (d, J=5.8 Hz, 2H), 2.39 (s, 3H). MS ESI.sup.+ 518.0
(M+H).sup.+.
Example 306
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-(4,4-difluorocyclohex-1-en-1-yl)-1-
H-indol-2-yl}methyl)-4-cyano-2-methylbenzamide
[0968] Using the procedure described for Example 4d, substituting
Example 303 for Example 4c and substituting
2-(4,4-difluorocyclohex-1-en-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
e for methylboronic acid provided the title compound. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 11.31 (d, J=2.1 Hz, 1H), 9.04 (t,
J=5.8 Hz, 1H), 8.43 (s, 1H), 8.35 (s, 1H), 8.04 (s, 2H), 7.80-7.72
(m, 2H), 7.56 (d, J=7.7 Hz, 1H), 7.52 (d, J=1.7 Hz, 1H), 7.10 (d,
J=1.8 Hz, 1H), 6.41 (d, J=1.9 Hz, 1H), 5.81 (s, 1H), 5.65 (s, 2H),
4.65 (d, J=5.6 Hz, 2H), 2.76-2.58 (m, 4H), 2.39 (s, 3H), 2.16 (tq,
J=13.9, 7.2, 6.7 Hz, 2H), 1.17 (d, J=6.8 Hz, 1H), 0.82 (d, J=6.8
Hz, 1H). MS ESI.sup.+551.0 (M+H).sup.+.
Example 307
N-({5-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-7-[(6-amino-9H-purin-9-yl)-
methyl]-1H-indol-2-yl}methyl)-4-cyano-2-methylbenzamide
[0969] Using the procedure described for Example 4d, substituting
Example 303 for Example 4c and substituting
1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridin-1(2-
H)-yl)ethanone for methylboronic acid provided the title compound.
1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.37 (s, 1H), 9.04 (t,
J=5.7 Hz, 1H), 8.24 (d, J=23.7 Hz, 2H), 7.83-7.72 (m, 2H), 7.56 (d,
J=7.8 Hz, 1H), 7.49 (dd, J=4.4, 1.7 Hz, 1H), 7.28 (s, 2H), 7.14 (s,
1H), 6.41 (d, J=1.9 Hz, 1H), 5.96 (dt, J=10.8, 3.4 Hz, 1H), 5.59
(s, 2H), 4.65 (d, J=5.8 Hz, 2H), 4.18-3.99 (m, 2H), 3.62 (dt,
J=12.0, 5.7 Hz, 2H), 2.53 (s, 1H), 2.43 (s, 1H), 2.39 (s, 3H), 2.04
(d, J=16.1 Hz, 3H). MS ESI.sup.+ 560.1 (M+H).sup.+.
Example 308
tert-butyl
4-(7-[(6-amino-9H-purin-9-yl)methyl]-2-{[(4-cyano-2-methylbenzo-
yl)amino]methyl})-1H-indol-5-yl)-3,6-dihydropyridine-1(2H)-carboxylate
[0970] Using the procedure described for Example 4d, substituting
Example 303 for Example 4c and substituting tert-butyl
4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-
-carboxylate for methylboronic acid provided the title compound.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 9.04 (t, J=5.7 Hz, 1H),
8.23 (d, J=21.1 Hz, 2H), 7.91-7.69 (m, 2H), 7.56 (d, J=8.0 Hz, 1H),
7.48 (d, J=1.6 Hz, 1H), 7.27 (s, 2H), 7.15 (d, J=1.7 Hz, 1H), 6.40
(d, J=2.0 Hz, 1H), 5.94 (s, 1H), 5.59 (s, 2H), 4.65 (d, J=5.7 Hz,
2H), 4.12-3.88 (m, 2H), 3.52 (t, J=5.8 Hz, 2H), 2.45 (s, 2H), 2.39
(s, 3H), 1.90 (s, 1H), 1.42 (s, 9H). MS ESI+618.0 (M+H).sup.+.
Example 309
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-(di-
methylamino)benzamide
[0971] Example 309 was prepared according to the procedure used for
the preparation of Example 232, substituting
3-(dimethylamino)benzoic acid for 2-(pyridin-4-yl)acetic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 2.95 (s, 6H), 4.67 (d,
J=5.6 Hz, 2H), 5.70 (s, 2H), 6.37 (d, J=1.8 Hz, 1H), 6.82 (d, J=2.0
Hz, 1H), 6.88-6.96 (m, 1H), 7.14-7.35 (m, 3H), 7.50 (d, J=1.9 Hz,
1H), 8.41 (s, 1H), 8.53 (s, 2H), 8.97 (t, J=5.7 Hz, 1H), 11.49 (d,
J=2.2 Hz, 1H). MS (APCI) m/z 475.2 [M+H].sup.+.
Example 310
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(et-
hylamino)benzamide
[0972] Example 310 was prepared according to the procedure used for
the preparation of Example 229, substituting 2-(ethylamino)benzoic
acid for 2-fluoro-6-hydroxybenzoic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 1.22 (t, J=7.1 Hz, 3H), 3.18 (q, J=7.1 Hz,
3H), 4.66 (s, 2H), 5.67 (s, 2H), 6.62 (t, J=7.8 Hz, 1H), 6.74 (d,
J=8.4 Hz, 1H), 6.94 (d, J=2.0 Hz, 1H), 7.33 (ddd, J=8.6, 7.1, 1.6
Hz, 1H), 7.50 (d, J=2.0 Hz, 1H), 7.62 (dd, J=7.9, 1.5 Hz, 1H), 8.34
(d, J=11.5 Hz, 2H). MS (APCI) m/z 475.2 [M+H].sup.+.
Example 311
4-{[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)amin-
o]methyl}-3-methoxybenzonitrile
[0973] Example 311 was prepared according to the procedure used for
the preparation of Example 208, substituting
4-formyl-3-methoxybenzonitrile for 2-bromobenzaldehyde. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 8.47 (s, 1H), 8.34 (s, 1H), 7.65
(d, J=1.9 Hz, 1H), 7.61-7.51 (m, 2H), 7.48 (dd, J=7.7, 1.5 Hz, 1H),
6.88 (d, J=1.9 Hz, 1H), 6.75 (s, 1H), 5.68 (s, 2H), 4.43 (s, 2H),
4.25 (s, 2H), 3.87 (s, 3H). MS (ESI+) m/z 473.1 (M+H).sup.+.
Example 312
1-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-(2--
methoxybenzyl)urea
[0974] To a suspension of Example 9b in tetrahydrofuran (1.5 mL)
was added 1-(isocyanatomethyl)-2-methoxybenzene (0.023 mL, 0.153
mmol). The reaction was stirred at room temperature for about 1
hour. The mixture was concentrated under reduced pressure and the
residue purified by preparative HPLC (Waters Sunfire C8, 0-100%
acetonitrile/water; 1% TFA) to give the title compound (0.066 g,
88%). .sup.1H NMR (400 MHz, CD.sub.3OD) .delta. 8.41 (s, 1H), 8.32
(s, 1H), 7.45 (d, J=1.9 Hz, 1H), 7.28-7.01 (m, 3H), 6.90 (d, J=8.2
Hz, 1H), 6.78 (t, J=7.5 Hz, 1H), 6.33 (s, 1H), 5.65 (s, 2H), 4.48
(s, 2H), 4.34 (s, 2H), 3.79 (s, 3H); MS m/z: 356
[M-adenine].sup.+.
Example 313
4-(acetylamino)-N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2--
yl}methyl)benzamide
[0975] Example 313 was prepared according to the procedure used for
the preparation of Example 232, substituting 4-acetamidobenzoic
acid for 2-(pyridin-4-yl)acetic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 2.07 (s, 3H), 4.67 (d, J=5.6 Hz, 2H), 5.66
(s, 2H), 6.37 (d, J=1.9 Hz, 1H), 6.82 (d, J=2.0 Hz, 1H), 7.49 (d,
J=2.0 Hz, 1H), 7.61-7.73 (m, 2H), 7.83-7.93 (m, 2H), 8.32 (s, 3H),
8.45 (s, 1H), 8.94 (t, J=5.7 Hz, 1H), 10.17 (s, 1H), 11.49 (d,
J=2.1 Hz, 1H). MS (APCI) m/z 489.1 [M+H].sup.+.
Example 314
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(pr-
opan-2-yl)benzamide
[0976] Example 314 was prepared according to the procedure used for
the preparation of Example 229, substituting 2-isopropylbenzoic
acid for 2-fluoro-6-hydroxybenzoic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 1.18 (d, J=6.9 Hz, 6H), 4.64 (s, 2H), 5.66
(s, 2H), 6.93 (d, J=2.0 Hz, 1H), 7.16-7.34 (m, 2H), 7.34-7.45 (m,
2H), 7.49 (d, J=2.0 Hz, 1H), 8.34 (s, 2H). MS (APCI) m/z 474.2
[M+H].sup.+.
Example 315
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-(4--
methoxyphenyl)propanamide
[0977] Example 315 was prepared according to the procedure used for
the preparation of Example 105, substituting
3-(4-methoxy-phenyl)-propionic acid for 4-methyl-pentanoic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.43 (s, 1H),
8.52-8.17 (m, 5H), 7.46 (d, J=1.9 Hz, 1H), 7.17-7.09 (m, 2H),
6.87-6.77 (m, 3H), 6.16 (d, J=1.8 Hz, 1H), 5.66 (s, 2H), 4.44 (d,
J=5.6 Hz, 2H), 3.70 (s, 3H), 2.81 (dd, J=8.7, 7.0 Hz, 2H), 2.45
(dd, J=8.6, 6.9 Hz, 2H). MS (APCI+) m/z 490.0 (M+H).sup.+.
Example 316
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-(3--
methoxyphenyl)propanamide
[0978] Example 316 was prepared according to the procedure used for
the preparation of Example 105, substituting
3-(3-methoxy-phenyl)-propionic acid for 4-methyl-pentanoic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.45 (s, 1H),
8.46-8.37 (m, 2H), 8.35 (s, 1H), 8.13 (s, 2H), 7.46 (d, J=2.0 Hz,
1H), 7.18 (t, J=8.0 Hz, 1H), 6.84-6.70 (m, 4H), 6.22 (d, J=1.8 Hz,
1H), 5.64 (s, 2H), 4.46 (d, J=5.5 Hz, 2H), 3.71 (s, 3H), 2.89-2.79
(m, 2H), 2.51-2.44 (m, 2H). MS (APCI+) m/z 490.0 (M+H).sup.+.
Example 317
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-[4--
(dimethylamino)phenyl]acetamide
[0979] Example 317 was prepared according to the procedure used for
the preparation of Example 105, substituting
(4-dimethylamino-phenyl)-acetic acid for 4-methyl-pentanoic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.46 (s, 1H),
8.57-8.47 (m, 4H), 8.43 (s, 1H), 7.49 (d, J=1.9 Hz, 1H), 7.24-7.15
(m, 2H), 6.87 (d, J=8.4 Hz, 2H), 6.82 (d, J=2.0 Hz, 1H), 6.31 (d,
J=1.8 Hz, 1H), 5.68 (s, 2H), 4.46 (d, J=5.6 Hz, 2H), 3.42 (s, 2H),
2.92 (s, 6H). MS (APCI+) m/z 489.0 (M+H).sup.+.
Example 318
4-{[({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)amin-
o]methyl}-N,N-dimethylbenzamide
[0980] Example 318 was prepared according to the procedure used for
the preparation of Example 208, substituting
4-formyl-N,N-dimethylbenzamide for 2-bromobenzaldehyde. .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 8.46 (s, 1H), 8.34 (s, 1H), 7.65
(d, J=1.8 Hz, 1H), 7.62-7.54 (m, 2H), 7.54-7.43 (m, 2H), 6.88 (d,
J=1.9 Hz, 1H), 6.75 (s, 1H), 5.68 (s, 2H), 4.43 (s, 2H), 4.30 (s,
2H), 3.18 (s, 1H), 3.00 (s, 3H), 2.89 (s, 3H). MS (ESI+) m/z 450.1
(M+H).sup.+.
Example 319
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-(2--
fluorophenyl)pyrrolidine-1-carboxamide
[0981] To a suspension of Example 9b (67.5 mg, 0.206 mmol) in THF
(3 mL) at 0.degree. C. was added N-ethyl-N-isopropylpropan-2-amine
(39.5 .mu.L, 0.226 mmol) and 4-nitrophenyl carbonochloridate (41.5
mg, 0.206 mmol). After the mixture was stirred at 0.degree. C. for
40 minutes, a solution of 3-(2-fluorophenyl)pyrrolidine (34 mg,
0.206 mmol) in THF (1 mL) was added, followed by addition of
Hunig's Base (43.1 .mu.L, 0.247 mmol). The mixture was stirred at
0.degree. C. for 30 minutes and then at ambient temperature for 2
hours. The mixture was diluted with 30 mL ethyl acetate, washed
with 1N aqueous sodium hydroxide solution and brine, dried over
anhydrous magnesium sulfate, filtered. The filtrate was
concentrated and the residue was purified by column chromatography
on silica gel (1-10% methanol in dichloromethane) to give the title
compound (40 mg, 0.077 mmol, 37.5% yield). .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 11.41 (s, 1H), 8.30 (s, 1H), 8.21 (d, J=5.4
Hz, 1H), 7.47 (d, J=1.9 Hz, 1H), 7.38 (dd, J=10.8, 4.7 Hz, 1H),
7.34-7.26 (m, 3H), 7.23-7.14 (m, 2H), 6.85 (d, J=1.9 Hz, 1H), 6.79
(t, J=5.7 Hz, 1H), 6.32 (d, J=1.4 Hz, 1H), 5.60 (s, 2H), 4.45 (d,
J=5.6 Hz, 2H), 3.82-3.73 (m, 1H), 3.58 (ddd, J=18.5, 13.3, 5.7 Hz,
2H), 3.45-3.25 (m, 2H), 2.25 (dd, J=10.6, 4.5 Hz, 1H), 2.13-1.94
(m, 1H). MS (ESI+) m/z 519.0 (M+H).sup.+.
Example 320
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(py-
rrolidin-1-ylcarbonyl)benzamide
[0982] Example 320 was prepared according to the procedure used for
the preparation of Example 229, substituting
2-(pyrrolidine-1-carbonyl)benzoic acid for
2-fluoro-6-hydroxybenzoic acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 1.73 (d, J=6.6 Hz, 4H), 3.13 (d, J=10.2 Hz, 3H), 3.37 (s,
2H), 4.63 (s, 2H), 5.70 (s, 2H), 6.89 (d, J=2.3 Hz, 1H), 7.34 (dd,
J=7.3, 1.5 Hz, 1H), 7.43-7.60 (m, 3H), 7.67 (dd, J=7.4, 1.5 Hz,
1H), 8.34 (d, J=5.1 Hz, 2H). MS (APCI) m/z 529.1 [M+H].sup.+.
Example 321
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(te-
trahydro-2H-pyran-4-yloxy)benzamide
[0983] Example 321 was prepared according to the procedure used for
the preparation of Example 229, substituting
2-((tetrahydro-2H-pyran-4-yl)oxy)benzoic acid for
2-fluoro-6-hydroxybenzoic acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 1.55 (dtd, J=12.8, 8.4, 4.0 Hz, 2H), 1.82-2.00 (m, 2H),
3.34-3.40 (m, 1H), 3.63 (dt, J=10.5, 4.7 Hz, 2H), 4.64 (tt, J=8.1,
4.0 Hz, 1H), 4.72 (s, 2H), 5.66 (s, 2H), 6.93 (d, J=1.9 Hz, 1H),
7.08 (t, J=7.5 Hz, 1H), 7.18 (d, J=8.2 Hz, 1H), 7.40-7.54 (m, 2H),
7.82 (dd, J=7.7, 1.9 Hz, 1H), 8.33 (d, J=11.0 Hz, 2H). MS (APCI)
m/z 532.2 [M+H].sup.+.
Example 322
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(pi-
peridin-1-yl)benzamide
[0984] Example 322 was prepared according to the procedure used for
the preparation of Example 229, substituting
2-(piperidin-1-yl)benzoic acid for 2-fluoro-6-hydroxybenzoic acid.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 1.42 (dq, J=34.3, 5.8
Hz, 6H), 2.95 (t, J=5.2 Hz, 4H), 4.74 (s, 2H), 5.65 (s, 2H), 6.96
(d, J=1.9 Hz, 1H), 7.30 (t, J=7.5 Hz, 1H), 7.41 (d, J=8.2 Hz, 1H),
7.45-7.61 (m, 2H), 7.98 (dd, J=7.7, 1.7 Hz, 1H), 8.31 (d, J=10.3
Hz, 2H). MS (APCI) m/z 515.2 [M+H].sup.+.
Example 323
9-{[5-chloro-2-({[3-(piperidin-1-ylmethyl)benzyl]amino}methyl)-1H-indol-7--
yl]methyl}-9H-purin-6-amine
[0985] Example 323 was prepared according to the procedure used for
the preparation of Example 208, substituting
3-(piperidin-1-ylmethyl)benzaldehyde for 2-bromobenzaldehyde.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.45 (s, 1H), 8.31 (s,
1H), 7.73-7.55 (m, 4H), 7.53 (s, 1H), 6.95-6.83 (m, 1H), 6.75 (s,
1H), 5.68 (s, 2H), 4.44 (s, 2H), 4.28 (d, J=4.2 Hz, 4H), 3.33 (d,
J=12.1 Hz, 2H), 2.89 (t, J=12.2 Hz, 2H), 1.83 (d, J=14.1 Hz, 2H),
1.76-1.47 (m, 3H), 1.46-1.27 (m, 1H). MS (ESI+) m/z 515.1
(M+H).sup.+.
Example 324
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(pi-
peridin-1-ylcarbonyl)benzamide
[0986] Example 324 was prepared according to the procedure used for
the preparation of Example 229, substituting
2-(piperidine-1-carbonyl)benzoic acid for 2-fluoro-6-hydroxybenzoic
acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 1.44 (d, J=25.2
Hz, 7H), 4.63 (s, 2H), 5.67 (s, 2H), 6.89 (d, J=1.8 Hz, 1H),
7.22-7.32 (m, 1H), 4.03-4.37 (m, -1H), 7.43-7.60 (m, 3H), 7.68 (d,
J=7.6 Hz, 1H), 8.29 (d, J=1.4 Hz, 2H), MS (APCI) m/z 543.2
[M+H].sup.+.
Example 325
9-({5-chloro-2-[({3-[2-(piperidin-1-yl)ethoxy]benzyl}amino)methyl]-1H-indo-
l-7-yl}methyl)-9H-purin-6-amine
[0987] Example 325 was prepared according to the procedure used for
the preparation of Example 208, substituting
3-(2-(piperidin-1-yl)ethoxy)benzaldehyde for 2-bromobenzaldehyde.
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.46 (s, 1H), 8.32 (s,
1H), 7.65 (d, J=1.9 Hz, 1H), 7.44 (t, J=7.9 Hz, 1H), 7.21-7.04 (m,
3H), 6.88 (d, J=1.9 Hz, 1H), 6.74 (s, 1H), 5.68 (s, 2H), 4.41 (s,
2H), 4.34 (t, J=4.9 Hz, 2H), 4.24 (s, 2H), 3.56-3.45 (m, 4H), 3.02
(t, J=12.0 Hz, 2H), 1.85 (d, J=13.8 Hz, 2H), 1.71 (m, 3H). MS
(ESI+) m/z 545.2 (M+H).sup.+.
Example 326
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-5-met-
hyl-3-phenyl-1,2-oxazole-4-carboxamide
[0988] Example 326 was prepared according to the procedure used for
the preparation of Example 232, substituting
5-methyl-3-phenylisoxazole-4-carboxylic acid for
2-(pyridin-4-yl)acetic acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 2.55 (s, 2H), 2.69 (s, 1H), 4.64 (d, J=5.7 Hz, 2H), 5.69
(s, 2H), 6.36 (d, J=1.8 Hz, 1H), 6.85 (d, J=2.0 Hz, 1H), 7.31-7.57
(m, 4H), 7.57-7.71 (m, 2H), 8.40 (s, 1H), 8.51 (s, 2H), 8.95 (t,
J=5.7 Hz, 1H), 11.56 (d, J=2.2 Hz, 1H). MS (APCI) m/z 513.
[M+H].sup.+.
Example 327
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(1--
methyl-1H-imidazol-2-yl)benzamide
[0989] Example 327 was prepared according to the procedure used for
the preparation of Example 229, substituting
2-(1-methyl-1H-imidazol-2-yl)benzoic acid for
2-fluoro-6-hydroxybenzoic acid. .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 3.56 (s, 3H), 4.61 (s, 2H), 5.65 (s, 2H), 6.94 (d, J=2.0
Hz, 1H), 7.51 (d, J=1.9 Hz, 1H), 7.59-7.76 (m, 3H), 7.85 (dtd,
J=20.1, 7.6, 1.4 Hz, 2H), 8.05 (dd, J=7.6, 1.4 Hz, 1H), 8.25-8.42
(m, 2H). MS (APCI) m/z 512.2 [M+H].sup.+.
Example 328
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-(be-
nzoylamino)benzamide
[0990] Example 328 was prepared according to the procedure used for
the preparation of Example 229, substituting 2-benzamidobenzoic
acid for 2-fluoro-6-hydroxybenzoic acid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 4.72 (s, 2H), 5.56 (s, 2H), 6.42 (s, 1H),
6.91 (d, J=1.9 Hz, 1H), 7.24 (t, J=7.8 Hz, 1H), 7.40-7.65 (m, 5H),
7.82-7.97 (m, 3H), 8.20 (s, 2H), 8.57 (d, J=8.4 Hz, 1H). MS (APCI)
m/z 551.2 [M+H].sup.+.
Example 329
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,2,3-
-benzothiadiazole-5-carboxamide
[0991] Example 329 was prepared according to the procedure used for
the preparation of Example 356 substituting
benzo[d][1,2,3]thiadiazole-5-carboxylic acid for
1H-indole-6-carboxylic acid. .sup.1H NMR (DMSO/D.sub.2O-d.sub.6)
.delta. 4.78 (s, 1H), 5.63 (s, 3H), 6.48 (s, 1H), 6.82-6.85 (m,
1H), 7.50-7.53 (m, 1H), 8.18 (s, 1H), 8.31 (dd, J=8.5, 1.5 Hz, 1H),
8.33 (s, 1H), 8.51 (d, J=8.6 Hz, 1H), 9.23-9.25 (m, 1H); MS (ESI)
m/z 490 (M+H).sup.+.
Example 330
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3H-im-
idazo[4,5-b]pyridine-5-carboxamide
[0992] Example 330 was prepared according to the procedure used for
the preparation of Example 370 substituting
3H-imidazo[4,5-b]pyridine-5-carboxylic acid for
3-isopropylisoxazolo[5,4-b]pyridine-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.74 (d, J=6.1 Hz, 2H), 5.66 (d,
J=7.4 Hz, 1H), 5.68 (s, 2H), 6.35-6.40 (m, 1H), 6.80 (d, J=2.0 Hz,
1H), 7.49 (d, J=1.9 Hz, 1H), 8.04 (d, J=8.3 Hz, 1H), 8.18 (d, J=8.3
Hz, 1H), 8.28-8.43 (m, 3H), 8.50 (s, 1H), 8.67 (s, 1H), 9.24 (t,
J=6.0 Hz, 1H), 11.45-11.59 (m, 1H); MS (ESI) m/z 473
(M+H).sup.+.
Example 331
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-be-
nzotriazole-6-carboxamide
[0993] Example 331 was prepared according to the procedure used for
the preparation of Example 367, substituting
1H-benzo[d][1,2,3]triazole-6-carboxylic acid for
1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.75 (s, 2H), 5.74 (s, 2H), 6.47
(s, 1H), 6.81-6.90 (m, 1H), 7.49-7.60 (m, 1H), 7.95-8.07 (m, 2H),
8.42 (s, 1H), 8.50-8.63 (m, 2H); MS (ESI) m/e 473 (M+H).sup.+.
Example 332
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-be-
nzotriazole-5-carboxamide
[0994] Example 332 was prepared according to the procedure used for
the preparation of Example 367, substituting
1H-benzo[d][1,2,3]triazole-5-carboxylic acid for
1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.75 (s, 2H), 5.74 (s, 2H), 6.47
(s, 1H), 6.81-6.87 (m, 1H), 7.48-7.61 (m, 1H), 7.96-8.09 (m, 2H),
8.43 (s, 1H), 8.52-8.58 (m, 2H); MS (ESI) m/z 473 (M+H).sup.+.
Example 333
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3H-im-
idazo[4,5-b]pyridine-6-carboxamide
[0995] Example 333 was prepared according to the procedure used for
the preparation of Example 367, substituting
1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid for
3H-imidazo[4,5-b]pyridine-6-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.76 (s, 2H), 5.76 (s, 2H), 6.48
(s, 1H), 6.80-6.86 (m, 1H), 7.51-7.57 (m, 1H), 8.49 (s, 1H),
8.60-8.66 (m, 2H), 8.86 (s, 1H), 9.00-9.04 (m, 1H); MS (ESI) m/z
473 (M+H).sup.+.
Example 334
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-5-flu-
oro-1H-benzotriazole-6-carboxamide
[0996] Example 334 was prepared according to the procedure used for
the preparation of Example 370, substituting
5-fluoro-1H-benzo[d][1,2,3]triazole-6-carboxylic acid for
3-isopropylisoxazolo[5,4-b]pyridine-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.72 (d, J=5.6 Hz, 2H), 5.71 (s,
2H), 6.46 (d, J=1.8 Hz, 1H), 6.82 (d, J=1.9 Hz, 1H), 7.53 (d, J=1.9
Hz, 1H), 7.84 (d, J=9.7 Hz, 1H), 8.29 (s, 1H), 8.40 (s, 1H), 8.54
(s, 1H), 9.10 (t, J=5.5 Hz, 1H), 11.57 (s, 1H); MS (ESI) m/z 491
(M+H).sup.+.
Example 335
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,3-b-
enzothiazole-6-carboxamide
[0997] Example 335 was prepared according to the procedure used for
the preparation of Example 367, substituting
benzo[d]thiazole-6-carboxylic acid for
1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.75 (s, 2H), 5.74 (s, 2H), 6.47
(s, 1H), 6.80-6.89 (m, 1H), 7.51-7.58 (m, 1H), 8.09 (dd, J=8.6, 1.7
Hz, 1H), 8.22 (d, J=8.6 Hz, 1H), 8.46 (s, 1H), 8.59 (s, 1H),
8.68-8.75 (m, 1H), 9.54 (s, 1H); MS (ESI) m/z 489 (M+H).sup.+.
Example 336
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,3-b-
enzothiazole-5-carboxamide
[0998] Example 336 was prepared according to the procedure used for
the preparation of Example 367, substituting
benzo[d]thiazole-5-carboxylic acid for
1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid. .sup.1H NMR
(DMSO-d.sub.6) .delta. 4.76 (s, 2H), 5.74 (s, 2H), 6.47 (s, 1H),
6.82-6.88 (m, 1H), 7.50-7.59 (m, 1H), 8.05 (dd, J=8.4, 1.7 Hz, 1H),
8.32 (d, J=8.4 Hz, 1H), 8.45 (s, 1H), 8.59 (s, 1H), 8.61-8.70 (m,
1H), 9.50 (s, 1H); MS (ESI) m/z 489 (M+H).sup.+.
Example 337
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)thieno-
[3,2-b]pyridine-6-carboxamide
[0999] Example 337 was prepared according to the procedure used for
the preparation of Example 370, substituting
thieno[3,2-b]pyridine-6-carboxylic acid for
3-isopropylisoxazolo[5,4-b]pyridine-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.75 (d, J=5.4 Hz, 2H), 5.71 (s,
2H), 6.46 (d, J=1.8 Hz, 1H), 6.81 (d, J=2.0 Hz, 1H), 7.51 (d, J=1.9
Hz, 1H), 7.66 (d, J=5.4 Hz, 1H), 8.35 (d, J=5.5 Hz, 1H), 8.39 (s,
1H), 8.53 (s, 1H), 8.99 (d, J=1.7 Hz, 1H), 9.18 (d, J=2.0 Hz, 1H),
9.33 (t, J=5.6 Hz, 1H), 11.56 (s, 1H); MS (ESI) m/z 489
(M+H).sup.+.
Example 338
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,3-b-
enzoxazole-6-carboxamide
[1000] Example 338 was prepared according to the procedure used for
the preparation of Example 367, substituting
benzo[d]oxazole-6-carboxylic acid for
1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.67 (s, 2H), 5.73 (s, 2H), 6.40
(s, 1H), 6.81-6.85 (m, 1H), 7.40 (dd, J=8.3, 2.0 Hz, 1H), 7.45 (d,
J=2.0 Hz, 1H), 7.51-7.55 (m, 1H), 8.20 (d, J=8.4 Hz, 1H), 8.36 (s,
1H), 8.43 (s, 1H), 8.58 (s, 1H); MS (ESI) m/z 473 (M+H).sup.+ and
491 (M+NH.sub.4).sup.+.
Example 339
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,3-b-
enzoxazole-5-carboxamide
[1001] Example 339 was prepared according to the procedure used for
the preparation of Example 367, substituting
benzo[d]oxazole-5-carboxylic acid for
1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.63-4.67 (m, 2H), 5.71 (s, 2H),
6.39 (s, 1H), 6.80-6.89 (m, 1H), 6.97 (d, J=8.5 Hz, 1H), 7.50-7.53
(m, 1H), 7.57 (dd, J=8.5, 2.2 Hz, 1H), 8.34 (s, 1H), 8.41 (s, 1H),
8.55 (s, 1H), 8.59-8.63 (m, 1H); MS (ESI) m/z 473 (M+H).sup.+ and
491 (M+NH.sub.4).sup.+.
Example 340
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)furo[3-
,2-b]pyridine-6-carboxamide
[1002] Example 340 was prepared according to the procedure used for
the preparation of Example 367, substituting
furo[3,2-b]pyridine-6-carboxylic acid for
1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.76 (s, 2H), 5.75 (s, 2H), 6.48
(s, 1H), 6.77-6.90 (m, 1H), 7.21-7.31 (m, 1H), 7.54 (d, J=1.9 Hz,
1H), 8.45 (s, 1H), 8.47 (d, J=2.3 Hz, 1H), 8.50-8.53 (m, 1H), 8.59
(s, 1H), 9.04-9.14 (m, 1H); MS (ESI) m/z 473 (M+H).sup.+.
Example 341
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl)}methyl)-2-hy-
droxy-1,3-benzothiazole-6-carboxamide
[1003] Example 341 was prepared according to the procedure used for
the preparation of Example 367, substituting
2-hydroxybenzo[d]thiazole-6-carboxylic acid for
1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.69 (s, 2H), 5.73 (s, 2H), 6.43
(s, 1H), 6.82-6.86 (m, 1H), 7.26 (d, J=8.4 Hz, 1H), 7.50-7.55 (m,
1H), 7.87 (dd, J=8.4, 1.8 Hz, 1H), 8.10-8.15 (m, 1H), 8.45 (s, 1H),
8.58 (s, 1H); MS (ESI) m/z 505 (M+H).sup.+.
Example 342
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-in-
dazole-6-carboxamide
[1004] Example 342 was prepared according to the procedure used for
the preparation of Example 367, substituting
1H-indazole-6-carboxylic acid for
1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.73 (s, 2H), 5.74 (s, 2H), 6.45
(s, 1H), 6.82-6.87 (m, 1H), 7.51-7.56 (m, 1H), 7.67 (dd, J=8.4, 1.4
Hz, 1H), 7.91 (d, J=8.2 Hz, 1H), 8.15 (s, 1H), 8.21 (s, 1H), 8.45
(s, 1H), 8.60 (s, 1H); MS (ESI) m/z 472 (M+H).sup.+.
Example 343
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-py-
rrolo[3,2-b]pyridine-5-carboxamide
[1005] Example 343 was prepared according to the procedure used for
the preparation of Example 370, substituting
1H-pyrrolo[3,2-b]pyridine-5-carboxylic acid for
3-isopropylisoxazolo[5,4-b]pyridine-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.74 (d, J=6.0 Hz, 2H), 5.70 (s,
2H), 6.39 (d, J=1.7 Hz, 1H), 6.66-6.69 (m, 1H), 6.80 (d, J=2.0 Hz,
1H), 7.50 (d, J=1.9 Hz, 1H), 7.84 (t, J=3.0 Hz, 1H), 7.93 (d, J=8.5
Hz, 1H), 7.98 (d, J=8.5 Hz, 1H), 8.42 (s, 1H), 8.45-9.00 (m, 3H),
9.20 (t, J=6.2 Hz, 1H), 11.51 (s, 1H), 11.70 (s, 1H); MS (ESI) m/z
472 (M+H).sup.+.
Example 344
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-be-
nzimidazole-5-carboxamide
[1006] Example 344 was prepared according to the procedure used for
the preparation of Example 367, substituting
1H-benzo[d]imidazole-5-carboxylic acid for
1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.74 (s, 2H), 5.72 (s, 2H), 6.44
(s, 1H), 6.83 (d, J=2.0 Hz, 1H), 7.50-7.55 (m, 1H), 7.90-7.96 (m,
1H), 8.08 (dd, J=8.6, 1.5 Hz, 1H), 8.33-8.38 (m, 1H), 8.42 (s, 1H),
8.57 (s, 1H), 9.35 (s, 1H); MS (ESI) m/z 472 (M+H).sup.+.
Example 345
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-be-
nzimidazole-6-carboxamide
[1007] Example 345 was prepared according to the procedure used for
the preparation of Example 370, substituting
1H-benzo[d]imidazole-6-carboxylic acid for
3-isopropylisoxazolo[5,4-b]pyridine-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.73 (d, J=5.5 Hz, 2H), 5.69 (s,
2H), 6.41 (d, J=1.8 Hz, 1H), 6.82 (d, J=1.8 Hz, 1H), 7.50 (d, J=1.9
Hz, 1H), 7.86 (d, J=8.6 Hz, 1H), 8.03 (dd, J=8.6, 1.5 Hz, 1H),
8.32-8.36 (m, 1H), 8.37 (s, 1H), 8.51 (s, 1H), 9.19 (s, 1H), 9.26
(t, J=5.6 Hz, 1H), 11.54 (s, 1H); MS (ESI) m/z 472 (M+H).sup.+.
Example 346
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-in-
dazole-5-carboxamide
[1008] Example 346 was prepared according to the procedure used for
the preparation of Example 367, substituting
1H-indazole-5-carboxylic acid for
1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.72 (s, 2H), 5.75 (s, 2H), 6.44
(s, 1H), 6.79-6.86 (m, 1H), 7.49-7.58 (m, 1H), 7.66 (d, J=8.8 Hz,
1H), 7.94 (dd, J=8.7, 1.6 Hz, 1H), 8.25-8.29 (m, 1H), 8.39-8.44 (m,
1H), 8.47 (s, 1H), 8.61 (s, 1H); MS (ESI) m/z 472 (M+H).sup.+.
Example 347
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-py-
rrolo[2,3-b]pyridine-5-carboxamide
[1009] Example 347 was prepared according to the procedure used for
the preparation of Example 367, substituting
1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid for
1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.73 (s, 2H), 5.75 (s, 2H), 6.46
(s, 1H), 6.64 (d, J=3.5 Hz, 1H), 6.83-6.86 (m, 1H), 7.52-7.55 (m,
1H), 7.60 (d, J=3.5 Hz, 1H), 8.48 (s, 1H), 8.53-8.56 (m, 1H), 8.61
(s, 1H), 8.78-8.82 (m, 1H); MS (ESI) m/z 472 (M+H).sup.+.
Example 348
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-chl-
oro-1H-pyrrolo[2,3-b]pyridine-5-carboxamide
[1010] Example 348 was prepared according to the procedure used for
the preparation of Example 370, substituting
4-chloro-1H-pyrrolo[2,3-b]pyridine-5-carboxylic acid for
3-isopropylisoxazolo[5,4-b]pyridine-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.71 (d, J=5.6 Hz, 2H), 5.68 (s,
2H), 6.48 (d, J=1.8 Hz, 1H), 6.59 (dd, J=3.5, 1.9 Hz, 1H), 6.83 (d,
J=2.0 Hz, 1H), 7.53 (d, J=1.9 Hz, 1H), 7.68 (t, J=2.9 Hz, 1H), 8.12
(s, 2H), 8.36 (d, J=11.8 Hz, 2H), 8.47 (s, 1H), 9.08 (t, J=5.8 Hz,
1H), 11.59 (s, 1H), 12.19 (s, 1H); MS (ESI) m/z 506
(M+H).sup.+.
Example 349
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-5-chl-
oro-1H-pyrrolo[2, 3-b]pyridine-6-carboxamide
[1011] Example 349 was prepared according to the procedure used for
the preparation of Example 370, substituting
5-chloro-1H-pyrrolo[2,3-b]pyridine-6-carboxylic acid for
3-isopropylisoxazolo[5,4-b]pyridine-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.69 (d, J=5.8 Hz, 2H), 5.64 (s,
2H), 6.45 (d, J=1.8 Hz, 1H), 6.51 (dd, J=3.5, 1.8 Hz, 1H), 6.85 (d,
J=2.0 Hz, 1H), 7.52 (d, J=1.9 Hz, 1H), 7.65-7.89 (m, 3H), 8.16 (s,
1H), 8.30 (s, 1H), 8.40 (s, 1H), 9.01 (t, J=5.9 Hz, 1H), 11.60 (s,
1H), 12.02 (s, 1H); MS (ESI) m/z 506 (M+H).sup.+.
Example 350
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-flu-
oro-1H-indazole-5-carboxamide
[1012] Example 350 was prepared according to the procedure used for
the preparation of Example 370, substituting
4-fluoro-1H-indazole-5-carboxylic acid for
3-isopropylisoxazolo[5,4-b]pyridine-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.71 (d, J=5.7 Hz, 2H), 5.70 (s,
2H), 6.42 (d, J=1.8 Hz, 1H), 6.82 (d, J=1.9 Hz, 1H), 7.45 (d, J=8.6
Hz, 1H), 7.52 (d, J=1.9 Hz, 1H), 7.67 (dd, J=8.6, 6.6 Hz, 1H), 8.33
(s, 1H), 8.40 (s, 1H), 8.54 (s, 1H), 8.83 (td, J=5.8, 2.9 Hz, 1H),
11.51 (s, 1H); MS (ESI) m/z 490 (M+H).sup.+.
Example 351
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-met-
hyl[1,2]oxazolo[5,4-b]pyridine-5-carboxamide
[1013] Example 351 was prepared according to the procedure used for
the preparation of Example 367, substituting
3-methylisoxazolo[5,4-b]pyridine-5-carboxylic acid for
1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 2.65 (s, 3H), 4.77 (s, 2H), 5.75
(s, 2H), 6.50 (s, 1H), 6.79-6.89 (m, 1H), 7.50-7.58 (m, 1H), 8.46
(s, 1H), 8.60 (s, 1H), 8.89 (d, J=2.1 Hz, 1H), 9.16 (d, J=2.1 Hz,
1H); MS (ESI) m/z 488 (M+H).sup.+.
Example 352
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-met-
hyl-1H-benzotriazole-5-carboxamide
[1014] Example 352 was prepared according to the procedure used for
the preparation of Example 367, substituting
1-methyl-1H-benzo[d][1,2,3]triazole-5-carboxylic acid for
1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.36 (s, 3H), 4.75 (s, 2H), 5.72
(s, 2H), 6.47 (s, 1H), 6.77-6.94 (m, 1H), 7.47-7.61 (m, 1H), 7.96
(d, J=8.8 Hz, 1H), 8.12 (dd, J=8.8, 1.5 Hz, 1H), 8.38 (s, 1H), 8.53
(s, 1H), 8.63-8.66 (m, 1H); MS (ESI) m/z 487 (M+H).sup.+.
Example 353
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-met-
hyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
[1015] Example 353 was prepared according to the procedure used for
the preparation of Example 367, substituting
3-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid for
1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 2.58 (s, 3H), 4.75 (s, 2H), 5.72
(s, 2H), 6.48 (s, 1H), 6.78-6.90 (m, 1H), 7.48-7.62 (m, 1H), 8.39
(s, 1H), 8.54 (s, 1H), 8.75-8.80 (m, 1H), 8.99-9.06 (m, 1H); MS
(ESI) m/z 487 (M+H).sup.+.
Example 354
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-ben-
zothiophene-5-carboxamide
[1016] Example 354 was prepared according to the procedure used for
the preparation of Example 367, substituting
benzo[b]thiophene-5-carboxylic acid for
1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.74 (s, 2H), 5.75 (s, 2H), 6.45
(s, 1H), 6.80-6.93 (m, 1H), 7.52-7.55 (m, 1H), 7.60 (d, J=5.5 Hz,
1H), 7.87 (d, J=5.5 Hz, 1H), 7.91 (dd, J=8.5, 1.8 Hz, 1H), 8.14 (d,
J=8.5 Hz, 1H), 8.44-8.48 (m, 2H), 8.60 (s, 1H); MS (ESI) m/z 488
(M+H).sup.+.
Example 355
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-ben-
zofuran-5-carboxamide
[1017] Example 355 was prepared according to the procedure used for
the preparation of Example 367, substituting
benzofuran-5-carboxylic acid for
1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.72 (s, 2H), 5.72 (s, 2H), 6.44
(s, 1H), 6.82-6.90 (m, 1H), 7.07-7.18 (m, 1H), 7.50-7.58 (m, 1H),
7.69-7.77 (m, 1H), 7.91 (dd, J=8.6, 1.9 Hz, 1H), 8.06-8.11 (m, 1H),
8.24-8.29 (m, 1H), 8.41 (s, 1H), 8.55 (s, 1H); MS (ESI) m/z 472
(M+H).sup.+.
Example 356
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-in-
dole-6-carboxamide
[1018] To a 4 mL vial was added a solution of
1H-indole-6-carboxylic acid (0.1 mmol) in N,N-dimethylacetamide
(0.35 mL), followed by a solution of HATU (52 mg, 0.14 mmol) in
N,N-dimethylacetamide (0.5 mL). Then a solution of Example 9b (15
mg, 0.05 mmol) in N,N-dimethylacetamide (1.0 mL) was added followed
by 30 .mu.L of N,N-diisopropylethylamine neat. The reaction was
shaken at 50.degree. C. overnight and purified by preparative HPLC
on a Phenomenex Luna C8 (2) 5 .mu.m 100 .ANG. AXIA column (30
mm.times.150 mm). A gradient of acetonitrile (A) and 0.05% ammonium
acetate in water (B) was used, at a flow rate of 50 mL/min (0-0.5
minutes 10% A, 0.5-6.0 minutes linear gradient 10-100% A, 6.0-7.0
minutes 100% A, 7.0-8.0 minutes linear gradient 100-10% A). An
Agilent 1100 Series Purification system was used, consisting of the
following modules: Agilent 1100 Series LC/MSD SL mass spectrometer
with API-electrospray source; two Agilent 1100 Series preparative
pumps; Agilent 1100 Series isocratic pump; Agilent 1100 Series
diode array detector with preparative (0.3 mm) flow cell; Agilent
active-splitter, IFC-PAL fraction collector/autosampler. The
make-up pump for the mass spectrometer used 3:1 methanol:water with
0.1% formic acid at a flow rate of 1 mL/min. Fraction collection
was automatically triggered when the extracted ion chromatogram
(EIC) for the target mass exceeded the threshold specified in the
method. The system was controlled using Agilent Chemstation (Rev
B.10.03), Agilent A2Prep, and Leap FractPal software, with custom
Chemstation macros for data export. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.71 (s, 2H), 5.62 (s, 2H), 6.40
(s, 1H), 6.49-6.56 (m, 1H), 6.81-6.91 (m, 1H), 7.48-7.50 (m, 1H),
7.52 (d, J=3.1 Hz, 1H), 7.58-7.67 (m, 2H), 8.03-8.07 (m, 1H), 8.18
(s, 1H), 8.33 (s, 1H); (ESI) m/e 471 (M+H).sup.+.
Example 357
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1H-in-
dole-5-carboxamide
[1019] Example 357 was prepared according to the procedure used for
the preparation of Example 367, substituting 1H-indole-5-carboxylic
acid for 1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid.
.sup.1H NMR (DMSO/D.sub.2O-d.sub.6) .delta. 4.69 (s, 2H), 5.72 (s,
2H), 6.41 (s, 1H), 6.58 (d, J=3.3 Hz, 1H), 6.81-6.87 (m, 1H),
7.43-7.46 (m, 1H), 7.49 (d, J=8.6 Hz, 1H), 7.51-7.54 (m, 1H), 7.70
(dd, J=8.5, 1.7 Hz, 1H), 8.15-8.24 (m, 1H), 8.43 (s, 1H), 8.57 (s,
1H); MS (ESI) m/e 471 (M+H).sup.+.
Example 358
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-met-
hyl-1,3-benzothiazole-6-carboxamide
[1020] Example 358 was prepared according to the procedure used for
the preparation of Example 356, substituting
2-methylbenzo[d]thiazole-6-carboxylic acid for
1H-indole-6-carboxylic acid. .sup.1H NMR (DMSO/D.sub.2O-d.sub.6)
.delta. 2.85 (s, 3H), 4.72 (s, 2H), 5.62 (s, 2H), 6.43 (s, 1H),
6.81-6.87 (m, 1H), 7.48-7.53 (m, 1H), 7.99-8.04 (m, 2H), 8.18 (s,
1H), 8.33 (s, 1H), 8.56-8.58 (m, 1H); MS ESI) m/z 503
(M+H).sup.+.
Example 359
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-met-
hyl-1,3-benzoxazole-6-carboxamide
[1021] Example 359 was prepared according to the procedure used for
the preparation of Example 367, substituting
2-methylbenzo[d]oxazole-6-carboxylic acid for
1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 2.14 (s, 3H), 4.65 (s, 2H), 5.71
(s, 2H), 6.38 (s, 1H), 6.79-6.86 (m, 1H), 7.37 (dd, J=8.4, 2.0 Hz,
1H), 7.41-7.44 (m, 1H), 7.49-7.54 (m, 1H), 7.92 (d, J=8.4 Hz, 1H),
8.40 (s, 1H), 8.55 (s, 1H).
Example 360
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-met-
hyl-1H-indazole-6-carboxamide
[1022] Example 360 was prepared according to the procedure used for
the preparation of Example 370, substituting
1-methyl-1H-indazole-6-carboxylic acid for
3-isopropylisoxazolo[5,4-b]pyridine-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.11 (s, 3H), 4.74 (d, J=5.6 Hz,
2H), 5.68 (s, 2H), 6.43 (d, J=1.8 Hz, 1H), 6.83 (d, J=1.9 Hz, 1H),
7.51 (d, J=1.8 Hz, 1H), 7.70 (dd, J=8.5, 1.3 Hz, 1H), 7.85 (d,
J=8.3 Hz, 1H), 8.13 (s, 1H), 8.25 (s, 1H), 8.34 (s, 1H), 8.49 (s,
1H), 9.15 (t, J=5.6 Hz, 1H), 11.54 (s, 1H); MS (ESI) m/z 486
(M+H).sup.+.
Example 361
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-met-
hyl-1H-benzimidazole-5-carboxamide
[1023] Example 361 was prepared according to the procedure used for
the preparation of Example 367, substituting
1-methyl-1H-benzo[d]imidazole-5-carboxylic acid for
1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.08 (s, 3H), 4.75 (s, 2H), 5.75
(s, 2H), 6.45 (s, 1H), 6.84 (d, J=1.9 Hz, 1H), 7.52-7.55 (m, 1H),
8.02 (d, J=8.5 Hz, 1H), 8.10-8.15 (m, 1H), 8.38-8.39 (m, 1H), 8.46
(s, 1H), 8.60 (s, 1H), 9.35 (s, 1H); MS (ESI) m/z 486
(M+H).sup.+.
Example 362
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-met-
hyl-1H-indazole-5-carboxamide
[1024] Example 362 was prepared according to the procedure used for
the preparation of Example 367, substituting
1-methyl-1H-indazole-5-carboxylic acid for
1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.10 (s, 3H), 4.72 (s, 2H), 5.74
(s, 2H), 6.44 (s, 1H), 6.83-6.89 (m, 1H), 7.50-7.57 (m, 1H), 7.73
(d, J=8.9 Hz, 1H), 7.97 (dd, J=8.9, 1.6 Hz, 1H), 8.22-8.25 (m, 1H),
8.39-8.44 (m, 1H), 8.45 (s, 1H), 8.59 (s, 1H); MS (ESI) m/z 486
(M+H).sup.+.
Example 363
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-met-
hyl-1H-benzimidazole-5-carboxamide
[1025] Example 363 was prepared according to the procedure used for
the preparation of Example 367, substituting
2-methyl-1H-benzo[d]imidazole-5-carboxylic acid for
1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 2.84 (s, 3H), 4.75 (s, 2H), 5.73
(s, 2H), 6.45 (s, 1H), 6.80-6.87 (m, 1H), 7.48-7.59 (m, 1H), 7.88
(d, J=8.6 Hz, 1H), 8.09 (dd, J=8.6, 1.6 Hz, 1H), 8.25-8.33 (m, 1H),
8.43 (s, 1H), 8.57 (s, 1H); MS (ESI) m/z 486 (M+H).sup.+.
Example 364
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-met-
hyl-1-benzofuran-5-carboxamide
[1026] Example 364 was prepared according to the procedure used for
the preparation of Example 367, substituting
2-methylbenzofuran-5-carboxylic acid for
1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid. .sup.1H NMR
(DMSO-d.sub.6) .delta. 2.47-2.49 (m, 3H), 4.69 (s, 2H), 5.71 (s,
2H), 6.42 (s, 1H), 6.67-6.72 (m, 1H), 6.83-6.87 (m, 1H), 7.50-7.53
(m, 1H), 7.59 (d, J=8.7 Hz, 1H), 7.80 (dd, J=8.6, 1.9 Hz, 1H),
8.07-8.12 (m, 1H), 8.40 (s, 1H), 8.54 (s, 1H); MS (ESI) m/z 486
(M+H).sup.+.
Example 365
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl)}methyl)-1-me-
thyl-1H-indole-6-carboxamide
[1027] Example 365 was prepared according to the procedure used for
the preparation of Example 370, substituting
1-methyl-1H-indole-6-carboxylic acid for
3-isopropylisoxazolo[5,4-b]pyridine-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 3.86 (s, 3H), 4.73 (s, 2H), 5.73
(s, 2H), 6.44 (s, 1H), 6.53 (d, J=3.1 Hz, 1H), 6.85 (d, J=1.9 Hz,
1H), 7.52 (dd, J=12.5, 2.5 Hz, 2H), 7.64 (d, J=1.6 Hz, 2H), 8.08
(d, J=1.2 Hz, 1H), 8.44 (s, 1H), 8.59 (s, 1H); MS (ESI) m/z 485
(M+H).sup.+.
Example 366
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-met-
hyl-1H-indole-5-carboxamide
[1028] Example 366 was prepared according to the procedure used for
the preparation of Example 367, substituting
1-methyl-1H-indole-5-carboxylic acid for
1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 3.83 (s, 3H), 4.70 (s, 2H), 5.72
(s, 2H), 6.42 (s, 1H), 6.58 (d, J=3.3 Hz, 1H), 6.82-6.87 (m, 1H),
7.39-7.45 (m, 1H), 7.49-7.57 (m, 2H), 7.75 (dd, J=8.6, 1.7 Hz, 1H),
8.14-8.23 (m, 1H), 8.43 (s, 1H), 8.56 (s, 1H); MS (ESI) m/z 485
(M+H).sup.+.
Example 367
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,2-d-
imethyl-1H-benzimidazole-5-carboxamide
[1029] To a 4 mL vial was added a solution of
1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid (0.1 mmol) in
N,N-dimethylacetamide (0.35 mL), followed by a solution of HATU (52
mg, 0.14 mmol) in N,N-dimethylacetamide (0.5 mL). Then a solution
of Example 9b (15 mg, 0.05 mmol) in N,N-dimethylacetamide (1.0 mL)
was added followed by 30 .mu.L of N,N-diisopropylethylamine. The
reaction was shaken at 50.degree. C. temperature overnight and
purified by preparative HPLC on a Phenomenex Luna C8 (2) 5 m 100
.ANG. AXIA column (30 mm.times.150 mm). A gradient of acetonitrile
(A) and 0.1% trifluoroacetic acid in water (B) was used, at a flow
rate of 50 mL/min (0-0.5 minutes 10% A, 0.5-6.0 minutes linear
gradient 10-100% A, 6.0-7.0 minutes 100% A, 7.0-8.0 minutes linear
gradient 100-10% A). An Agilent 1100 Series Purification system was
used, consisting of the following modules: Agilent 1100 Series
LC/MSD SL mass spectrometer with API-electrospray source; two
Agilent 1100 Series preparative pumps; Agilent 1100 Series
isocratic pump; Agilent 1100 Series diode array detector with
preparative (0.3 mm) flow cell; Agilent active-splitter, IFC-PAL
fraction collector/autosampler. The make-up pump for the mass
spectrometer used 3:1 methanol:water with 0.1% formic acid at a
flow rate of 1 mL/min. Fraction collection was automatically
triggered when the extracted ion chromatogram (EIC) for the target
mass exceeded the threshold specified in the method. The system was
controlled using Agilent Chemstation (Rev B.10.03), Agilent A2Prep,
and Leap FractPal software, with custom Chemstation macros for data
export. .sup.1H NMR (DMSO/D.sub.2O-d.sub.6) .delta. 2.86 (s, 3H),
3.97 (s, 3H), 4.76 (s, 2H), 5.75 (s, 2H), 6.45 (s, 1H), 6.84 (d,
J=1.9 Hz, 1H), 7.50-7.57 (m, 1H), 8.00-8.05 (m, 1H), 8.12-8.18 (m,
1H), 8.29-8.32 (m, 1H), 8.46 (s, 1H), 8.60 (s, 1H); MS (ESI) m/z
500 (M+H).sup.+.
Example 368
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-eth-
yl-1H-benzimidazole-6-carboxamide
[1030] Example 368 was prepared according to the procedure used for
the preparation of Example 367, substituting
2-ethyl-1H-benzo[d]imidazole-6-carboxylic acid for
1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 1.45 (t, J=7.6 Hz, 3H), 3.10-3.27
(m, 2H), 4.75 (s, 2H), 5.73 (s, 2H), 6.45 (s, 1H), 6.84 (d, J=1.9
Hz, 1H), 7.54 (d, J=1.9 Hz, 1H), 7.88 (d, J=8.6 Hz, 1H), 8.09 (dd,
J=8.7, 1.6 Hz, 1H), 8.27-8.31 (m, 1H), 8.42 (s, 1H), 8.57 (s, 1H);
MS (ESI) m/z 500 (M+H).sup.+.
Example 369
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-cya-
no-1H-indole-5-carboxamide
[1031] Example 369 was prepared according to the procedure used for
the preparation of Example 367, substituting
3-cyano-1H-indole-5-carboxylic acid for
1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 4.73 (s, 2H), 5.73 (s, 2H), 6.45
(s, 1H), 6.81-6.86 (m, 1H), 7.52-7.56 (m, 1H), 7.69 (d, J=8.6 Hz,
1H), 7.91 (dd, J=8.6, 1.7 Hz, 1H), 8.30-8.37 (m, 2H), 8.41 (s, 1H),
8.56 (s, 1H); MS (ESI) m/z 496 (M+H).sup.+.
Example 370
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-3-(pr-
opan-2-yl)[1,2]oxazolo[5,4-b]pyridine-5-carboxamide
[1032] To a 4 mL vial was added a solution of
3-isopropylisoxazolo[5,4-b]pyridine-5-carboxylic acid (0.16 mmol)
in N,N-dimethylacetamide (0.5 mL), followed by a solution of HATU
(80 mg, 0.2 mmol) in N,N-dimethylacetamide (0.5 mL). Then a
solution of Example 9b (23 mg, 0.07 mmol) in N,N-dimethylacetamide
(1.0 mL) was added followed by 50 .mu.L of
N,N-diisopropylethylamine. The reaction was shaken at 50.degree. C.
overnight and purified by preparative HPLC on a Phenomenex Luna C8
(2) 5 .mu.m 100 .ANG. AXIA column (30 mm.times.150 mm). A gradient
of acetonitrile (A) and 0.1% trifluoroacetic acid in water (B) was
used, at a flow rate of 50 mL/min (0-0.5 minutes 10% A, 0.5-6.0
minutes linear gradient 10-100% A, 6.0-7.0 minutes 100% A, 7.0-8.0
minutes linear gradient 100-10% A). An Agilent 1100 Series
Purification system was used, consisting of the following modules:
Agilent 1100 Series LC/MSD SL mass spectrometer with
API-electrospray source; two Agilent 1100 Series preparative pumps;
Agilent 1100 Series isocratic pump; Agilent 1100 Series diode array
detector with preparative (0.3 mm) flow cell; Agilent
active-splitter, IFC-PAL fraction collector/autosampler. The
make-up pump for the mass spectrometer used 3:1 methanol:water with
0.1% formic acid at a flow rate of 1 mL/min. Fraction collection
was automatically triggered when the extracted ion chromatogram
(EIC) for the target mass exceeded the threshold specified in the
method. The system was controlled using Agilent Chemstation (Rev
B.10.03), Agilent A2Prep, and Leap FractPal software, with custom
Chemstation macros for data export. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 1.45 (d, J=7.0 Hz, 6H), 4.77 (d,
J=5.3 Hz, 2H), 5.70 (s, 2H), 6.47 (d, J=1.8 Hz, 1H), 6.82 (d, J=1.9
Hz, 1H), 7.52 (d, J=1.8 Hz, 1H), 8.36 (s, 1H), 8.50 (s, 1H), 8.98
(d, J=2.1 Hz, 1H), 9.17 (d, J=2.1 Hz, 1H), 9.42 (t, J=5.5 Hz, 1H),
11.58 (s, 1H); MS (ESI) m/z 516 (M+H).sup.+.
Example 371
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-(pr-
opan-2-yl)-1H-benzotriazole-5-carboxamide
[1033] Example 371 was prepared according to the procedure used for
the preparation of Example 356, substituting
1-isopropyl-1H-benzo[d][1,2,3]triazole-5-carboxylic acid for
1H-indole-6-carboxylic acid. .sup.1H NMR (DMSO/D.sub.2O-d.sub.6)
.delta. 1.66 (d, J=6.7 Hz, 6H), 4.74 (s, 2H), 5.20-5.32 (m, 1H),
5.62 (s, 2H), 6.44 (s, 1H), 6.80-6.86 (m, 1H), 7.49-7.52 (m, 1H),
7.99-8.12 (m, 2H), 8.19 (s, 1H), 8.33 (s, 1H), 8.60-8.68 (m, 1H);
MS (ESI) m/z 515 (M+H).sup.+.
Example 372
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-(pr-
opan-2-yl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
[1034] Example 372 was prepared according to the procedure used for
the preparation of Example 356, substituting
1-isopropyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid for
1H-indole-6-carboxylic acid. .sup.1H NMR (DMSO/D.sub.2O-d.sub.6)
.delta. 1.53 (d, J=6.7 Hz, 6H), 4.74 (s, 2H), 5.26 (p, J=6.7 Hz,
1H), 5.62 (s, 2H), 6.45 (s, 1H), 6.80-6.84 (m, 1H), 7.48-7.52 (m,
1H), 8.20 (s, 1H), 8.33 (d, J=3.8 Hz, 2H), 8.77 (d, J=2.1 Hz, 1H),
9.06 (d, J=2.1 Hz, 1H); MS (ESI) m/z 515 (M+H).sup.+.
Example 373
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-4-met-
hoxy-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
[1035] Example 373 was prepared according to the procedure used for
the preparation of Example 367, substituting
4-methoxy-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid
for 1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid. .sup.1H
NMR (DMSO/D.sub.2O-d.sub.6) .delta. 2.59 (s, 3H), 3.96 (s, 3H),
4.04 (s, 3H), 4.73 (s, 2H), 5.74 (s, 2H), 6.50 (s, 1H), 6.75-6.91
(m, 1H), 7.47-7.62 (m, 1H), 8.46 (s, 1H), 8.54-8.61 (m, 2H); MS
(ESI) m/z 531 (M+H).sup.+.
Example 374
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2,3-d-
imethyl-1H-indole-6-carboxamide
[1036] Example 374 was prepared according to the procedure used for
the preparation of Example 370, substituting
2,3-dimethyl-1H-indole-6-carboxylic acid for
3-isopropylisoxazolo[5,4-b]pyridine-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 2.18 (s, 3H), 2.35 (s, 3H), 4.69
(d, J=5.6 Hz, 2H), 5.68 (s, 2H), 6.38 (d, J=1.7 Hz, 1H), 6.83 (d,
J=1.9 Hz, 1H), 7.41 (d, J=8.3 Hz, 1H), 7.49 (d, J=1.9 Hz, 1H), 7.57
(dd, J=8.3, 1.5 Hz, 1H), 7.87 (d, J=1.4 Hz, 1H), 8.35 (s, 1H), 8.49
(s, 1H), 8.89 (t, J=5.7 Hz, 1H), 10.97 (s, 1H), 11.48 (s, 1H); MS
(ESI) m/z 499 (M+H).sup.+.
Example 375
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2,3-d-
imethyl-1H-indole-5-carboxamide
[1037] Example 375 was prepared according to the procedure used for
the preparation of Example 367, substituting
2,3-dimethyl-1H-indole-5-carboxylic acid for
1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 2.22 (s, 3H), 2.35 (s, 3H), 4.71
(s, 2H), 5.73 (s, 2H), 6.43 (s, 1H), 6.82-6.86 (m, 1H), 7.32 (d,
J=8.4 Hz, 1H), 7.50-7.55 (m, 1H), 7.63 (dd, J=8.5, 1.7 Hz, 1H),
8.03-8.08 (m, 1H), 8.42 (s, 1H), 8.57 (s, 1H); MS (ESI) m/z 499
(M+H).sup.+.
Example 376
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1-(2--
hydroxyethyl)-2-methyl-1H-benzimidazole-5-carboxamide
[1038] Example 376 was prepared according to the procedure used for
the preparation of Example 367, substituting
1-(2-hydroxyethyl)-2-methyl-1H-benzo[d]imidazole-5-carboxylic acid
for 1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid. .sup.1H
NMR (DMSO/D.sub.2O-d.sub.6) .delta. 2.90 (s, 3H), 3.86 (t, 2H),
4.55 (t, J=4.8 Hz, 2H), 4.76 (s, 2H), 5.75 (s, 2H), 6.45 (s, 1H),
6.81-6.84 (m, 1H), 7.51-7.56 (m, 1H), 8.05 (d, J=8.7 Hz, 1H), 8.13
(dd, J=8.6, 1.6 Hz, 1H), 8.29-8.33 (m, 1H), 8.46 (s, 1H), 8.60 (s,
1H); MS (ESI) m/z 530 (M+H).sup.+.
Example 377
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-6-met-
hyl-1-(propan-2-yl)-1H-pyrazolo[3,4-b]pyridine-5-carboxamide
[1039] Example 377 was prepared according to the procedure used for
the preparation of Example 367, substituting
1-isopropyl-6-methyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid
for 1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid. .sup.1H
NMR (DMSO/D.sub.2O-d.sub.6) .delta. 1.50 (d, J=6.7 Hz, 6H), 2.68
(s, 3H), 4.70 (s, 2H), 5.21 (p, J=6.7 Hz, 1H), 5.73 (s, 2H), 6.49
(s, 1H), 6.83-6.87 (m, 1H), 7.54-7.56 (m, 1H), 8.19 (s, 1H), 8.29
(s, 1H), 8.44 (s, 1H), 8.58 (s, 1H); MS (ESI) m/z 529
(M+H).sup.+.
Example 378
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-1,2,3-
-trimethyl-1H-indole-5-carboxamide
[1040] Example 378 was prepared according to the procedure used for
the preparation of Example 367, substituting
1,2,3-trimethyl-1H-indole-5-carboxylic acid for
1,2-dimethyl-1H-benzo[d]imidazole-5-carboxylic acid. .sup.1H NMR
(DMSO/D.sub.2O-d.sub.6) .delta. 2.25 (s, 3H), 2.36 (s, 3H), 3.69
(s, 3H), 4.71 (s, 2H), 5.71 (s, 2H), 6.43 (s, 1H), 6.78-6.90 (m,
1H), 7.43 (d, J=8.6 Hz, 1H), 7.49-7.56 (m, 1H), 7.70 (dd, J=8.6,
1.7 Hz, 1H), 8.10 (d, J=1.6 Hz, 1H), 8.38 (s, 1H), 8.53 (s, 1H); MS
(ESI) m/z 513 (M+H).sup.+.
Example 379
N-({7-[(6-amino-9H-purin-9-yl)methyl]-5-chloro-1H-indol-2-yl}methyl)-2-but-
yl-1,3-benzoxazole-5-carboxamide
[1041] Example 379 was prepared according to the procedure used for
the preparation of Example 356, substituting
2-butylbenzo[d]oxazole-5-carboxylic acid for 1H-indole-6-carboxylic
acid. .sup.1H NMR (DMSO/D.sub.2O-d.sub.6) .delta. 0.93 (t, J=7.4
Hz, 3H), 1.40 (dq, J=14.7, 7.4 Hz, 2H), 1.80 (p, J=7.5 Hz, 2H),
2.98 (t, J=7.4 Hz, 2H), 4.71 (s, 2H), 5.62 (s, 2H), 6.42 (s, 1H),
6.81-6.86 (m, 1H), 7.49-7.51 (m, 1H), 7.78 (d, J=8.6 Hz, 1H),
7.92-7.98 (m, 1H), 8.18 (s, 1H), 8.23-8.25 (m, 1H), 8.33 (s, 1H);
MS (ESI) m/z 529 (M+H).sup.+.
Determination of Biological Activity
[1042] Test compounds were dispensed by a Labcyte Echo in 384-well
low volume assay plates with 3-fold serial dilutions from 50 .mu.M
to 0.00075 .mu.M. 5 .mu.L of SUV420H1 enzyme (Abbvie) at 90 nM was
added to all wells except the no enzyme control wells, and
incubated for 30 minutes at room temp before 5 .mu.L of Histone
Peptide H4(8-30)me1 (Anaspec) at 5 nM and SAM at 4 nM was added to
all wells. The plates were incubated in a humidified chamber
overnight at room temp and then 10 .mu.L of the detection reagent
that contained RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM sodium
chloride, 1.0% Igepal CA-630 (NP-40), 0.5% sodium deoxycholate and
0.1% sodium dodecyl sulfate) (Sigma) with 2 nM of Terbium chelate
anti S-adenosyl-L-homocysteine (SAH) (Abbvie) antibody and Oregon
Green labeled SAH at 4 nM was added. The plates were further
incubated for 4 hours at room temperature. The plates were read in
a Perkin Elmer Envision using a TR-FRET protocol with Excitation
set at 335 nm and Emission at 520 and 495 nm. To generate dose
response curves the data is normalized to percent inhibition by
setting the average of the plus and minus enzyme control wells to
0% and 100% inhibition respectively. The IC.sub.50 values for the
compounds are generated by fitting the normalized data with
Accelrys Assay Explorer 3.3 to a sigmoidal curve model using linear
regression, Y=(100*x.sup.n)/(K.sup.n+x.sup.n), where Y is the
measured response, x is the compound concentration, n is the Hill
Slope and K is the IC.sub.50 and the lower and higher asymptotes
are constrained to 0 and 100 respectively.
[1043] The IC.sub.50 of the test compounds are presented in Table
1.
TABLE-US-00001 TABLE 1 TR-FRET SAH_SUV420H1 Example Number
IC.sub.50 (.mu.M) 1 >50 2 36.9 3 35.0 4 14.1 5 13.9 6 1.46 7
22.2 8 2.82 9 1.17 10 1.87 11 0.178 12 0.334 13 0.135 14 0.186 15
0.154 16 0.44 17 0.635 18 0.561 19 ND 20 0.866 21 0.78 22 0.458 23
ND 24 ND 25 ND 26 0.474 27 1.21 28 0.426 29 0.252 30 1.17 31 0.901
32 3.33 33 0.528 34 0.723 35 1.09 36 2.41 37 0.321 38 0.81 39 0.345
40 0.425 41 0.236 42 0.45 43 ND 44 0.56 45 0.356 46 0.541 47 0.354
48 1.33 49 0.193 50 0.223 51 0.294 52 0.244 53 0.59 54 1.18 55
0.293 56 0.24 57 0.457 58 7.88 59 7.51 60 38.4 61 20.3 62 1.12 63
4.03 64 3.08 65 5.08 66 4.29 67 0.20 68 0.972 69 0.663 70 1.0 71 ND
72 1.81 73 0.722 74 1.18 75 0.89 76 1.33 77 2.63 78 0.632 79 0.548
80 1.85 81 0.334 82 0.939 83 0.831 84 0.569 85 0.605 86 0.915 87
>50 88 1.43 89 2.6 90 2.24 91 2.67 92 >50 93 9.73 94 31.1 95
>50 96 16.3 97 11.4 98 11.8 99 25.1 100 10.9 101 >50 102 6.36
103 25.3 104 18.2 105 8.17 106 3.32 107 10.9 108 17.0 109 10.6 110
10.7 111 8.8 112 32.0 113 >50 114 8.16 115 3.53 116 8.28 117
14.1 118 18.4 119 6.41 120 1.49 121 2.56 122 4.77 123 44.9 124 23.9
125 4.62 126 2.23 127 6.0 128 3.34 129 28.4 130 2.39 131 3.23 132
6.25 133 31.9 134 1.27 135 4.54 136 10.5 137 2.04 138 1.64 139
0.767 140 6.09 141 0.783 142 9.48 143 24.0 144 4.6 145 2.4 146 14.2
147 5.79 148 1.03 149 2.04 150 0.382 151 6.75 152 1.08 153 4.4 154
4.77 155 3.59 156 7.92 157 2.06 158 4.75 159 >50 160 16.8 161
0.856 162 0.237 163 0.127 164 0.139 165 0.233 166 0.0889 167 0.225
168 0.333 169 0.0801 170 0.208 171 0.173 172 0.0661 173 0.0412 174
0.101 175 0.0828 176 0.0875 177 0.106 178 0.116 179 0.365 180 0.13
181 2.86 182 5.2 183 1.78 184 0.84 185 0.691 186 0.263 187 1.87 188
0.507 189 3.36 190 0.91 191 2.98 192 2.14 193 20.0 194 1.95 195
>50 196 0.905 197 1.07 198 12.6 199 0.0939 200 0.10 201 0.0589
202 0.0641 203 0.0277 204 0.0532 205 3.43 206 1.05 207 0.943 208
1.89 209 1.92 210 3.34 211 9.33 212 3.64 213 2.76 214 2.84 215 3.91
216 2.47 217 2.43 218 2.33 219 3.13 220 4.05 221 6.24 222 3.54 223
8.25 224 2.77 225 >50 226 0.275 227 0.79 228 2.42 229 >50 230
16.7 231 2.48 232 1.98 233 0.236 234 0.0606 235 0.0492 236 0.0338
237 0.0288 238 0.0457 239 0.0547 240 0.164 241 3.63 242 2.64 243
5.46 244 1.94
245 2.03 246 7.29 247 9.38 248 0.571 249 3.31 250 4.44 251 >50
252 2.14 253 36.1 254 >50 255 15.5 256 >50 257 0.493 258 4.58
259 3.53 260 3.55 261 1.99 262 2.75 263 1.75 264 3.23 265 2.14 266
0.911 267 3.43 268 4.64 269 5.6 270 3.75 271 2.98 272 0.378 273 1.5
274 11.3 275 13.2 276 0.039 277 0.0351 278 0.0674 279 0.0493 280
0.0419 281 0.141 282 0.0723 283 0.0526 284 0.0908 285 0.0579 286
0.0411 287 0.0878 288 0.0431 289 0.0613 290 2.8 291 12.9 292 32.2
293 20.5 294 >50 295 0.607 296 0.623 297 6.04 298 5.98 299 1.84
300 4.15 301 0.75 302 >50 303 0.0723 304 0.0491 305 0.0367 306
0.0564 307 0.0297 308 0.050 309 7.31 310 13.2 311 3.24 312 >50
313 >50 314 1.93 315 4.08 316 13.0 317 4.5 318 3.49 319 3.39 320
8.03 321 8.22 322 29.9 323 0.345 324 12.5 325 3.12 326 6.2 327 5.28
328 ND 329 0.41 330 1.06 331 2.58 332 2.02 333 1.7 334 2.04 335
0.401 336 0.431 337 0.0985 338 2.85 339 6.87 340 0.807 341 3.03 342
0.947 343 4.82 344 3.04 345 0.624 346 4.66 347 29.1 348 7.27 349
8.78 350 2.74 351 0.393 352 1.28 353 >50 354 5.96 355 4.87 356
2.65 357 12.0 358 0.889 359 4.28 360 0.747 361 2.15 362 0.636 363
4.3 364 3.28 365 1.88 366 2.87 367 0.591 368 7.61 369 >50 370
1.69 371 21.5 372 0.97 373 0.0844 374 0.261 375 12.4 376 2.95 377
2.71 378 6.26 379 0.765 ND = Not Determined
[1044] It is understood that the foregoing detailed description and
accompanying examples are merely illustrative and are not to be
taken as limitations upon the scope of the invention, which is
defined solely by the appended claims and their equivalents.
Various changes and modifications to the embodiments will be
apparent to those skilled in the art. Such changes and
modifications, including without limitation those relating to the
chemical structures, substituents, derivatives, intermediates,
syntheses, formulations, or methods, or any combination of such
changes and modifications of use of the invention, may be made
without departing from the spirit and scope thereof.
* * * * *